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1Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences,
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3Department of Pharmaceutical Health Services Research, University of Maryland School of
Pharmacy, Baltimore, MD, USA
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5Japan Institute of Pharmacovigilance, Osaka, Japan
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Background: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies
for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide.
Objectives: To (1) describe the potential benefits and harms of NIs for influenza in all age groups by
reviewing all clinical study reports (CSRs) of published and unpublished randomised, placebo-controlled
trials and regulatory comments; and (2) determine the effect of oseltamivir (Tamiflu®, Roche) treatment on
mortality in patients with 2009A/H1N1 influenza.
Methods: We searched trial registries, electronic databases and corresponded with regulators and
sponsors to identify randomised trials of NIs. We requested full CSRs and accessed regulators’ comments.
We included only those trials for which we had CSRs. To examine the effects of oseltamivir on
2009A/H1N1 influenza mortality, we requested individual patient data (IPD) from corresponding authors of
all included observational studies.
Results: Effect of oseltamivir and zanamivir (Relenza®, GlaxoSmithKline) in the prevention and treatment
of influenza: Oseltamivir reduced the time to first alleviation of symptoms in adults by 16.8 hours
[95% confidence interval (CI) 8.4 to 25.1 hours]. Zanamivir reduced the time to first alleviation of
symptoms in adults by 0.60 days (95% CI 0.39 to 0.81 days). Oseltamivir reduced unverified pneumonia in
adult treatment [risk difference (RD) 1.00%, 95% CI 0.22% to 1.49%]; similar findings were observed
with zanamivir prophylaxis in adults (RD 0.32%, 95% CI 0.09% to 0.41%). Oseltamivir treatment of adults
increased the risk of nausea (RD 3.66%, 95% CI 0.90% to 7.39%) and vomiting (RD 4.56%, 95% CI
2.39% to 7.58%). In the treatment of children, oseltamivir induced vomiting (RD 5.34%, 95% CI
1.75% to 10.29%). Both oseltamivir and zanamivir prophylaxis reduced the risk of symptomatic influenza
in individuals (oseltamivir RD 3.05%, 95% CI 1.83% to 3.88%; zanamivir RD 1.98%, 95% CI 0.98% to
2.54%) and in households (oseltamivir RD 13.6%, 95% CI 9.52% to 15.47%; zanamivir RD 14.84%,
95% CI 12.18% to 16.55%). Oseltamivir increased psychiatric adverse events in the combined on- and
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off-treatment periods (RD 1.06%, 95% CI 0.07% to 2.76%) and the risk of headaches while on treatment
(RD 3.15%, 95% CI 0.88% to 5.78%). Effect of oseltamivir on mortality in patients with 2009A/H1N1
influenza: Analysis of summary data of 30 studies as well as IPD of four studies showed evidence of
time-dependent bias. After adjusting for time-dependent bias and potential confounding variables,
competing risks analysis of the IPD showed insufficient evidence that oseltamivir reduced the risk of
mortality (hazard ratio 1.03, 95% CI 0.64 to 1.65).
Conclusions: Oseltamivir and zanamivir cause small reductions in the time to first alleviation of influenza
symptoms in adults. The use of oseltamivir increases the risk of nausea, vomiting, psychiatric events in
adults and vomiting in children. Oseltamivir has no protective effect on mortality among patients with
2009A/H1N1 influenza. Prophylaxis with either NI may reduce symptomatic influenza in individuals and in
households. The balance between benefits and harms should be considered when making decisions about
use of NIs for either prophylaxis or treatment of influenza.
Study registration: This study is registered as PROSPERO CRD42012002245.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Clinical study reports Detailed reports of a clinical trial, usually submitted to regulators, following a
prescribed International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use format. Roche’s reports follow a modular structure (see Appendix 9).
Reports can be several hundred pages long and contain details of the planned design, conduct (protocol),
analysis (reporting analysis plan) and results of the trial.
Compliharm Term describing events defined as either complications or harms according to ambiguous
criteria that appeared to include time of analysis (with times either unspecified or inconsistent among trials)
and whether or not participants were infected (by influenza). In oseltamivir treatment trials some potential
harms or complications could be caused by both medication or influenza infection (e.g. vomiting), hence
our classification as a compliharm.
Consolidated Standards of Reporting Trials-based extraction Extraction, synthesis and appraisal
method used in this review for data from clinical study reports. Reconstructions were done by pairs of
review authors and assessed in the authors’ plenary session to decide whether or not included trials
could proceed to stage 2 of the analysis. The structure of the reconstruction follows that of the
Consolidated Standards of Reporting Trials statement.
Freedom of information Enshrined by law in the US and European Medicines Agency policy in Europe.
Freedom-of-information requests in this review have been a means of access to clinical study reports and
regulatory comments (regulatory information).
Individual patient data Anonymised individual data listings of characteristics and results, which form the
basis for the synthetic analyses in clinical study reports.
Japanese Summary Basis for Approval (of a drug) Summary of the application dossiers included as
one of the documents that is prepared and attached by the sponsoring pharmaceutical company.
These are submitted to the regulatory body for approval of a new drug.
Modules Basic structure of Roche’s trial reports. Today, the term ‘Modules’ refers to the components of
a regulatory submission, as set by the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use (2011). Clinical study reports are just
one ‘module’ of a regulatory submission.
Protocol Document reporting the trial’s planned design and conduct, with amendments (when relevant).
Confusingly, also used in submissions and regulatory documents as synonymous with study.
Public health drugs Drugs in which a considerable quantity of public money has been invested and/or
are on the World Health Organization essential drugs list.
Regulatory information Term comprising clinical study reports (data) and regulatory comments
and reviews.
Reporting Analysis Plan Plan of analysis that is usually linked to the trial protocol, explaining what and
how the authors intend to analyse.
Table of content of regulatory reviews and comments on industry submissions Our table of
content indicates which trial is cited, in which document, on which page and how many times.
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Table of contents-evidence Annotated version of the table of contents. Comments and annotation are
preliminary and form the basis for the weaving of the important aspects into the review narrative.
Time lock Date (12 April 2011) after which no documentation would be reviewed in the January 2012
version of the review. A cut-off was made necessary by the sheer scale of our data holdings. We were
initially funded to review the full clinical study reports of the 10 treatment trials included in the Kaiser et al.
paper (Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on
influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med
2003;63:1667–72). We were able to access the 10 module 1s and regulatory comments (approximately
6000 pages in total). As the funder-stipulated deadline to producing our review progressively shortened,
and our understanding of the issues evolved, we received notification that although the balance of the
10 study reports was unlikely to be accessible by our deadline, we would receive substantial quantities of
regulatory documents from the European Medicines Agency in four tranches. When we held our second
face-to-face meeting in April 2011 we had just received our first tranche of clinical study reports,
consisting of just over 10,000 pages, bringing our total holdings to 16,000 pages. We decided that we did
not have the resources to review any further documentation within our current funding and imposed a
data time lock. Any documentation received after this date would be reviewed if and when we had more
resources. The balance of documents (a further 14,000 pages) are included in this review.
Trial ID Means of identifying a trial. Usually made up of letters and numbers (WV15799). At times the
ID bears a letter suffix indicating the last version of the protocol followed in the trial (e.g. WV15799H,
i.e. trial carried out following amendment H).
Trial programme Series of trials designed and carried out to achieve registration or to answer specific
questions. Usually, programmes of the same drug or intervention focus on the same indication or the same
study population.
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List of abbreviations
APACHE Acute Physiology and Chronic
Health Evaluation
BMJ British Medical Journal
CDC US Centers for Disease Control
and Prevention
CENTRAL Cochrane Central Register of
Controlled Trials
CI confidence interval
CONSORT Consolidated Standards of
Reporting Trials
CRF case report form
CSR clinical study report
CTCAE V4.0 Common Terminology Criteria for
Adverse Events Version 4.0
DARE Database of Abstracts of Reviews
of Effects
df degrees of freedom
EMA European Medicines Agency
FDA US Food and Drug Administration
FOI freedom of information
GSK GlaxoSmithKline
HEED Health Economic Evaluations
Database
HR hazard ratio
ILI influenza-like illness
IPD individual patient data
ITT intention to treat
ITTI intention-to-treat-influenza-infected
ITTIINAB intention-to-treat influenza-infected
index cases who had negative
virology at baseline
MD mean difference
NCI-CTC
V2.0
National Cancer Institute-Common
Toxicity Criteria Version 2.0
NDA New Drug Application
NHS EED National Health Service Economic
Evaluation Database
NI neuraminidase inhibitor
NICE National Institute for Health and
Care Excellence
NNTB number needed to treat to benefit
NNTH number needed to treat to harm
NSAID non-steroidal anti-inflammatory
drug
OR odds ratio
PEP post-exposure prophylaxis
RCT randomised controlled trial
RD risk difference
RR risk ratio
SAP statistical analysis plan
SBA Summary Basis of Approval
td-Cox Cox regression including treatment
as a time-dependent exposure
TOC table of contents
WHO World Health Organization
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Plain English summary
Regulatory information on trials of oseltamivir (Tamiflu) and
zanamivir (Relenza) for influenza in adults and children
Oseltamivir and zanamivir have been stockpiled in many countries to treat and prevent seasonal and
pandemic influenza, before an influenza vaccine matched to the circulating virus becomes available.
How this review has been approached
We have updated and combined our reviews on the antiviral drugs zanamivir and oseltamivir for influenza
in adults and children on the basis of the manufacturers’ reports to regulators (clinical study reports) and
the regulators’ comments. We have called these comments and reports ‘regulatory information’.
What we have found
We have used data from 46 trials (20 oseltamivir and 26 zanamivir studies) in this review. We found that
both drugs shorten the duration of symptoms of influenza-like illness (unconfirmed influenza or ‘the flu’)
by less than a day (there was no effect in asthmatic children, but in otherwise healthy children there was).
Oseltamivir did not affect the number of hospitalisations. In children with asthma there was no clear effect
on the time to first alleviation of symptoms.
Prophylaxis trials showed that oseltamivir and zanamivir reduced the risk of symptomatic influenza.
Oseltamivir use was associated with nausea, vomiting, headaches and psychiatric events; these last two
were when it was used to prevent influenza (prophylaxis).
Low-quality data, adjusted for some likely biases, failed to show a reduction in mortality in very ill patients
with H1N1 2009 and treated with oseltamivir compared with those who did not receive influenza
antiviral drugs.
DOI: 10.3310/hta20420 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 42
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Heneghan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi

Scientific summary
Introduction
The World Health Organization (WHO) lists oseltamivir (Tamiflu®, Roche) as an essential influenza
pandemic drug and worldwide there is considerable stockpiling for emergency use, but there is uncertainty
on the reliability of the evidence base of oseltamivir and its fellow neuraminidase inhibitor (NI) zanamivir
[Relenza®, GlaxoSmithKline (GSK)] and on their safety and efficacy.
In 2009 it emerged that there was substantial reporting bias in published evidence, and this led us to
develop a new approach in order to update and amalgamate two pre-existing Cochrane reviews on NIs in
children and adults. Over a period of 4 years we worked to obtain full, unabridged, clinical study reports
for all trials in both drugs’ evidence development programme. We based our current review and its 2012
predecessor uniquely on clinical study reports and other regulatory material, including regulators reports,
that were available in the USA as Summary Basis of Approval and in the EU as European Public
Assessment Report.
This undertaking was facilitated by the change of policy at the European Medicines Agency (EMA) in
late 2010, allowing release for the first time of clinical study reports that were used during the Market
Authorisation Application and its processing. Additionally, this process received the backing of the
British Medical Journal, which launched its open data campaign on the basis of our quest for clinical
study reports.
Here we present our methods and results, based on the full set of clinical study reports that fit our
inclusion criteria. The reports, together with all relevant correspondence and the editors’ and referees’
comments, are also available. We also report our efforts to develop methods of reviewing clinical study
reports and putting the trial evidence in the context of the numerous non-randomised studies that have
been published since the 2009 influenza outbreak in order to present a complete picture of the topic.
Objectives
Our objective was to assess the effects of the NIs zanamivir and oseltamivir for influenza on the basis of
regulatory material and within their context of use. Specifically, we aimed to:
1. describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all
clinical study reports of published and unpublished randomised, placebo-controlled trials and
regulatory comments
2. determine the effect of oseltamivir on mortality in patients with 2009A/H1N1 influenza.
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Methods
To evaluate the effectiveness of NIs for preventing and treating influenza in adults and children:
l We searched trial registries, electronic databases (to 22 July 2013) and regulatory archives, and
corresponded with manufacturers to identify all trials. We also requested clinical study reports. We
focused on the primary data sources of manufacturers but we checked that there were no published
randomised controlled trials (RCTs) from non-manufacturer sources by running electronic searches in
the following databases: the Cochrane Central Register of Controlled Trials, MEDLINE, MEDLINE
(via Ovid), EMBASE, EMBASE.com, PubMed (not MEDLINE), the Database of Abstracts of Reviews of
Effects, the NHS Economic Evaluation Database and the Health Economic Evaluations Database.
l We included evidence from RCTs testing the effects of NIs for prophylaxis, post-exposure prophylaxis
and treatment of influenza.
l We included only trials on people who were exposed to naturally occurring influenza, with or
without symptoms.
l We analysed the effects of zanamivir and oseltamivir on time to first alleviation of symptoms, influenza
outcomes, complications, hospitalisations and adverse events in the intention-to-treat population.
l The sizeable quantity of available data led us to subdivide the extraction, appraisal and analysis of the
data into a two-stage exercise. In stage 1 we assessed the reliability and completeness of the identified
trial data. We decided to include in stage 2 of the review (full analysis following standard Cochrane
methods) only data that satisfied the following three criteria: (1) completeness, (2) internal consistency
and (3) external consistency.
l We used regulatory information to assess the possible correlation between citation frequency of
oseltamivir treatment trials in the US Food and Drug Administration regulatory documents and
trial size.
l We used the random-effects approach of DerSimonian and Laird (DerSimonian R, Laird N.
Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88), based on mean differences with
95% confidence interval (CI) for analysis of time to first alleviation of symptoms. For all other outcomes
we used the random-effects approach for binary data of DerSimonian and Laird, where tau-squared
was estimated using the inverse variance method.
To determine the effect of oseltamivir on mortality in patients with 2009A/H1N1 influenza:
l We searched MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature,
Web of Science and the Latin American and Caribbean Health Sciences Literature databases
(see Appendix 16 for details of our search strategy) for observational studies. We also hand-searched
bibliographies from two relevant documents published by the WHO and two previous reviews.
l We included any study of patients with 2009A/H1N1 influenza reporting mortality outcomes and
exposure to oseltamivir with at least 5% of patients untreated with influenza antiviral drugs and five or
more deaths overall.
l We requested individual patient data (IPD) from the corresponding authors of all included studies and
kept a record of all correspondence that ensued. IPD was provided for four studies, sent via e-mail in
Excel® 2010 (Microsoft Corporation, Redmond, WA, USA) or Stata 12 files (StataCorp LP, College
Station, TX, USA), checked for consistency and analysed in SAS version 9.4 for Windows (SAS Institute
Inc., Cary, NC, USA).
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Results
Effectiveness of neuraminidase inhibitors in the treatment of influenza
We obtained 107 clinical study reports from the EMA, GSK and Roche. We included 53 trials in stage 1
and 46 in stage 2, including 20 oseltamivir (9623 participants) and 26 zanamivir trials (14,628 participants).
Most of the zanamivir studies and half of the oseltamivir studies were at high risk of selection bias as a
result of inadequate reporting.
In adult treatment, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% CI 8.4
to 25.1 hours; p< 0.0001). There was no effect in asthmatic children, for whom symptoms increased by
5.2 hours (11.1 hours lower to 21.4 hours higher), but in otherwise healthy children there was reduction
by 29 hours (95% CI 12 to 47 hours; p= 0.001). Zanamivir reduced the time to first alleviation of
symptoms in adults by 0.60 days (95% CI 0.39 to 0.81 days; p< 0.00001) but the effect in children
was not significant. In subgroup analysis there was no difference in treatment effect for zanamivir on
time to first alleviation of symptoms in adults in the influenza-infected and non-influenza-infected
subgroups (p= 0.53).
Oseltamivir significantly reduced unverified pneumonia [risk difference (RD) 1.00%, 95% CI 0.22% to
1.49%] in the treated population. The effect was not significant in the five trials that used a more detailed
diagnostic form for pneumonia. There was no significant effect on pneumonia in children [risk ratio
(RR) 1.06, 95% CI 0.62 to 1.83]. There was no significant effect of zanamivir treatment on pneumonia
(RR 0.90, 95% CI 0.58 to 1.40). In two zanamivir adult trials, pneumonia reporting was based on a stricter
definition of X-ray confirmation and there was also no significant treatment effect (RR 1.02, 95% CI 0.35
to 3.02). In prophylaxis, zanamivir significantly reduced the risk of unverified pneumonia in adults
(RD 0.32%, 95% CI 0.09% to 0.41%) but not oseltamivir.
In adult treatment, oseltamivir increased the risk of nausea (RD 3.66%, 95% CI 0.90% to 7.39%) and
vomiting (RD 4.56%, 95% CI 2.39% to 7.58%). The proportion of participants with fourfold increases
in antibody titre was significantly lower with oseltamivir (RR 0.92, 95% CI 0.86 to 0.97). Oseltamivir
significantly decreased the risk of diarrhoea (RD 2.33%, 95% CI 0.14% to 3.81%) and cardiac events
(RD 0.68%, 95% CI 0.04% to 1.0%) during the on-treatment period. The rate of psychiatric adverse
events increased in dose-dependent fashion based on a likelihood ratio test (p= 0.038) in the two ‘pivotal’
treatment trials that included two oseltamivir arms with doses of 150mg and 300mg daily. There was
no indiction of a dose–response effect of treatment on psychiatric adverse events in the only prophylaxis
study with multiple dose treatment groups. In the treatment of children, oseltamivir induced vomiting
(RD 5.34%, 95% CI 1.75% to 10.29%). There was a significantly lower proportion of children on
oseltamivir with a fourfold increase in antibodies (RR 0.90, 95% CI 0.80 to 1.00).
Effectiveness of neuraminidase inhibitors in the prevention of influenza
In prophylaxis trials, NIs reduced the risk of symptomatic influenza in individuals (oseltamivir RD 3.05%,
95% CI 1.83% to 3.88%; zanamivir RD 1.98%, 95% CI 0.98% to 2.54%) and in households (oseltamivir
RD 13.6%, 95% CI 9.52% to 15.47%; zanamivir RD 14.84%, 95% CI 12.18% to 16.55%). There was
no significant effect on asymptomatic influenza (oseltamivir RR 1.14 95%, CI 0.39 to 3.33; zanamivir
RR 0.97, 95% CI 0.76 to 1.24). In oseltamivir prophylaxis, psychiatric adverse events were increased
in the combined on- and off-treatment periods (RD 1.06%, 95% CI 0.07% to 2.76%). Oseltamivir, on
treatment, increased the risk of headaches (RD 3.15%, 95% CI 0.88% to 5.78%), renal events
(RD 0.67%, 95% CI –0.01% to 2.93%) and nausea (RD 4.15%, 95% CI 0.86% to 9.51%).
Comparison of core reports compared with full clinical study reports
With more detailed information, no previous assessment of ‘high’ risk of bias was reclassified as ‘low’ or
‘unclear’ in the main analysis, and over half (55%, 34/62) of previous assessments of ‘low’ risk of bias
were reclassified as ‘high’. Most ‘unclear’ risk of bias (67%, 28/42) was reclassified as ‘high’ risk of bias
when our judgements were based on full clinical study reports.
DOI: 10.3310/hta20420 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 42
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Heneghan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxv
Effect of oseltamivir on mortality in patients with 2009A/H1N1 influenza
A total of 154 full-text articles were assessed for eligibility. Of these, 30 observational studies were eligible
and a total of 11,013 patients were available for qualitative synthesis. Overall, there were 1301 deaths
(12%) with the percentage of deaths receiving oseltamivir similar to that of survivors (83% vs. 82%). The
IPD came from four studies including 3071 patients and 242 (8%) deaths. Analysis of the IPD showed no
evidence of reduced risk of mortality with oseltamivir [hazard ratio (HR) 1.03, 95% CI 0.64 to 1.65].
Discussion
Effectiveness of neuraminidase inhibitors in the prevention and treatment
of influenza
The evidence that we have presented and synthesised shows that both NIs have symptom-relieving effects,
especially for self-reported outcomes, shortening symptom duration and reducing the frequency of
symptoms such as cough. For oseltamivir, this effect perhaps extends to cardiac symptoms, despite the
short duration of treatment (5 days). We are unsure what to make of this finding but we think it deserves
further investigation.
We could not decide the level of diagnostic ascertainment of diagnosis of pneumonia and other
complications. In a metaregression of all 32 included studies that reported on ‘pneumonia’, we found
evidence that treatment effects for pneumonia are statistically different depending on the method
of diagnosis.
Antibody suppression seems stronger for oseltamivir than zanamivir, probably because of the difference in
bioavailability. It may be that evidence of other effects, such as hyperglycaemia and renal impairment
(although significance was marginal) in the prophylaxis trials may be due to inhibition of the host’s
endogenous neuraminidase, which impairs the cell function of various organs.
A weak dose-dependent association between oseltamivir and psychiatric harms is evident in the two
pivotal treatment trials (but not in all oseltamivir treatment trials combined). It is possible that influenza-like
illness and influenza symptoms masked the harms in those who were already symptomatic and therefore
recruited in the treatment trials (and influenza-type symptoms were excluded as adverse events to
be reported).
Comparison of core reports compared with full clinical study reports
The Cochrane risk-of-bias tool was sometimes difficult to apply to clinical study reports. This may be
because the tool was constructed to assess journal publications and comprises a checklist. As information
increased in the core reports, our assessment of bias became more detailed and changed some of our
assessments. Our experience suggests that a more detailed extraction sheet is needed to prompt reviewers
to consider additional aspects of the study design when assessing bias.
Effect of oseltamivir on mortality in patients with 2009A/H1N1 influenza
Analysis of the summary data on the 30 studies as well as the IPD showed evidence of time-dependent
bias, with bias increasing with increasing odds of treatment. Analysis of the IPD using standard Cox
regression on the 2056 patients with survival times gave a HR of 0.75. However, when the
time-dependent nature of oseltamivir exposure, as well as the competing risk of hospital discharge were
taken into account, the HR adjusting for potential confounding variables was 1.03.
Our results are substantially different from those of three other reviews, which based their primary analysis
of mortality on three small studies of 681 patients, none of which had 2009A/H1N1, did not consider
time-dependent treatment exposure or appeared to not take appropriate account of time-dependent
treatment exposure.
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Conclusions
Oseltamivir and zanamivir cause small reductions in the time to alleviation of influenza symptoms except
for asthmatic children. The use of oseltamivir increases the risk of nausea, vomiting, psychiatric events in
adults and vomiting in children. Observational studies do not show that oseltamivir has a protective effect
on patients with 2009A/H1N1 influenza for mortality. Evidence suggests that the risk of bias has been
insufficiently reported in other Cochrane reviews that are limited to published research. The balance
between benefits and harms should be considered when making decisions about the use of NIs for either
prophylaxis or treatment of influenza.
Research priorities
We could not reach a consensus on whether or not further trials are warranted and whether or not current
trials should be discontinued. Any future trial designs should ensure that the presence of complications
is ascertained using objective diagnostic criteria. Procedures for trial unblinding and dates of unblinding
should be routinely reported. Registration should be made compulsory for all studies in which human
beings are randomly assigned to experimental arms. There is a further need to develop the systematic
review methods for the evaluation of other drugs, using full clinical study reports. Priority could perhaps be
given to first drugs of a new family, drugs considered to be innovative or those that are likely to have a big
market impact. Such reviews should be publicly funded, and independent from both regulators and
manufacturers. To determine the risks and benefits of drugs there will be a need to move to more
comprehensive reviews that incorporate more clinical study report data.
Study registration
This study is registered as PROSPERO CRD42012002245.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction and rationale
S ince the mid-2000s the use of neuraminidase inhibitors (NIs) has been endorsed and billions of poundshave been spent stockpiling the two anti-influenza drugs oseltamivir (Tamiflu®, Roche) and zanamivir
[Relenza®, GlaxoSmithKline (GSK)] in preparation for an influenza pandemic. When the H1N1 pandemic
emerged in 2009, the drugs were rolled out worldwide for the treatment and prevention of influenza and
its complications. At that time, we were asked to conduct a systematic review for Cochrane to update
evidence on their efficacy, during which it emerged that the validity of a key study underpinning the
evidence on efficacy was unclear. After 3.5 years of making requests to the drug manufacturers, they
provided us with full clinical study reports (CSRs).
Emergence of problems
The reasons for the stockpiling of oseltamivir and zanamivir are not well known, but the decision may be
based on assumptions that the drugs would reduce hospital admissions and serious complications of
influenza, such as pneumonia, by half and slow down the spread of the virus.1–3 Some of these
assumptions were supported by a peer-reviewed pooled analysis of 10 randomised trials of oseltamivir
published in the Archives of Internal Medicine in 2003 by Kaiser et al.4 This analysis seemed to be of high
quality and formed a powerful scientific rationale for stockpiling,5 but during our review in 2009 it became
apparent that the data underlying it were largely unpublished and inaccessible to independent scrutiny.
Roche, the manufacturer of oseltamivir, funded the Kaiser review, employed some of its authors and had
also sponsored the 10 trials. For 3.5 years Roche did not release the full CSRs despite a public pledge to do
so made during the H1N1 ‘swine flu’ outbreak of 2009.6,7
Research for our 2009 review also highlighted inconsistencies in decision-making. The US Food and Drug
Administration (FDA), which had access to the full CSRs, concluded on the product label that ‘Tamiflu has not
been shown to prevent such complications [serious bacterial infections]’. The European Medicines Agency
(EMA), which had only partial reports, and another prominent US agency, the Centers for Disease Control
and Prevention (CDC), came to the exact opposite conclusion – all apparently based on the same trials.8
Owing to the risk of reporting bias as a result of the large amounts of unpublished data there are
uncertainties about the stated benefits of oseltamivir and about the conclusions of previous Cochrane reviews
of NIs in adults and children.9,10 To address this, we worked for 4 years to obtain full CSRs of the oseltamivir
trial programme. CSRs are considered to be the most exhaustive summaries of randomised controlled trials
(RCTs) of drugs. They are usually composed of a main report of the trial (in introduction, methods, results and
discussion style), with numerous appendices containing important supplementary data that are needed to
understand and interpret the trial [e.g. protocol, protocol amendments, statistical analysis plan (SAP), blank
case report forms (CRFs), certificates of analysis, randomisation list and informed consent forms].11 In the case
of oseltamivir, CSRs were of a mean length of approximately 1300 pages (median around 900 pages). As a
result of increasing availability, CSRs may in the future be incorporated into systematic reviews and other
forms of evidence synthesis.12,13
Rationale for this review
In the midst of the A/H1N1 influenza outbreak in June 2009, the Australian and UK governments
commissioned an update of our long-standing Cochrane review on NIs for influenza in (otherwise) healthy
adults (known as A047). At the time of publication of the 2009 update and its linked investigation by the
British Medical Journal (BMJ), we underestimated the extent of the oseltamivir evidence development
programme, expecting it to comprise around 36 trials, with only a proportion of these fitting our inclusion
criteria. We were also unaware of the size and the level of detail that the CSRs contained.
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Today, the obvious source of information on CSRs would be trial registries and company websites, but
most trials of both NIs were carried out before inception or wide acceptance of centralised registries and
company websites. In 2009–11, company websites did not, and still do not, have extensive lists of trials
with downloadable CSRs. Many people had never heard of CSRs before media coverage of our work. We
decided to construct our list by using multiple cross-referencing methods. We constructed a list beginning
with clinical trials that were identified from previous review updates.
To ensure that the list did not include duplicate entries, we assigned to each trial a unique trial ID. ‘Author’
was insufficient to provide a unique trial ID, because different authors can be present across different
versions of the same trial (i.e. the authors of CSRs can be different from publications arising from the same
clinical trial).
Once we had as complete a list of trials as possible, we contacted manufacturers and sent them our draft
list, asking them to check the accuracy and completeness of our list. Roche, GSK and BioCryst all did so,
and informed us of additional trials.
We requested from Roche and GSK a series of regulatory documents under freedom of information (FOI)
policies from both the FDA and the EMA. No substantial comments were made by Roche on the protocol
of the Cochrane A159 review,14 which has been publicly available since December 2010.
Soon after the publication of the review, the BMJ agreed to publish our correspondence with Roche, GSK,
EMA, CDC and World Health Organization (WHO), recording our attempts at retrieving the full reports
without any conditions attached, and to understand the basis for promotion of the drugs (especially
oseltamivir) by public health bodies. The correspondence (which is hundreds of pages long) formed the
basis for what then became the BMJ Open Data Campaign and a stimulus for the later AllTrials campaign.
Public exposure of this approach and considerable media coverage led to the unconditional release of
77 reports of oseltamivir of 82 studies sponsored by Roche and the equivalent of the 30 studies we had
requested from GSK. For the full correspondence, see www.bmj.com/tamiflu and www.bmj.com/relenza.
The reports (amounting to over 100,000 pages) are made available with this review for the first time at:
https://datadryad.org/resource/doi:10.5061/dryad.77471/2, a positive step for open science. We have
described the posting of these reports in a blog posting at: http://blog.datadryad.org/2014/04/17/
tamiflu-data/, and a list of neuraminidase reviews, with peer review comments and responses relevant
to review A159,14 is available at www.bmj.com/content/suppl/2014/04/09/bmj.g2545.DC1/
jeft017746.ww8_default.pdf.
Before receiving the full reports, we resumed reviewing the remainder of the material that we had received
in 2011. This mainly consisted of module 2s (Roche terminology for pre-study documents). Module 2s
contained the information that was originally unavailable to us from Roche: study protocols with their
amendments, randomisation lists, blank CRFs, certificates of analysis describing appearance and content of
active and control capsules and, at times, SAPs. CRFs are containers for the rawest form of recorded data
at the individual participant level.
While designing the tool to capture trial methods and assess bias, we also considered whether or not
access to module 2 information (and later the full study reports) changed our perception of the trial and
specifically our ‘risk-of-bias’ assessment. We found that access to what are supposed to be full study
reports should provide clarity and remove the rationale for ‘unclear’ risk-of-bias judgements, and ideally
remove the concept of risk leaving just ‘bias’, at least for certain study design elements, such as attrition
bias. Either a design element introduces bias or it does not. In the case of the 15 full oseltamivir CSRs we
reviewed when constructing our tool, only one report contained a protocol that predated the beginning
of participant enrolment, only two reports had SAPs that clearly predated participants’ enrolment and
three reports had clearly dated protocol amendments. No CSR reported a clear date of unblinding.
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During the latter part of 2013, we received from the manufacturers tens of thousands of pages of full
CSRs for both programmes combined.
These events form the basis for this review.
Aims and objectives
The main goals of the reviews included in this report were to:
1. describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all CSRs of
published and unpublished randomised, placebo-controlled trials and regulatory comments
2. determine the effect of oseltamivir on mortality in patients with 2009A/H1N1 influenza.
Research questions
The research questions addressed in this report are as follows:
l What are the potential benefits and harms of NIs for the prevention and treatment of influenza in
adults and children?
l Does influenza virus-specific mechanism of action proposed by the producers fit the clinical evidence?
l Does treatment with oseltamivir confer protection against mortality in patients with 2009A/
H1N1 influenza?
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Chapter 2 Neuraminidase inhibitors for preventing
and treating influenza in adults and children
Abstract
Background
Neuraminidase inhibitors are stockpiled and recommended by public health agencies for treating and
preventing seasonal and pandemic influenza. They are used clinically worldwide.
Objective
To describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all CSRs of
published and unpublished randomised, placebo-controlled trials and regulatory comments.
Search methods
We searched trial registries, electronic databases (to 22 July 2013) and regulatory archives, and corresponded
with manufacturers to identify all trials. We also requested CSRs. We focused on the primary data sources of
manufacturers but we checked that there were no published RCTs from non-manufacturer sources by running
electronic searches in the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, MEDLINE (via Ovid), EMBASE, EMBASE.com, PubMed (not MEDLINE), Database of Abstracts of
Reviews of Effects (DARE), NHS Economic Evaluation Database (NHS EED) and Health Economic Evaluations
Database (HEED).
Selection criteria
Randomised, placebo-controlled trials on adults and children with confirmed or suspected exposure to
naturally occurring influenza.
Data collection and analysis
We extracted CSRs and assessed risk of bias using purpose-built instruments. We analysed the effects of
zanamivir and oseltamivir on time to first alleviation of symptoms, influenza outcomes, complications,
hospitalisations and adverse events in the intention-to-treat (ITT) population. All trials were sponsored by
the manufacturers.
Main results
We obtained 107 CSRs from the EMA, GSK and Roche. We accessed comments by the FDA, EMA and
Japanese regulator. We included 53 trials in stage 1 (a judgement of appropriate study design) and 46 in
stage 2 (formal analysis), including 20 oseltamivir (9623 participants) and 26 zanamivir trials (14,628
participants). Inadequate reporting put most of the zanamivir studies and half of the oseltamivir studies at
a high risk of selection bias. There were inadequate measures in place to protect 11 studies of oseltamivir
from performance bias due to non-identical presentation of placebo. Attrition bias was high across the
oseltamivir studies and there was also evidence of selective reporting for both the zanamivir and
oseltamivir studies. The placebo interventions in both sets of trials may have contained active substances.
Time to first symptom alleviation
For the treatment of adults, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours
[95% confidence interval (CI) 8.4 to 25.1 hours; p< 0.0001]. This represents a reduction in the time to first
alleviation of symptoms from 7 to 6.3 days. There was no effect in asthmatic children, but in otherwise
healthy children there was a reduction by a mean difference (MD) of 29 hours (95% CI 12 to 47 hours;
p= 0.001). Zanamivir reduced the time to first alleviation of symptoms in adults by 0.60 days (95% CI 0.39
to 0.81 days; p< 0.00001), equating to a reduction in the mean duration of symptoms from 6.6 to
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6.0 days. The effect in children was not significant. In subgroup analysis we found no evidence of a
difference in treatment effect for zanamivir on time to first alleviation of symptoms in adults in the
influenza-infected and non-influenza-infected subgroups (p= 0.53).
Hospitalisations
Treatment of adults with oseltamivir had no significant effect on hospitalisations [risk difference (RD)
0.15%, 95% CI –0.78% to 0.91%]. There was also no significant effect in children or in prophylaxis.
Zanamivir hospitalisation data were unreported.
Serious influenza complications or those leading to study withdrawal
In adult treatment trials, oseltamivir did not significantly reduce those complications classified as serious or
those that led to study withdrawal (RD 0.07%, 95% CI –0.78% to 0.44%), or in child treatment trials;
neither did zanamivir in the treatment of adults or in prophylaxis. There were insufficient events to
compare this outcome for oseltamivir in prophylaxis or zanamivir in the treatment of children.
Pneumonia
Oseltamivir significantly reduced self-reported, investigator-mediated, unverified pneumonia [RD 1.00%,
95% CI 0.22% to 1.49%, number needed to treat to benefit (NNTB) 100, 95% CI 67 to 451] in the
treated population. The effect was not significant in the five trials that used a more detailed diagnostic
form for pneumonia. There were no definitions of pneumonia (or other complications) in any trial. No
oseltamivir treatment studies reported effects on radiologically confirmed pneumonia. There was no
significant effect on unverified pneumonia in children. There was no significant effect of zanamivir on
either self-reported or radiologically confirmed pneumonia. In prophylaxis, zanamivir significantly reduced
the risk of self-reported, investigator-mediated, unverified pneumonia in adults (RD 0.32%, 95% CI 0.09%
to 0.41%; NNTB 311, 95% CI 244 to 1086) but not oseltamivir.
Bronchitis, sinusitis and otitis media
Zanamivir significantly reduced the risk of bronchitis in adult treatment trials (RD 1.80%, 95% CI 0.65% to
2.80%; NNTB 56, 95% CI 36 to 155), but not oseltamivir. Neither NI significantly reduced the risk of otitis
media and sinusitis in both adults and children.
Harms of treatment
Oseltamivir in the treatment of adults increased the risk of nausea [RD 3.66%, 95% CI 0.90% to 7.39%;
number needed to treat to harm (NNTH) 28, 95% CI 14 to 112] and vomiting (RD 4.56%, 95% CI
2.39% to 7.58%; NNTH 22, 95% CI 14 to 42). The proportion of participants with fourfold increases in
antibody titre was significantly lower in the treated group than in the control group (RR 0.92, 95% CI 0.86
to 0.97; I2 statistic= 0%) (5% absolute difference between arms). Oseltamivir significantly decreased the
risk of diarrhoea (RD 2.33%, 95% CI 0.14% to 3.81%; NNTB 43, 95% CI 27 to 709) and cardiac events
(RD 0.68%, 95% CI 0.04% to 1.0%; NNTB 148, 95% CI 101 to 2509) compared with placebo during the
on-treatment period. There was a dose–response effect on psychiatric events in the two oseltamivir ‘pivotal’
treatment trials: WV15670 and WV15671, at 150mg (standard dose) and 300mg daily (high dose)
(p= 0.038). In the treatment of children, oseltamivir induced vomiting (RD 5.34%, 95% CI 1.75% to
10.29%; NNTH 19, 95% CI 10 to 57). There was a significantly lower proportion of children on oseltamivir
with a fourfold increase in antibodies (RR 0.90, 95% CI 0.80 to 1.00; I2 statistic= 0%).
Prophylaxis
In prophylaxis trials, oseltamivir and zanamivir reduced the risk of symptomatic influenza in individuals
(oseltamivir RD 3.05%, 95% CI 1.83% to 3.88%; NNTB 33, 95% CI 26 to 55; zanamivir RD 1.98%,
95% CI 0.98% to 2.54%; NNTB 51, 95% CI 40 to 103) and in households (oseltamivir RD 13.6%,
95% CI 9.52% to 15.47%; NNTB 7, 95% CI 6 to 11; zanamivir RD 14.84%, 95% CI 12.18% to 16.55%;
NNTB 7, 95% CI 7 to 9). There was no significant effect on asymptomatic influenza (oseltamivir, RR 1.14,
95% CI 0.39 to 3.33; zanamivir RR 0.97, 95% CI 0.76 to 1.24). Non-influenza, influenza-like illness (ILI)
could not be assessed as a result of data not being fully reported. In oseltamivir prophylaxis studies,
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psychiatric adverse events were increased in the combined on- and off-treatment periods (RD 1.06%, 95%
CI 0.07% to 2.76%; NNTH 94, 95% CI 36 to 1538) in the study treatment population. While on
treatment, oseltamivir increased the risk of headaches (RD 3.15%, 95% CI 0.88% to 5.78%; NNTH 32,
95% CI 18 to 115), renal events (RD 0.67%, 95% CI –0.01% to 2.93%; NNTH 150, NNTH 35 to NNTB
> 1000) and nausea (RD 4.15%, 95% CI 0.86% to 9.51%; NNTH 25, 95% CI 11 to 116).
Authors’ conclusions
Oseltamivir and zanamivir have small, non-specific effects on reducing the time to alleviation of influenza
symptoms in adults, but not in asthmatic children. Using either drug as prophylaxis reduces the risk of
developing symptomatic influenza. Treatment trials with oseltamivir or zanamivir do not settle the question
of whether or not the complications of influenza (such as pneumonia) are reduced, because of a lack of
diagnostic definitions. The use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting,
psychiatric effects and renal events in adults and vomiting in children. The lower bioavailability may explain
the lower toxicity of zanamivir compared with oseltamivir. The balance between benefits and harms should
be considered when making decisions about use of both NIs for either the prophylaxis or treatment of
influenza. The influenza virus-specific mechanism of action proposed by the manufacturers does not match
the observed clinical evidence.
Background
This review (known as A159) reports our work using unpublished CSRs (see Appendix 1, Glossary) and
regulatory documents containing comments and reviews to evaluate the safety and efficacy of NIs.
We have called the body of clinical studies and regulatory comments ‘regulatory information’.
For the history and evolution of the review, see Appendix 1.
Description of the condition
Influenza is mostly a mild, self-limiting infection of the upper airways with local symptoms, including
sniffles, nasal discharge, dry cough and sore throat, and systemic symptoms such as fever, headache, aches
and pains, malaise and tiredness.
Occasionally, patients with influenza develop complications such as pneumonia, otitis media and
dehydration or encephalopathy with or without liver failure, which may be due to the effects of the
influenza virus itself or associated secondary bacterial infections and/or adverse effects of drugs such as
antipyretics [including salicylates and other non-steroidal anti-inflammatory drugs (NSAIDs)].15
Influenza is not clinically distinguishable from ILI.16 Epidemic influenza in humans is caused by influenza A
and B viruses. Currently, influenza A/H1N1, influenza A/H3N2 and influenza B cause most influenza
infections worldwide.12
Description of the intervention
Neuraminidase inhibitors comprise inhaled zanamivir (Relenza®, GSK), oral oseltamivir (Tamiflu®, Gilead
Sciences and F. Hoffman-La Roche), parenteral peramivir (Rapivab®, BioCryst Ltd), inhaled laninamivir
(Inavir®, Daiichi Sankyo Co. Ltd)17 and others still under development.18 The use of NIs has increased
dramatically since the outbreak of A/H1N1 in April 2009, partly because of the rise in amantadine
(Symmetrel®, Endo Pharmaceuticals Inc.)/rimantadine (Flumadine®, Forest Pharmaceuticals Inc.) resistance
and, in the early stages of the outbreak, the lack of a vaccine, which meant that NIs became a widespread
public health intervention. WHO had previously encouraged member states to stockpile and gain
experience of using NIs.19–21
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How the intervention might work
Although NIs may reduce the ability of the virus to penetrate the mucus in the very early stage of
infection,6,22–24 their main mechanism of action is thought to lie in their ability to inhibit influenza viruses
from exiting host cells.23,25 The manufacturers state that oseltamivir does not prevent infection or affect
antibody production,26 but it reduces symptom duration probably by reducing viral load, spread and
release of cytokines,8,27 diminishing the chance of complications and interrupting person–person viral
spread. Oseltamivir phosphate (Tamiflu) is the prodrug of oseltamivir carboxylate, the effective form.
Oseltamivir phosphate dissociates in the gastrointestinal tract to form oseltamivir, which is absorbed and
metabolised into oseltamivir carboxylate by hepatic carboxylesterase. Oseltamivir may have a central
depressant action15 and may also inhibit human sialidase,28 causing abnormal behaviour. Inhaled zanamivir
reaches a far lower plasma concentration than its intravenous administration.29
Any treatment that reduces the complications of influenza (e.g. pneumonia) and the excretion of the virus
from infected people might be a useful public health measure to contain an epidemic by limiting the
impact and spread of the virus. In addition to symptomatic treatment, prophylactic use for interrupting the
spread of disease has informed pandemic planning over the past decade.
Why it is important to do this review
There are three major reasons for conducting this review, in addition to questions of efficacy associated
with the clinical use of NIs for influenza:
1. Influenza antivirals are a commonly used and stockpiled drug against past and future pandemics on the
basis of international and national recommendations. These recommendations are based on the
claimed and assumed ability of the drug to reduce complications and transmission.2,3 In theory,
containing the spread of influenza allows time for an organised response with longer-term interventions
(such as vaccines), which take time to produce.3
2. The risk of reporting bias and publication bias leads to uncertainty about the effects of NIs and the
results of previous Cochrane reviews of NIs in adults6,10,30,31 and children.32
3. Oseltamivir is now on the list of WHO essential drugs.33,34
Process
Review A159 is an amalgamation of two long-standing Cochrane reviews on the effects of NIs for
influenza in healthy adults14 (also published in the BMJ31) and children,35 and it is based on the assessment
of trials through their CSRs and other regulatory information; a decision we made after finding substantial
reporting bias in the journal publications of the relevant trials.
For the full rationale for this process, see Appendix 1.
Examples of discrepancies and reporting bias
We identified that 60% (3145/5267) of patient data from randomised, placebo-controlled, Phase III
treatment trials of oseltamivir have never been published. This includes M76001,36 the biggest treatment
trial ever undertaken on oseltamivir (with just over 1400 people of all ages). Exclusion of unpublished
data changed our previous findings regarding the ability of oseltamivir to reduce the complications
of influenza.8,31 In some cases, mistakes in the attribution of adverse events were discovered only through
matching summary tables with individual participant listings.37–39
A modified approach
We have modified the routine Cochrane processes to improve our previous methods, which we now
consider to be inadequate. To resolve inconsistencies and under-reporting, we changed our approach
by no longer including trial data as reported in papers published in biomedical journals. Instead, we treated
CSRs as our basic unit of analysis. CSRs are often sent to national drug regulators, such as the FDA and
the EMA (formerly the European Agency for the Evaluation of Medicinal Products), which require far more
stringent standards for completeness and accuracy of reporting than biomedical journals. Journal articles
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can be regarded as a very succinct synthesis of a CSR. In addition to seeking CSRs, we decided to read and
review regulatory documentation. The FDA in particular (and the EMA to a far lesser extent) makes many
of its scientific reviews available on its website. Unlike Cochrane review authors, regulators can have access
to the whole data set and their comments can provide useful insight, helping to achieve a better
understanding of trial programmes.
Clinical study reports generally remain hidden from public view and are not readily available for wider
scientific scrutiny, despite the wealth of information that they contain for those willing and able to spend
the time reading them and despite calls to make all relevant trial data public,11,40 as well as the known
problems with reporting biases.41,42
Implications
This modified approach to a Cochrane review aims to provide patients, clinicians and policy-makers
with the most transparent and independent information possible about NIs for influenza. In addition,
it should contribute to improving a European regulatory and pharmacovigilance legal framework, which
commentators consider weak.40,43 We believe that as NIs have become public health drugs, recommended
and stockpiled globally, independent scrutiny of all of the evidence relating to harms and effects on
complications is necessary to provide patients, policy-makers and physicians with a complete and unbiased
view of their risks and benefits.
Implication for A/H1N1 (2009) influenza
In response to our 2010 review,14,31 some have argued that its findings cannot be applied to the 2009
A/H1N1, suggesting that it is a new virus and that, we thus need new evidence.44–48 Novel A/H1N1 is a
new strain of a subtype that has been circulating since 1977, but it also resembles the A/H1N1 strain that
has been circulating since before 195749 or before the 1918 pandemic.50 Influenza subtype A/H1N1 was
indeed circulating at the time when the clinical trials, included in our previous reviews, were recruiting.
In addition, oseltamivir and zanamivir were approved by regulators worldwide for the treatment and
prevention of influenza types A and B, not specific subtypes or strains of influenza A and B. The
expectation of regulatory approval is thus that the effects of these drugs demonstrated in clinical trials
will apply to future strains of influenza A and B. Use of these drugs during the pandemic was not off-label.
It was approved use on the assumption that the clinical trial evidence underpinning regulatory approval
applied to novel A/H1N1. We reviewed the clinical trial evidence with the expectation that our results,
similar to regulators, will apply to all influenza viruses.
Wider implications
The modified approach in this Cochrane review developed from the realisation that prior methods used to
review NIs were inadequate. There is little reason to think that the lessons learned are limited to these
particular drugs.40,42,51–53 On this basis, our independent scrutiny, using all possible trial information, may
inform both the wider debate on the adequacy of existing regulatory frameworks in the adoption of new
drugs and the question of whether or not other systematic reviews should move to this new, more
rigorous, approach, which focuses on trial programmes rather than single trials54,55 (see Appendix 1,
Glossary). Although there is substantial evidence for the effects of reporting bias in estimates of
effectiveness, less is known of its impact on the evidence of harms.56 We decided to quantify the
additional resources required to follow our modified methodological approach to assess the feasibility of
other systematic reviews proceeding in a similar fashion.
Objective
To describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all CSRs of
published and unpublished randomised, placebo-controlled trials and regulatory comments.
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Methods
Criteria for considering studies for this review
Types of studies
We included evidence from RCTs testing the effects of NIs for prophylaxis, post-exposure prophylaxis (PEP)
and treatment of influenza. Prophylaxis is the mode of use of NIs when there is expectation of possible
near-future exposure to influenza.
Post-exposure prophylaxis is the use of NIs following probable exposure to influenza but before symptoms
develop. Treatment is the use of NIs in persons showing probable signs of influenza.
Owing to discrepancies between published and unpublished reports of the same trials, we included only
those trials for which we had unabridged CSRs (e.g. with consecutively numbered pages), even though
they may be parts of CSRs (i.e. module 1 only) and information on reports of trials that were considered
‘pivotal’ (i.e. first- or second-line evidence to regulators in support of the registration application).
Types of participants
We included previously healthy people (children and adults). ‘Previously healthy’ includes people with chronic
illness (such as asthma, diabetes, hypertension), but excludes people with illnesses with more significant
effects on the immune system (such as malignancy or human immunodeficiency virus infection). We included
only trials on people who were exposed to naturally occurring influenza with or without symptoms. We
targeted the ITT and safety populations, as our prior review discovered compelling evidence that the
intention-to-treat-influenza-infected (ITTI) subpopulation – the subpopulation deemed to be influenza-
infected – was not balanced between treatment groups in the Roche oseltamivir trials. In addition, estimates
from the ITT population will be more generalisable to clinical practice, where routine testing for influenza is
not common in many countries (and even where it is used is of variable accuracy).
Types of interventions
Neuraminidase inhibitors administered by any route compared with placebo during the period in which
medication was assumed and during the follow-up (on- and off-treatment) periods.
Types of outcome measures
Primary outcomes
Primary outcome measures for treatment studies
1. Symptom relief.
2. Hospitalisation and complications.
3. Harms.
Primary outcome measures for prophylaxis studies
1. Influenza (symptomatic and asymptomatic, always with laboratory confirmation) and ILI.
2. Hospitalisation and complications.
3. Interruption of transmission (in its two components, reduction of viral spread from index cases and
prevention of onset of influenza in contacts).
4. Harms.
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Secondary outcomes
Secondary outcome measures for treatment studies
1. Symptom relapse after finishing treatment.
2. Drug resistance.
3. Viral excretion.
4. Mortality.
Secondary outcome measures for prophylaxis studies
1. Drug resistance.
2. Viral excretion.
3. Mortality.
Although overall symptom reduction is well documented, our interest was particularly focused on
complications and adverse events, as this is where evidence is currently scarce or inconclusive.31,32 Our
preliminary examination of some regulatory documents and some published versions of the studies had
identified that some symptoms and sequelae of influenza (such as pneumonia) had been classified as
either a ‘complication of influenza’ or as an ‘adverse event of the treatment’, or both. This is somewhat
confusing and we intended to analyse ‘compliharms’ (see Appendix 1, Glossary) irrespective of the
classification as a ‘complication of influenza’ or as an ‘adverse event of the treatment’ (see Appendix 2) in
oseltamivir trials. Complications of particular interest included pneumonia, bronchitis, otitis media and
sinusitis, as these were the secondary illnesses often collected in the Roche oseltamivir trials and we agreed
that these events are clinically important. Initially, we constructed a table to illustrate the design
methodology that was used for each complication by study (Table 1). The table included the following
variables: definition of which events are termed complications; where complications are first defined in the
CSR; diagnosis method; and availability of data. We then stratified our analysis by method of diagnosis
with three possible criteria: (1) laboratory-confirmed diagnosis (e.g. based on radiologically or
microbiologically confirmed evidence of infection); (2) clinical diagnosis without laboratory confirmation
(diagnosed by a doctor after a clinical examination); and (3) other type of diagnosis, such as self-reported
by patient. We conducted analysis of any complication (pneumonia, bronchitis, otitis media and sinusitis)
that was classified as serious or led to study withdrawal.
In all cases of influenza complications reporting (pneumonia, bronchitis, sinusitis, otitis media) there is a
variable degree of participant self-reporting, of investigator mediation (e.g. in writing down the details in
the CRF) and lack of verification with investigations, such as culture or imaging. The ‘self-reported,
investigator-mediated, unverified’ title is relevant to all complications but for brevity we use it as sparingly
as possible.
For harms, we were limited by the frequency of occurrence of the adverse events collected in the trials.
Consequently, we meta-analysed (1) all serious adverse events; (2) all adverse events leading to study
withdrawal; (3) all withdrawals; (4) all adverse events within a CSR’s defined body system; and (5) a small
group of common adverse events as defined in the FDA drug label for oseltamivir. There were too few
events to meta-analyse: (1) deaths; (2) serious adverse events by body system; and (3) any events that had
an overall incidence of < 0.5%. We did not meta-analyse outcomes with fewer than 10 events in total.
We conducted analyses separately for on-treatment and off-treatment periods. However, in two cases for
which (on-treatment) treatment effects were borderline statistically significant (prophylaxis with oseltamivir:
renal body system on-treatment and psychiatric body system on-treatment), we conducted additional
analysis combining on- and off-treatment periods to maximise statistical power. We conducted
dose–response harms analysis for two treatment trials8,58 combined and one prophylaxis study,59 as these
trials investigated the active agent at multiple doses. These studies8,58,59 included standard-dose and
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high-dose oseltamivir arms. For these analyses we used logistic regression, adjusting for study effects if
appropriate (i.e. for the two treatment trials8,58) and testing for trend using a likelihood ratio test. We
tested the hypothesis that increased dose of drug leads to increased incidence of adverse effects.
Search methods for identification of studies
To identify trials in the manufacturer-funded clinical trial programmes for NIs, as well as non-manufacturer-
funded clinical trials of NIs, we used a variety of methods that were applied to a variety of sources from
the literature, manufacturers and regulatory bodies. These methods, as well as our methodology for
identifying and obtaining relevant CSRs, are detailed in Appendices 1, 4 and 5.
Electronic searches
We used electronic searches to identify trials that were not identified by the methods outlined in
Appendix 1, particularly for non-manufacturer-funded clinical trials (see Appendix 3 for details). For the
2012 review, we updated our searches of the electronic databases of published studies that were
previously carried out for the Cochrane reviews on NIs in children35 and healthy adults,14 and then updated
the searches again on 22 July 2013.
Searching other resources
For the description of our searches for regulatory information (FDA, EMA, Roche, GSK, the Japanese
Pharmaceuticals and Medical Devices Agency), see Appendix 4.
Data collection and analysis
Collection and inventory of the evidence base was facilitated by the tools that were specifically developed
for the review (see Appendix 5). The overall risk of bias is presented graphically in Figure 1 and
summarised in Figure 2.
Selection of studies
For this 2013 review, two authors (PD and TJ) reapplied the inclusion criteria for the oseltamivir CSRs and
resolved disagreements by discussion. Two review authors (ES and IO) applied the criteria for the zanamivir
CSRs, whereas one review author (CH) arbitrated.
For the procedures followed in the 2012 review, see Appendix 7.
Data extraction and management
The sizeable quantity of available data led us to subdivide the extraction, appraisal and analysis of the data
into a two-stage exercise. In stage 1 we assessed the reliability and completeness of the identified trial
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Incomplete outcome data (attrition bias): symptoms
Incomplete outcome data (attrition bias):
complications of influenza
Incomplete outcome data (attrition bias): safety data
Selective reporting (reporting bias)
Other bias
Low risk of bias
Unclear risk of bias
High risk of bias
Blinding of participants and personnel
(performance bias)
0% 25% 50% 75% 100%
Blinding of outcome assessment (detection bias)
FIGURE 1 Risk-of-bias graph: review of authors’ judgements about each risk-of-bias item, presented as percentages
across all included studies. ‘Other bias’ includes potentially active placebos.
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FIGURE 2 Risk-of-bias summary: review of authors’ judgements about each risk-of-bias item for each included
study. ‘Other bias’ includes potentially active placebos. +, low risk of bias; –, high risk of bias.
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data. We decided to include in stage 2 of the review (full analysis following standard Cochrane methods)
only data that satisfied the following three criteria:
1. Completeness CSRs/unpublished reports include both identifiable CONSORT (Consolidated Standards of
Reporting Trials) statement-specified methods to enable replication of the study. Identifiable CONSORT
statement-specified results (primary outcomes, tables, appendices) must be available.
2. Internal consistency All parts (e.g. denominators) of the same CSRs/unpublished report are
broadly consistent.
3. External consistency Consistency of data as reported in regulatory documents, other versions of the
same CSRs/unpublished reports and other references, to be established by cross-checking.
This was a different approach to that used in the previous version of the current review,9 as we had only
incomplete information at that time and applied only the second and third criteria.
Stage 1
For details of the use of the CONSORT-based extraction template and the assessment for stage 1 inclusion
in the A159 review,9 see Appendix 5. In this review, assessment for inclusion in stage 1 was part of the
inclusion procedure.
Stage 2
In stage 2, one review author extracted data and a second review author checked it. We extracted data on
to standard forms, checked and recorded it.
Use of regulatory information
We used regulatory information to assess the possible correlation between citation frequency of oseltamivir
treatment trials in the FDA regulatory documents and trial size.
Post-protocol analyses
After publication of the A159 protocol in December 2010, but before validation of our CONSORT-based
extractions in the spring of 2011, we decided to carry out analyses (which we called post-protocol
analyses) to test five null hypotheses that we had formulated while reading, summarising and
reconstructing the CSRs. The hypotheses originated from our observations of discrepancies and other
unexpected observations in the CSRs’ data, and were informed by reading regulatory information.
Appendix 8 reports the rationale, methods to formulate and test, and the results of the hypotheses.
The hypotheses reflect the uncertainty prevailing in the evidence base at a time when full CSRs were not
available for all studies.
Assessment of risk of bias in included studies
Previous studies comparing regulatory with published or internal company sources of evidence have
reported a variety of different biases that affect medical knowledge.41,42,56,101 We will report in detail
elsewhere our comments on using the Cochrane risk-of-bias tool102 to appraise CSRs and for trial
programmes, and our efforts to construct an instrument for assessing risk of bias in complete CSRs.
A full description of the methods used to quantify biases will be published in another paper.
Measures of treatment effect
To estimate treatment effects we first calculated the risk ratios (RRs) and used the average (mean) control event
rate and the pooled RRs reported in the figures to calculate the RDs. For consistency, we adopted this method
for both the ‘Summary of findings’ tables and for the RDs reported in the text. For the analysis we chose to
report the RRs, as they are more consistent across the studies, and we have reported the heterogeneity for the
pooled RR. We reinterpreted the results using the RD, as this result is applicable to clinical decision-making.
We calculated MDs for time to first alleviation of symptoms. For time to first alleviation of symptoms we also
estimated the treatment effect as the percentage reduction in the average time to first alleviation of symptoms
in the placebo group. Most zanamivir CSRs stated treatment effects only in terms of medians in each treatment
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group, as well as p-values from a hypothesis test comparing the time-to-event distributions. These data are
insufficient for conducting a meta-analysis. However, often sufficient time-to-event data were reported to
allow us to estimate restricted means and standard deviations. Restricted means are based on the maximum
time reported where alleviation occurred. There were some patients for whom alleviation was censored at the
maximum follow-up time; therefore, restricted means are underestimates of the true means. However, the
proportion of patients who were censored was generally low and similar in both treatment arms, hence this
limitation is unlikely to have led to bias. The length of follow-up varied across trials and this has led to high
variation in the estimated means and standard deviations across trials.
A post hoc analysis was undertaken after we discovered seven zanamivir trials that provided data on time to
first alleviation of symptoms with and without relief medication. Each patient in the studies may or may not
have taken relief medication [e.g. paracetamol (acetaminophen)] during the trial. Alleviation of symptoms
may have occurred while the patient was taking relief medication and the ‘standard’ comparison was made
using this scenario. However, an additional analysis used a stricter definition, for which alleviation of
symptoms could be achieved only without the use of relief medication. For example, a patient may have
achieved alleviation using relief medication after 5 days but took 7 days to achieve alleviation without the
use of relief medication. The comparison we reported is for all patients for whom we used the stricter
definition for the zanamivir group (alleviation without relief medication) and the less-strict definition for the
placebo group (alleviation with relief medication).
We planned to use the tridimensional dose-relatedness, timing and patient susceptibility methodology to
assess the likelihood of harms causality,103 but the quality of the data available did not allow for this.
Unit of analysis issues
Problems with unit of analysis are described in ‘Post-protocol hypotheses’ (see Appendix 8).
Dealing with missing data
We developed a comprehensive strategy for dealing with data that we know are missing at the trial level,
that is, unpublished trials (see Search methods for identification of studies, above, and Appendices 1,
4 and 5) and unreliable published records, which are a very concentrated summary of CSRs. For example,
in the oseltamivir trial programme, some trials’ CSRs (e.g. WP16263104) consist of 8545 pages. This has a
1000-fold greater length than its published version,105 which consists of seven pages. The purpose of this
review is to provide as complete a picture as possible of trial programmes, without reliance on the
published literature. Appendix 9 reports an example of the content of a typical Roche CSR.
Assessment of heterogeneity
We used tau-squared (inverse variance method) and the I2 statistic to estimate between-study variance as
measures of the level of statistical heterogeneity, and the chi-squared test to test for heterogeneity.
Assessment of reporting biases
We carried out assessment of reporting biases (comparing CSR with the relevant publication) only in the
first publication of A159.106 For this version, as we had complete CSRs for the trial programmes of the two
drugs, we expected to find all of the relevant information in these documents and adopted a binary
assessment (high risk, low risk or unclear bias).
Data synthesis
We used the random-effects approach of DerSimonian and Laird107 based on MDs for analysis of time to
first alleviation of symptoms. For all of the other outcomes we used the random-effects approach for
binary data of DerSimonian and Laird107 where tau-squared was estimated using the inverse
variance method.
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Although overall symptom reduction is well documented, our interest was particularly focused on
complications and adverse events, as this is where evidence is currently scarce or inconclusive.31,32,35
Our preliminary examination of CSRs identified that some symptoms and sequelae of influenza (such as
‘pneumonia’) had been classified as either a ‘complication of influenza’ or as an ‘adverse event of the
treatment’, or both. We called this somewhat confusing classification ‘compliharms’. We decided to deal
with compliharms as follows. We identified complications of particular clinical interest as ‘pneumonia’,
bronchitis, otitis media and sinusitis. We tabulated the type of data capture used for each complication
(‘secondary illness’) by study, including the following variables: definition of what events are termed
complications; which part of the CSR captured data on complications; who reported and captured the
data; which diagnostic method was used; whether or not, and where, the diagnostic pathway was (usually
a form); and whether or not prescriptions for treatment were captured. We then aimed to stratify our
analysis by method of diagnosis with three possible criteria: (1) laboratory-confirmed diagnosis (e.g. based
on radiologically or microbiologically confirmed evidence of infection); (2) clinical diagnosis without
laboratory confirmation (diagnosed by a doctor/investigator after a clinical examination); and (3) other type
of diagnosis, such as self-reported by patient. We also conducted analysis of any complication (such as
‘pneumonia’, bronchitis, otitis media and sinusitis) that was classified as serious or led to study withdrawal.
We tested the effects of oseltamivir in prophylaxis of influenza and ILI. However, the CSRs of prophylaxis
trials do not define ILI but report eight different definitions for influenza with laboratory confirmation
(see web extra influenza definitions, Appendix 11).
This is a complex and confusing set of definitions, in which, for example, the definition for upper
respiratory tract infection with systemic disturbance is the same as one of the definitions for asymptomatic
influenza. After discovering the absence of a definition for ILI, and the complex and confusing definitions
for laboratory-confirmed influenza, we classified ILI as having two or more symptoms from the following:
nasal congestion, headache, chills/sweats, sore throat, cough, fatigue, myalgia and fever. These were the
symptoms reported in the efficacy listing of individual patients in module 3 of the prophylaxis trials CSRs.
In two oseltamivir treatment trials8,58 and one prophylaxis study59 there were three treatment arms
comparing placebo, standard dose and high dose. For time to first alleviation of symptoms, we restricted
comparison to placebo against standard dose (as this is how it was reported in the original report).
However, for all other outcomes we combined the standard and high-dose treatment arms. There was
little apparent difference in the incidence of outcomes between the standard- and high-dose arms, and
combining the arms did not appear to cause heterogeneity. However, in two cases there was some
evidence of a dose–response effect. These cases are described more fully below (see Results, Analysis
of harms).
The majority of zanamivir trials compared placebo with inhaled zanamivir. However, some trials also
included an intranasal zanamivir treatment arm and a combined arm of inhaled and intranasal treatment.
The multiple zanamivir arms were generally combined for meta-analysis, as effects appeared similar and
did not appear to cause heterogeneity.
Subgroup analysis and investigation of heterogeneity
We investigated the robustness of complications outcomes using subgroup analysis by method of
diagnosis. We investigated high estimates of heterogeneity, where possible, using subgroup analysis.
For example, we conducted a subgroup analysis of time to first alleviation of symptoms in studies of
oseltamivir treatment in children by partitioning studies into those of otherwise healthy children and those
of children with chronic illness (asthma). Based on a referee’s comment, we conducted a subgroup analysis
on time to first alleviation of symptoms by infection status for zanamivir. We could not do a similar analysis
for oseltamivir because we did not have data on the non-influenza-infected patients, and we could not
correctly identify the patients with influenza infection as a result of the effect of oseltamivir on antibodies.
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In the trial programmes for both oseltamivir and zanamivir there was large variation in treatment effects for
pneumonia across the populations studied (i.e. adults and children, as well as treatment and prophylaxis),
hence we conducted a metaregression to investigate this heterogeneity. We included all of the studies that
reported pneumonia (32 studies in total) and investigated the four binary factors: age group (adults vs.
children), drug (oseltamivir vs. zanamivir): indication (treatment vs. prophylaxis) and method of diagnosis.
For oseltamivir studies, the method of diagnosis was based on either data collected on non-specific adverse
events or secondary/intercurrent illness forms, or data collected on specific ‘diagnosis of secondary illness’
forms that included objective criteria such as X-ray confirmation. For zanamivir, two trials included X-ray
confirmation of pneumonia. We conducted the metaregression in Stata/SE, version 13 for Windows
(StataCorp LP, College Station, TX, USA) using the metareg command. There were some studies where one
treatment group had zero events, therefore we added 0.5 events to all treatment groups for all studies prior
to analysis. The dependent variable in the regression was log-relative risk. A further post hoc analysis was
undertaken after we discovered that seven trials provided data on time to first alleviation of symptoms with
and without relief medication. Each patient in the studies may or may not have taken relief medication
during the trial. Alleviation of symptoms may have occurred while the patient was taking relief medication,
and the ‘standard’ comparison was made using this scenario. However, an additional analysis used a stricter
definition, for which alleviation of symptoms could be achieved only without the use of relief medication.
For example, a patient may have achieved alleviation using relief medication after 5 days but took 7 days to
achieve alleviation without the use of relief medication. The comparison we reported is for all patients, for
which we used the stricter definition for the zanamivir group (alleviation without relief medication) and the
less strict definition for the placebo group (alleviation with relief medication).
Sensitivity analysis
Sensitivity analyses applicable to our post-protocol analyses have been covered above (see Methods).
We used the fixed-effect method of Mantel and Haenszel as a sensitivity analysis to supplement our primary
analyses using the random-effects method of DerSimonian and Laird.107 Random-effects meta-analysis is
known to be overly conservative with sparse data. Hence, we conducted sensitivity analysis using Peto’s
method on two occasions for which we had sparse data and borderline statistically significant results
(prophylaxis with oseltamivir: renal body system on-treatment and psychiatric body system on-treatment).
Results
Description of studies
We searched trial registries, electronic databases and regulatory archives, and corresponded with
manufacturers to identify all trials and requested CSRs. Although this review focuses on the primary data
sources of manufacturers, we checked that there were no published RCTs from non-manufacturer sources
by running electronic searches in the following databases: CENTRAL 2013, Issue 6, limited to year published
2010–13 (20 search results); MEDLINE (January 2011 to July week 2, 2013) (56 search results) and MEDLINE
(via Ovid) from 1 January 2011 to July week 2, 2013 (56 search results); EMBASE (January 2011 to July 2013)
(90 search results) and EMBASE.com from 1 January 2011 to July 2013 (90 search results); and PubMed (not
MEDLINE) with no date limit (21 records). We searched PubMed to identify publisher-submitted records that
will never be indexed in MEDLINE and the most recently added records not yet indexed in MEDLINE. To
identify reviews that may possibly have referenced further trials we searched DARE 2013, Issue 2 of 4 April
(four search results); NHS EED, Issue 2 of 4 April 2013 (two search results); both resources parts of The
Cochrane Library (accessed 22 July 2013); and HEED (searched 22 July 2013) (three search results).
Results of the search
Use of regulatory information
We were able to download 2673 pages from the FDA website. The table of contents (TOC) is provided in
Tables 2–5. We used these pages to identify all of the trials that had been conducted within a drug’s trial
programme. There was no correlation between citation frequency of oseltamivir treatment trials in the
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TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the FDA (USA)
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
113502
113625
113678
114045
NAI108166
105934
NAI106784
107485
108127
112311
112312
113268
GCP/95/045
NAI10901 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin2.pdf
15.15
NAI10902
NAI3000877 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin2.pdf
15 Seven documents with
14 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin3.pdf
13
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
19, 19, 20
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
1, 1, 3, 4, 4
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview9.pdf
7.7
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/
21036ltr.pdf
2
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_MEDR.pdf
33
NAI3000978 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
1.2 Seven documents with
110 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P1.pdf
10, 10, 12, 13, 13, 14, 14, 17,
29, 42, 61, 62, 64, 64, 65, 65, 68
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TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the
FDA (USA) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P2.pdf
33, 34, 36, 43, 43, 43, 43, 52,
52, 52, 53, 53, 56, 57
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
5, 5, 5, 6, 6, 8, 8
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_MEDR.pdf
3, 3, 3, 3, 3, 3, 3, 4, 4, 5, 8, 9,
9, 10, 10, 11, 11, 11, 14, 14,
15, 16, 17, 19, 19, 19, 20, 20,
22, 23, 23, 23, 24, 24, 24, 25,
25, 25, 25, 25, 25, 26, 26, 26,
27, 27, 28, 28, 28, 29, 29, 31,
31, 31, 31
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_MICROBR.pdf
3, 3, 4, 4, 4
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_STATR.pdf
2, 2, 2, 4, 7, 12, 18, 18, 18, 19
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P1.pdf
31.56 One document with two
instances
NAI3001079 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
1.2 Six documents with 65
instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P1.pdf
10, 12, 13, 14, 14, 15, 17, 62,
62, 62, 64
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P2.pdf
34, 34, 36, 43, 53
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
5, 5, 6, 6
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_MEDR.pdf
3, 3, 3, 3, 3, 4, 5, 18, 19, 21,
21, 22, 23, 23, 23, 23, 24, 25,
25, 25, 26, 26, 26, 26, 27, 27,
27, 28, 28, 29, 29, 29, 30, 31,
31, 31, 32
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_STATR.pdf
2, 2, 13, 13, 13, 19
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
6 One document with one
instance
continued
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TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the
FDA (USA) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
NAI3001281 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
1 One document with one
instance
NAI3001582
NAI3002083
NAI3002884
NAI3003486
NAI40012
NAIA1009 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P1.pdf
56 Four documents with
17 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P2.pdf
1, 1, 1, 48, 49, 52
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
5, 5, 6
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_MEDR.pdf
3, 3, 6, 7, 20, 31, 31
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
18 Five documents with five
instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
9
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P2.pdf
52
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
11
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_STATR.pdf
2
NAIA300291 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin1.pdf
15 Thirteen documents with
122 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin2.pdf
6, 6, 7, 7, 14, 15, 22, 22, 23
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin3.pdf
1, 4, 4, 12, 12, 12, 12, 17
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview1.pdf
4, 14, 14, 14, 14, 14, 15, 15,
15, 15, 16
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TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the
FDA (USA) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview2.pdf
1, 2, 3, 4, 4, 5, 6, 6, 6, 8, 8, 9,
9, 9, 12, 12, 15, 16, 16, 16, 17
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview3.pdf
5, 5, 6, 6, 6, 7, 7, 7, 8, 8, 9, 9,
9, 10, 11, 12, 13, 13, 14, 15,
15, 17, 18, 18, 19, 20, 21
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview4.pdf
1, 1, 1, 1, 2, 6
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
4, 5, 10, 12
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
1, 1, 2, 2, 2, 2, 3, 3, 4, 4, 5, 5,
7, 8, 10, 11, 12, 14, 16, 16, 16,
16, 16, 17
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
2, 2, 6, 6, 8, 8, 9, 10
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview9.pdf
10
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
stats.pdf
7
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
5
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview1.pdf
15 One document with one
instance
NAIA300392 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
17, 17, 18 Three documents with six
instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
4.4
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview9.pdf
22
NAIA300493 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin3.pdf
14 Four documents with
eight instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
7
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TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the
FDA (USA) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
18, 18, 19
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
4, 4, 4
NAIA300594 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin3.pdf
14 Five documents with
12 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview1.pdf
5
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
12, 12, 12, 13, 14, 15, 15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
14.15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_ADMINCORRES_P2.pdf
38
NAIB1002
NAIB300299 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin1.pdf
15 Fourteen documents with
99 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin2.pdf
14, 15, 15, 15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin3.pdf
11.12
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview1.pdf
4, 14, 14, 14, 14, 14, 14, 14, 14
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview2.pdf
9, 9, 9, 9, 9, 9, 10, 11, 12, 12,
12, 12, 13, 13, 13, 14, 14, 14,
15, 15, 16, 16, 16, 17
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview3.pdf
4, 5, 6, 6, 6, 7, 7, 7, 8, 8, 8, 9,
9, 11, 12, 12, 13, 13, 14, 15,
17, 18, 18, 19, 20, 21
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview4.pdf
1, 1, 1, 1, 2
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
4
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
4, 5, 10, 12
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TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the
FDA (USA) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
2, 3, 3, 7, 8, 10, 11, 14, 15, 16,
16, 16
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
7, 8, 8, 8, 9, 9
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview9.pdf
10.2
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
stats.pdf
7
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
5.5
NAI3001180
NAIB200797 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin1.pdf
15 Seven documents with
18 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin2.pdf
15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview1.pdf
5
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview4.pdf
14, 15, 15, 16, 16, 17, 17, 17, 18
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
3
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
8, 10, 10, 15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
2
NAIA200690
NAIB200696
NAIB1007
C94-009 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
17 One document with
one instance
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TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the
FDA (USA) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
C94-085 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
17 Two documents with
two instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview9.pdf
22
NAIB1001 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
17 One document with
one instance
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/20000426_001/21–036-
S001_RELENZA_BIOPHARMR.pdf
6 One document with
one instance
NAIA200589 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin1.pdf
15 Ten documents with
44 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin2.pdf
7, 17, 10
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin3.pdf
2.4
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview1.pdf
4.5
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview4.pdf
2, 2, 3, 3, 3, 3, 5, 6, 6, 6, 6, 8,
8, 8, 9, 11, 12, 12, 13, 14, 14,
14, 14, 14, 15, 18
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
7.7
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
3.4
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
2, 5, 9, 15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
10
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
microbiology.pdf
21
NAIB200595 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin1.pdf
15 Nine documents with
43 instances
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
admin2.pdf
17, 20, 20, 22, 23
NEURAMINIDASE INHIBITORS FOR PREVENTING AND TREATING INFLUENZA IN ADULTS AND CHILDREN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
TABLE 2 Table of contents for studies of zanamivir described in regulatory documentation from the
FDA (USA) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview1.pdf
5.5
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview4.pdf
3, 3, 3, 7, 8, 8, 8, 9, 10, 11, 11,
11, 11, 11, 12, 12, 12, 13, 14,
14, 14, 14, 14, 14, 14, 15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
7.7
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
3.4
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview7.pdf
2, 9, 15
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview8.pdf
2
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
microbiology.pdf
21
NAIA/
B200878
Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview6.pdf
4 One document with
one instance
NAIA2010 Tamiflu and Relenza/Relenza/Relenza –
NDA 021036/19990726_000/021036-
medreview5.pdf
16 One document with
one instance
NAIA/
B200988
167-02
167-03
167-05
167-04
JNAI-03
JNAI-02
JNAI-0171
JNAI-0773
JNAI-0472
PE-01100
167-10170
167T3-11
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TABLE 3 Table of contents for studies of oseltamivir described in regulatory documentation from the FDA (USA)
Referenced
study File name
Pages on which study is
mentioned (separated by
commas) Note
NP15717 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
46.46 Six documents with
13 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
14, 15, 15
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P2.pdf
2
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_BioPharmr.pdf
5, 8, 10, 13, 31
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
NP15718 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
17 One document with
one instance
NP15728 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
16.35 Three documents with
six instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
11
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
45, 46, 47
NP15757 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
92, 93, 104, 122, 126, 131,
144, 144, 145
One document with
nine instances
NP15826 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
47 Nine documents with
26 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20040624_016/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_ADMINCORRES.pdf
6
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P2.pdf
2
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TABLE 3 Table of contents for studies of oseltamivir described in regulatory documentation from the
FDA (USA) (continued )
Referenced
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_BioPharmr.pdf
4, 5, 5, 8, 8, 8, 10, 17, 29, 30,
30, 30, 30, 30, 31, 31
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Medr.pdf
9.1
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
9.1
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20040624_016/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_ADMINCORRES.pdf
6
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
NP15827 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
10.12 Two documents with
seven instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
16, 16, 17, 17, 17
WP15525 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
21, 25, 26, 27, 27, 27, 27, 42,
42, 44
Three document with
13 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P2.pdf
2.2
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_BioPharmr.pdf
29
WP15647 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
24, 27, 27 Two documents with
four instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
44
WP15648 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
39 Three documents with
eight instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
44.44
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
94, 128, 153, 153, 154
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TABLE 3 Table of contents for studies of oseltamivir described in regulatory documentation from the
FDA (USA) (continued )
Referenced
study File name
Pages on which study is
mentioned (separated by
commas) Note
WP15676 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
28.33 Three documents with
four instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
11
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
45
WV156708 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
2, 44, 44 Six documents with
45 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
6, 19, 37, 38, 39, 39, 39, 39,
40, 41, 41, 42, 43, 44, 48, 48,
49, 49
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
1, 25, 25, 35, 35, 39, 39, 47
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
3, 3, 4, 4, 5, 5, 5, 8, 9, 10, 17,
17, 21, 22
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
189
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
WV1567158 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
2, 44, 44 Seven documents with
50 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
6, 16, 19, 24, 24, 25, 25, 26, 27,
27, 28, 32, 34, 35, 36, 37, 38,
39, 39, 39, 40, 41, 46, 49, 49
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
1, 25, 25, 35, 38, 47
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
3, 4, 4, 5, 5, 5, 5, 9, 10, 10, 15,
17, 21
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
189
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TABLE 3 Table of contents for studies of oseltamivir described in regulatory documentation from the
FDA (USA) (continued )
Referenced
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
WV1567359 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
3 Three documents with
50 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
18, 18, 18, 20, 21, 21, 21, 22, 39
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
58, 59, 71, 71, 71, 71, 71, 72,
72, 73, 73, 76, 76, 76, 76, 76,
77, 77, 79, 82, 83, 83, 84, 122,
124, 125, 126, 128, 131, 131,
132, 133, 134, 134, 145, 145,
156, 169, 177, 189
WV1569759 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
39 Two documents with
40 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
58, 59, 71, 71, 71, 71, 71, 72,
72, 73, 73, 76, 76, 76, 76, 76,
77, 77, 79, 82, 83, 83, 84, 122,
126, 128, 131, 131, 131, 132,
133, 134, 145, 145, 152, 153,
156, 162, 189
WV1570861 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
3 Three documents with
39 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
23, 35, 39, 41
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
71, 71, 71, 71, 71, 72, 72, 72,
72, 75, 75, 75, 75, 77, 77, 78,
79, 79, 82, 82, 122, 125, 125,
126, 131, 134, 134, 135, 135,
149, 151, 152, 152, 153
WV15708D Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
3 Two documents with
three instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
23.35
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TABLE 3 Table of contents for studies of oseltamivir described in regulatory documentation from the
FDA (USA) (continued )
Referenced
study File name
Pages on which study is
mentioned (separated by
commas) Note
WV1573062 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_bior.pdf
44.44 Five documents with
15 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
6, 9, 19, 49, 50, 50
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
1, 1, 25, 25, 27
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
189
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
3
WV15731 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P2.pdf
17 Four documents with
nine instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Medr.pdf
5, 30, 37
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Microbr.pdf
5.6
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
5, 30, 37
WV15758863 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P1.pdf
12, 19, 19, 36 Nine documents with
92 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P2.pdf
2, 8, 17, 39, 39, 57, 57
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_BioPharmr.pdf
3, 4, 5, 5, 5, 8, 10, 17, 27, 30
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Corres.pdf
6.9
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Medr.pdf
5, 5, 9, 9, 10, 11, 12, 12, 16,
18, 18, 18, 19, 19, 31, 31, 31,
33, 33, 35, 36, 37, 37, 37, 37,
37, 37, 37, 40, 43
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Microbr.pdf
2, 4, 5, 6
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
5, 5, 9, 9, 10, 11, 12, 12, 16,
18, 18, 18, 19, 19, 31, 31, 31,
33, 33, 35, 36, 37, 37, 37, 37,
37, 37, 37, 40, 43
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TABLE 3 Table of contents for studies of oseltamivir described in regulatory documentation from the
FDA (USA) (continued )
Referenced
study File name
Pages on which study is
mentioned (separated by
commas) Note
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20040624_016/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_ADMINCORRES.pdf
6, 6, 8
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
2.3
WV1575964 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P1.pdf
12.13 Seven documents with
44 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P2.pdf
39
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Medr.pdf
5, 10, 30, 30, 30, 30, 31, 32,
32, 33, 34, 37, 37, 37, 40, 44
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Microbr.pdf
2, 4, 4, 5, 6
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
5, 10, 30, 30, 30, 30, 31, 32,
32, 33, 34, 37, 37, 37, 40, 44
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20040624_016/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_ADMINCORRES.pdf
6, 6, 9
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
2
WV1579965 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
28, 28, 28, 28, 28, 29, 29, 30, 30,
30, 30, 30, 31, 31, 31, 31, 32, 32,
32, 32, 32, 33, 33, 34, 34, 35, 35,
35, 36, 37, 37, 37, 37, 37, 38, 38,
38, 39, 39, 40, 40, 40, 40, 40, 58,
60, 71, 71, 71, 71, 71, 72, 72, 73,
76, 76, 76, 77, 78, 79, 84, 85,
122, 125, 125, 126, 126, 128,
131, 140, 140, 140, 143, 147,
149, 156, 162, 169, 175, 187,
203, 208, 208
Four documents with
89 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Medr.pdf
10.11
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
10.11
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20040624_016/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_ADMINCORRES.pdf
6.7
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TABLE 3 Table of contents for studies of oseltamivir described in regulatory documentation from the
FDA (USA) (continued )
Referenced
study File name
Pages on which study is
mentioned (separated by
commas) Note
WV1581266 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
3, 6, 10, 12 Two documents with
nine instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
6, 8, 10, 25, 35
WV1581967 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P1.pdf
6, 10, 12, 15 Two documents with
eight instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/19991027_000/
21087_Tamiflu_medr_P2.pdf
2, 6, 6, 39
WV1582568 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20001117_002/
21–087SE1–002_review.pdf
41, 41, 41, 41, 42, 42, 42, 42,
42, 42, 43, 44, 58, 59, 71, 71,
71, 71, 71, 72, 72, 72, 72, 73,
73, 75, 75, 77, 77, 78, 79, 79,
79, 80, 80, 80, 81, 82, 85, 125,
125, 126, 126, 128, 131, 134,
134, 135, 135, 137, 137, 138,
145, 150, 151, 152, 152, 155,
156, 162, 169, 180, 204, 211
One document with
64 instances
WV1587164 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P1.pdf
12.13 Seven documents with
42 instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Admindocs_P2.pdf
39
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Medr.pdf
5, 11, 30, 31, 31, 32, 32, 32, 33,
34, 37, 37, 37, 37, 37, 37, 40
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Microbr.pdf
2, 5, 6
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
5, 11, 30, 31, 31, 32, 32, 32, 33,
34, 37, 37, 37, 37, 37, 37, 40
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021087/20040624_016/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_ADMINCORRES.pdf
6
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20040624_010/
021087_S016_TAMIFLU CAPSULES –
DRY POWDER_BIOPHARMR.pdf
2
WV1587266 Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Medr.pdf
11.33 Two documents with
four instances
Tamiflu and Relenza/Tamiflu/Tamiflu –
NDA 021246/20001214_000/
21–246_Tamiflu_Statr.pdf
11.33
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TABLE 4 Table of contents for studies of zanamivir described in regulatory documentation from NICE (UK)
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
NAI106784
107485
108127
112311
112312
113268
GCP/95/045
NAI10901
NAI10902
NAI30008 Relenza treatment submission executive
summary.pdf
4 Three documents with
10 instances
Relenza treatment submission full
document.pdf
5, 26, 26, 26, 146
Relenza treatment submission main
text.pdf
5, 26, 26, 26
NAI30009 NAI30010 study report pdf\FINAL
NAI30010 for sign-off.pdf
102 Seven documents with
461 instances
NAI30009 study report pdf\CSR30009.pdf
NAI30009 study report pdf\NAI 30009
HO final FSR.pdf
NAI30009 study report pdf\suptables.pdf
NAI30009 study report pdf\tables.pdf
Relenza treatment submission full
document.pdf
16, 16, 17, 18, 18, 18, 18, 19,
27, 30, 31
Relenza treatment submission main
text.pdf
16, 16, 17, 18, 18, 18, 18, 19,
27, 30, 31, 76, 128, 130, 132,
134, 144
NAI30010 NAI30010 study report\Final NAI30010
for sign-off.pdf
Seven documents with
399 instances
NAI30010 study report pdf\NAI30010
HO final FSR.pdf
NAI30010 study report pdf\suptables.pdf
NAI30010 study report pdf\tables.pdf
Relenza prophylaxis submission.pdf 2, 5, 8, 11, 12, 19, 20, 21, 23, 24
Relenza treatment submission full
document.pdf
16, 16, 17, 18, 18, 18, 27, 30,
31, 76, 135, 137, 139, 141,
143, 144
Relenza treatment submission main
text.pdf
16, 16, 17, 18, 18, 18, 27, 30, 31
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TABLE 4 Table of contents for studies of zanamivir described in regulatory documentation from
NICE (UK) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
NAI30012 Relenza treatment submission executive
summary.pdf
4 Three documents with
eight instances
NAI30012 Relenza treatment submission full
document.pdf
5, 26, 26, 146
NAI30012 Relenza treatment submission main
text.pdf
5, 26, 26
NAI30015 Relenza treatment submission full
document.pdf
146 One document with one
instance
NAI30020
NAI30028
NAI30031
NAI30034
NAI40012
NAIA1009 NAI30010 study report pdf\FINAL
NAI30010 for sign-off.pdf
101 Two documents with
three instances
NAI30009 study report pdf\CSR30009.pdf 28.34
NAIA300291 NAI30010 study report pdf\FINAL
NAI30010 for sign-off.pdf
102 Nine documents with
513 instances
NAI30009 study report pdf\CSR30009.pdf 34.95
NAI30009 study report pdf\NAI30009
HO final FSR.pdf
22
NAIA3002 study report pdf\NAIA3002
full study report.pdf
NAIA3002 study report pdf\NAIA3002
supporting tables 2.pdf
NAIA3005 study report pdf\A3005cr01.pdf 25
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28, 47, 49
Relenza treatment submission full
document.pdf
16, 16, 17, 17, 18, 19, 27, 30,
31, 63, 63, 63, 76, 106, 106,
107, 107, 109, 109, 112, 112,
114, 114, 115, 115, 144
Relenza treatment submission main
text.pdf
16, 16, 17, 17, 18, 19, 27, 30,
31
NAIA3003 Relenza prophylaxis submission.pdf 10 One document with
one instance
NAIA3004 Relenza prophylaxis submission.pdf 10 One document with
one instance
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TABLE 4 Table of contents for studies of zanamivir described in regulatory documentation from
NICE (UK) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
NAIA3005 NAI30010 study report pdf\FINAL
NAI30010 for sign-off.pdf
36, 94, 94, 94, 95, 96, 96, 101 Five documents with
310 instances
NAI30010 study report pdf\NAI30010
HO FSR.pdf
6.18
NAIA3005 study report pdf
\A3005cr01.pdf
NAIA3005 study report pdf\TABS.pdf
Relenza prophylaxis submission.pdf 2, 5, 6, 12, 13, 13, 15, 15, 16,
16, 17, 17, 18, 18
NAIB1002
NAIB3001 NAI30009 study report pdf\CSR30009.pdf 34, 50, 95 Eleven documents with
374 instances
NAI30009 study report pdf\NAI 30009
HO final FSR.pdf
10.22
NAI30010 study report pdf\FINAL
NAI30010 for sign-off.pdf
102
NAI30010 study report pdf \NAI30010
HO FSR.pdf
17.17
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28
NAIA3005 study report pdf\A3005cr01.pdf 25
NAIB3001 study report pdf\NAIB3001
full study report.pdf
NAIB3001 study report pdf\NAIB3001
supporting tables 1.pdf
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28
Relenza treatment submission full
document.pdf
16, 16, 17, 18, 18, 18, 18, 27,
30, 31, 32, 63, 63, 63, 76, 99,
99, 101, 101, 103, 103, 105,
105, 144, 162
Relenza treatment submission main
text.pdf
16, 16, 17, 18, 18, 18, 18, 27,
30, 31, 32
NAIB3002 NAI30009 study report pdf\CSR30009.pdf 34.95 Ten documents with
579 instances
NAI30009 study report pdf\NAI 30009
HO final FSR.pdf
22
NAI30010 study report pdf\FINAL
NAI30010 for sign-off.pdf
102
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28, 48, 50
NAIA3005 study report pdf\A3005cr01.pdf 25
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TABLE 4 Table of contents for studies of zanamivir described in regulatory documentation from
NICE (UK) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
NAIB3002 study report pdf\NAIB3002
full study report.pdf
NAIB3002 study report pdf
\NAIB3002supporting tables 1.pdf
NAIB3002 study report pdf
\NAIB3002supporting tables 2.pdf
Relenza treatment submission full
document.pdf
16, 16, 17, 17, 18, 19, 27, 30,
31, 63, 63, 63, 76, 117, 117,
117, 118, 118, 120, 120, 122,
122, 124, 124, 125, 125, 127,
127, 144
Relenza treatment submission main
text.pdf
16, 16, 17, 17, 18, 19, 27, 30,
31
NAI30011 Relenza treatment submission full
document.pdf
146 One document with
one instance
NAIB2007 NAI30009 study report pdf\CSR30009.pdf 95 10 documents with
379 instances
NAI30009 study report pdf\NAI 30009
HO final FSR.pdf
10
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28, 28, 29
NAIA3005 study report pdf\A3005cr01.pdf 25
NAIB2007 study report pdf\b2007cr.pdf
NAIB2007 study report pdf\TABLES.pdf
NAIB3001 study report pdf\NAIB3001
full study report.pdf
25.26
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28, 28, 29
Relenza treatment submission full
document.pdf
16, 16, 17, 18, 18, 19, 27, 30,
31, 76, 91, 91, 92, 92, 94, 94,
96, 96, 98, 98, 144
Relenza treatment submission main
text.pdf
16, 16, 17, 18, 18, 19, 27, 30,
31
NAIA2006 NAIA2005 study report pdf\a2005cr.pdf 38, 73, 74 Four documents with
six instances
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28
NAIA3005 study report pdf
\A3005cr01.pdf
25
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28
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TABLE 4 Table of contents for studies of zanamivir described in regulatory documentation from
NICE (UK) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
NAIB2006 NAIA3002 study report pdf\NAIA3002
full study report.pdf
28 Three documents with
three instances
NAIA3005 study report pdf
\A3005cr01.pdf
25
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28
NAIB1007
C94-009
C94-085
NAIB1001
NAIB_1001
NAIA2005 NAI30009 study report pdf\CSR30009.pdf 95 Twelve documents with
895 instances
NAIA2005 study report pdf\a2005cr.pdf
NAIA2005 study report pdf\APPS_ALL.pdf
NAIA2005 study report pdf\TBS_ALL.pdf
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28, 28, 48, 48
NAIA3005 study report pdf\A3005cr01.pdf 25
NAIB2005 study report pdf\b2005cr.pdf 7, 7, 22, 25, 26, 34, 34, 42, 71,
72, 72
NAIB2007 study report pdf\b2007cr.pdf 76
NAIB3001 study report pdf\NAIB3001
full study report.pdf
25
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28, 28, 47, 47
Relenza treatment submission full
document.pdf
16, 16, 16, 16, 17, 18, 27, 30,
76, 77, 77, 77, 79, 79, 79, 80,
80, 82, 82, 84, 84, 85, 144, 144
Relenza treatment submission main
text.pdf
16, 16, 16, 16, 17, 18, 27, 30
NAIB2005 NAI30009 study report pdf\CSR30009.pdf 95 Twelve documents with
838 instances
NAIA2005 study report pdf\a2005cr.pdf 7, 8, 8, 24, 24, 25, 43, 70, 74,
74
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28, 28, 48, 48
NAIA3005 study report pdf\A3005cr01.pdf 25
NAIB2005 study report pdf\APPSNEW.pdf
NAIB2005 study report pdf\b2005cr.pdf
NAIB2005 study report pdf\TBS_ALL.pdf
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TABLE 4 Table of contents for studies of zanamivir described in regulatory documentation from
NICE (UK) (continued )
Mentioned
study File name
Pages on which study is
mentioned (separated by
commas) Note
NAIB2007 study report pdf\b2007cr.pdf 76
NAIB3001 study report pdf\NAIB3001
full study report.pdf
25
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28, 28, 47, 47
Relenza treatment submission full
document.pdf
16, 16, 16, 16, 17, 18, 27, 30,
76, 77, 79, 79, 85, 85, 85, 86,
86, 88, 88, 90, 90, 144, 144
Relenza treatment submission main
text.pdf
16, 16, 16, 16, 17, 18, 27, 30
NAIA/B2008 NAI30009 study report pdf\CSR30009.pdf 95 Six documents with
16 instances
NAI30009 study report pdf\NAI 30009
HO final FSR.pdf
10
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28, 28, 29, 29
NAIA3005 study report pdf\A3005cr01.pdf 25
NAIB3001 study report pdf\NAIB3001
full study report.pdf
25, 26, 26, 26, 77
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28, 28, 29, 29
NAIA2010 NAIA3005 study report pdf\A3005cr01.pdf 25 One document with
one instance
NAIA/
B200988
NAIA3002 study report pdf\NAIA3002
full study report.pdf
28 Three documents with
three instances
NAIA3005 study report pdf
\A3005cr01.pdf
25
NAIB3002 study report pdf\NAIB3002
full study report.pdf
28
167-02
167-03
167-05
167-04
JNAI-03
JNAI-02
JNAI-01
JNAI-07
JNAI-04
PE-01100
167-10170
167T3–11
NICE, National Institute for Health and Care Excellence.
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TABLE 5 Table of contents for studies of oseltamivir described in regulatory documentation from NICE (UK)
Referenced
study
File name
volumea
Pages where study is mentioned
(separated by commas) Note
GS97-802
133312
GS-97-801
JP15734
JP15735
JV1582374
JV1582475
JV16284
M7600136 1 33, 36, 37, 37, 38, 38, 39, 67, 68, 94, 95, 224 One document with 12 instances
M76006
ML20910
ML22789
ML22879
MV21118
MV22841
NCT00298233
NCT00555893
NCT00707941
NCT00799760
NCT00830323
ML25018
NCT00867139
NCT00873886
NCT01002729
NP15717 6 32, 75, 76, 77 Two documents with five
instances
8 68
6 73.98 One document with two
instances
NP15718
NP15728
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TABLE 5 Table of contents for studies of oseltamivir described in regulatory documentation from
NICE (UK) (continued )
Referenced
study
File name
volumea
Pages where study is mentioned
(separated by commas) Note
NP15757 8 68 One document with one instance
NP15826 6 32, 75, 75, 75, 76, 76, 77, 78, 79, 80, 98 One document with 11 instances
NP15827 8 68 One document with one instance
NP22770
NP25138
NP25139
NV16871
NV20234
NV20235
NV20236
NV20237
NV22155
NV25118
NV25182
PP16351
WP15517 1 185.245 One document with two
instances
WP15525 1 185.245 One document with two
instances
WP15647
WP15648
WP15676
WP15901
WP22849
WV144181
WV156708 1 33, 36, 37, 37, 38, 38, 39, 47, 48, 48, 49, 49,
50, 53, 54, 54, 55, 163, 171, 188, 207, 209,
224, 245, 245, 252, 253, 253
Seven documents with 1193
instances
10 7, 36, 37, 37
2
3
4 90
6 35.98
8 65
2 20, 20, 20, 20, 20 One document with five
instances
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TABLE 5 Table of contents for studies of oseltamivir described in regulatory documentation from
NICE (UK) (continued )
Referenced
study
File name
volumea
Pages where study is mentioned
(separated by commas) Note
WV1567158 1 33, 36, 37, 37, 38, 38, 39, 47, 48, 49, 49, 50,
53, 54, 54, 55, 163, 171, 188, 207, 209, 224,
245, 245
Seven documents with
1222 instances
10 7, 36, 37, 37
2 82
4
5
6 35.98
8 66
WV1567359 8 66 One document with one instance
WV15673D 8 66 One document with one instance
WV1569759 8 One document with one instance
WV15697D 8 One document with one instance
WV1570760 1 33, 36, 37, 37, 38, 67, 68, 224, 245, 245,
245, 246
One document with 12 instances
WV1570861
WV15708D
WV1573062 1 33, 36, 37, 37, 38, 38, 39, 47, 53, 54, 55, 186,
207, 224, 245, 245, 246
Four documents with
22 instances
10 7, 36, 37
2 82
4 90
WV15731 6 98 One document with one instance
WV1575863 1 36, 37, 82, 83, 84, 85, 86, 92, 94, 95, 97, 106,
224, 246
Four documents with
424 instances
6
7
8 68
WV1575964 1 36, 37, 94, 95, 95, 109, 113, 114, 121, 122,
224, 246
One document with 12 instances
WV1579965 1 137, 139, 139, 232, 233 Three documents with
499 instances
8
9
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FDA regulatory documents and trial size. The biggest treatment trial36 is cited only four times in three
documents, whereas other contemporary treatment trials are cited far more.8,58,60,62,66 One trial,8 for
example, is cited 46 times in the FDA documents. However, the combined enrolled denominator of the
four treatment trials completed at the time8,58,60,62 was 1442, smaller than 1459.36 This suggested that the
FDA’s regulatory evaluation of Roche’s New Drug Application (NDA) was based predominantly on what
Roche had presented to them as ‘pivotal’, or trials that best demonstrated the properties of oseltamivir,
not the complete evidence base of all oseltamivir trials. One possible alternative explanation for this
observation could have been the interval between trial completion, generation of the report and NDA
submission. This explanation is supported by the relatively brief interval between completion of the
M76001 trial36 (19 February 1999) and submission (on 30 April 1999) of NDA 021087 to the FDA.
However, the core part of the submission (the clinical development programme) contains data from two
(at the time of writing) ongoing trials.66,67
The basis of the selection of trials to regulators is therefore unclear but appears to be dictated by criteria
other than availability and size. The importance of trials (to manufacturers and possibly to regulators) may
not be based on the same criteria that systematic reviewers would use (i.e. the capability of the trial to
answer questions).
TABLE 5 Table of contents for studies of oseltamivir described in regulatory documentation from
NICE (UK) (continued )
Referenced
study
File name
volumea
Pages where study is mentioned
(separated by commas) Note
WV1581266 1 36, 37, 37, 38, 38, 39, 67, 68, 68, 107, 107,
107, 108, 108, 121, 121, 122, 123, 224, 246
Two documents with
197 instances
10
WV1581967 1 33, 36, 37, 37, 38, 58, 58, 59, 59, 60, 61, 62,
62, 65, 65, 67, 68, 224, 246
Two documents with
173 instances
10
WV1582568 8 66, 66 One document with two
instances
WV1587164 1 109, 246 One document with two
instances
WV1587266 1 36, 37, 37, 38, 38, 39, 67, 68, 68, 107, 107,
108, 108, 121, 121, 122, 123, 224
One document with 18 instances
WV1587667 1 246, 246 One document with two
instances
WV1597867 1 67, 70, 175, 246, 246 One document with five
instances
WV16193
ML1636976
NICE, National Institute for Health and Care Excellence.
a Number of the volume of the Tamiflu NICE submission.
Notes
Oseltamivir trials citation by trial ID and source NICE file. Page numbers separated by commas (where applicable) indicate
which trial is cited where in which file. Blank spaces indicate no citation for known trials.
All of the studies have been searched in the folder ‘Roche submission’.
When there is the number of the volume but no pages are mentioned, it means that the code of the study is cited more
than 100 times.
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Owing to the vast size of FDA documents, sometimes hundreds of pages long, it was difficult to determine
important emerging themes solely by reading. To identify items of interest in the FDA comments we
used word clouds.108 Word clouds give greater prominence to words that appear more frequently in the
source document. The resulting graphic representation showed words such as ‘diary’ and ‘baseline’ to be
heavily mentioned in the relevant (abridged) text from the FDA’s Medical Officer Review.109 Examining the
‘diary’ entry in more detail, we found the following FDA comment:
The majority of subjects participating in the treatment trials had only used the first diary card. The
second diary card was issued in 15% to 20% of participants. In response to FDA’s request, the
applicant provided a summary of diary card dispensing in the 8/6/99 submission. It became apparent
that instructions on when to start a second diary card were not uniformly followed in three trials.8,58,62
There were examples of patients who had alleviated symptoms yet also received a second diary card.
Conversely, there were also examples of patients who did not alleviate all symptoms but did not
receive a second diary card. Thus the second diary card was used inconsistently which is viewed as a
flaw of these trials. The lack of consistency in collecting symptom information after alleviation
precluded a complete documentation of symptom fluctuation. Also missing second diary cards in
subjects who had not alleviated symptoms were responsible for the majority of censored data which
may have potentially influenced the results of efficacy analysis. In order to address the impact of
censoring, the applicant performed several sensitivity analyses, which will be summarized in the
Integrated Summary of Efficacy.
This comment highlights problems with the follow-up procedure of treatments trials, which may have
impaired the regulator’s ability to draw conclusions on the duration of effect of oseltamivir. It also provides
a good example of how graphic methods can help to identify crucial comments in vast regulatory files.
Several other experiments with text from the same FDA document showed that the choice of text to be
represented as a word cloud heavily influenced cloud construction, visibility of words and hence our ability
to detect important comments. It is for this reason that we decided to adopt a mixed approach: mapping
citations while reading FDA comments and integrating such comments in our appraisal of the evidence.
Regulatory comments were all the more important because, at the time that we developed this method,
we had few CSRs, and comments helped to identify the gaps in our knowledge of the trial programmes.
Once the TOC had been constructed, we postulated that, given the huge work involved in reviewing lots
of regulatory files, our new instrument could also help us by indicating which parts were more important
than others, thus focusing our efforts. We experimented with a variety of methods, which are reported
above (see Data collection and analysis).
Clinical study reports
After prolonged correspondence and media pressure (see Appendix 1), we were able to access the trial
programmes for both oseltamivir and zanamivir without clauses restricting their accessibility to
third parties.
Electronic searches
Two review authors (CDM and MT) independently scanned the titles and abstracts of the electronic
searches. Three identified studies110–112 were published versions of trials that were possibly unknown to us.
We wrote to the first trial author to ask for CSRs, or equivalent, on 12 November 2013, and the author
confirmed that the trials had not been completed.
Included studies
The absence of documentation of trial programmes for both drugs, listing all sponsored trials completed
or under way, meant that we had to rely on a variety of sources for the reconstruction of the trial
programmes and identification of relevant CSRs. This complexity is reflected in the flow chart presented
in Figure 3, illustrating the study selection process for this review. The two main pathways were the
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spontaneous release of 77 full CSRs by Roche and the requests to regulatory authorities and GSK for all
of the relevant reports.
We carried out the inclusion into stage 1 using the CSRs, titles, abstracts and any other relevant
information. Through this process we identified 208 potentially relevant studies (139 oseltamivir trials,
61 zanamivir trials and eight peramivir trials). We excluded 123 studies (see Appendix 10, listed in the
‘characteristics of excluded studies’ table) as clearly ineligible. A further 19 studies are awaiting
classification (Table 6). We requested 66 trials from study sponsors, the EMA and the FDA. From these
Studies considered for inclusion
(n = 208)
• Oseltamivir, n = 139
• Zanamivir, n = 61
• Peramivir, n = 8
Studies for which clinical
study reports were requested
from study sponsors, EMA 
and FDA 
(n = 66)
Studies did not meet
the inclusion criteria
(n = 60)
53 trials meeting review
eligibility criteria received
from sponsors and EMA
(23 oseltamivir trials in
18 clinical study reports;
30 zanamivir trials in 29
clinical study reports)
Risk-of-bias assessment and
CONSORT extractions carried
out on the basis of clinical
study reports of 23 oseltamivir
trials and 30 zanamivir trials
(stage 1)
20 oseltamivir trials and 
26 zanamivir trials progressed
 to stage 2 of inclusion
Between April and November 2013
Roche sent us 77 clinical study
reports for 83 studies following
unanticipated announcement
that they would provide
redacted complete clinical
study reports for all
Roche-sponsored trials of
oseltamivir
Studies identified through the following sources: publicly
available documents from the FDA, EMA and Japan PMDA;
manufacturer trial registry websites; NICE 2000 submission;
electronic database searches; and correspondence with manufacturers 
• Oseltamivir studies identified, n = 121 (83 delivered by Roche)
• Zanamivir studies identified, n = 61 (30 delivered by GSK) 
• Peramivir studies identified, n = 8 (none delivered) 
• Laninamivir study identified, n = 1 (ongoing) 
Oseltamivir studies
received from Roche
assessed for inclusion
(n = 83)
• Oseltamivir, n = 3
• Zanamivir, n = 2
• Zanamivir, n = 2
• Oseltamivir, n = 36
• Zanamivir, n = 30
• Oseltamivir, n = 89
• Zanamivir, n = 31
• Peramivir, n = 2
• Other, n = 1
• Oseltamivir, n = 12
• Peramivir, n = 6
• Laninamivir, n = 1
Studies awaiting
classification 
(n = 19)
Studies excluded
 (n = 123)
Trials excluded due to
incomplete clinical study report
(n = 5)
Trials excluded because they
did not fit the inclusion criteria
(n = 2)
FIGURE 3 Flow diagram describing the number of studies identified, inclusion, exclusion and progression from
identification to stage 1 to stage 2 of the review. PMDA, Japanese Pharmaceuticals and Medical Devices Agency.
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TABLE 6 Characteristics of studies awaiting assessment (ordered by study ID)
JPRN-JapicCTI-111647
Methods A randomised, double-blind, placebo-controlled study to confirm the efficacy in the prevention of
influenza virus infection (Phase 3 study)
Duration of the study 1 October 2011 to 30 June 2012
Sponsor Daiichi Sankyo Co., Ltd
Participants –
Interventions Laninamivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
ML20589
Methods Economic and social benefits of treating and preventing influenza in aged care facilities
Sponsor The University of Sydney, Australia
anzctr.org.au number ACTRN12606000278538
Participants –
Interventions Oseltamivir, three different regimens
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
ML20910
Methods A study of Tamiflu (oseltamivir) treatment in laboratory-confirmed influenza
Sponsor Hoffmann-La Roche, NCT00436124
Participants –
Interventions Oseltamivir
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
ML21776
Methods Study to evaluate nosocomial transmission of influenza
Sponsor University Hospitals, Leicester
NCT00798421
Participants –
Interventions –
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
MV21118
Methods Early oseltamivir treatment of influenza in children aged 1–3 years
Sponsor Hospital District of Southwestern Finland
NCT00593502
Participants –
Interventions Oseltamivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
continued
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TABLE 6 Characteristics of studies awaiting assessment (ordered by study ID) (continued )
MV21737
Methods Long-term influenza prophylaxis with inhaled zanamivir or oral oseltamivir
Sponsor University of Oxford
NCT00980109
Participants –
Interventions Oseltamivir, zanamivir, placebo
Outcomes –
Notes Awaiting assessment as we do not yet have the clinical study reports for this study
MV21879
Methods Oseltamivir randomised controlled efficacy trial
Sponsor International Centre for Diarrhoeal Disease Research, Bangladesh
NCT00707941
Participants –
Interventions Oseltamivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
MV22841
Methods An observational clinical trial of influenza A/H1N1 2009 resistance under standard-duration
oseltamivir treatment
Sponsor Not known
Participants –
Interventions Oseltamivir
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
MV22940
Methods A randomised controlled trial on the effect of post-exposure oseltamivir prophylaxis on influenza
transmission in nursing homes
Sponsor National Institute for Public Health and the Environment (RIVM), The Netherlands
NCT01053377
Participants –
Interventions Oseltamivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
NCT00419263
Methods Evaluation of the efficacy and safety of peramivir in subjects with uncomplicated acute influenza
Sponsor BioCryst Pharmaceuticals
Participants –
Interventions Peramivir
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
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TABLE 6 Characteristics of studies awaiting assessment (ordered by study ID) (continued )
NCT00453999
Methods Evaluation of the efficacy and safety of peramivir in adults with acute serious or potentially
life-threatening influenza
Sponsor BioCryst Pharmaceuticals
Participants –
Interventions Peramivir
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
NCT00486980
Methods Intramuscular peramivir for the treatment of uncomplicated influenza
Sponsor BioCryst Pharmaceuticals
Participants –
Interventions Peramivir
Outcomes –
Notes Awaiting assessment as we do not yet have the clinical study reports for this study
NCT00555893
Methods Efficacy study of early versus late oseltamivir administration for treating and preventing influenza
Participants –
Interventions Oseltamivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
NCT00610935
Methods Intramuscular peramivir in subjects with uncomplicated acute influenza
Sponsor Marshfield Clinic Research Foundation
Participants –
Interventions Peramivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
NCT00705406
Methods A Phase II, multicentre, randomised, placebo-controlled, study to evaluate the efficacy and safety
of intramuscular peramivir 600mg in subjects with uncomplicated acute influenza
Sponsor BioCryst Pharmaceuticals
Participants –
Interventions Peramivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
continued
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TABLE 6 Characteristics of studies awaiting assessment (ordered by study ID) (continued )
NCT00958776
Methods A study to evaluate the efficacy and safety of IV peramivir in addition to standard of care
compared to standard of care alone in adults and adolescents who are hospitalised due to
influenza
Sponsor BioCryst Pharmaceuticals
Participants Peramivir
Interventions –
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
NCT00980109
Methods Long-term influenza prophylaxis with inhaled zanamivir or oral oseltamivir
Sponsor University of Oxford
Participants –
Interventions Oseltamivir, zanamivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
NCT01032837
Methods A study of Tamiflu (oseltamivir) for treatment of influenza with a focus on (H1N1) 2009 flu strain
Sponsor Hoffmann-La Roche
Participants –
Interventions Oseltamivir, placebo
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
NV20236
Methods A study of Tamiflu (oseltamivir) for seasonal prophylaxis of influenza in children
Sponsor Hoffmann-La Roche
NCT00412555
Participants –
Interventions Oseltamivir
Outcomes –
Notes Awaiting assessment, as we do not yet have the clinical study reports for this study
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different methods, the total number of trials available for assessment for inclusion in our review at
stage 1 was 53.
Twenty-three studies of oseltamivir8,36,57–69,74–76 and 28 of zanamivir70–73,77–100 were included in stage 1. It
was not uncommon for more than one trial to be reported in the same CSRs. This was either because of
the amalgamation of two or more trials due to low influenza virus circulation and difficulties in recruitment
(e.g. WV15812/WV1587266) or because the trials bore different ID numbers when, in reality, they followed
the same protocol, albeit in two different hemispheres (e.g. WV15759/WV1587164).
We also identified six completed or ongoing studies of peramivir in dose–response or
placebo-controlled studies.113–118
The included trials were predominantly conducted in adults during influenza seasons in both hemispheres.
A small number of studies were conducted in older people who were residing in care homes and in people
with underlying respiratory diseases. All trials were sponsored by the manufacturers.
Oseltamivir
Of the 23 oseltamivir trials in stage 1, 15 were multicentre trials conducted in both the northern and
southern hemispheres, whereas eight were carried out in only one country (USA, five; Japan, two; China,
one). In total, 9623 participants were included (6574 in treatment trials and 3049 in prophylaxis trials). The
age of the participants ranged from 1 to 82 years and the duration of follow-up varied from 6 to 42 days.
Two of the trials were conducted within nursing homes; 20 were within free-living populations; and one
was performed in inpatient and outpatient departments. Three trials were conducted in children (two of
the trials were among children with chronic asthma, n= 660; one trial was performed among otherwise
healthy children, n= 669), whereas participants in 20 trials were adults. In some trials the eligible
population included participants who were at increased risk of influenza complications, or with diagnoses
of asthma or chronic obstructive pulmonary disease, but the majority included only otherwise healthy
adults. In one trial,62 participants were stratified by smoking status, whereas those in another trial were
stratified by the presence or absence of otitis media.63
All trials compared orally administered oseltamivir (either as capsules or reconstituted powder)
with placebo.
Of the 23 trials, we included 20 RCTs for the analysis examining the use of oseltamivir compared with
placebo. Two RCTs were excluded from the meta-analysis because they were only synopsis reports74,75 and
another because it was not a full CSR.76
We finally included 20 oseltamivir trials into stage 2: 11 on treatment in adults,8,36,57,58,60–62,66,67,69,74–76,108–112
four in children57,63,64 and five on prophylaxis:51,61,65,68 two in adults,51 two in the elderly61,68 and one in
households.65 Of the 15 included treatment trials of oseltamivir, only three8,36,63 were successful in recruiting
the a priori planned sample size.
Zanamivir
Of the 28 included zanamivir trials, 18 were multicentre trials that were conducted in both the northern
and southern hemispheres and 10 were carried out in only one country (Japan, five; USA, three; Finland,
one; Germany, one). In total 14,628 participants were included (7678 in treatment trials and 6950 in
prophylaxis trials). Participants’ age ranged from 5 to 12 years to > 65 years, and duration of follow-up
varied from 5 to 35 days.
Two of the trials were performed within nursing homes; several were within free-living populations; one
was performed within a university student population. In some trials the eligible population included
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participants at increased risk of influenza complications, or with diagnoses of asthma or chronic obstructive
pulmonary disease, but the majority included only adults who were otherwise healthy.
Zanamivir was administered as an intranasal spray, an inhalation or a combination of both, and placebos
were designed to match. Administration was by the participant in the majority of trials and by nursing staff
in the trials within nursing homes. Twenty-two trials compared inhaled zanamivir with placebo and six
trials compared inhaled zanamivir, or intranasal zanamivir, with placebo or usual care.
Of the 28 trials,70–73,77–100 we included 26 RCTs70–73,77–82,84–91,93–100 for the analysis, examining the use of
zanamivir compared with placebo. Two trials83,92 were excluded from the meta-analysis because one was
only a synopsis83 and one compared zanamivir to usual care and not placebo.92
We finally included 26 zanamivir trials: 14 on treatment in adults,71–73,77,80–82,87,89,91,95,97–99 two in children78,84
and 10 trials in prophylaxis.70,79,85,86,88,90,93,94,96,100
Our attempt at collecting sufficient information from regulatory files to reconstruct missing CSRs also failed
because the information appeared to be insufficient for a reliable reconstruction.
Excluded studies
We excluded 123 studies from entering stage 1 for various reasons. Some were pharmacokinetic studies,
had an active comparator, compared higher-dose schedules with lower-dose schedules or were ongoing
trials. A further 19 trials are awaiting assessment (see Table 6).
Risk of bias in included studies
Study-level assessments are reported in the risk-of-bias tables (see Figure 2). To address the problem of
reporting bias, we ignored published trial reports and directed our attention to CSRs and regulatory
information. Our problems in reviewing the copious material at our disposal were how to identify and
analyse important details in the midst of thousands of pages of information and how to construct a
coherent appraisal of large and complex trial programmes.
In addition, as we gained unrestricted access to the full CSRs (apart from personal de-identifying
redactions) we took the view that all information needed to judge risk of bias should be present.
Therefore, when this information was not available, we judged the corresponding risk-of-bias element as
at ‘high’ risk of bias. For example, when details of the random sequence generation are missing from
journal publications of clinical trials, it is customary to record this as ‘unknown’ risk of bias. This judgement
usually carries the assumption that the random sequence generation details are available in more detailed
reports. But when these details were still missing, even in full CSRs, we chose to rate this risk-of-bias
element at ‘high’ risk of bias.
In the following paragraphs we report some of the salient findings using the current Cochrane format but
applying the logic of reviewing regulatory data.
Allocation (selection bias)
In 10 of the 20 oseltamivir studies included in stage 2, the description of random sequence generation is
missing. All of the zanamivir trials but one84 had reporting bias due to the absence of description of
random sequence generation.
Blinding (performance bias and detection bias)
The placebo and active drug capsule cap were not identical in 11 of the 20 trials of oseltamivir. This may
have compromised blinding of participants. For all but one of the zanamivir trials we did not have the
certificates of analysis to enable us to reconstruct the appearance, taste and texture of the two principles.
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Incomplete outcome data (attrition bias)
In addition to the missing diary cards in three treatment trials (see Results of the search, above), we were
unable to identify all of the data for all of the outcomes in all of the oseltamivir trials and in eight of the
zanamivir trials. For example, hospitalisations were not reported in zanamivir trials and inconsistently
reported in oseltamivir trials. The relevant data in this review come from a table of hospitalisations sent to
us by Roche in late 2013. In addition, in some trials we were unable to track individual participants
through tables, narratives and individual listings. The issue of compliharms impeded the ascertainment of
harms in oseltamivir treatment trials (see Appendix 1). We had difficulty in following the logic of
compliharms, even with access to full CSRs. The definition of adverse events in the RCTs of oseltamivir and
zanamivir is different from the ordinary definition of the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use E2D guideline, which is as
follows: ‘An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal
product and which does not necessarily have to have a causal relationship with this treatment. An adverse
event can therefore be any unfavourable and unintended sign (e.g. an abnormal laboratory finding),
symptom, or disease temporally associated with the use of a medicinal product, whether or not considered
related to this medicinal product’ [www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Efficacy/E2D/Ste p4/E2D_Guideline.pdf (accessed 27 December 2013)].
As an example, the definition of adverse events in one study58 is as follows: ‘following the alleviation of
influenza-like symptoms, the recurrence of a single respiratory or constitutional symptom was recorded as
an adverse event, however, the reappearance of more than one symptom was recorded as influenza-like
syndrome (i.e. secondary illness) and therefore do not appear as adverse events’ (p. 35)58 and: ‘any adverse
change from the subject’s baseline (pre-treatment) condition, which occurred during the course of the
study after treatment had started, whether considered related to treatment or not’. Treatment included all
investigational agents (including placebo and comparative agents) administered during the course of the
study)’ (our emphasis).8 As a consequence, adverse events that are similar to the symptoms of influenza
(such as headache and mild gastrointestinal adverse events) tend to be excluded from the treatment trials.
We identified a report of a site inspection for one adult prophylaxis trial.59 The FDA carried out the
inspection in September 2000 at various trial sites in the USA, including the West Virginia site (which was
responsible for enrolling many hundreds of participants). A FDA official letter reported several violations,
including failure to report serious harms to the sponsor (Roche) as the protocol required and in addition
stated: ‘. . . we view the statement in the payment section of the consent form used in the study that
subjects . . . will receive $300.00 for participating in and completing the study. No payment will be made
to you if you withdraw from the study for personal reasons . . . to be an improper procedure. When
subjects are to be paid for participating in a study, the payment should be prorated for the subject’s actual
participation in the study in order to avoid the possibility of coercion’ (p. 177).119 However, the FDA
allowed the data (which had been published 1 year earlier in a prime journal) to stand in support of
Roche’s application for the prophylaxis indication. We do not know whether or not the participant contract
was standard (i.e. whether or not the observation of possible improper procedures could be generalised to
other sites and other trials) but the document cited by the FDA inspector is the subject of one of our
(as yet unfulfilled) FOI requests. The possibility of financial pressure, if confirmed, could seriously confound
dropout rates because of harms or any other causes in prophylaxis trials.
The significantly higher incidence of diarrhoea in placebo recipients of treatment trial WV1567158 was
identified by the FDA reviewers who remarked ‘Diarrhea was reported more frequently among subjects
receiving placebo than among subjects receiving Ro 64-0796 [oseltamivir]. Diarrhoea, although not specified
as an inclusion criterion, has been documented to be a clinical manifestation of influenza infection. The
reduction in the incidence of diarrhoea for the treatment groups compared with the placebo group could be
considered as a possible treatment effect of Ro 64–0796’.109 However, according to the Japanese Summary
Basis for Approval of oseltamivir capsules for prophylaxis, diarrhoea was reported more frequently in the
oseltamivir arm (49/986) than in the placebo group (38/973) in the summarised table of adverse events from
three trials.59,61,68 Our findings are inconsistent with the explanation by the FDA.
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Selective reporting (reporting bias)
All of the oseltamivir trials and almost half of the zanamivir trials had selected reporting. The oseltamivir
trials showed a consistent trend of missing original protocols (except for one trial36), changing outcome
definitions while the trial was running, protocol amendments even after the trial had been completed,
inconsistent approaches to outcome data collection, missing SAPs, missing date of unblinding and the use
of self-reported outcomes such as pneumonia.8,36,47,60,68,69 This represents 55% of pneumonia event data.
As an example, in trial WV15670,8 secondary illnesses were patient reported. The body of the CSR states
that complications requiring antibiotic treatment were specified a priori, but, even in the final version of
the protocol, for which we have the full text, there is no predefined list of secondary illnesses (i.e. no
mention of pneumonia, bronchitis, sinusitis or otitis in the protocol); complications did not have anything
to do with antibiotic treatment according to the protocol; and the CRF did not mention specific secondary
illnesses by name. Zanamivir trials reported outcomes that were not specified in the protocol provided.
We found evidence of possible selective reporting bias when we analysed the Japanese Summary Basis for
Approval data on prophylaxis. The regulatory data report tables for individual trials, as well as 10 pages of
summarised tables for three trials of prophylaxis.59,61,70 Tables for individual trials include data for high-dose
arms but report few psychiatric adverse events overall. However, the summarised tables list a variety of
psychiatric adverse events, including psychotic and suicidal adverse events, but not adverse events from the
high-dose group. As a preliminary exploratory analysis, we combined the following suspected serious
adverse events collectively: hallucination and delusion, which are classified grade 3 (serious) by the National
Cancer Institute-Common Toxicity Criteria Version 2.0 (NCI-CTC V2.0); psychosis (hallucination and
delusion are the two major symptoms of this disease); suicidal attempt, which is classified grade 3 (serious)
by the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE V4.0); and hostility, which
includes aggression, hostility, violence and murder, commonly considered as serious events although not
listed in the NCI-CTC V2.0 or CTCAE V4.0. Numbers of suspected serious psychotic/suicidal adverse events
(including hallucination, psychosis, schizophrenia, paranoia, aggression/hostility and attempted suicide)
were five in the oseltamivir group and zero in the placebo group during the on-treatment period; when
the off-treatment period data are added, the total was eight compared with one. The prophylaxis
programme is crucial in understanding the harms profile of the drug, as the potential for harms witnessed
to be confounded by the apparently numerous symptoms and signs of influenza infection is far less,
as many participants do not become infected with influenza. This makes a causality assessment
more straightforward.
Other potential sources of bias
All but three of the oseltamivir treatment trials were under-recruited. Several of the zanamivir trials were
also under-recruited. We noted the use of different relief medication across different centres within the
same trial, and in one zanamivir trial,85 according to the protocol, participants receiving antibiotics for
bacterial respiratory tract infection should have been excluded but in the trial this did not happen. In the
zanamivir trial,86 the definition of ‘confirmed influenza’ was amended after protocol closure.
We also noted several other items that were not included in all full CSRs:
l Study protocols dated prior to participant enrolment (missing for many oseltamivir trials).
l Certificates of analysis for the intervention/placebo preparations.
l Patient enrolment dates explicitly reported (only trial inception and cessation dates are given; in
zanamivir trials these are partially redacted).
l Explicitly reported date of trial unblinding. We frequently noted the statement ‘the database was
authorised on xxxx’ to identify the unblinding date but an explicit date is important to report. In some
cases, the date of unblinding was reported, but the actual date within the month was redacted. This
practice also applied to zanamivir protocol amendments.
l Authorship and accountability for the writing of the CSRs.
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l SAPs in some cases.
l Patient consent forms (missing from most zanamivir trials).
l Patient information form (missing from most zanamivir trials).
l List of randomisation codes (variably included).
l CRF templates in zanamivir trials do not allow for determining who completes the form (patient
or clinician).
l Core data sheet.
Other important documents that we did not have included:
l study manual of procedures
l minutes of safety data monitoring committee meetings.
The placebo interventions in both sets of trials may have contained active substances. The placebo for
zanamivir trials contained lactose powder, which can potentially cause bronchospasm, whereas the
placebo for oseltamivir trials contained dehydrocholic acid and dibasic calcium phosphate dehydrate, which
can cause gastrointestinal symptoms.
Data on participants by influenza-infected status (in treatment trials) and for participants with ILI
(in prophylaxis trials) were not reported in the oseltamivir CSRs.
Finally, data on the effects of rescue or relief medication (mainly paracetamol/acetaminophen) were
incomplete in CSRs of oseltamivir trials and not reported separately in all of the zanamivir trials.
Effects of interventions
Analysis of time to first symptom alleviation
In adult treatment, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% CI 8.4
to 25.1 hours; I2 statistic= 0%), representing a 10% reduction from 7 days to 6.3 days (Figure 4). There
was no significant effect in asthmatic children: increased by 5.2 hours (95% CI 11.1 hours lower to
21.4 hours higher; I2 statistic= 0%). But there was an effect in otherwise healthy children, based on one
trial (29 hours, 95% CI 12 to 47 hours; p= 0.001) (see Table 9). Zanamivir reduced time to first alleviation
of symptoms in adults by 0.60 days (95% CI 0.39 to 0.81 days; I2 statistic= 9%), which equates to a
14.4-hour (10%) reduction in symptoms from 6.6 days to 6.0 days (Figure 5). There was no significant
effect in children: time to first alleviation of symptoms was 1.08 days lower in the zanamivir group
(95% CI 2.32 lower to 0.15 days higher; I2 statistic= 72%).
In eight zanamivir trials that reported on use of relief medication, in all of the participants the median days
to alleviation in both the placebo and the treatment arms was less than those who did not use relief
medications (Table 7). In seven zanamivir trials, time to first alleviation of symptoms was also reported with
and without rescue medication. Using these data we were able to compare zanamivir without rescue
medication with placebo with rescue medication. Overall, there was a non-significant 0.41-day decrease
(95% CI 0.47 days lower to 1.29 days higher; I2 statistic= 67%) in time to first alleviation of symptoms in
the placebo with rescue medication group, suggesting that zanamivir itself is no better than rescue
medication, and possibly even less effective, although the varying levels of use of rescue medication in the
seven trials did give rise to large heterogeneity (Figure 6).
In a subgroup analysis of time to first alleviation of symptoms in adults by infection status, we found no
evidence of a difference in treatment effect for zanamivir on the influenza-infected subgroup compared
with the non-influenza-infected subgroup (p= 0.53). The treatment effect was 0.67 days (95% CI 0.35 to
0.99 days; I2 statistic= 17%) for influenza-infected patients and 0.52 days (95% CI 0.18 to 0.86 days;
I2 statistic= 0%) for non-influenza-infected patients.
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Analysis of hospitalisations
In oseltamivir treatment of adults, there was no significant difference in hospitalisation rate between
treatment groups (RR 0.92, 95% CI 0.57 to 1.50; I2 statistic= 0%) or in treatment of children (RR 1.92,
95% CI 0.70 to 5.23; I2 statistic= 0%), with wide CIs; or in prophylaxis (RR 1.14, 95% CI 0.66 to 1.94;
I2 statistic= 0%). Data on hospitalisations for the zanamivir studies were not reported.
Analysis of influenza complications
Pneumonia
In adult treatment trials, oseltamivir significantly reduced self-reported, investigator-mediated, unverified
pneumonia (RR 0.55, 95% CI 0.33 to 0.90; I2 statistic= 0%; RD 1.00%, 95% CI 0.22% to 1.49%;
NNTB 100, 95% CI 67 to 451) in the treated population. The effect was significant in the six trials that
collected data on non-specific adverse events or secondary/intercurrent illness forms (RR 0.44, 95% CI 0.22
to 0.88; I2 statistic= 0%; RD 0.99%, 95% CI 0.21% to 1.38%; NNTB 101, 95% CI 73 to 470). However,
it was not significant in the five trials (two CSRs) that used more detailed diagnostic data collection forms,
and in no studies that reported on radiological confirmation of pneumonia (Figure 7). There was no
significant effect on pneumonia in children (RR 1.06, 95% CI 0.62 to 1.83; I2 statistic= 0%). In two
zanamivir adult trials,81,82 pneumonia reporting was based on a stricter definition of X-ray confirmation and
there was also no significant treatment effect (RR 1.02, 95% CI 0.35 to 3.02; I2 statistic= 39%). In nine
zanamivir trials,77,79,80,87,89,91,97–99 pneumonia was a self-reported, investigator-mediated, unverified outcome
(see Figures 8 and 9). Overall, there was no significant effect of zanamivir on mixed verified and unverified
pneumonia in adult treatment (RR 0.90, 95% CI 0.58 to 1.40; I2 statistic= 0%). In prophylaxis trials,
zanamivir reduced the risk of self-reported, investigator-mediated, unverified pneumonia in adults
(RR 0.30, 95% CI 0.11 to 0.80; I2 statistic= 0%; RD 0.32%, 95% CI 0.09% to 0.41%; NNTB 311,
95% CI 244 to 1086).
In a metaregression of ‘pneumonia’ based on 32 studies, treatment effects were not statistically different
by age group (p= 0.22), drug (p= 0.89) or indication (p= 0.14). However, treatment effects were
statistically different by method of diagnosis (p= 0.025). For unclear objective diagnosis of pneumonia, the
treatment effect was RR 0.51 (95% CI 0.35 to 0.75; I2 statistic= 0%), whereas for objective diagnosis data
collection of pneumonia, the treatment effect was 1.01 (95% CI 0.69 to 1.47; I2 statistic= 0%).
Serious complications and study withdrawals
In oseltamivir trials, treatment did not significantly affect complications classified as serious or those that
led to withdrawal from the trial in adults (RR 0.91, 95% CI 0.40 to 2.06; I2 statistic= 0%) or in children
(RR 1.98, 95% CI 0.58 to 6.72; I2 statistic= 0%). This outcome could not be assessed in oseltamivir
prophylaxis because of an insufficient number of events. There was no significant effect of zanamivir, in
adult treatment, in reducing the risk of any complication classified as serious or which led to study
withdrawal (RR 1.10, 95% CI 0.46 to 2.63; I2 statistic= 0%) or in prophylaxis (RR 1.09, 95% CI 0.36 to
3.26; I2 statistic= 0%). This outcome could not be assessed in children because of an insufficient number
of events.
Bronchitis, sinusitis and otitis media
Neither zanamivir nor oseltamivir significantly reduced the risk of bronchitis or sinusitis in prophylaxis trials.
In adults, treatment with oseltamivir did not significantly reduce the risk of bronchitis (RR 0.75, 95% CI
0.56 to 1.01; I2 statistic= 36%), sinusitis (RR 1.03, 95% CI 0.76 to 1.40; I2 statistic= 0%) or otitis media
(RR 1.11, 95% CI 0.57 to 2.15; I2 statistic= 0%). The result for bronchitis was sensitive to the methods
used, as a fixed-effects analysis showed a significant effect (p= 0.02). Oseltamivir did not significantly
affect complications in treatment of children, including otitis media (RR 0.80, 95% CI 0.62 to 1.02;
I2 statistic= 0%).
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Treatment with zanamivir significantly reduced the risk of bronchitis in adults (RR 0.75, 95% CI 0.61 to
0.91; I2 statistic= 0%; RD 1.80%, 95% CI 0.65% to 2.80%; NNTB 56, 95% CI 36 to 155), but did not
reduce the risk of sinusitis or otitis media. In children, zanamivir treatment did not significantly reduce the
risk of sinusitis (RR 0.87, 95% CI 0.12 to 6.45; I2 statistic= 40%) or otitis media (RR 1.00, 95% CI 0.59 to
1.72; I2 statistic= 0%).
See Table 1 for a summary of the methodology used for collecting and assessing complications in
oseltamivir treatment trials. For the overall results for oseltamivir in adults see Table 8 and for children see
Table 9. Table 10 shows the overall results for zanamivir in adults and Table 11 shows the results
for children.
Analysis of influenza outcomes in prophylaxis studies
Symptomatic influenza was lower in the oseltamivir arms than the placebo arms in studies of prophylaxis
(RR 0.45, 95% CI 0.30 to 0.67; I2 statistic= 0%; RD 3.05%, 95% CI 1.83% to 3.88%; NNTB 33,
95% CI 26 to 55), but there were no differences for all other influenza outcomes, including overall ILI
reported as an adverse event on-treatment. In household prophylaxis, one small study with missing
outcome data and selective reporting, including 405 participants, showed a significant reduction of
symptomatic influenza in the oseltamivir arm compared with placebo (RR 0.20, 95% CI 0.09 to 0.44;
RD 13.6%, 95% CI 9.52% to 15.47%), but in the same study there was no significant reduction in
asymptomatic influenza (RR 1.14, 95% CI 0.39 to 3.33). Asymptomatic influenza was not significantly
reduced and there was no non-influenza ILI reported throughout the study period.
In prophylaxis trials we could not analyse effects on ILI because of a lack of definition in the CSRs.
However, using our definition (see Methods), oseltamivir did not reduce ILI in participants (RR 0.95,
95% CI 0.86 to 1.06). See Appendix 11 for further analysis of symptomatic ILI.
The Roche trial programme assessing the effects of oseltamivir in PEP, submitted to the FDA on
22 May 2000, consisted of two trials.65,120 We included only one trial65 because the other120 was not
placebo controlled. WV1579965 was a double-blind, cluster-randomised trial in which contact clusters
of index cases were randomised to oseltamivir 75mg a day or placebo for 7 days. The manufacturer
concluded that the trial proved that oseltamivir could prevent influenza in contacts by interrupting
transmission from index cases. Interruption of transmission has two components: reduction of viral spread
from index cases (measured by nasal shedding of influenza viruses) and prevention of onset of influenza
in contacts measured with a mixture of symptoms and signs and ‘laboratory confirmation’ (i.e. viral culture
from the upper airways and/or at least a fourfold rise in antibody titres measured between baseline and
2–3 weeks later). The design of the WV1579965 is weak. All index cases were left untreated except for a
paracetamol rescue pack, making it impossible to assess the effect of oseltamivir on nasal voidance of
index cases. Nasal viral voidance was measured only in symptomatic participants thereby missing out on
potential asymptomatic infected people.
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Zanamivir similarly significantly reduced the risk of symptomatic influenza for individuals (RR 0.39, 95% CI
0.22 to 0.70; I2 statistic= 45%; RD 1.98%, 95% CI 0.98% to 2.54%; NNTB 51, 95% CI 40 to 103), as
well as households (RR 0.33, 95% CI 0.18 to 0.58; I2 statistic= 40%; RD 14.84%, 95% CI 12.18% to
16.55%; NNTB 7, 95% CI 6 to 9). However, it did not reduce the risk of asymptomatic influenza in the
prophylaxis of individuals (RR 0.97, 0.76 to 1.24; I2 statistic= 0%) or asymptomatic individuals in PEP of
households (RR 0.88, 95% CI 0.65 to 1.20; I2 statistic= 0%). See Table 10 for the overall results for
zanamivir in adults and Table 11 for results in children. See Tables 12 and 13 for the overall results for
zanamivir in adults.
Analysis of harms
Oseltamivir treatment
Nausea, vomiting and diarrhoea Oseltamivir in the treatment of adults is associated with increased risk
of nausea (RR 1.57, 95% CI 1.14 to 2.15; I2 statistic= 43%; RD 3.66%, 95% CI 0.90% to 7.39%;
NNTH 28, 95% CI 14 to 112) and vomiting (RR 2.43, 95% CI 1.75 to 3.38; I2 statistic= 12%; RD 4.56%,
95% CI 2.39% to 7.58%; NNTH 22, 95% CI 14 to 42). It is associated with a decreased risk of diarrhoea
(RR 0.67, 95% CI 0.46 to 0.98; I2 statistic= 44%; RD 2.33%, 95% CI 0.14% to 3.81%; NNTB 43, 95% CI
27 to 709) compared with placebo during on-treatment periods. Both nausea and vomiting were
associated with significant heterogeneity, when treatment effects appeared larger in otherwise healthy
adults than in the elderly and the chronically ill. However, one trial of otherwise healthy adults69 also
showed smaller effects. Vomiting was more common in those children on oseltamivir treatment than in
those on placebo treatment (RR 1.70, 95% CI 1.23 to 2.35; I2 statistic= 0%; RD 5.34%, 95% CI 1.75%
to 10.29%; NNTH 19, 95% CI 10 to 57).
Cardiac effects The cardiac effects of oseltamivir are unclear. Exposure to oseltamivir may reduce cardiac
general events compared with placebo (RR 0.49, 95% CI 0.25 to 0.97; I2 statistic= 0%; RD 0.68%,
95% CI 0.04% to 1.00%; NNTB 148, 95% CI 101 to 2509), excluding one trial70 in which electrocardiography
was included in the safety parameters. However, exposure to oseltamivir may increase corrected QT interval
prolongation (including borderline) as reported in trial WV1627770 (RD 4.0%, 95% CI 0.71% to 7.30%;
NNTH 25, 95% CI 14 to 140) compared with placebo during on-treatment periods.
Psychiatric effects In treatment trials, there was no significant increase in risk between oseltamivir and
on-treatment psychiatric adverse events overall (RR 0.93, 95% CI 0.43 to 2.03; I2 statistic= 0%). However,
there was a dose–response effect in the two ‘pivotal’ treatment trials.8,58 In the identically designed trials8,58
there were two active treatment groups: 150mg (standard dose) and 300mg (high dose) oseltamivir per
day. In the dose–response analysis there was an increased risk of psychiatric body system adverse events
over the entire follow-up period (p= 0.038, based on likelihood ratio test). In one trial,8 the event rates
were 1 of 204, 1 of 206 and 4 of 205 in the placebo, 75-mg and 150-mg arms, respectively, whereas the
second trial58 had rates of 2 of 235, 0 of 242 and 5 of 242, respectively.
Effect on antibodies (post-protocol hypotheses) The proportion of patients being diagnosed as
influenza infected in oseltamivir treatment of adults was significantly lower in the treated group than in
the control group (RR 0.95, 95% CI 0.91 to 0.99; I2 statistic= 0%). The proportion of patients with
fourfold increases in antibody titre was significantly lower in the treated group than in the control group
(RR 0.92, 95% CI 0.86 to 0.97; I2 statistic= 0%). This represents an absolute difference of 5% between
treatment groups. There was a lower proportion of children on oseltamivir with a fourfold increase in
antibodies (RR 0.90, 95% CI 0.80 to 1.00; I2 statistic= 0%).
DOI: 10.3310/hta20420 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 42
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Heneghan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
TA
B
LE
12
Za
n
am
iv
ir
vs
.p
la
ce
b
o
fo
r
p
re
ve
n
ti
n
g
in
fl
u
en
za
in
ad
u
lt
s
Pa
ti
en
t
o
r
p
o
p
u
la
ti
o
n
:
h
ea
lt
h
y
ad
u
lt
s
w
it
h
o
u
t
in
fl
u
en
za
Se
tt
in
g
s:
co
m
m
u
n
it
y,
n
u
rs
in
g
h
o
m
es
In
te
rv
en
ti
o
n
:
za
n
am
iv
ir
vs
.p
la
ce
b
o
fo
r
p
ro
p
h
yl
ax
is
O
u
tc
o
m
es
Ill
u
st
ra
ti
ve
co
m
p
ar
at
iv
e
ri
sk
s,
a
st
u
d
y
p
o
p
u
la
ti
o
n
(9
5%
C
I)
R
el
at
iv
e
ef
fe
ct
(9
5%
C
I)
N
u
m
b
er
o
f
p
ar
ti
ci
p
an
ts
(s
tu
d
ie
s)
R
D
,%
(9
5%
C
I)
N
N
TB
o
r
N
N
TH
(9
5%
C
I)
A
ss
u
m
ed
ri
sk
C
o
rr
es
p
o
n
d
in
g
ri
sk
Pl
ac
eb
o
Za
n
am
iv
ir
vs
.p
la
ce
b
o
fo
r
p
ro
p
h
yl
ax
is
Sy
m
pt
om
at
ic
in
flu
en
za
in
pr
op
hy
la
xi
s
of
in
di
vi
du
al
s
33
pe
r
10
00
13
pe
r
10
00
(7
to
23
)
RR
0.
39
(0
.2
2
to
0.
70
)
52
75
(4
)
1.
98
(0
.9
8
to
2.
54
)
N
N
TB
51
(4
0
to
10
3)
A
sy
m
pt
om
at
ic
in
flu
en
za
in
pr
op
hy
la
xi
s
of
in
di
vi
du
al
s
50
pe
r
10
00
48
pe
r
10
00
(3
8
to
60
)
RR
0.
97
(0
.7
6
to
1.
24
)
52
75
(4
)
0.
14
(–
1.
1
to
1.
1)
N
N
TB
72
9
(N
N
TB
91
to
∞
to
N
N
TH
91
)
Sy
m
pt
om
at
ic
in
flu
en
za
in
ho
us
eh
ol
d
pr
op
hy
la
xi
s
19
0
pe
r
10
00
42
pe
r
10
00
(2
5
to
68
)
RR
0.
22
(0
.1
3
to
0.
36
)
82
4
(2
)
14
.8
4
(1
2.
18
to
16
.5
5)
N
N
TB
7
(6
to
9)
A
sy
m
pt
om
at
ic
in
flu
en
za
in
ho
us
eh
ol
d
pr
op
hy
la
xi
s
10
7
pe
r
10
00
97
pe
r
10
00
(6
4
to
14
5)
RR
0.
90
(0
.6
to
1.
35
)
82
4
(2
)
1.
32
(–
2.
2
to
3.
84
)
N
N
TB
76
(N
N
TB
26
to
∞
to
N
N
TH
46
)
C
om
pl
ic
at
io
ns
:
pn
eu
m
on
ia
in
ad
ul
t
pr
op
hy
la
xi
s
5
pe
r
10
00
1.
5
pe
r
10
00
(1
to
4)
RR
0.
30
(0
.1
1
to
0.
8)
76
62
(6
)
0.
32
(0
.0
9
to
0.
41
)
N
N
TB
31
1
(2
44
to
10
86
)
C
om
pl
ic
at
io
ns
:
br
on
ch
iti
s
in
ad
ul
t
pr
op
hy
la
xi
s
15
pe
r
10
00
8
pe
r
10
00
(3
to
18
)
RR
0.
49
(0
.0
2
to
1.
19
)
76
62
(6
)
0.
79
(–
0.
29
to
1.
24
)
N
N
TB
12
7
(t
o
N
N
TB
81
to
∞
to
N
N
TH
34
1)
a
To
es
tim
at
e
tr
ea
tm
en
t
ef
fe
ct
s
w
e
fir
st
ca
lc
ul
at
ed
ris
k
ra
tio
s
an
d
us
ed
th
e
av
er
ag
e
(m
ea
n)
co
nt
ro
le
ve
nt
ra
te
an
d
po
ol
ed
ris
k
ra
tio
s
re
po
rt
ed
in
fig
ur
es
to
ca
lc
ul
at
e
ris
k
di
ff
er
en
ce
s.
NEURAMINIDASE INHIBITORS FOR PREVENTING AND TREATING INFLUENZA IN ADULTS AND CHILDREN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
TA
B
LE
13
O
se
lt
am
iv
ir
vs
.p
la
ce
b
o
fo
r
p
re
ve
n
ti
n
g
in
fl
u
en
za
in
ad
u
lt
s
Pa
ti
en
t
o
r
p
o
p
u
la
ti
o
n
:
h
ea
lt
h
y
ad
u
lt
s
w
it
h
o
u
t
in
fl
u
en
za
Se
tt
in
g
s:
co
m
m
u
n
it
y,
n
u
rs
in
g
h
o
m
es
In
te
rv
en
ti
o
n
:o
se
lt
am
iv
ir
vs
.p
la
ce
b
o
fo
r
p
ro
p
h
yl
ax
is
O
u
tc
o
m
es
Ill
u
st
ra
ti
ve
co
m
p
ar
at
iv
e
ri
sk
s,
a
st
u
d
y
p
o
p
u
la
ti
o
n
(9
5%
C
I)
R
el
at
iv
e
ef
fe
ct
(9
5%
C
I)
N
u
m
b
er
o
f
p
ar
ti
ci
p
an
ts
(s
tu
d
ie
s)
R
D
,%
(9
5%
C
I)
N
N
TB
o
r
N
N
TH
(9
5%
C
I)
A
ss
u
m
ed
ri
sk
C
o
rr
es
p
o
n
d
in
g
ri
sk
Pl
ac
eb
o
O
se
lt
am
iv
ir
vs
.p
la
ce
b
o
fo
r
p
ro
p
h
yl
ax
is
Sy
m
pt
om
at
ic
in
flu
en
za
in
ad
ul
t
pr
op
hy
la
xi
s
of
in
di
vi
du
al
s
55
pe
r
10
00
25
pe
r
10
00
(1
7
to
37
)
RR
0.
45
(0
.3
0
to
0.
67
)
24
79
(3
)
3.
05
(1
.8
3
to
3.
88
)
N
N
TB
33
(2
6
to
55
)
Sy
m
pt
om
at
ic
in
flu
en
za
in
ho
us
eh
ol
d
pr
op
hy
la
xi
s
17
0
pe
r
10
00
34
pe
r
10
00
(1
5
to
75
)
RR
0.
2
(0
.0
9
to
0.
44
)
40
5
(1
)
13
.6
(9
.5
2
to
15
.4
7)
N
N
TB
7
(6
to
11
)
A
dv
er
se
ev
en
ts
:
ps
yc
hi
at
ric
bo
dy
sy
st
em
s
in
ad
ul
t
pr
op
hy
la
xi
s
(a
ll
ev
en
ts
on
-
an
d
of
f-
tr
ea
tm
en
t)
13
pe
r
10
00
23
pe
r
10
00
(1
4
to
40
)
RR
1.
80
(1
.0
5
to
3.
08
)
34
34
(4
)
–
1.
06
(–
2.
76
to
–
0.
07
)
N
N
TH
94
(3
6
to
15
38
)
A
dv
er
se
ev
en
ts
:h
ea
da
ch
e
in
ad
ul
t
pr
op
hy
la
xi
s
(o
n-
tr
ea
tm
en
t)
17
5
pe
r
10
00
20
7
pe
r
10
00
(1
84
to
23
3)
RR
1.
18
(1
.0
5
to
1.
33
)
34
34
(4
)
–
3.
15
(–
5.
78
to
–
0.
88
)
N
N
TH
32
(1
8
to
11
5)
A
dv
er
se
ev
en
ts
:n
au
se
a
in
ad
ul
t
pr
op
hy
la
xi
s
(o
n-
tr
ea
tm
en
t)
43
pe
r
10
00
85
pe
r
10
00
(5
2
to
13
8)
RR
1.
96
(1
.2
to
3.
2)
34
34
(4
)
–
4.
15
(–
9.
51
to
–
0.
86
)
N
N
TH
25
(1
1
to
11
6)
A
dv
er
se
ev
en
ts
:v
om
iti
ng
in
ad
ul
t
pr
op
hy
la
xi
s
(o
n-
tr
ea
tm
en
t)
10
pe
r
10
00
20
pe
r
10
00
(7
to
55
)
RR
1.
91
(0
.7
to
5.
22
)
34
34
(4
)
–
0.
95
(–
4.
41
to
0.
31
)
N
N
TH
10
6
(N
N
TB
31
9
to
∞
to
N
N
TH
23
)
A
dv
er
se
ev
en
ts
:
he
ad
ac
he
in
ad
ul
t
pr
op
hy
la
xi
s
(o
ff
-t
re
at
m
en
t)
37
pe
r
10
00
33
pe
r
10
00
(2
3
to
46
)
RR
0.
88
(0
.6
3
to
1.
24
)
34
34
(4
)
0.
44
(–
0.
89
to
1.
37
)
N
N
TB
22
6
(N
N
TB
74
to
∞
to
N
N
TH
11
3)
a
To
es
tim
at
e
tr
ea
tm
en
t
ef
fe
ct
s
w
e
fir
st
ca
lc
ul
at
ed
ris
k
ra
tio
s
an
d
us
ed
th
e
av
er
ag
e
(m
ea
n)
co
nt
ro
le
ve
nt
ra
te
an
d
po
ol
ed
ris
k
ra
tio
s
re
po
rt
ed
in
fig
ur
es
to
ca
lc
ul
at
e
ris
k
di
ff
er
en
ce
s.
DOI: 10.3310/hta20420 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 42
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Heneghan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
Oseltamivir prophylaxis
Headaches and nausea In oseltamivir prophylaxis, there was an increased risk of headaches on-treatment
(RR 1.18, 95% CI 1.05 to 1.33; I2 statistic= 0%; RD 3.15%, 95% CI 0.88% to 5.78%; NNTH 32, 95% CI
18 to 115) (Figure 8) and nausea on-treatment (RR 1.96, 95% CI 1.20 to 3.20; I2 statistic= 49%; RD
4.15%, 95% CI 0.86% to 9.51%; NNTH 25, 95% CI 11 to 116). There was also a dose–response effect
for headaches in study52 (p= 0.013, based on likelihood ratio test), for which on-treatment rates were 202
of 519, 225 of 520 and 242 of 520 in the placebo, standard-dose and high-dose arms, respectively.
Psychiatric effects Figure 9 shows that in prophylaxis trials of oseltamivir there was a significant increase
in patients with psychiatric adverse events over the on- and off-treatment periods (RR 1.80, 95% CI 1.05
to 3.08; I2 statistic= 0%; RD 1.06%, 95% CI 0.07% to 2.76%; NNTH 94, 95% CI 36 to 1538). Initial
analysis of patients with psychiatric adverse events in the on-treatment period showed a borderline
statistically significant result (p= 0.06), hence we conducted sensitivity analysis using Peto’s method
(p= 0.05) as well as the analysis reported in Figure 9.
Table 14 shows a summary of all of the psychiatric adverse events in oseltamivir prophylaxis trials. Of
particular note was an oseltamivir patient in one study68 who had severe confusion on day 27 and was
hospitalised. On day 28 the patient was taken off medication and the event resolved. On day 29 the
patient was discharged from hospital and subsequently resumed medication. However, confusion
reappeared on day 32. The initial event was misclassified in the CSR as ‘mental impairment’ but has since
been corrected in an erratum published in the same journal that published the original trial manuscript.37,38
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FIGURE 8 Oseltamivir vs. placebo for prophylaxis, outcome: adverse events – headache in adult prophylaxis
(on-treatment). df, degree of freedom; IV, inverse variance.
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FIGURE 9 Oseltamivir vs. placebo for prophylaxis: adverse events – psychiatric body system in adult prophylaxis
(on- and off-treatment). df, degree of freedom; IV, inverse variance.
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Renal effects There was a non-significant increase in renal events on-treatment (RR 3.17, 95% CI 0.96 to
10.49; I2 statistic= 0; RD 0.67%, 95% CI –0.01% to 2.93%; NNTH 150, 95% CI NNTH 35 to ∞ to NNTB
> 1000). However, in sensitivity analysis using Peto’s method the result for renal events was statistically
significant (p= 0.02).
Zanamivir
Serious adverse events There was no significant effect on serious adverse events in adult treatment trials
(RR 0.86, 95% CI 0.49 to 1.50; I2 statistic= 0%).
Nausea, vomiting and diarrhoea In treatment trials, there was no significant effect on diarrhoea in
adults (RR 0.87, 95% CI 0.66 to 1.14; I2 statistic= 5%) or headache (RR 0.84, 95% CI 0.60 to 1.18;
I2 statistic= 0). However, during the on-treatment phase, nausea and vomiting were significantly less
frequent in the zanamivir arm (RR 0.60, 95% CI 0.39 to 0.94; I2 statistic= 0%; RD 1.63%, 95% CI 0.24%
to 2.48%; NNTB 62, 95% CI 41 to 411).
Renal, psychiatric and other harms There was no significant effect observed on the renal system
(RR 0.84, 95% CI 0.41 to 1.72; I2 statistic= 0%) or the psychiatric system (RR 1.16, 95% CI 0.57 to 2.38;
I2 statistic= 0%). In adult treatment trials of zanamivir, there was no significantly increased risk of any other
reported adverse events, and there was no significant increase in adverse effects observed in prophylaxis
trials, including psychiatric (RR 1.05, 95% CI 0.48 to 2.29; I2 statistic= 25%) and renal effects (RR 0.67,
95% CI 0.35 to 1.26; I2 statistic= 0%) on-treatment. There was no significant increase in harms associated
with zanamivir treatment of children but data were sparse.
TABLE 14 Psychiatric adverse events in oseltamivir prophylaxis trials
Event type
Oseltamivir Placebo Total
Number of events % Number of events % Number of events %
Confusion 5 0.25 1 0.07 6 0.17
Depression 14 0.7 6 0.42 20 0.58
Hallucinations 2 0.1 0 0.00 2 0.06
Anxiety 7 0.35 8 0.56 15 0.44
Psychosis 2 0.1 1 0.07 3 0.09
Schizophrenia 1 0.05 0 0.00 1 0.03
Bipolar disorder 0 0 1 0.07 1 0.03
Sleeping disorder 2 0.1 0 0.00 2 0.06
Aggression 1 0.05 0 0.00 1 0.03
Stress symptoms 3 0.15 0 0.00 3 0.09
Restlessness 1 0.05 0 0.00 1 0.03
Nervousness 1 0.05 0 0.00 1 0.03
Suicide ideation 1 0.05 0 0.00 1 0.03
Paranoia 1 0.05 0 0.00 1 0.03
Alcohol related 6 0.3 2 0.14 8 0.23
Total 47 2.35 19 1.32 66 1.92
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Effect on antibodies There was no significant effect of zanamivir treatment on influenza diagnosis
(RR 1.02, 95% CI 0.98 to 1.06; I2 statistic= 0%) or probability of a fourfold increase in antibody titre
(RR 1.06, 95% CI 0.96 to 1.06; I2 statistic= 0%).
Deaths
In oseltamivir treatment trials, there was one death overall. This event occurred as a result of acute
respiratory syndrome in a placebo patient without influenza in study.66 In prophylaxis trials, there were
four deaths in total, all in elderly patients, with two in the placebo group and two in the oseltamivir group.
Causes of death were reported as two cancers, one myocardial infarction and one intestinal perforation.
However, for both deaths in the oseltamivir arms the participants experienced acute renal failure
on-treatment prior to death.
There were eight deaths in total in the zanamivir trials. Six of the deaths were caused by neoplasias or
cardiovascular events in elderly patients with multiple pathologies. However, two deaths were reported as
being due to influenza A pneumonia. One participant was on inhaled rimantadine plus placebo and the
other on zanamivir.
The results of post-protocol hypotheses are in Appendix 8.
Discussion
Oseltamivir and zanamivir have small, non-specific effects on reducing time to alleviation of ILI symptoms in
adults but not in asthmatic children. Using either drug as prophylaxis reduces the risk of developing
symptomatic influenza. Treatment trials with oseltamivir or zanamivir do not settle the question of whether
or not complications of influenza, such as pneumonia, are reduced, because of a lack of diagnostic
definitions. Use of oseltamivir increases the risk of adverse effects such as nausea, vomiting, psychiatric
effects and renal events in adults, and the risk of vomiting in children. The lower bioavailability may explain
the lower toxicity of zanamivir than that of oseltamivir. The influenza virus-specific mechanism of action
proposed by the producers does not fit the clinical evidence, which shows no such effects.
Reconstructing trial lists and indexing regulatory comments
Calls for incorporating unpublished data to supplement published trial data in systematic reviews and
meta-analyses highlight deficiencies in the current methods for obtaining the most complete understanding
of a drug’s effects.121 Our methodological approach entailed comprehensive searching of unpublished
sources, with a particular emphasis on obtaining unpublished and internal reports from drug manufacturers,
intended for regulatory submission, and comments from national regulatory bodies. Our decision not to use
published evidence as a basis for trial appraisal and data extraction meant that we had to reconcile and
synthesise information from multiple unpublished sources. We had to devise a new method of searching,
indexing, retrieving and reviewing trial data, and to combine this understanding with regulatory comments
to produce an informative review. The first step in this process entailed the need to develop our own
reconstruction of the trial programme without initial help from outside sources. The reconstructed list of
trials and then programmes took a whole-time equivalent researcher 20 days to compile. Owing to the
complexity of the task, we suggest that, in the future, some of the essential phases, such as checking the
trial identification number across multiple documents and databases, be conducted in pairs.
One of the comments received on our protocol suggested that discrepancies between published and
unpublished versions of the same data set could be due to mistakes in the non-peer reviewed, unedited
CSRs (which may be corrected by the time of publication). Our experience, especially with the non-reporting
of serious adverse events, points to the opposite being the case.122 Considering the fact that unintentional
errors can occur, we believe that the response should not be a resort to published papers as ‘most accurate’
and best unit of analysis, but rather that CSRs – as by far the most comprehensive record of a trial – remain
the key unit of analysis, with the expectation that they be amended and kept as accurate as possible over
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time, with complete documentation of reasons for any amendments. We believed that the results of our
review would be undermined without accessing a more complete body of evidence that we knew to be
outside the public domain.
In theory, trial registers would be expected to provide a comprehensive picture of a drug’s trial
programme. However, registers were not our primary instruments to reconstruct zanamivir and oseltamivir
trial programmes. Both drugs’ programmes were mainly run in the late 1990s, before trial registration
became the norm. In addition, registers may suffer from some of the problems that we were trying to
address. Bourgeois et al.123 audited entries for 546 trials of five major classes of drugs on ClinicalTrials.gov,
the biggest prospective register of clinical trials, and found evidence of risk of reporting bias and delay
in reporting of results. Another review of 152 trials found that the description of 123 (or 81%) of the
trials in the sample had been changed in at least one key element in the time between registration and
publication. The most frequent changes regarded outcomes.124 Despite the current limits of registers, both
specifically to this review and in the way they are run and updated, we believe that registers are an
obvious first choice to start reconstruction of trials programmes. Searching for unpublished material has
not yet become standard practice in conducting Cochrane reviews,125 and is currently variably reported.126
The indexing and review of regulatory files was also a very laborious task. It took a whole-time equivalent
researcher 3 days to review the FDA regulator’s comments and gain a basic understanding of the content.
Four additional days were needed to read and annotate the FDA zanamivir files and 28 days for reading and
annotating the oseltamivir files and building the table of contents-evidence (see Appendix 11). The exercise
had to be repeated several times to cross-check content and expand annotations. Construction of the TOC
was laborious. A first attempt at electronic mapping the TOC content took 12 and 8 hours, respectively,
for the FDA and National Institute for Health and Care Excellence (NICE) regulatory documents. This was
carried out using the Adobe Acrobat (Adobe Systems; https://acrobat.adobe.com/us/en/acrobat/how-to/
ocr-software-convert-pdf-to-text.htm) optical character recognition search facility, which enabled mapping
of citation counts by document and by trial ID. Initially, we used the trial prefix followed by the serial
number (‘WV15670’) as ID. This procedure, however, had one major drawback linked to the nature of
regulatory documents. As regulatory documents consist of notes, correspondence and reviews, the same
trial is cited in a non-standardised way. For example, trial WV156708 is cited as ‘WV15670’ 15 times, as
‘WV_15670’ 12 times and simply as ‘15670’ 19 times. Thorough searches must be conducted using all of
the different terms. As this can be very time-consuming, we decided to compare an Acrobat search with a
Boolean string strategy containing all of the possible citation formats (e.g. WV15758 OR WV 15758 OR Trial
15758 OR Trial15758 OR Trials 15758 OR Trials15758 OR 15758 OR study 15758 OR study15758) (this is
logically equivalent to ‘WV 15758 OR WV 15758’) with a term-by-term search (i.e. separately searching for
WV15758 and then for WV 15758 and so on). We reasoned that if the yield were comparable, the Boolean
strategy would have been faster. The yield of citations of the two strategies was the same for six of seven
‘tracker’ studies, but use of a Boolean string was considerably faster (an average of 3 vs. 14 hours) than the
term-by-term strategy. The NICE submission citations took 2 hours to list in a TOC using a Boolean strategy.
We adopted the Boolean search strategy to construct our TOC. Ultimately, it is possible that a search with
the trial numerals (‘15670’) may be sufficient to identify the vast majority of citations. To validate this
method of searching further, our methods should be repeated on other sets of regulatory documents.
Once we had reconstructed the trial programmes, we submitted the results to GSK and Roche for their
input. We received detailed feedback from both but, into 2011, Roche’s list of trials was still incomplete.
Despite the laboriousness of the methods, we believe that we ended up with a far more comprehensive and
less biased set of evidence than that available through the current system of journal-based publications.
This shift in our data synthesis paradigm was made necessary by the numerous and documented
discrepancies between regulatory and published evidence and by the sizeable risk of publication bias of the
oseltamivir trial programme. The importance of reconstructing the trial programme by first generating a
complete trial list was further reinforced upon discovering bias and oversights in regulators’ handling of the
trial programme. Regulators focus on a few mutually agreed ‘pivotal’ trials, the data analyses of which are
replicated by the FDA but not by the EMA. Both largely ignored trial M76001,36 the largest oseltamivir
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treatment trial that was conducted prior to initial registration of the drug (and still unpublished). Although
the manufacturer may not have offered it as a ‘pivotal’ trial, far smaller and even ongoing studies were
included in the evidence base to support Roche’s year 1999 NDA number 021087 (treatment of
uncomplicated acute illness due to influenza infections in adults who have been symptomatic for no more
than 2 days). The history of the EMA scrutiny is harder to assess as we could find no reports of trial site visits
or of data analysis replication, but we identified a pooled analysis of treatment trials, very similar to the
Kaiser 2003 analysis,4 which formed the basis for the EMA conclusion that oseltamivir affected complications
reported, for example on EMA’s 4 October 2012 Summary of Product Characteristics (www.bmj.com/
tamiflu/ema). We requested modules 3–5 (individual listings, demographic data and the statistical analysis
report) from the EMA. However, for most oseltamivir trials, the EMA does not have the relevant documents
and neither apparently does the National Competent Authorities (e-mail from the EMA, 24 May 2011; e-mail
from Dutch regulator Medicines Evaluation Board, 20 July 2011). This means that the modules do not
appear to have been either submitted to or requested by regulators, raising questions as to the extent of
scrutiny of the clinical trials during the regulatory review of oseltamivir in Europe.
Our new method
Reviewing large quantities of complicated data and linked comments is a very difficult and delicate process.
The main problem is not so much the appraisal following standard rules and possible synthesis of data (as
when we review published information), but the reconstructions and logical threading of a trial programme
generating huge amounts of data needing appraisal. Also the manufacturer’s full regulatory submission,
which may have even more information than a full CSR, remains confidential. Most of the essential data
required are available in CSRs, together with masses of less important data, but, as we have explained, even
in this case there may be important omissions, such as mislaid diary cards (Figures 10 and 11) for follow-up.
Manufacturers are under obligation to provide regulators with all of the data requested to enable them to
reach a decision: in doing so they produce vast submissions. None of the authors (all experienced systematic
reviewers) had any experience of reviewing regulatory information, but we could not find any workable
shortcuts. We believe that providing a critical overview of a trial programme rather than minute dissection
of each trial is necessary. This can be done by identifying the important topics in the trial programme
(such as the effects of the drug on symptoms, infection, complications, transmission and well-being) and
following them throughout the programme, putting the evidence together coherently. This includes
carrying out a high-level overview of the mode of action of the drug in different populations for different
indications. Understanding a drug’s mode of action underpins correct reporting of its strengths and
limitations. In addition, a large part of the regulatory submission is made up of chemistry, microbiological,
animal model pharmacodynamic and pharmacokinetic studies, which are important for shedding light on
the trial programme but which seldom feature in systematic reviews. We are unsure whether or not this
information could be considered as core information, but an exhaustive review of a trial programme should
include reviews dedicated to such topics.
These methods revealed possible problems in trial conduct and validity, including the lack of comparability
between arms induced by subset analysis and by the randomisation analysis fork, high positivity rate of
influenza, high gastrointestinal events in the placebo arms, possibly active placebo content and possible
procedural breaches in several trials. The ideal option is to carry out analyses on the basis of the ITT
population, in which units of randomisation and analysis are the same and many of the potential problems
listed are either not present or minimised. We are continuing to develop further methods for using
such data.
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FIGURE 10 Example diary card from CRF for zanamivir trial (1).
FIGURE 11 Example diary card from CRF for zanamivir trial (2).
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Regulatory comments
Reviewing regulatory comments was essential to expand our understanding of the trial programme. We
expected that detailed reading of regulatory material would allow us to understand discrepancies between
US and European regulators’ conclusions regarding the effects of oseltamivir, particularly (but not limited
to) their putative effect on complications.8 We were interested in what led the FDA to have far more
cautious and conservative statements – as witnessed in the Tamiflu product label and FDA letters – in
comparison with European regulators. Our access to huge amounts of FDA regulatory data allowed for
many insights but gave us little visibility of manufacturers’ responses.
Some of the statements (such as NIs reduce bacterial complications) made by the manufacturer in the
CSRs, and, subsequently, in contemporaneous publications and advertisements, appeared unsupported by
the evidence provided at the time. The FDA drug regulatory reviewers’ comments, although laborious to
summarise and contextualise (because of the non-availability of the whole pharmaceutical submission),
were confirmed by our reading of the CSRs. However, we were unable to find a statement explaining how
the FDA reviewed each NDA. FDA reviewing methods appeared to be a mixture of spot checks, re-run of
statistical analyses and on-site inspections. A FDA methods volume or standard operational procedure may
be among the documents not available from the web but accessible through a FOI request. Neither the
FDA nor the EMA have inventories of held documents, making it very difficult to know what to ask for
under FOI rules. We concentrated on downloading or asking for specific CSRs and related documents or
reviewers’ comments on a particular NDA. The quantity of information held by regulators is likely to be
large. For example, NDA 21–246, regarding the use of Tamiflu in the treatment of influenza in children,
submitted to the FDA on 15 June 2000, consisted of 137 volumes of study documents and possibly several
electronic files. Although we do not know exactly how long a volume was, we have seen references to up
to hundreds of pages in each volume.
Requesting specific documents and packages of information is especially important to allow a more
efficient and timely reviewing process when confronted with a large volume of evidence, most of which
could be of peripheral value. A request for a specific document is likely to be dealt with far more efficiently
than a generic request for ‘all documentation relating to oseltamivir’. This is one of the reasons why
developing a TOC for any drug or family of drugs (no matter how time-consuming) is an absolute
prerequisite for any serious attempt at reviewing regulatory evidence. This introduces another very difficult
problem: how to handle huge quantities of structured information and the ethics of drawing conclusions
from what is still a fragmentary (albeit sizeable) evidence base.
Overall, the FDA assessment of the performance of oseltamivir was ‘modest’. This adjective appears
six times in a 50-page review document.109 For example, in the Division Director Memorandum dated
25 October 1999, under the heading ‘Public health role of antiviral treatment’ the FDA109 states: ‘The clinical
relevance of the modest treatment benefit is a highly subjective question’ (p. 3). The FDA refused to accept
claims of oseltamivir’s effects on influenza complications as ‘false or misleading’ statements in promotional
materials.122 A FDA warning letter seems to imply, for example, that oseltamivir’s mode of action is ‘proposed’
or ‘possibly’ (that proposed by the manufacturers) (i.e. not certain).127 However, FDA reviewers appear to have
missed important problems in Roche’s clinical trials (such as the imbalance in the numbers of individuals
classified as influenza infected in oseltamivir treatment trials). Importantly, there appears to have been no
investigation into the coherence of the evidence with the proposed mode of action of the drug.
Summary of main results
For the first time, a Cochrane review is based on all relevant full CSRs of a class of drugs integrated by
regulatory comments. Also for the first time, all CSRs of trials in a manufacturer’s programme (regardless
of their relevance to the review) are available to readers without any restriction (apart from minimal
redactions to protect anonymity further). The role of Roche and GSK in making this possible should be
recognised, as well as that of the BMJ, which kept the issue in the public eye until it was resolved.
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The evidence we have presented and synthesised shows that both of the NIs in this review have
symptom-relieving effects, especially for self-reported outcomes. They appear to have symptom-relieving
properties that make people with ILI and self-reported, investigator-mediated, unverified pneumonia
feel better by shortening symptom duration and reducing the frequency of symptoms, such as cough.
For oseltamivir, this effect perhaps extends to cardiac symptoms, despite the short duration of treatment
(5 days). We are unsure what to make of this finding but we think it deserves further investigation.
The issue which triggered our change of evidence-seeking methods is partly resolved: no definitions of
secondary illnesses were given anywhere in the CSRs [e.g. ‘pneumonia’ was defined as ‘pneumonia’ in the
CRFs (see Table 1) and diagnostic criteria were not given]; clinical diagnosis in the absence of criteria and
without X-ray has only a moderate chance of being correct.
We could not decide the level of diagnostic ascertainment of diagnosis of pneumonia and other
complications, as it is unclear from the CSRs. Definitions of pneumonia were not given and the algorithm for
classification of an event as pneumonia was not supplied. In oseltamivir trials, the CRF trigger for recording
of adverse events and secondary illness was a question to the participant posed by the investigator. A typical
phrasing is as follows: ‘Secondary illness reminder: Has the patient reported any sinusitis, otitis, bronchitis,
other chest infection or pneumonia since baseline?’ This was followed by a yes/no box to be ticked and an
additional form was to be filled out by the investigator for collecting details on the secondary illness. A
record of medications outside trial allocation was elicited in addition to the participant’s diary card. The
original and Medical Dictionary for Regulatory Activities terms suggest diagnoses for all secondary illnesses
and adverse events but there is no indication as to how the original and preferred terms were assigned. We
therefore considered these outcomes to be ‘self-reported, investigator-mediated, unverified’ outcomes. For a
subset of trials, secondary/intercurrent illness and adverse event data were collected on a single, one-page
form. In our meta-analyses, we called this subanalysis ‘Trials which collected data on non-specific adverse
events or secondary/intercurrent illness form’. For a different subset of trials, CRFs contained space to record
diagnostic tests, such as chest X-rays, tympanometry and sinus X-rays for all secondary illness but there was
no reporting of such variables in the CSRs (Figures 12–15). In our meta-analyses, we called this subanalysis
‘Trials which collected data on specific “Diagnosis of Secondary Illness” form’. None of the complications
was defined as primary outcomes in any trial, which may explain the poverty of data definition.
In a metaregression of all of the 32 included studies that reported on ‘pneumonia’, we found evidence
that treatment effects for pneumonia are statistically different depending on the method of diagnosis.
Unclear objective diagnosis was associated with an apparent 46% reduction in pneumonia as a result of
treatment with NIs, whereas the use of objective criteria in the data collection showed no evidence of
effect, with a RR of 1.0. Age group (adults vs. children), drug (oseltamivir vs. zanamivir) and indication
(treatment vs. prophylaxis) showed no evidence of association with treatment effect.
Meaningful conclusions on the effect of either NI on complications of influenza are difficult to draw
based on the trial evidence. In part, this was due to the lack of standardised definitions. In addition,
meta-analyses of these outcomes that lacked definitions were based on few events and therefore
not robust. Caution is therefore urged in interpreting the meta-analysis result, which suggests that
100 patients (95% CI 67 to 451 patients) need to be treated with oseltamivir for one less self-reported,
investigator-mediated, unverified pneumonia. The same applies to the zanamivir treatment result, which
suggests a reduced risk of self-reported, investigator-mediated, unverified bronchitis in adults (NNTB 56,
95% CI 36 to 155). The evidence suggested that oseltamivir had a similar effect, although the result was
non-significant.
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FIGURE 12 Sample ‘Adverse event or intercurrent illness’ form (oseltamivir study M7600136).
FIGURE 13 Sample ‘Secondary illness’ form (oseltamivir study WV156708).
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FIGURE 14 Sample ‘Diagnosis of secondary illness’ form, page 1/2 (oseltamivir study WV1597867).
FIGURE 15 Sample ‘Diagnosis of secondary illness’ form, page 2/2 (oseltamivir study WV1597867).
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As stated above, there is no evidence that definitions of complications in paediatric, elderly or adult trials
were ever prepared and incorporated in the trials’ design. Therefore, the reporting of cases of ‘otitis
media’, ‘pneumonia’, ‘sinusitis’ or ‘bronchitis’ are of unclear significance and importance, making it
impossible to attribute a cause and draw conclusions.128 This is probably why the FDA-approved oseltamivir
package insert, since 17 November 2000, has consistently stated: ‘serious bacterial infections may begin
with influenza-like symptoms or may coexist with or occur as complications during the course of influenza.
TAMIFLU has not been shown to prevent such complications’. The original product label did not contain
such a statement but, on 14 April 2000, after oseltamivir was approved for sale in the USA, the FDA sent
Roche an untitled letter about ‘Misleading Efficacy Claims’, which the FDA had noted in Roche’s
promotional materials (p. 3129). One of the statements that Roche made was: ‘Tamiflu reduces incidence of
secondary complications (i.e. bacterial infections) by 45%’. The FDA commented: ‘Further, you have
claimed reductions in severity and incidence of secondary infections with Tamiflu that are misleading
because they are not supported by substantial evidence’ (p. 3129). We do not know how Roche responded
to the FDA but in subsequently available Roche promotional material information, Roche’s statements
were consistent with the FDA’s demands.8
There is uncertainty in the ‘complications’ and ‘secondary illnesses’ outcome definition, therefore we
carried out an analysis on the data from adult treatment trials on those complications classified as serious
or those which led to study withdrawal. For oseltamivir, there was no evidence that treatment affected
such complications (RD 0.07%, 95% CI –0.78% to 0.44%). This outcome could not be assessed in
oseltamivir prophylaxis due to an insufficient number of events. For zanamivir, there was no significant
evidence of a treatment effect on such complications (RD –0.04%, 95% CI –0.64% to 0.24%). This
outcome could not be assessed in children because of an insufficient number of events.
Contrary to the FDA, the EMA’s oseltamivir Summary of Product Characteristics states that oseltamivir
significantly reduces the incidence of ‘specified lower respiratory tract complications (mainly bronchitis)
treated with antibiotics’ in individuals aged ≥ 13 years. This claim is based on ‘a pooled analysis of all
influenza-positive adults and adolescents (N= 2413) enrolled into treatment studies’, of which 1063 were
in the placebo group and 1350 were in the oseltamivir-treated population.130 This statement appears in the
EMA files as early as 2001.131 These exact denominators appear in the Kaiser et al.4 2003 meta-analysis.
The design of the trials – as defined in the protocol with amendments, SAP and CRFs – does not allow
any further inferences. The effect on outcomes that were originally considered of secondary or tertiary
importance (such as bronchitis and pneumonia) would have been clarified with better clinical definitions
and investigations, as were some of the serious adverse events. These benefited from a paragraph-length
narrative, which reported most of the salient features of the event.
Our previous decision to analyse the effects of oseltamivir and zanamivir on the ITT population has been
confirmed for oseltamivir, with the demonstration of the effect on antibody responses in participants in
treatment trials, although no such effect is discernible for zanamivir. This effect leads to the introduction of
selection bias, with a significantly reduced probability of being diagnosed with influenza and an imbalance
in the two arms if the ITTI population is analysed. The effect of oseltamivir on antibodies appears to be
carried over to children with ILI. Its finding contradicts statements made by the manufacturer.
The apparent incomparability between arms of the influenza-infected subpopulations in the oseltamivir
trials raises the question of how an appropriate analysis should be conducted. If influenza-infected groups
are comparable (as appears to be the case in zanamivir treatment trials) then an appropriate analysis
strategy (based on Senn132) would be to first determine the effect of treatment in the ITT population. If
there is evidence of a treatment effect then treatment by infected status interaction could be tested. If there
was evidence of an interaction then estimates of treatment effect could be derived separately for the
influenza-infected and non-influenza-infected subpopulations. However, this analysis should be conducted
on the ITT population using a single appropriate statistical model, obviating the need to conduct separate
analysis on the influenza-infected subpopulation. Roche used geometric mean titres indicating antibody
responses in the ITTI population to support their statement that oseltamivir does not affect antibody
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responses (e.g. in Table 15 and linked text of module 1 of trial WV1579965). However, the use of such
measures can be misleading. What are required for such an analysis are data on how many ITT population
participants responded by arm, at what level of antibody response and how many were tested. Such data
could not be identified with certainty. A further effect of choosing a subpopulation analysis (ITTI in
treatment trials and ITTIINAB (ITT influenza-infected index cases who had negative virology at baseline) in
prophylaxis trials) as the primary analysis is the restriction of the generalisability of results. This is especially
so in the case of design flaws (e.g. in the case of the PEP trial WV15799,65 in which all index cases were
not treated and around 55% of participants were dropped from the ITTIINAB analysis). In this cluster
trial design, households should be included as random effects in the analysis to take account of
within-household correlations.
A significant but slight reduction of the proportion with serum antibody (mostly haemagglutination
inhibition antibody) titre rise by fourfold or more among those who were tested was shown in this review.
This was consistent with the evidence from animal tests using a subclinical dose of oseltamivir in influenza
A/H1N1-infected mice.133 Takahashi et al.133 reported a non-significant slight reduction of haemagglutinin-
specific secretory immunoglobulin G antibody in the serum and spleen, whereas they reported about an
80% significant reduction of haemagglutinin-specific secretory immunoglobulin A antibody in the nasal
wash and bronchoalveolar fluids on day 12. From this evidence, they warned that the risk of reinfection
may increase in patients showing a low mucosal immunoglobulin A antibody response following oseltamivir
administration. These experiments were done because they had the unexpected finding that patients with
paediatric influenza who were treated orally with oseltamivir for 5 days had significantly low levels
(about 60% reduction on day five) of anti-influenza secretory-immunoglobulin A nasopharyngeal fluids
compared with levels in patients who were not treated with oseltamivir.134 Their findings are consistent
with our findings that serum haemagglutinin inhibition antibody response was decreased by oseltamivir
administration, although secretory immunoglobulin G antibody could not be analysed in our study because
the data were not reported in the CSRs.133,134 These findings are also consistent with the evidence on the
mode of action of oseltamivir from animal models8,58,135 and from viral challenge, randomised,
placebo-controlled studies in humans.27
Pro-inflammatory cytokines, including interleukin 6, tumour necrosis factor alpha and interferon gamma,
were completely suppressed by oseltamivir administered 28 hours after the experimental inoculation of
influenza virus, whereas the reduction of viral titre in nasal lavages was partial.27
There is decisive evidence that administration of oseltamivir in animals challenged by respiratory syncytial
virus, which lacks a neuraminidase gene, showed a symptom-relieving effect (decreased weight loss) and
inhibition of viral clearance.136 These effects were accompanied by a decreased cluster of differentiation
+8 T-cell surface sialoglycosphingolipid GM1 level, which is regulated by the endogenous sialidase/
neuraminidase in response to viral challenge along with suppression of cytokine expression.136 They are
consistent with those findings from the pharmaceutical company and their investigators. The findings of the
study by Moore et al.136 suggest a risk of infection and exacerbation of infection by pathogens other than
influenza virus despite the apparent reduction of symptoms from infection.
TABLE 15 Proportions of contacts with positive serology data (WV1579965 ITTIINAB population)
Positive serology
Group
TotalPlacebo, n (%) Tamiflu, n (%)
No 166 (83.0) 192 (93.7) 358
Yes 34 (17.0) 13 (6.3) 47
Total 200 205 405
Chi-squared p= 0.001.
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Sufficient plasma concentration of oseltamivir carboxylate from orally administered oseltamivir phosphate
may act directly on the host endogenous neuraminidase to reduce (or suppress) the immune response
even at the dose of 20mg twice a day for 5 days. However, the bioavailability of inhaled zanamivir seems
to be very broad: about 10–70%, as estimated by the area-under-the-curve data from the inhalation and
intravenous study from the Japanese Summary Basis for Approval. The difference in peak concentration
(Cmax) was much larger (sixfold to 37-fold). This means that inhaled zanamivir could reach a high enough
concentration to reduce the immune response, if it is administered at a high dose or for a long period, or if
the patient is very susceptible. In fact, a double-blind, placebo-controlled trial137 using healthy volunteers to
investigate the effect of zanamivir treatment (20 mg/day for 14 days) on the humoral immune response
to influenza vaccine showed that the zanamivir group responded with significantly lower antibody titres to
the H1N1. Pro-inflammatory cytokines, including interleukin 6, tumour necrosis factor alpha, interferon
gamma and other chemokines, were almost completely suppressed in the viral challenge RCT using a very
high dose (600mg) of intravenous zanamivir before inoculation of the influenza virus in human adults.138
These findings all suggest that the low immune response, with a low level of pro-inflammatory cytokines,
induced by the action of oseltamivir carboxylate, may reduce the symptoms of influenza irrespective of an
inhibition of influenza virus replication, which is widely believed to be the main mode of action of NIs.
In addition, the potential hypothermic or antipyretic effect of oseltamivir (but not zanamivir) as a central
nervous system depressant may also contribute to the apparent reduction of host symptoms.139,140
Zanamivir had no effect on pneumonia symptoms in treatment trials, even when the diagnosis was
supported by a chest radiograph, nor did it affect antibody responses, but it did affect bronchitis. We think
that this shows a symptom-relieving effect of both drugs, which also applies to more severe, if undefined,
syndromes. Both drugs relieve ILI symptoms by around 0.6–0.7% day’s reduction although this is first relief
and not necessarily complete relief. In the case of oseltamivir, the mix-up with the follow-up cards does
not allow us to draw any conclusions on a possible length of the duration of symptom relief. Also of note
is the fact that this important information came to light from the FDA reports and not from the CSRs of
the relevant trials.8,58 This points to the incomplete nature of reporting in the CSRs and the important role
of Summary Basis of Approval (SBA) regulatory information.
In a subgroup analysis we found no evidence of a difference in treatment effect for zanamivir on time
to first alleviation of symptoms in adults in the influenza- and non-influenza-infected subgroups.
Both subgroups showed strong evidence of treatment effect of 0.5–0.7% day’s reduction in time to first
alleviation of symptoms. This strongly supports our hypothesis that these drugs do not have an
influenza-specific effect.
Oseltamivir relieves symptoms in otherwise healthy children, but no effect was noted with zanamivir, which
may be because of the limited power of the two eligible trials, with just over 700 children in total.
However, oseltamivir does not have any effect on asthmatic children with ILI, a population that should
benefit most from its use. One explanation for this finding is in the nature of the young asthmatic
population, which is well cared for and used to regular powerful medications and close follow-up. The
incremental benefit of oseltamivir is thus likely to be undetectable in such a population. An alternative
explanation could be the higher susceptibility of the immune system to suppression by oseltamivir
carboxylate in asthmatic children compared with those in the placebo group. The finding that oseltamivir
administered to asthmatic children reduces symptoms faster than in placebo recipients at the beginning of
the study, but during the off-treatment period more recovered later than those administered placebo, gives
some support to this explanation.
There is no evidence of an effect of oseltamivir on hospitalisations. Hospitalisations are an important but
poorly defined outcome in the oseltamivir protocols, inconsistently reported in the CSRs and overlooked in
the zanamivir protocols and reports.
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The oseltamivir trials did not detect any influenza-related deaths, reflecting the relatively benign nature of
influenza in the study populations. The zanamivir trials detected eight deaths, of which only two were likely
to be caused by influenza and both occurred in the intervention arms. All of the trials were likely to be
underpowered to detect differential effects on mortality, but the absence of deaths in placebo recipients
again underlines the benign nature of influenza. In fact, mortality in Japan during the 2009A/H1N1
influenza outbreak was 198 among about 20 million patients with influenza (1 in 100,000 infected).
Early deterioration leading to death was observed more frequently in oseltamivir recipients than in zanamivir
recipients or no antiviral recipients.141
Overall, the two drugs have similar benefits but markedly different toxicity profiles. On average, for every
28 (95% CI 14 to 112) adults treated with oseltamivir there will be one more report of nausea and for every
22 (95% CI 14 to 42) adults and 19 (95% CI 10 to 57) children there will be one more report of vomiting.
Oseltamivir seems to have an apparent protective effect on diarrhoea, contrary to the other evidence of
gastrointestinal disturbance. This finding might be as an effect of a placebo containing dehydrocholic acid
or it might be one of the results of the ILI symptom-relieving effects (similar to relief of tachycardia and
palpitation). The other apparent gastrointestinal events, such as nausea and vomiting, may be the result of
central nervous disorders indicated by ‘only day 1 increase of vomiting’ in treatment trials in children.
For every 62 (95% CI 41 to 411) adults exposed to zanamivir there will be one fewer case of nausea and
vomiting, but no such effect was visible in children, probably because of a lack of power. Zanamivir
does not appear to affect the frequency of bowel movements.
In the prophylaxis data set, ‘influenza without laboratory confirmation’ (i.e. ILI) was only partially reported in
the oseltamivir CSRs and not reported in the zanamivir CSRs, except for one report,86 in which no significant
reduction was observed (zanamivir 9% vs. placebo 10%). As a consequence we are unable to report on
that outcome. The size of the reduction in influenza symptoms in oseltamivir prophylactic trials is inferior in
magnitude to that seen in hand washing to prevent severe acute respiratory syndrome, based on seven
case–control studies [odds ratio (OR) 0.77, 95% CI 0.70 to 0.84; I2 statistic= 68%; RD –0.12, –0.16 to 0.08;
I2 statistic= 26%], the NNTB being approximately ‘50’ for prophylaxis with oseltamivir and ‘8’
with handwashing.142
There is a significant reduction in the proportion of patients with symptomatic influenza with both NIs.
However, these findings do not reflect the true efficacy for prevention of influenza because they conceal the
positivity of laboratory testing (measured through tests of viral shedding and fourfold antibody titre rise).
We found an apparent prophylactic effect of zanamivir on pneumonia (which was not defined in CRFs)
when it was used for 14–28 days. However, we found no evidence of significant effects on other
complications and no evidence of an effect of oseltamivir on complications or hospitalisations.
Oseltamivir induced nausea in people who were undergoing prophylaxis but there was insufficient
evidence to show an association with vomiting.
On-treatment renal adverse events were three times more common in the oseltamivir arms than in the
placebo arms, with 150 treated patients leading to one additional event. The two participants who died in the
oseltamivir arms both experienced acute renal failure while on-treatment, although only one of those events
was listed as an adverse event. The unlisted event was in a 91-year-old female who was ‘withdrawn from
the study on Study Day 15 because her estimated creatinine clearance was less than 30ml/minute (WV15708,
p. 44).61 The screening laboratory examinations, that were carried out 10 days before the start of study
treatment, were normal’. Hyperglycaemic adverse events (aggravated diabetes mellitus or hyperglycaemia)
were also more common in the oseltamivir arms, with eight events in total (one in WV15673/WV15697,59
two in WV1570861 and five in WV1582568) compared with none in the corresponding placebo arms. These
data are only presented descriptively, as they are too few (< 10) to meta-analyse formally, as prespecified in
our analysis plan.
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Finally, oseltamivir caused headaches and psychiatric harms in adult prophylaxis trials. Headaches are one
of the most prominent harms of oseltamivir. There is evidence of a dose–response effect in prophylaxis
trials (p= 0.013),59 in which headaches were observed in 202 of 519, 225 of 520 and 242 of
520 participants in the placebo, oseltamivir 75mg once daily and twice daily arms, respectively.
In the psychiatric category, several rare and severe single events (nervousness, aggression, hallucinations,
psychosis, suicide ideation and paranoia) were reported significantly more frequently in the intervention
arm. Added to other more frequently reported but not significantly different events (such as depression
and confusion), this gave a large effect and a relatively small NNTH of 94 (95% CI 36 to 1538). The
importance of such a finding lies in the distribution of oseltamivir to large numbers of asymptomatic
individuals following pandemic plans. There were no prophylaxis trials in children that met our inclusion
criteria, therefore we cannot report on prophylaxis harms in this important population.
The question of why oseltamivir treatment trials failed to identify a clear association between oseltamivir
and psychiatric harms, although a weak dose-dependent association was observed, is a moot point. It is
possible that ILI and influenza symptoms masked the harms in those who were already symptomatic and
therefore recruited in the treatment trials (and influenza-type symptoms were excluded as adverse events to
be reported). The reporting issue of compliharms may have helped to mask such events. Alternatively,
it could be that these events are rare in the populations studied and that there was insufficient power to
detect an association. The CI was wide (0.43 to 2.03) and does not rule out a doubling in risk as a result of
treatment, as was found in the prophylaxis trials. It is also possible that the risk of psychiatric harm increases
with increasing dose (as the data from two trials8,58 suggest) and increasing duration of treatment (as the
prophylaxis trials suggest).
Toovey et al.143 assessed the issue and failed to find an association between neurological and psychiatric
adverse events and oseltamivir exposure. The outcomes studied were not based on the a priori definition
of psychiatric adverse events as defined in the CSRs. The definition was constructed post hoc, based on a
selected group of adverse events taken from the psychiatric, neurological and injury body systems in the
reports. The issues are described fully in another report144 and Toovey’s response.145 Toovey et al.143
reviewed only retrospective observational studies and did not review three prospective cohort studies
conducted in Japan.
A meta-analysis of three prospective cohort studies of neuropsychiatric adverse events (NPAEs) in Japanese
children show a pooled OR for abnormal behaviours due to oseltamivir exposure of 1.55 (95% CI 1.21 to
1.98; p= 0.0005) without significant heterogeneity.146 In one prospective study147 of several thousand
children with influenza, carried out to test the hypothesis of a causal relation between oseltamivir and
neuropsychiatric events, abnormal behaviour was observed more frequently in oseltamivir recipient children
than in control subjects (RR 1.57, 95% CI 1.34 to 1.83). Abnormal behaviour was observed in 3.4 per
100 person-days (or 13.8%) in the oseltamivir group compared with 2.2 per 100 person-days (or 8.8%) in
the control group. Reanalysis of this study population, focusing on delirium and unconsciousness, also
showed a significant association between oseltamivir and neuropsychiatric events, especially in the very
early phase of the illness within a day of commencement of fever.148 These indicate that prospective and
intentional collection with this scale of participants may be necessary in treatment RCTs.
Animal toxicity study results firmly support the effect of oseltamivir on the central nervous system. One of
these is the hypothermic effect of oseltamivir (but not zanamivir) administered orally, intraperitoneally139,140
and intracerebroventricularly.140 The other is that intraduodenal or intravenous administration of oseltamivir
to mature rats induced respiratory arrest shortly followed by cardiac arrest. These studies clearly show
central depressant effects of oseltamivir.149 Moreover, in the post-marketing toxicology phase studies by
Roche, many symptoms that the manufacturer considered ‘item-related’ were observed: alterations in
respiration including decreased respiratory rate/gasping and altered mucous membrane/skin colour (pale)
prior to death. Although the manufacturer denied the causality,150 symptoms at 2 hours after administration
that showed dose-related increase were lack of olfactory orientation, lack of cliff aversion and low/very low
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arousal. Twenty-four of 52 pups that did not exhibit cliff aversion were later found dead. Fourteen of
17 animals with low or very low arousal died thereafter. These findings are consistent with the clinically
observed psychiatric symptoms in the RCTs and post-marketing spontaneous reports.
Zanamivir was well tolerated. However, a potentially active placebo may have masked the occurrence of
bronchospasm in zanamivir trials.
Treatment trials were mostly under-recruited and often their results pooled post hoc in two, or even three,
trials, and yet they showed very high influenza positivity rates. One possible explanation for this lies in the
intensive surveillance carried out in the predefined trial centre areas and the restricted time span of
recruitment during high likelihood of positivity periods. This may be why many centres with low levels of
recruitment are listed in the CSRs; this limits the generalisability of the results to everyday life.
In a primary or secondary prophylaxis indication the postulated central effect of oseltamivir is confined
to suppressing symptoms, as infection was not prevented even when oseltamivir was administered prior to
the inoculation of influenza virus both in animals135 and in humans,27 and the prophylaxis trials. However,
the central problem remains the incompatibility of the two contrasting claims of its activity against
antibody production. If, as reported in many documents, oseltamivir does not interfere with antibody
production (e.g. see FDA151 and Roche Investigators’ Guide152), how is it possible that oseltamivir prevents
cases of influenza when part of the definition of prevented cases in oseltamivir trials was based on the
absence of antibody response?
The apparent ability of oseltamivir to interfere with antibody response calls into question the mode of
action of the drug and puts in doubt the proposed effects of oseltamivir. One possibility in treatment trials
is that oseltamivir administration, by interfering with antibody production, has the effect of selecting the
strongest antibody responders in the ITTI subpopulation. These individuals are classified as influenza cases
and are included in the oseltamivir arm of the ITTI population. This selected subpopulation probably
represents the healthiest or those least likely to experience complications. An alternative consequence
could be that interference with antibody production in the oseltamivir arm led to active arm participants
being more likely to develop complications as a result of impaired immune function.
Evidence from prophylaxis and secondary prophylaxis trials suggests that in addition to the apparent similar
mode of action as in the treatment studies, suppression of viral shedding in nasal swabs may be of
importance. In the former, participants who become positive (i.e. who are subsequently classified as cases
of influenza) in the oseltamivir arms are the few who mount a strong response despite oseltamivir
interference. The remainder (who are significantly more than in the placebo arm) are classified as prevented
or avoided cases. However, as prophylaxis CSRs do not report antibody responses and viral isolate results for
the ITT populations either, it is impossible to tell whether or not this proposed mode of action fits all of the
evidence. The effect of oseltamivir on nasal shedding is consistent with the proposed mode of action of NIs
in preventing the virus from leaving the host respiratory epithelial cells, which are covered by a mucous
layer. Compared with the rather small reduction of symptoms of ILI and reduction in antibody rise (up to
10%) by both oseltamivir and zanamivir, the extent of the reduction of symptomatic influenza is almost
half. This may be as a result of reduction of influenza viruses in the nasal swab sample.
In prophylaxis there is no evidence that oseltamivir reduces symptomatic ILI. Oseltamivir reduces the
number of prophylaxis participants testing positive (based on antibody rise and/or culture test). However,
this finding is weakened by oseltamivir’s interference with the viral replication on the swab and effect on
antibody production. In addition oseltamivir does not affect asymptomatic influenza and there is no
evidence that it interferes with person-to-person spread.
Similar to the FDA,109,153 because of the problems with the design of study WV1579965 we could not draw
any conclusions on the ability of oseltamivir to interrupt viral transmission.
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This is important as the results of the trial65 formed part of the WHO3 rationale for use of the drug to
interrupt transmission from person to person, and allow time before the arrival of vaccines in the event of
a pandemic furnishing a seemingly powerful rationale for stockpiling oseltamivir.
This shows the importance of availability of full CSRs, something the WHO did not have.
Antibody suppression seems stronger for oseltamivir than zanamivir, probably because of the difference in
bioavailability. It may be that evidence of other effects, such as hyperglycaemia and renal impairment (though
significance was marginal) in the prophylaxis trials may be due to inhibition of the host’s endogenous
neuraminidase, which impairs the cell function of various organs.15 Overall, the significance of oseltamivir for
nasal shedding is unclear but problems with sampling and culture undermine any claims as to its secondary
prophylactic properties, as the FDA made clear in its response.109
The dose–response increase in psychiatric events in the ‘pivotal’ oseltamivir treatment trials and the increase
in vomiting only on day 1 in treatment trials in children may be caused by the sudden onset of the central
action of unchanged oseltamivir.15 Brain concentration of unchanged oseltamivir increases during the
early phase of influenza in juvenile animals150 as a result of a reduced or low function of p-glycoprotein, a
major transporter of oseltamivir at the blood–brain barrier.15,149 The likely centrally mediated mode of
action of oseltamivir is supported by the finding of adverse events in healthy people in prophylaxis trials.
However, these effects may also be derived from a delayed action that is associated with host endogenous
neuraminidase inhibition by oseltamivir,15 because this appeared after more than 1 week’s exposure to the
drug and lasted for > 2 weeks. Other effects, such as pain in the limbs, hyperglycaemia or diabetic events,
reduction of antibody rise and reduction of cytokine induction, may also result from the suppression of the
host’s endogenous neuraminidase by oseltamivir.136 Pain in the limbs and metabolic control events (mainly
hyperglycaemia) were in excess in the oseltamivir arms, but we did not carry out a formal meta-analysis, as
they were not prespecified in our analysis plan and the number of events was < 10 for metabolic events.
Statements made about the capacity of oseltamivir to interrupt viral transmission and reduce complications
are not supported by any data that we have been able to access.
We have not reviewed other NIs, such as laninamivir and peramivir, or other antivirals, such as the
adamantanes (amantadine and rimantadine) or antipyretic/anti-inflammatory agents. Laninamivir and
peramivir may be more potent as NIs because their bioavailability is far higher than zanamivir and may
affect the host’s endogenous neuraminidase. Adamantanes are well known centrally active agents and
may be more harmful than oseltamivir and zanamivir. Anti-inflammatory antipyretics (except paracetamol)
may be more toxic than NIs.15 Hence, the other NIs, adamantanes and anti-inflammatory antipyretics may
not be alternatives to oseltamivir and zanamivir.
Overall completeness and applicability of evidence
We used the Cochrane seven-domain risk-of-bias instrument to assess bias. The availability of partial or
complete CSRs decreased the uncertainty and allowed definitive judgements to be made. Previous unclear
risk of bias became certainty of bias or certainty of absence of bias. Certainty or low levels of uncertainty are
due to our expectations regarding the complete CSRs. We were expecting to have all relevant and consistent
information available for our reviews, but, when it was not, our judgements changed because we found
gaps in the availability of information and inconsistent information. We are still uncertain as to whether or
not the complete study reports represent an exhaustive and coherent source of trial narrative and data.
In the case of treatment trials, conclusions and generalisations are drawn from a subpopulation in which
the two arms do not appear comparable as a result of the apparent ability of oseltamivir to interfere with
influenza antibody production. The effect of oseltamivir on the gastrointestinal tract appears to be notable,
although a definitive statement will be possible only once the mode of action and dosage of dibasic
calcium phosphate dihydrate and dehydrocholic acid have been clarified. The high percentage of influenza
infections appears to be in contrast with the need to pool or delay several trials and the small recruitment
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size of others because of a lack of influenza circulation. In the case of PEP trials, the selection of the
infected population has the effect of excluding from the analysis large percentages (in some cases > 50%)
of participants. This brings the generalisability of the results of these trials into question.
Much has been made in the trial programmes of viral nasal voidance as a marker of effect. However, its
measurement was unreliable in treatment trials, as this verbatim quote from the FDA review shows:
Duration of viral shedding was measured from treatment initiation to the time of the first negative
virus culture with no subsequent positive cultures. Upon reviewing a list of viral shedding patterns
provided by the applicant on 8/16/99, two problems emerged: (1) the pattern of virus shedding was
fluctuating in at least 33 subjects (i.e. pos-neg-pos-neg, with or without a subsequent negative result).
(2) In at least 100 subjects, the last virus shedding sample was the first negative sample in sequence,
meaning there was not a subsequent negative confirmation. Given the fluctuating pattern of virus
shedding, to estimate the duration of viral shedding based on the occurrence of a single first negative
data poses a high level of uncertainty.
FDA, p.14109
In all of the programmes, the effect on complications was based on unclear and potentially unreliable
definitions, often at the discretion of local clinicians, and confirmation (e.g. radiological confirmation of
pneumonia) was not consistently reported when it did occur. In the ITT population, the correct population
for analysis, there is no credible effect of oseltamivir against pneumonia as the significance of the term
‘pneumonia’ is not clarified.
In the case of PEP trial,65 nasal voidance was measured only in symptomatic subjects, as an adjunct to the
protocol version. However, this does not prevent the manufacturers from making claims of effect for all of
these outcomes.
Other general requirements, such as presentation within 36–48 hours, raise questions about the
generalisability of the research evidence. However, underlying all our doubts is the conflicting evidence on
the mode of action of the drug.
Most of the trials were substantially under-recruited and so had insufficient power individually to answer
the research question.
Quality of the evidence
We assessed all full CSRs of relevant trials. An example of the kind of detail available in complete CSRs and
the importance of the trial timeline in assessing the presence of bias is the observation that of the CSRs for
the included trials, only one contained a protocol that predated the beginning of participant enrolment, only
two had SAPs that clearly predated participant enrolment and three had clearly dated protocol amendments.
No oseltamivir CSR included a clear date of unblinding.
All reports in our review were sponsored by the manufacturers. It is known that published studies
sponsored by the pharmaceutical industry are more likely to have outcomes favouring the sponsor than
studies that have other sponsors.154,155 As the evidence relates to published studies, we do not know
whether or not the findings are applicable to CSRs.
Potential biases in the review process
The main limitation of our study is our relative inexperience in dealing with large quantities of information
and our lack of familiarity with certain trial documents, such as randomisation lists. Randomisation lists
appeared to be of two types. The first was a pre-randomisation list of random codes with which
participants’ IDs cannot be matched with the participant IDs used within other sections of the CSR. The
second was a post hoc randomisation list to which individual participants can be matched but the original
generated codes are not shown. In both cases the truly random generation of the sequence could not be
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properly assessed because either the original codes are not provided or the original codes cannot be
matched to patients.
We have created methods and procedures to address the risk of reporting bias that we identified in
published trials, but remain uncertain about the success of these new methods.
Agreements and disagreements with other studies or reviews
Several reviews of NIs are now available,156–160 including several separate versions of our previous
reviews.30–32,35 All are mainly based on published information and reach similar conclusions to our 2006
review, which sparked the reader’s comment and subsequent investigation and change of methods.
Following publication of our review update in December 2009, Roche asked the Harvard-based academics
Hernan and Lipsitch161 to repeat the Kaiser analysis4 to confirm or reject Kaiser’s conclusions. They were not
provided with any funding to carry out this analysis and Roche ultimately provided them with patient-level
data sets and module 1 for the 10 Kaiser trials and one more treatment trial.69 An important methodological
difference between Hernan and Lipsitch’s analysis161 and that of Kaiser4 was Hernan and Lipsitch’s decision
to privilege a true ITT analysis over the subpopulation analysis featured in the Kaiser analysis. Our Cochrane
review also analyses the ITT population.
The Kaiser analysis4 concluded that oseltamivir provided two statistically significant reductions: in lower
respiratory tract complications and in hospitalisations.
Hernan and Lipsitch161 evaluated lower respiratory tract complications and found a statistically significant,
but smaller, reduction in the risk of these complications.
Hernan and Lipsitch161 omitted evaluating the Kaiser paper’s conclusion that oseltamivir reduced the risk of
hospitalisation. They wrote, ‘it was not possible to assess the potential benefit for high-risk participants who are
hospitalised, because the sample size of most studies was too small to consider hospitalisation as an outcome’.
Hernan and Lipsitch161 do not elaborate on or highlight their apparent methodological disagreement with
the Kaiser 2003 analysis4 and it is not reflected in the news article published on the Harvard website
entitled ‘Oseltamivir effect on complications confirmed by reanalysis’ (http://ccdd.hsph.harvard.edu/
NewsEvents/Oseltamivir-reanalysis). In fact, Hernan and Lipsitch161 did not confirm one of the key
conclusions of the Kaiser paper.4
Unfortunately, the Hernan–Lipsitch analysis161 has been cited by influential bodies, such as the European
Centre for Disease Prevention and Control, as ‘confirmation of the original Kaiser meta-analysis’ (http://ecdc.
europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?ID=561&List=a3216f4c%2Df040%
2D4f51%2D9f77%2Da96046dbfd72) despite the fact that Hernan and Lipsitch161 did not confirm one of the
key conclusions of the Kaiser paper.4
For complications, although Hernan and Lipsitch161 clearly produced similar results to Kaiser,4 we do not
think that this means that the result is more credible. In view of our findings, we suggest that these results
should be interpreted with caution. We have published our preliminary comments.162 The approach Hernan
and Lipsitch161 took in analysing data was insufficient to provide a credible, independent check on validity,
and reinforces the importance of detailed, critical assessment of entire trial programmes, with access to
full-length study reports. Our analysis questions the coherence between the evidence and the proposed
mode of action of oseltamivir.
The Ebell et al.163 review concluded that there was ‘no evidence that oseltamivir reduces the likelihood of
hospitalisation, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT
population’. This conclusion was based on module 1 of the 10 Kaiser trials plus WV16277.69 These are the
same 11 trials included by Hernan and Lipsitch.161
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Conclusions
Main conclusions
These data show that oseltamivir and zanamivir cause small reductions in the time to alleviation of
influenza symptoms in adults, but not in asthmatic children. The use of oseltamivir increases the risk of
nausea, vomiting and psychiatric events in adults and vomiting in children and may reduce risk of
diarrhoea and cardiac events in adults. Observational studies fail to show that oseltamivir has a protective
effect on mortality among patients with 2009A/H1N1 influenza. Prophylaxis with either oseltamivir or
zanamivir may reduce symptomatic influenza in individuals and in households but there was no reduction
in all other influenza outcomes, including overall ILI reported as an adverse event on-treatment. In previous
Cochrane reviews it is likely that evidence from published data was insufficient to fully assess risk of bias
within the trials. Our results do not discount a potential benefit of using zanamivir and oseltamivir in
individuals under particular situations, for example in immunocompromised or in compassionate cases, for
which few other therapeutic options may exist. However, NIs themselves may be immunosuppressants.
The balance between benefits and harms should be considered when making decisions about use of NIs
for either prophylaxis or treatment of influenza.
Implications for practice
These results show that both oseltamivir and zanamivir reduce the time to symptomatic improvement in
adults (but not asthmatic children) with ILI. The size of this effect is small – approximately half a day. We
have no data comparing oseltamivir or zanamivir with paracetamol and other antipyretics. We did not find
convincing evidence that either oseltamivir or zanamivir reduces the risk of complications of influenza,
particularly pneumonia, or reduce risk of hospitalisation or death. Even in individuals at higher risk of
complications, such as children with asthma or the elderly, there was no evidence of a beneficial effect for
reducing risks of complications.
The findings demonstrate a minimal effect on prevention of influenza by oseltamivir or zanamivir among
individuals or families. This suggests little support for their use as prophylactic agents, for example during
influenza epidemics.164
Implications for research
The considerable body of evidence from RCTs included in this review indicates either no effect or a
relatively small absolute effect size against the complications of influenza. Such an effect, even if
statistically significant, would be too small to warrant treatment with NIs in a primary care setting,
especially as effective diagnosis and treatments for rare complications (such as pneumonia) are available.
Lack of evidence of an effect on hospitalisations probably indicates lack of severity in the first place.
Assuming an influenza incidence rate of 2% (similar to that in the control arms of oseltamivir treatment
trials) to detect a 25% clinically significant reduction in pneumonia, 21,500 participants would have to be
enrolled in a clinical trial.
Our findings have implications for research on the mechanism of action of NIs, with special regard to any
direct central action of oseltamivir and the inhibitory effect of the host endogenous neuraminidase of
various organs and systems. We could not reach a consensus on whether or not further trials are
warranted and whether or not current trials should be discontinued.
Published trials are unlikely to provide the level of detail to allow the results of a drug trial to be properly
evaluated and risk presenting a partial and potentially biased report of trial conduct and findings. This has
implications not only for the reporting of trials but also the weight that can be applied to published
studies alone.
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Our calculation is likely to underestimate population size, as the 2% incidence rate was derived from trials
that used enhanced ad hoc surveillance systems. Any trial design would have to ensure that the presence
of complications is ascertained using objective diagnostic criteria (e.g. with confirmation using imaging or
laboratory testing for pneumonia). Such trials would also have to consider the ethical implications of
conducting studies for which the estimate of benefit (based on 11 RCTs) in otherwise healthy people is
likely to be small, and would have to be balanced against the apparent risks of adverse effects from NIs.
We think research should be aimed at more effective preventative measures and early identification
of complications.
The methods used to conduct our evidence synthesis need to be repeated across further interventions and
by other researchers, and may need to be refined further. Given the considerable resources involved in using
these methods, a system is needed to prioritise reviews of important drugs so that such methods are
reserved for drugs that meet certain conditions. Priority could perhaps be given to first drugs of a new family,
drugs considered to be innovative or those that are likely to have a big market impact. Such reviews should
be publicly funded and be independent of both regulators and manufacturers. Researchers who conduct
these ‘high-scrutiny’ reviews need to be free of recent ties to either government or the pharmaceutical
industry. Systematic review groups such as The Cochrane Collaboration should consider adopting these
methods for other drugs and whether, perhaps, to scrutinise the published reviews of prioritised drugs.
Implications for policy
These findings suggest that the current recommendations for oseltamivir as an essential medicine for the
treatment of seriously ill patients or those in higher-risk groups with influenza 2009A/H1N1 need
revision.33,34 The small benefits in symptomatic improvement and the lack of evidence for an effect on
serious complications need to be balanced with the adverse effects found with these drugs in
meta-analyses, especially diabetic/hyperglycaemic, renal and neuropsychiatric effects in all of those
people for whom the WHO recommends its use.
Policy-makers should be cautious in interpreting and using the findings of systematic reviews including only
published studies, particularly those that comprise only a portion of an entire drug trial programme or
which contain only a portion of the results of trials. The current findings suggest that numerous national
and international bodies may have been based on inadequate or poor-quality information.165 This could be
obviated by ensuring that documentary evidence relating to a trial on humans (including CSRs, regulatory
documents, evidence syntheses) should be archived electronically with no statute of limitations.
Several steps are required to provide patients, clinicians and policy-makers with the most transparent
assessment of the relative benefits and risks of new drugs.
Based on the length of time it has taken to provide a definitive answer on the efficacy of the NIs, the
challenges in obtaining the full information and the methods that we needed to develop to conduct the
evidence synthesis, we believe the main implication of our review is the need for reform of multiple
components of the research and development, regulatory and assessment pathway of new drugs.
Pharmaceutical sponsors of drug trials should follow a data access and sharing procedure which is similar
to that of the EMA, and sponsors should make all full CSRs available to be downloaded from their
websites and shared freely once a regulatory decision has been made. Redactions should be kept to the
minimum. Part of this process needs to include a full list of the entire drug development programme to
avoid assessment of an incomplete set of trials. Researchers and industry employees who are listed in trial
documents should be considered to have legal responsibility for the conduct and reporting of a trial.
NEURAMINIDASE INHIBITORS FOR PREVENTING AND TREATING INFLUENZA IN ADULTS AND CHILDREN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Regulators should post an inventory of their documentary holdings on their websites with a brief
description of the main content and size of each file. They should make all information available shortly
after making a registration decision on a drug and within a reasonable time period. The information
should be in electronic format and anonymised (i.e. participants’ details should be removed to prevent
each person being identified but no further).
Trial registries have improved the reporting of new trials. However, on their own they will not be adequate
to resolve the problems we encountered. The completeness of trial registries needs to be tested with a
random sampling procedure. Clear instructions for the reporting and updating of their content should be
promulgated and penalties imposed on breaches of these procedures. Trial registration should include the
original and final versions of a trial protocol, with a full declaration of dated amendments. Procedures for
trial unblinding and dates of unblinding should be routinely reported. Registration should be made
compulsory for all studies in which human beings are randomly assigned to experimental arms. Ethical and
consent procedures for all trials should include obligations of the trial sponsor to ensure that results are
made public. Failure to report the existence of a trial on humans and to make results available should be
considered as an ethical breach of conduct and be subject to appropriate penalties.
Authors’ note: In reviewing over 2 GB of data there is the possibility of mistakes. The authors would
be grateful if readers could identify these. We promise that, if we concur, the record will be
amended accordingly.
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Chapter 3 Effect of oseltamivir on mortality in
patients with 2009A/H1N1 influenza: a systematic
review and individual patient data meta-analysis of
observational studies
Abstract
Objectives
To determine the effect of oseltamivir on mortality in 2009A/H1N1 influenza patients.
Design
Systematic review of observational studies.
Data sources
Summary and individual patient data (IPD) from published observational studies.
Eligibility criteria for selecting studies
Any study of 2009A/H1N1 influenza patients reporting mortality outcomes and exposure to oseltamivir
with at least 5% of patients untreated with influenza antivirals and five or more deaths overall.
Main outcome measures
Mortality.
Results
A total of 1117 studies were identified and screened, with 154 full-text articles assessed for eligibility. Of
these, 30 observational studies of hospitalised patients were eligible and a total of 11,013 patients were
available for qualitative synthesis. Overall there were 1301 deaths (12%) with the percentage of deaths
receiving oseltamivir similar to that of survivors (83% vs. 82%). We found evidence of time-dependent bias
in the summary data and the IPD. The IPD came from four studies including 3071 patients and 242 (8%)
deaths. After taking account of time-dependent bias, potential confounding variables, and the competing
risk of hospital discharge, analysis of the IPD showed insufficient evidence that oseltamivir reduced the risk
of mortality [hazard ratio (HR) 1.03, 95% CI 0.64 to 1.65].
Conclusions
We found insufficient evidence from 30 observational studies to support oseltamivir having a protective
effect on 2009A/H1N1 influenza patients for mortality. However, the included studies were observational
and IPD analysis was based on only four studies without adjustment for baseline severity of illness or other
drug use hence the findings should be interpreted with caution. Observational studies with time-dependent
treatment exposure appear to be at a high risk of time-dependent bias unless an appropriate analysis
is conducted.
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Introduction
Influenza is a seasonal, mostly mild and self-limiting infection of the upper airways. Occasionally, patients
with influenza develop complications, including pneumonia, encephalopathy and multiorgan failure, often
requiring hospitalisation and, in a small number of cases, patients die. Influenza is mainly caused by
influenza A and B viruses and the predominant subtype of viruses changes from season to season. A novel
strain of influenza 2009A/H1N1 was the predominant cause of influenza infections worldwide resulting in
the WHO declaring a pandemic in April 2009.
Oral oseltamivir is an antiviral and a NI. It has been used primarily in Japan and the USA prior to 2009.
However, its use increased dramatically in the A/H1N1 pandemic when oseltamivir became a widespread
public health intervention.166
Mortality is a generally rare, but important, outcome of influenza and RCTs have not been powered to
address this outcome. To our knowledge, there have been five deaths in comparative Phase II/III RCTs of
oseltamivir;167,168 however, none of the deaths was in a patient with confirmed influenza. Reviews of
observational studies of influenza 2009A/H1N1 have shown protective effects of NIs on mortality169–173 and
oseltamivir is now listed as an essential medicine,174 although there is insufficient evidence based on
randomised studies to show that oseltamivir reduces complications of influenza106 and case series have
suggested increased mortality.15,141
The objective of this systematic review was to determine the effect of oseltamivir treatment on mortality in
patients with 2009A/H1N1 influenza. We focused on 2009A/H1N1 influenza specifically because WHO
and others have suggested that studies of antivirals for seasonal influenza may not be relevant to the
current novel form of circulating influenza,46,47 and current antiviral treatment policies have been largely
influenced by the results of observational studies of 2009A/H1N1 influenza.
Methods
Ethics approval was not required for this research because it is a systematic review of published studies.
Any study comparing oseltamivir with no treatment in patients with confirmed 2009A/H1N1 influenza and
reporting mortality outcomes was eligible for inclusion. The definitions for mortality and treatment
exposure were as used in the individual studies. We did not include studies where < 5% of patients or
< 10 patients were untreated and studies in which fewer than five patients in total died. If there were
multiple publications of the same or overlapping cohorts of patients we included the largest cohort in our
review. Studies reported in languages other than English were potentially eligible for inclusion but only if
data were clearly reported by mortality and treatment status. Studies that were reported in abstracts but
not published in full were not eligible for inclusion. We searched MEDLINE, EMBASE, Cumulative Index to
Nursing and Allied Health Literature, Web of Science and Latin American and Caribbean Health Sciences
Literature databases (see Appendix 12 for details of our search strategy). We also hand-searched
bibliographies from two relevant documents published by WHO169,175 and two previous reviews.171,172
Three reviewers separately assessed the studies identified during the search and applied inclusion criteria.
Any disagreements were resolved by discussion. Data from included studies were extracted and checked
by a second reviewer. Variables included in the extraction were citation; study design; study setting
(country, city, institution); study population (sex, age groups, types of patients, severity of disease); time
period of study; how and if influenza was confirmed; number of patients (by survival status and antiviral
treatment received); and timing of hospital admission and treatment from onset of symptoms.
To address the limitations of using summary information from observational studies for meta-analysis,
we requested IPD from the corresponding authors of all of the included studies and kept a record of all
of the correspondence that ensued (see Appendix 13 for a template of the letters that we sent to the
corresponding authors).
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Our primary analysis was to compare use or non-use of oseltamivir as a binary exposure between patients
with fatal and non-fatal outcome. We planned to use Cochran’s Q chi-squared statistic to test for statistical
heterogeneity and the I2 statistic to estimate heterogeneity and perform a random-effects meta-analysis of
the primary outcome using the method of DerSimonian and Laird.107 For studies with no events in one of
the treatment groups we added a continuity correction of one event to all four cells of the study to enable
estimation of ORs. Small study effects were intended to be formally assessed using the method of Harbord
et al.176 and investigated using a funnel plot. In fact we used the method of Rucker et al.177 to test for
small studies effect as a result of their method of moments test being the only one we could find that is
appropriate when heterogeneity is substantial (τ2> 0.1). The Meta-analysis of Observational Studies in
Epidemiology guidelines were followed in the reporting of this systematic review.178 A protocol outlining our
proposed study is available from: www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002245.
In the subgroup of studies for which we obtained IPD we planned to investigate the time-dependent effect of
oseltamivir on mortality (by fitting treatment as a time-dependent exposure in a Cox regression model), adjust
for potential confounding variables and identify predictors of treatment using logistic regression. A detailed
example of the methodology we used for fitting a time-dependent variable in SAS version 9.4 (SAS Institute
Inc., Cary, NC, USA) is provided in the following web link: http://support.sas.com/documentation/cdl/en/
statug/63347/HTML/default/viewer.htm#statug_phreg_sect049.htm. Analysis 1 is appropriate for our study
because we had one time-dependent exposure variable and a number of baseline covariates. Potential
confounding variables that were investigated included patient comorbidities (respiratory, cancer, obesity, heart
disease, infection, immunosuppression, diabetes, neurological), age and time from onset of symptoms to
hospital presentation. After taking account of time-dependent bias (using proper hazard-based analyses for
which oseltamivir is included as a time-dependent exposure) and missing data (using multiple imputation and
adjusting for potential confounding variables), we planned to report the overall estimate of treatment effect
of oseltamivir on mortality, as well as the treatment effect by the timing of treatment categorised into early
(≤ 2 days from onset of symptoms) or late (> 2 days from onset of symptoms). Survival analyses were stratified
by study, and logistic models were adjusted for study. Multivariable analysis was conducted when all potential
confounders were included in the models. Multiple imputation was implemented in a sensitivity analysis to
assess the potential influence of missing data using proc mi and proc mianalyze commands in SAS. We
specified multivariate imputation by a fully conditional specification method using regression models that we
developed for predicting the missing data and created 20 imputed data sets. Covariates included in the
regression models were mortality status, age, study, treatment group, time from onset to presentation and
comorbidities (as detailed above).
On the basis of a recommendation by Wolkewitz and Schumacher,179 we conducted competing risks
survival analysis on the IPD, for which the competing risks were death and hospital discharge. Wolkewitz
and Schumacher179 suggest that a fundamental assumption in survival analysis is that the death hazard
remains the same after censoring. This may be violated because discharged patients are usually in a better
health condition than patients who remain in hospital. Hence, discharge from hospital should be directly
modelled and treated as a competing event for dying in hospital. We performed competing risks analysis
using the method of Fine and Gray180 on the three cohorts that provided data on hospital discharge, with
adjustment for all potential confounders but no imputation for missing data. Oseltamivir treatment was
fitted as a time-dependent exposure because time-dependent bias may also occur for hospital discharge
because, for example, patients who recover quickly may not get the opportunity for antiviral treatment.
Results
On the basis of searches conducted on 15–18 February 2013, we identified 1107 potential studies for
inclusion. We identified a further 10 studies through hand-searching. After assessing the abstracts of these
studies, we agreed that 154 full manuscripts were required for further assessment. Of these 154 full
manuscripts, 124 were excluded for the reasons given in Figure 16 and references are provided in Appendix 14.
We initially excluded 18 studies because they did not present a breakdown of numbers of patients dying as a
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result of oseltamivir exposure. We wrote to the corresponding authors of these studies requesting this
additional summary data and received replies from 12, of which six provided data that we were able to use.
In total, 30 studies181–210 are included in the qualitative synthesis (Table 16 and see Figure 16).
Quality of the included studies
We included observational studies that reported on series of cases with laboratory-confirmed 2009A/H1N1
influenza. There were no randomised or prospective cohort studies or case–control studies comparing
death or severe cases with matched uncomplicated patients despite the call for this type of study.211,212
Table 16 shows information on the design characteristics of the included studies and Table 17 provides
details on outcomes and analysis methods used. The proportion of patients treated in the studies ranged
from 35% to 94%, with a median of 82%.
Although all 30 studies classified patients by treatment exposure, only two defined it: one as ‘at least one
dose of oseltamivir’181 and the other as ‘at least one day of treatment’182 [although it was unclear how they
classified patients who received one dose only; there were 26 such patients excluded from the study
[Iratxe Puebla, PLOS ONE journal editor, 7 August 2012, personal e-mail communication)]. It is unknown
how many other studies failed to report excluded patients but we note that a number of studies had
missing information on mortality status and/or treatment status (for 200 patients in one study,183 for which
missing data were more common in patients with less-severe disease), whereas other studies reported
complete information. None of the included studies reported over-the-counter medication use prior to
Number of records
screened
(n = 1117)
 Number of records after
 duplicates removed
(n = 1117)
Number of studies included in
quantitative synthesis
(meta-analysis)
(n = 4)
Number of studies included in
qualitative synthesis
(n = 30)
Number of full-text
articles assessed
for eligibility
(n = 154)
Number of records
identified through
database searching
(n = 1670)
Number of additional
records identified
through other sources
(n = 10)
Number of records
excluded
(n = 963)
Reasons for exclusion
• Most patients received antiviral medication, n = 77
• Overlap with other included studies, n = 10
• Did not provide breakdown of numbers of patients
   dying by oseltamivir exposure, n = 12
• Fewer than five deaths, n = 12
• Not a clinical study, n = 5
• Other reasons, n = 8
Number of full-text articles excluded, with reasons
(n = 124)
FIGURE 16 Flow diagram showing process for inclusion and analysis of observational studies examining the effect
of oseltamivir on mortality in patients with 2009A/H1N1 influenza.
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TABLE 16 Characteristics of the 30 included studies
Study
Setting and
population Time period
Definition for
death
Description of
treatment
exposure
Drug use before
admission
Siston et al.183 USA, pregnant
women
April to
December 2009
Maternal influenza
deaths
Antiviral (492/496
received oseltamivir)
Not reported
Louie et al.181 California, all ages,
critically ill
3 April 2009 to
10 August 2010
Died from pandemic
H1N1 infection
One dose of antiviral
(1671/1675 received
oseltamivir)a
Not reported
Jain et al.189 USA, all ages,
hospitalised
April to June 2009 Not reported Antiviral (188/200
received oseltamivir)
Antiviral, antibiotic
Farias et al.190 Argentina,
children, critical
15 June to
31 July 2009
Mortality at
28 days
Oseltamivir Not reported
Yang et al.191 Beijing, all ages,
hospitalised
Up to
31 December 2009
Cause of death
2009 H1N1
influenza
NI Not reported
Altmann et al.185 Germany, children,
critically ill
August 2009 to
30 April 2010
Not reported Oseltamivir Not reported
Enstone et al.192 UK, all ages,
hospitalised
11 May 2009 to
31 January 2010
Deaths attributed to
pandemic (H1N1)
2009
Received antiviral
as inpatients
Patients infected
in hospital
Dominguez-
Cherit et al.184
Mexico, all ages,
critically ill
24 March to
1 June 2009
ICU and hospital
mortality at 14, 28,
60 days
NI (44/45 received
oseltamivir)
Not reported
Kumar et al.187 Canada, adults,
critically ill
16 April to
12 August 2009
28- and 90-day
mortality
Oseltamivir Not reported
Nguyen-Van-Tam
et al.186
UK, all ages,
hospitalised
27 April to 30
September 2009b
In-hospital death Oseltamivir Antiviral
Chitnis et al.193 Wisconsin, USA, all
ages, hospitalised
23 April 23 to
15 August 2009
Not reported Antiviral (99%
got oseltamivir)
Not reported
ANZIC194 Australasia,
pregnant women,
intensive care
1 June to
31 August 2009
Maternal death Oseltamivir Not reported
Yung et al.195 Australasia From 1 June to
31 August 2009
In-hospital death Oseltamivir Not reported
Javadi et al.196 Iran, all ages,
hospitalised
September 2009 to
February 2010
Not reported Oseltamivir Not reported
Miranda-Choque
et al.197
Peru, children,
hospitalised
June to September
2009
Death related to
pandemic influenza
Oseltamivir Antibiotics
Poeppl et al.198 Austria, all ages,
hospitalised
20 September 2009
to 2 February 2010
In-hospital death Oseltamivir Not reported
Riquelme et al.199 International, all
ages, hospitalised
April to
October 2009
In-hospital
all-cause mortality
Oseltamivir Not reported
Yokota et al.200 Brazil, all ages,
hospitalised
July 2009 Death caused by
pandemic (H1N1)
2009
Oseltamivir Oseltamivir
Thompson et al.188 USA, all ages,
hospitalised
14 September 2009
to 13 January 2010
Influenza-related
in-hospital death
Neuraminidase
antiviral
Not reported
continued
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TABLE 16 Characteristics of the 30 included studies (continued )
Study
Setting and
population Time period
Definition for
death
Description of
treatment
exposure
Drug use before
admission
Bagdure et al.201 Colorado, USA,
children,
hospitalised
1 May to 30
November 2009
Death in hospital
or emergency
room
Oseltamivir Not reported
Blumental et al.202 Belgium, children
> 2 years,
hospitalisedc
1 July 2009 to
31 January 2010
Not reported but
all were due to
influenza
Oseltamivir Not reported
Chemaly et al.203 International,
hospitalised cancer
patients
During the
2009–10 H1N1
pandemic
Death within
60 days of onset
of symptoms
Oseltamivir Not reported
Çiftçi et al.204 Turkey, children,
hospitalised
17 July 2009 to
10 February 2010
Not reported but
causes described
Oseltamivir Not reported
del Rosal et al.205 Spain, children,
hospitalised
1 May to
30 November 2009
Not reported but
causes described
Oseltamivir Not reported
Kusznierz et al.206 Argentina, all ages,
hospitalised
May to December
2009
Not reported Oseltamivir Not reported
Mickiene˙ et al.207 Lithuania, adults,
hospitalised
1 November 2009
to 15 March 2010
Not reported Antiviral (all received
oseltamivir)
Not reported
Moretti et al.208 Brazil, all ages,
hospitalised
28 April to
31 December 2009
Not reported Oseltamivir Not reported
Brink et al.209 Sweden, all ages,
critically ill
August 2009 to
February 2010
Mortality at 28
and 90 days after
admission
Oseltamivir Oseltamivir,
antibiotics
Rahamat-
Langendoen
et al.210
Netherlands, all
ages, hospitalised
June 2009 to
July 2010
Not reported Oseltamivir Not reported
Yang et al.182 China, children,
hospitalised with
pneumoniad
1 September to
31 December 2009
In-hospital and
60-day mortality
1-day oseltamivira Not reported
ICU, intensive care unit.
a Data on a larger cohort of patients were supplied by the corresponding author.
b A second wave of patients was also included in the data supplied by the corresponding author.
c Cohort of < 2 years was not included as there were no deaths.
d Adult cohort not included as > 95% received oseltamivir.
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hospital presentation. This may be important as, for example, NSAIDs have been shown to increase
mortality in influenza-infected animals.213
Although a number of the included studies conducted analyses adjusting for potential confounding
variables, such as patient comorbidities, they used logistic regression or standard survival analysis, which
may not be appropriate for observational studies in which treatment exposure is time dependent. This type
of analysis misallocates the time from initiation of the study (e.g. hospital admission) to start of antiviral
treatment and leads to time-dependent bias. Beyersmann et al.214 provide mathematical proof that
analyses which ignore the time-dependent nature of an exposure variable lead to biased estimates of
treatment effect in favour of treatment. Time-dependent bias is also referred to as immortal time bias,215
survivor treatment selection bias216 and survival bias.217 It causes selection bias because patients who die
early do not get an opportunity to receive treatment. In addition, patients who are extremely sick may not
be given the opportunity to receive treatment because other more critical procedures take priority. Only
two of the included studies182,184 attempted to take account of time-dependent bias but they appeared to
have used flawed approaches. One study excluded all deaths within 3 days of onset of symptoms and the
other obtained results that appear incorrect because their analysis – taking into account time-dependent
bias – increased the treatment effect in favour of oseltamivir. Only six studies reported data on time from
hospital admission to treatment initiation (see Table 17). Beyersmann et al.214 suggest that time-dependent
bias can be avoided by proper hazard-based analyses. See Appendix 15 for a detailed description and
example of time-dependent bias.
Analysis of summary data from included studies
Table 17 shows a summary of the numbers and percentages of patients with oseltamivir exposure by
survival status for each of the 30 included studies. In total there are 11,013 patients included and 1301
deaths (12%). Overall, the percentage receiving oseltamivir among deceased patients (1085/1301= 83%)
was similar to the percentage receiving oseltamivir among survivors (7918/9712= 82%). Meta-analysis of
the included studies showed moderate heterogeneity [I2= 44%, χ2= 51.93, degrees of freedom (df)= 29,
p= 0.006, τ2= 0.217] and no evidence of small study effects (p= 0.25). Figure 17 shows a funnel plot of
the 30 included studies.
To investigate heterogeneity we conducted a random-effects metaregression using the metareg command
in Stata/IC. Factors investigated included age group (adults vs. children), severity of illness (critically ill vs.
hospitalised), log-odds of death (another measure of severity of illness) and log-odds of treatment.
This last factor was included to investigate the potential effect of time-dependent bias on treatment effects.
If time-dependent bias is apparent then we would expect it to have a greater influence in cohorts that had
higher odds of treatment. This is because if few patients were untreated then patients dying before
initiation of treatment would tend to have a large influence on the odds of patients dying in the untreated
group. Results showed no effect of age group (p= 0.40) or severity of illness (p= 0.38), but evidence of an
effect of log-odds of death (p= 0.024) when, as odds of death increases, the treatment effect in favour of
oseltamivir increases, and log-odds of treatment (p= 0.003), when, as odds of treatment increases, the
treatment effect in favour of oseltamivir increases. These effects appear to be independent as p-values in
multivariable analysis are 0.031 and 0.006, respectively.
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To illustrate these effects we conducted subgroup analysis by odds of treatment: ‘< 5’ compared with ‘≥ 5’
and percentage of death: ‘< 10%’ compared with ‘≥ 10%’. An odds of treatment of ‘≥ 5’ equates to a
percentage of ≥ 83.3%. Results show treatment effect is in favour of oseltamivir and more heterogeneous
in cohorts when odds of treatment were ‘≥ 5’. Conversely, in cohorts for which odds were ‘< 5’,
heterogeneity is smaller and overall effect is in favour of no treatment (Figure 18). Similarly, treatment
effect is in favour of oseltamivir and more heterogeneous in cohorts in which percentage of death was
≥ 10%; conversely, in cohorts in which the percentage is < 10%, heterogeneity is smaller and overall
effect is in favour of no treatment (Figure 19).
Meta-analysis of individual patient data
We were able to obtain IPD from four included studies.185–188 One was a German study of 93 critically ill
children;185 another was a UK study of 1520 hospitalised patients of all ages;186 another was a Canadian
study187 of 605 critically ill adults; and the last study188 was a US study of 926 hospitalised patients of
all ages. After removing data from patients who received zanamivir and patients with missing death status
(n= 73, 2%), we had data for 3071 patients, of whom 242 (8%) died, 1803 (59%) were discharged,
140 (4%) remained in hospital and 886 (29%) had missing date of discharge. Details of responses and
non-responses from corresponding authors of included studies to our request for IPD are shown in Table 18.
In Table 19 we present results of analysis of our primary outcome using five different methods. The first is
logistic regression; the second is standard Cox regression; the third is Cox regression including treatment
as a time-dependent exposure (td-Cox); the fourth is td-Cox with inclusion of potential confounders as
covariates; and the fifth is td-Cox with inclusion of covariates as well as imputing missing time from
hospital admission to death/discharge (for which 33% of values are missing, mainly due to the US study
not providing date of discharge for survivors), time from hospital admission to oseltamivir exposure
(for which 10% of values of the patients treated with oseltamivir are missing) and time from onset of
symptoms to hospital admission (16% missing). The percentages of missing data were smaller for the
deaths than the survivors (0.4% vs. 36% for time to death/discharge for example), suggesting that data
collection was more thorough for patients who died.
0.0
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FIGURE 17 Funnel plot of the 30 included studies. Please note that the pseudo 95% confidence limits are shown by
the dotted lines. The funnel shape, bounded by the confidence limits, represents the expected distribution of
studies where, assuming no heterogeneity, 95% of the treatment effect estimates should lie.
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Study ID OR (95% CI) % weight
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3.07 (0.69 to 13.63)
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2.69 (0.34 to 21.19)
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0.34 (0.07 to 1.72)
2.14 (0.26 to 17.60)
0.52 (0.26 to 1.07)
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0.16 (0.05 to 0.53)
1.43 (0.31 to 6.60)
1.56 (0.37 to 6.65)
0.46 (0.34 to 0.64)
0.79 (0.29 to 2.12)
0.22 (0.06 to 0.88)
0.29 (0.07 to 1.27)
0.56 (0.40 to 0.79)
0.90 (0.67 to 1.20)
1.55
4.03
1.45
1.45
2.92
1.30
1.48
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6.56
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Louie 2012181
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Yang 2012182
Brink 2012209
Subtotal (I2 = 22.1%, p = 0.214)
Overall (I2 = 44.2%, p = 0.006)
Note: weights are from random-effects analysis
FIGURE 18 Meta-analysis of included studies by odds of treatment with oseltamivir.
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FIGURE 19 Meta-analysis of included studies by proportion of death.
TABLE 18 Responses and non-responses from corresponding authors of included studies to our request for IPD
Outcome from our request Number of studies
Obtained IPD 4
No response to request 20
Response to our request but did not provide IPDa 6
a Reasons given for not providing IPD were as follows:
l ‘We have no variables you need. We are epidemiologists, we didn’t collect clinical data.’
l ‘Unfortunately, the dataset is currently being used for a similar project.’
l ‘Unfortunately we just didn’t collect the data to be able to make a contribution.’
l ‘We will not be able to contribute this time due to current overload of work.’
l ‘The information we collected is less detailed than what you ask for.’
l ‘Unfortunately it will be difficult to provide you the data as this was a multi-institutional study with centres from
outside the US’.
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Results show that when the time-dependent nature of treatment is taken into account appropriately the
treatment effects change direction, although none of the results is statistically significant. Adjusting for
potential confounders and imputing missing data made little difference to the results. Table 20 shows
results of the first three analysis methods by study, and a detailed analysis of the Canadian study,187 shown
in Appendix 15, further illustrates why the time-dependent nature of treatment needs to be taken account
of appropriately. This study was used for illustration because it had the most deaths and 93% of patients
were treated, hence we would expect time-dependent bias to be large. However, bias is also apparent in
the other studies if treatment is incorrectly assumed to be time independent (see Table 20). Table 21
shows distributions of potential confounding variables by treatment received stratified by study with
p-values based on the chi-squared test. Detailed examination suggests a possible explanation for the reason
oseltamivir is associated with greater risk of mortality in the Altmann et al.185 and Nguyen-Van-Tam et al.186
studies. In these two studies,185,186 comorbidities are generally more prevalent in the group that
received treatment.
In Table 22 we show the variables that were associated with oseltamivir treatment. Respiratory and
neurological comorbidities, as well as cancer, were all associated with increased odds of treatment, whereas
the ages of < 20 years and > 64 years, as well as missing time from symptom onset to hospital presentation,
were associated with lower odds of treatment. Early presentation was not associated with increased odds of
treatment. In multivariable competing risks analysis, respiratory comorbidity was protective for mortality
irrespective of exposure to treatment (HR 0.60, 95% CI 0.43 to 0.84) and each 10 years increase in age was
associated with increased risk of death by 22% (95% CI 10% to 35%). Respiratory comorbidity was also
associated with 15% (95% CI 3% to 28%) increased likelihood of discharge suggesting despite the
comorbidity these patients had a good prognosis. Furthermore, a two-sample t-test showed respiratory
comorbidity was associated with slightly lower Acute Physiology and Chronic Health Evaluation (APACHE) II
scores in the Kumar et al.187 study [mean (SD) 20 (10)10 vs. 22 (10);10 p= 0.014].
The results of mortality analyses by timing of treatment (Table 23) further illustrate the importance of
appropriate analysis of a time-dependent treatment exposure. Logistic regression shows a statistically
significant reduced odds of death associated with early treatment compared with no treatment, and
estimates from standard Cox regression suggest treatment reduces risk of death compared with no
treatment, although the result is not statistically significant. However, when time-dependent exposure to
treatment is included appropriately in the Cox model, the results show no evidence treatment is beneficial.
There is a suggestion that patients receiving late treatment do worse than those who received early
treatment; however, this can be at least partially explained by the patients receiving late treatment having
worse prognosis due to being older and having increased likelihood of a number of comorbidities,
including infection, cardiovascular, diabetes and obesity (Table 24).
TABLE 19 Results of analysis of primary outcome of death by oseltamivir exposure
Method Estimatea 95% CI p-value
1. Logistic regression 0.93 0.65 to 1.33 0.71
2. Standard Cox regressionb 0.75 0.51 to 1.10 0.14
3. Cox regression with time-dependent treatment exposure (td-Cox)b 1.11 0.75 to 1.65 0.59
4. td-Cox adjusting for covariatesb 1.10 0.74 to 1.63 0.64
5. td-Cox with imputation and adjusting for covariates 1.11 0.77 to 1.62 0.57
a OR for logistic regression; HR for all other analyses.
b Based on the three studies for which date of discharge for survivors was available.
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TABLE 21 Comorbidities and presentation timing by treatment and study
Variable No-treatment group, n (%) Oseltamivir group, n (%) p-value
Altmann et al.185
Age group (years)
< 20 35 (100) 53 (100) –
20–64 0 (0) 0 (0)
65+ 0 (0) 0 (0)
Presentation timing
< 2 days 17 (48) 21 (40) 0.65
> 2 days 15 (43) 28 (53)
Missing 3 (9) 4 (7)
Infection 25 (71) 49 (92) 0.019
Cardiovascular 5 (14) 6 (11) 0.93
Neurological 17 (49) 37 (70) 0.075
Cancer 1 (3) 4 (8) 0.65
Immunosuppression 3 (9) 8 (15) 0.56
Respiratory 13 (37) 32 (60) 0.055
Obesity 0 (0) 0 (0) –
Diabetes 0 (0) 0 (0) –
Nguyen-Van-Tam et al.186
Age group (years)
< 20 216 (54) 355 (33) < 0.0001
20–64 163 (41) 656 (61)
65+ 18 (5) 72 (7)
Presentation timing
< 2 days 140 (35) 467 (43) < 0.0001
> 2 days 97 (25) 346 (32)
Missing 160 (40) 270 (25)
Infection – – –
Cardiovascular 31 (8) 159 (15) 0.0006
Neurological 39 (10) 170 (16) 0.005
Cancer 8 (2) 43 (4) 0.096
Immunosuppression 10 (3) 34 (3) 0.65
Respiratory 115 (29) 496 (46) < 0.0001
Obesity 9 (2) 40 (4) 0.23
Diabetes 24 (6) 77 (7) 0.55
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TABLE 21 Comorbidities and presentation timing by treatment and study (continued )
Variable No-treatment group, n (%) Oseltamivir group, n (%) p-value
Kumar et al.187
Age group (years)
< 20 0 (0) 8 (2) 0.23
20–64 32 (82) 480 (88)
65+ 7 (18) 56 (10)
Presentation timing
< 2 days 11 (28) 135 (25) 0.26
> 2 days 26 (67) 402 (74)
Missing 2 (5) 7 (1)
Infection 22 (56) 332 (61) 0.69
Cardiovascular 16 (41) 215 (40) 0.99
Neurological 1 (3) 30 (6) 0.67
Cancer 0 (0) 36 (7) 0.19
Immunosuppression 2 (5) 33 (6) 1.0
Respiratory 18 (46) 298 (55) 0.38
Obesity 8 (21) 135 (25) 0.68
Diabetes 9 (23) 138 (25) 0.90
Thompson et al.188
Age group (years)
< 20 96 (40) 292 (43) 0.001
20–64 104 (43) 327 (48)
65+ 42 (17) 59 (9)
Presentation timing
< 2 days 137 (57) 362 (53) 0.048
> 2 days 90 (37) 295 (44)
Missing 15 (6) 21 (3)
Infection – – –
Cardiovascular 46 (19) 94 (14) 0.071
Neurological 23 (10) 79 (12) 0.43
Cancer 3 (1) 22 (3) 0.16
Immunosuppression 10 (4) 73 (11) 0.003
Respiratory 89 (37) 275 (41) 0.34
Obesity 42 (17) 149 (22) 0.15
Diabetes 50 (21) 101 (15) 0.048
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TABLE 22 Variables associated with oseltamivir treatment
Variable OR for treatment 95% CI p-value
Age (years)
< 20a 0.61 0.50 to 0.74
0.38 to 0.72
< 0.0001
> 64 0.52
Time from onset of symptoms to hospital
presentationb
0.89 (early vs. late) 0.72 to 1.09
0.34 to 0.57
< 0.0001
0.44 (missing vs. late)
Neurological comorbidity 1.57 1.18 to 2.09 0.002
Cancer 2.93 1.55 to 5.54 0.001
Respiratory comorbidity 1.56 1.30 to 1.88 < 0.0001
a Reference group: age 20–64 years.
b Early ≤ 2 days; late > 2 days; missing= timing of treatment missing.
TABLE 23 Results of analysis of primary outcome of death by timing of oseltamivir exposure
Method Estimatea,b 95% CI p-value
1. Logistic regression 0.54 (early vs. none) 0.33 to 0.89 0.008
1.12 (late vs. none) 0.76 to 1.66
1.11 (missing vs. none) 0.73 to 1.71
2. Standard Cox regressionc 0.68 (early vs. none) 0.40 to 1.16 0.12
0.85 (late vs. none) 0.56 to 1.29
0.69 (missing vs. none) 0.44 to 1.06
3. Cox regression with time-dependent
treatment exposure (td-Cox)c
0.89 (early vs. none) 0.52 to 1.52 0.69
1.15 (late vs. none) 0.74 to 1.77
1.25 (missing vs. none) 0.72 to 2.16
4. td-Cox adjusting for covariatesc 0.92 (early vs. none) 0.54 to 1.57 0.76
1.16 (late vs. none) 0.75 to 1.79
1.14 (missing vs. none) 0.65 to 1.99
5. td-Cox with imputation and adjusting
for covariates
1.10 (early vs. none) 0.60 to 1.47 0.64
1.28 (late vs. none) 0.86 to 1.90
a OR for logistic regression; HR for all other analyses.
b Early ≤ 2 days; late > 2 days; missing= timing of treatment missing; none= no treatment given.
c Based on the three studies for which date of discharge for survivors was available.
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Competing risks survival analysis on the three cohorts that provided date of hospital discharge showed
insufficient evidence that oseltamivir is associated with mortality (HR 1.03, 95% CI 0.64 to 1.65) but the
results showed an association with increased likelihood of hospital discharge for survivors (HR 1.44, 95% CI
1.26 to 1.64).
Discussion
We have systematically reviewed the literature on the relationship between mortality from influenza
2009A/H1N1 and oseltamivir exposure. We included 30 studies in our review and obtained IPD for four of
those studies. Analysis of both the summary data of the 30 studies, as well as the IPD, showed evidence
of time-dependent bias, with bias increasing with increasing odds of treatment. Analysis of the IPD using
Cox regression, with treatment exposure included as a time-dependent variable, adjusting for covariates
and imputing missing data, has shown insufficient evidence that oseltamivir is associated with a reduction
in mortality. Furthermore, early treatment with oseltamivir did not appear to have a beneficial effect on
survival compared with no treatment. Competing risks survival analysis also showed insufficient evidence of
association of treatment with mortality but the results showed an association with increased likelihood of
hospital discharge for survivors.
Analysis of the IPD using logistic regression included 3071 patients and showed an OR of 0.93, whereas
standard Cox regression on the 2056 patients with survival times gave a HR of 0.75, reflecting that untreated
subjects who died did so earlier than those treated. When the time-dependent nature of oseltamivir
exposure was incorporated into the Cox model, results showed a HR of 1.11, a marked difference from
0.75, illustrating the large time-dependent bias associated with standard Cox regression. After adjusting for
covariates, the HR was virtually unchanged (1.10) and multiple imputation of the missing data had a
negligible effect (HR 1.11). A competing risks survival analysis showed a consistent result, with a HR of 1.03
for mortality. We suggest that the competing risks analysis result may be the most appropriate because it
takes into account the competing risk of discharge for treated patients, although a limitation is that it is based
on only three studies because the fourth (US) study did not have data available for date of discharge.
TABLE 24 Comorbidities by treatment timing
Variable Early treatment group, n (%) Late treatment group, n (%) p-value
Age group (years)
< 20 313 (42) 237 (23) < 0.0001
20–64 375 (51) 686 (68)
65+ 55 (7) 90 (9)
Infectiona 80 (19) 201 (30) 0.0001
Cardiovascular 106 (14) 235 (23) < 0.0001
Neurological 101 (14) 133 (13) 0.83
Cancer 24 (3) 42 (4) 0.38
Immunosuppression 51 (7) 63 (6) 0.66
Respiratory 344 (46) 486 (48) 0.52
Obesity 87 (12) 179 (18) 0.0007
Diabetes 78 (11) 159 (16) 0.002
a Data not provided by Nguyen-Van-Tam et al.186
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The metaregression result that showed increasing mortality rate is associated with an increasingly
favourable outcome for treatment is difficult to interpret because of the presence of time-dependent bias
that cannot be quantified with access to only summary data. The metaregression result suggests that
increasingly severe patients may lead to a better efficacy/toxicity trade-off of treatment. However, without
the IPD it is unknown where, if anywhere, oseltamivir becomes a beneficial treatment. An alternative
explanation is that cohorts with higher mortality rates were associated with greater time-dependent bias,
as a greater proportion of patients died before they had the opportunity to receive antiviral treatment.
Confounding by indication is a possibility in observational studies and it is possible that sicker patients
were more likely to get treatment. We were not able to adjust for severity of illness at baseline, as this
information was not generally available for the included studies. However, APACHE II score was available
for Kumar et al.187 and comparison of treated with untreated patients showed no evidence of a difference
in severity of illness (see Appendix 15). Prevalence of some comorbidities appeared higher for treated
patients than untreated patients for two of the studies for which we had IPD, and this is reflected in the
higher odds of mortality for treated patients in those studies. We adjusted for variables associated with
treatment in the IPD analysis and this made little difference to the results. In addition, the competing risks
survival analysis showed that treated patients who survived were discharged sooner than untreated
patients. It is plausible that late treatment could indicate a sicker patient, as normally it takes time for
patients to become severely ill. Patients who were treated late were older, and had greater prevalence of
some comorbidities than patients who were treated early. This could at least partially explain why these
patients had an increased risk of mortality.
Our results are different from those of three other recent reviews. Hsu et al.172 included studies of seasonal
influenza and 2009A/H1N1 influenza and based their primary analysis of mortality on three small studies
of 681 patients, none of whom had 2009A/H1N1. They did not consider the time-dependent nature of
treatment exposure and reported an OR of 0.23 (95% CI 0.13 to 0.43) based on summary data only.
Muthuri et al.171 focused on 2009A/H1N1 influenza, included 20 studies, did not consider time-dependent
treatment exposure and reported an OR of 0.72 (95% CI 0.51 to 1.01) based on summary data only.
Muthuri et al.170 conducted an analysis of almost 30,000 patients from 78 studies using IPD; of the
78 studies included, only 22 would have been eligible for our study. For example, all included patients in
27 studies received NIs and 16 studies had no mortality. It is unclear how these studies were included in a
mortality comparison between NIs and no treatment because, in meta-analyses, studies with no events and
studies without a control group are dropped from the analysis. Muthuri et al.’s crude analysis results170 are
consistent with ours but the results from their analysis taking into account the time-dependent treatment
exposure are different and appear to be incorrect, as they result in an increased protective effect of
treatment. As Beyersmann et al.214 show, mathematically time-dependent bias is always in the same
direction (i.e. in the direction of showing a larger protective effect of treatment than is actually the case).
Furthermore, the authors’ reply to criticisms of their analysis218 shows a crude HR of 0.36 (95% CI 0.32 to
0.41) for antiviral use modelled as a time-constant exposure without taking into account clustering or
immortal time bias. However, this result is logically inconsistent with the descriptive data, which show that
crude mortality in the antiviral group is larger than that of the no-treatment group (9.7% vs. 9.2%).
The results of this systematic review of observational studies are consistent with a recent Cochrane review9
of NIs for influenza based on a full set of manufacturer compiled CSRs of RCTs and regulatory information.
The Cochrane review9 showed no evidence that NIs reduce the risk of hospitalisation or risk of
complications classified as serious or leading to study withdrawal, a result consistent with oseltamivir not
having a protective effect on mortality. The likelihood of treated survivors being discharged earlier is
inconsistent with these findings, but is consistent with symptomatic relief that is not specific to influenza
infection. The reasons for this inconsistency is unclear.
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The problem of time-dependent bias is not confined to survival outcomes. For example, Beyersmann et al.214
show time-dependent bias for the effect of hospital-acquired pneumonia on hospital length of stay. Yorifuji
et al.147 show the importance of taking account of time-dependent exposure of oseltamivir appropriately
in a prospective observational study of Japanese children for which the outcomes related to abnormal
behaviours. In the case of observational studies of 2009A/H1N1 influenza, outcomes by oseltamivir exposure –
including pneumonia, hospitalisation and intensive care unit admission – have been compared and
reported171,172 without regard to the time-dependent nature of treatment exposure. Beyersmann et al.214
state that ‘because time-dependent bias inevitably leads to erroneous findings, it is a major concern that it
is common in the clinical literature’. Van Walraven et al.219 surveyed the medical literature and found that
‘in medical journals, time-dependent bias is concerningly common and frequently affects key factors
and the study’s conclusion’. It is critical that analyses of all outcomes reported from observational studies
with time-dependent exposures take account of time-dependent bias appropriately.
Strengths
We systematically searched five widely used databases over a 4-year period, as well as hand-searched
relevant WHO documents and previous reviews. There were no restrictions on the type of research articles
or studies considered for inclusion in the review. Studies from the Americas, UK and Europe, Australasia,
Asia and the Middle East were included. We were able to obtain IPD for four studies that included > 3000
patients and more than 240 deaths. Using the IPD we were able to take account of the time-dependent
nature of treatment exposure appropriately, impute missing time to event data and adjust for important
covariates in the analysis. We were also able to take account of the competing risk of hospital discharge in
estimating the effect of oseltamivir on mortality.
Limitations
Limitations of this review include the observational nature and quality of the included studies. All included
studies were of hospitalised patients, and severity of illness of patients at baseline was not always
reported. Limited information was provided on drug use prior to admission and no study reported NSAID
use. Only two studies reported a definition for treatment and the comparison groups were assumed to be
the subsets of patients who were not exposed to antivirals. The percentage of unexposed patients was
often small (median 18%). Reasons for non-treatment with antivirals were not provided and none of the
studies described a policy or criteria used for selecting patients for treatment. Our IPD analysis showed that
patients with certain comorbidities were more likely to be treated, whereas children, the elderly and
patients with unknown duration of symptoms were less likely to be treated.
We were able to obtain IPD for only four of the included studies, thus limiting the amount of statistical
power that we had for our IPD analysis and potentially resulting in a biased subset of the 30 included
studies. However, some of the responses to our request for IPD suggest critical data to assess the impact
of oseltamivir on mortality were not collected. Furthermore, the IPD we obtained appears to be a
representative sample of the 30 included studies as the ORs for mortality were similar for the IPD (0.93 –
see Table 19) and the summary data (0.90 – see Figure 19). These estimates are also consistent with the
crude OR of 0.92 reported by Muthuri et al.170 Furthermore, the studies were from four different countries
with varying mortality rates (4–20%), varying odds of treatment (60–93%) and included patients with ages
from 0 to 102 years.
There were missing data for time to death/discharge and time to treatment (33% and 10% missing,
respectively) in the four studies for which we had IPD. The majority of missing data for time to death/
discharge was due to one study that did not report date of discharge for survivors. Analysis excluding this
study showed similar results to those based on all four studies, hence we do not believe the missing time
to discharge data has introduced a significant bias.
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Conclusion
Our systematic review has found insufficient evidence that oseltamivir is associated with a reduced risk of
mortality. However, this result is based primarily on an IPD analysis of just 4 of 30 eligible observational
studies without adjustment for baseline severity of illness or other drug use. Analysis of all 30 included
observational studies using summary data showed evidence of time-dependent bias that had an increasing
effect with increasing odds of treatment. Observational studies with time-dependent treatment exposure
are at high risk of time-dependent bias unless an appropriate analysis is conducted.
EFFECT OF OSELTAMIVIR ON MORTALITY IN PATIENTS WITH 2009A/H1N1 INFLUENZA
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Appendix 1 The story of A159
The 2009 review: from A047 to A159
In the midst of the A/H1N1 influenza outbreak in June 2009, the Australian and UK governments
commissioned an update of our long-standing Cochrane review on NIs for influenza in (otherwise) healthy
adults (known as A047). Prior to the emergence of influenza A/H1N1 in 2009, governments worldwide
stockpiled nearly CHF (Swiss francs) 7.6B worth of oseltamivir.166 The WHO considered antivirals for influenza
important (WHO has recently added oseltamivir to the list of essential medicines169,174,175). Oseltamivir and
zanamivir have been prescribed for the treatment of influenza worldwide since the outbreak of 2009 A/H1N1
influenza. The review (on healthy adults) had first been published in 1999 (as A047) and was updated in
2006 and 2008. At the same time a similar review on children32 (or A046) had also been published.
As the review had been updated the previous year, we initially anticipated that the commissioned 2009
update would not require substantial effort and would probably reflect only updated pharmacovigilance
data and not the incorporation of new trial evidence.6
In the end, the 2009 update was inconclusive regarding whether or not oseltamivir reduced the risk of
complications of influenza,14 as we were unable to verify the data underlying manufacturer and
government claims to this effect. The claims were based on clinical trial evidence included in a published
pooled analysis of 10 manufacturer-funded clinical trials of oseltamivir for the treatment of influenza in
people aged ≥ 13 years.4 Eight of the 10 trials in the Kaiser et al.4 pooled analysis have never been
published,31 and their complete data sets were not available from either the authors or the manufacturers.
Some of the published trials had been ghost written.43 The largest of the 10 Kaiser trials (M7600136),
involving over 1400 people, had been briefly reported in conference abstract format but the person whose
name appeared on the abstract could not recall ever presenting its results or being involved with the
study.43 Our early requests for data from the 10 Kaiser studies were met with an offer from Roche to sign
a confidentiality agreement with an embedded secrecy clause preventing us from mentioning the existence
of the agreement. The unsigned agreement can be seen at www.bmj.com/highwire/filestream/440792/
field_highwire_adjunct_files/0.
At the time of publication of the 2009 update and its linked investigation by the BMJ, we were unaware
of the size and depth of the oseltamivir evidence development programme. We thought it comprised
around 36 trials and we expected that only a proportion of these would fit our inclusion criteria. We also
did not realise the size and the level of detail that the CSRs contained.
On 31 December 2009, Roche released the core reports (or module 1s) of the 10 Kaiser trials with no legal
agreement signed (only a web-based agreement that we would not share the documents with other
commercial companies). After requesting Roche to provide us with the full study reports, Roche said that
the module 1s were all that were needed for us to complete our job.6 The missing modules (or parts),
numbered 3–4 according to the trial in question, contained protocols, amendments, individual listings and
demographic information. It seemed to us that these documents would have contained some important
additional material for understanding the trials, their design and interpretation but we were not sure.
In 2010 we started exploring the relationship between the available module 1s for the only two Kaiser
trials that had been published (Doshi8 or Nicholson et al.,220 and WV1567158 or Treanor et al.221).
At about this time we started getting concerned that the oseltamivir trial programme was considerably
larger than we first thought. Our interest was awakened by the casual discovery of a confidential 2009
Roche Tamiflu Investigator’s Brochure, which was freely accessible on the web. This reported a clinical trial
programme of over 60 studies. Searching for an unpublished and hitherto unseen data set requires
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constructing a reasonably accurate list of all studies of the drug in question. The Roche Investigator’s
Brochure did not mention some studies that we were aware of and reinforced an idea that we had become
clear was essential: the need to develop our own list of trials, because a single, authoritative, up-to-date
and complete list of all clinical trials conducted on humans using both drugs did not seem to exist.
When thinking about our next update we decided not to use publications because the majority of
treatment trial evidence for Tamiflu remained unpublished; we had found some discrepancies between
CSRs and published equivalents; and, mostly, CSRs were so much more detailed and comprehensive than
short journal articles, enabling a more thorough critical analysis of the trials. We also decided to expand
the scope of A047 by including evidence relating to people of all ages except for immune-suppressed
individuals. This, de facto, amounted to the creation of one new review (A159) with a new protocol
subsuming A047 and A046. The protocol for A159 was publicly posted in December 2010.
A new source of evidence for A159
Today, the obvious source of information on CSRs would be trial registries and company websites, but
most trials of both NIs were carried out before inception or wide acceptance of centralised registries and
company websites. In 2009–11, company websites did not, and still do not, have extensive lists of trials
with downloadable CSRs. Most people had never heard of CSRs before media coverage of our efforts.
We decided to construct our list by using multiple cross-referencing methods. We constructed a list
beginning with clinical trials identified from previous review updates. To this end, we added additional
trials in humans from multiple sources, including manufacturer submissions to regulators, drug product
information sheets, previous published reviews, Health Technology Assessment (HTA) documents and
public and manufacturers’ registers,5,156,157,159,160 such as www.ClinicalTrials.gov and www.roche-trials.com.
Regulatory documents also aided the identification of unknown trials. Finally, we also conducted traditional
database and grey literature searches (see Appendix 3) to identify previously unknown trials.
One of the first things we learned was that to ensure that the list did not include duplicate entries, we had
to assign to each trial a unique trial ID. ‘Author’ is not a good choice of unique trial ID, as different authors
can be present across different versions of the same trial (i.e. the authors of CSRs can be different from
publications arising from the same clinical trial). Nor are any other details connected to publications a good
option for unique trial ID because not all studies are published. Some trials will have company-specific codes
and some will have public clinical trial registry numbers, or both, or neither. To simplify recognition and
terminology we used the manufacturer protocol ID as our unique trial ID.
Our list was going to be useful only if it had sufficient details to enable us to decide whether or not it met
our inclusion criteria. For each unique trial ID, we gathered the following details:
1. unique trial ID
2. other IDs
3. phase of study
4. sponsor
5. short description
6. official trial title
7. first authors (name and e-mail)
8. type of trial
9. comparator
10. outcomes assessed
11. date of trial
12. study period (days)
13. population
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14. number of participants planned
15. number of participants enrolled
16. number of participants completing
17. trial status (e.g. completed, ongoing or early termination)
18. publication status (a citation or understanding of why it was not published)
19. how identified (to record how the trial was discovered)
20. notes.
Once we had as complete a list of trials as possible, we contacted manufacturers and sent them our draft
list, asking them to check the accuracy and completeness of our list. Roche, GSK and BioCryst all did so
and, in doing so, we learned of hitherto unknown trials.
Occasionally, the existence of further unknown trials was detected weeks and months after we thought
we had a ‘complete’ list. This may be inevitable, given that trial identification often takes place in
unpredictable ways, for example while reading through detailed regulatory reports.
We engaged in prolonged correspondence with Roche and GSK, and requested a series of regulatory
documents under freedom of information policies from both the FDA and EMA. No substantial comments
were made by Roche on the protocol of 159, which has been publicly available in one form or another
since December 2010.
Specifically, we applied to EMA under their new release policy for 26 CSRs in their holdings relating to
oseltamivir and GSK’s zanamivir. The result was the delivery (starting in late March 2011) of 16 CSRs,
all containing modules 1 and 2 plus one complete report for oseltamivir (trial WP16263104). (See table 1 in
Doshi et al.6) None was available for zanamivir, as the EMA had not played a part in its market
authorisation. These formed the basis for the 2012 version of A159.
At the date of completion of data searches for A159 (12 April 2011), Roche had provided us with only
partial CSRs despite five requests for full CSRs. The material obtained from Roche included the first section
(or so-called ‘module 1′ or ‘core report’) of a full CSR, each of which contain four to five modules
(see Appendix 9) for the 10 oseltamivir treatment trials included in the Kaiser et al.4 meta-analysis. Not
contained in the provided module 1s are trial protocols with the list of amendments and original reporting
analysis plans (RAPs). These module 1s comprise 3195 pages. Roche had not made available any further
material and indicated that it did not intend to answer our requests for clarification on aspects of trials and
for availability of the missing parts of complete CSRs. In addition we had a 53-page report in English of the
treatment trial ML16369,76 sponsored by Shanghai Roche Pharmaceutical Ltd. Regardless of success with
our requests to obtain full CSRs, we decided to update our review with available material and subsequently
update it as and when additional data became available.
Our searches of publication databases did not add any significant information.
Following a change of policy at the EMA, prompted by similar efforts of the Nordic Cochrane Centre,222
we received an additional eight CSRs (10,737 pages) in response to a FOI request. An additional 14,700
pages of further CSRs and 33 pages of regulators’ comments arrived after our search deadline. All of the
materials received from the EMA are related to oseltamivir. The EMA has no access to information for
zanamivir, as it is a nationally authorised product in Europe (correspondence with Xavier Luria, 23 March
2011, and David Mackay, 20 July 2011). At present, we hold all of the module 1s and module 2s of
oseltamivir trials we have requested. From GSK we have received the promise of IPD. Many of the CSRs
used in this review were obtained via FOI requests.
We still await a FDA decision regarding similar requests sent to FDA in January 2011.
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We were able to download 2673 pages of SBA documents from the FDA website, 31 from EMA and 508
pages of Japanese SBA. We indexed the content and then constructed an extended table of contents,
giving a summary of each file, thereby facilitating navigation of these complex documents. Once the table
of contents had been constructed, we postulated that, given the huge work involved in reviewing lots of
regulatory files, including CSRs, we needed new instruments to indicate which parts were more important
than others, thus focusing our efforts. We experimented with a variety of methods reported in the earlier
version of the review. We have now devised and used what, for us, is a satisfactory instrument for critically
assessing CSRs in their entirety. We intend to publish this separately.
The EMA releases, coupled with documents from the FDA SBA for both drugs, formed the basis for the
version of A159 that we eventually published in January 2012. The review reported our efforts to get to
the bottom of the issue of the effects of NIs by appraising evidence from unpublished CSRs (see Appendix 1)
and regulatory documents containing comments and reviews. We called the body of clinical studies and
regulatory comments ‘regulatory information’, as all of these documents are either created for, or by,
regulators. To our knowledge, this was the first Cochrane review ever conducted on the basis of regulatory
documents only.
Owing to funding timelines and the sizeable amount of regulatory information already available to us,
we decided to review material available as at 12 April 2011. This meant reviewing FDA SBA material and
core reports (module 1s) in our possession from EMA data releases received by this time.
Study selection and extraction in 2011
In 2011 our methods were a mixture of established and novel, reflecting the size of the task, our lack of
experience in dealing with large amounts of very detailed regulatory information and the lack of a
complete set of CSRs. For example, scanning of titles and abstracts was doubled, but selection of studies
for inclusion from the list constructed during our search was quadrupled, with disagreements resolved
by discussion.
For many studies we had only titles and, in some cases, a very brief description of content, thus we
assigned three categories to our trials:
1. definitely included
2. definitely excluded
3. trials for which we needed further information.
We excluded studies that were definitely not meeting the inclusion criteria on the basis of the available
information (e.g. the title described the trial as a pharmacokinetic study). Where appropriate we requested
further information from the trials’ sponsor: usually copies of the CSRs (minus participant identification) for
each trial that was definitely included or for which we needed further information. We did not contact
first/corresponding authors of published versions of the trials on the basis of our experience with the
2009 review.
Data extraction and management reflected the lack of established methods for reviewing regulatory
material. We subdivided the extraction, appraisal and analysis of the data into a two-stage exercise,
including studies in the analysis phase only if we judged their reports to be reliable and complete. To help
structure the information we used CONSORT statement-based extraction forms aimed at assembling a
concise version of the CSRs, which included all of the important methods, as well as defined and extracted
all relevant outcomes. We colour-coded the original text to flag up uncertainty or lack of clarity or need for
more information from other (then inaccessible) parts of the CSR.
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During this process we excluded all six peramivir trials, as we were informed by the manufacturers that no
CSRs would be available. The 2012 A159 review was based on 15 oseltamivir clinical study core reports
and 10 very brief zanamivir study reports. The former came from EMA, whereas the latter had been part of
a GSK submission to UK NICE, which the BMJ had passed on to us together with the SBA material. Our
2010 protocol for A159 was not very detailed on how we would handle this mass of information for the
simple reason that no one had ever done it before. We quite literally were learning as we were going
along, and our understanding of the structure and content of CSRs evolved. We created and tested five
post-protocol hypotheses (see Appendix 8), which had originated from the findings in the reports. The best
example was our finding of an unnaturally high (up to 80%) influenza positivity rate in treatment trials,
which, in some cases, had been pooled because of lack of viral circulation. We hypothesised that screening
for influenza positivity had been carried out prior to enrolment of people with ILI. This was not borne out
by the evidence available to us. We know now that a far simpler explanation is more likely: careful
selection of the time period for trial participant enrolment, based on when surveillance data suggested that
high influenza activity led to the recruitment of small numbers of participants from each of many centres
with a high likelihood of influenza positivity, but at the time we had limited information available.
The 2012 A159 review analyses were based on the ITT population, which we had found to be the only
reliable analysis unit, as oseltamivir appeared to have an effect on antibody production in people with
influenza, leading to an imbalance in numbers of subjects in the influenza-infected (so-called ITTI)
subpopulation. This, in effect, introduced confounding in what otherwise should have been well-designed
double-blind trials. The only effect that was clearly identifiable was a modest shortening of ILI symptoms by
less than a day. This led us to believe that oseltamivir had an aspecific powerful effect on symptoms, not
mediated by any action on influenza viruses but possibly via an anti-inflammatory mechanism. Clearly,
the trials had been designed with a commercial focus in mind and some of the claims made by the
manufacturer (especially on the effect on interruption of transmission and on pneumonia) were not
supported by the evidence in our possession.
2012 to the present day
Soon after the publication of the review, the BMJ agreed to publish our correspondence with Roche, GSK,
the EMA, the CDC and WHO, recording our attempts at retrieving the full reports without any conditions
attached and to understand the basis for promotion of the drugs (especially oseltamivir) by public health
bodies. The correspondence (which is hundreds of pages long) formed the basis for what then became the
BMJ Open Data Campaign and a stimulus for the later AllTrials campaign. Public exposure of our efforts
and copious media coverage had the direct effect of ensuring the unconditional release of 77 reports of
oseltamivir of 82 studies sponsored by Roche, and the equivalent of the 30 studies we had requested
from GSK. For the full correspondence, see www.bmj.com/tamiflu and www.bmj.com/relenza.
The reports (amounting to over 140,000 pages) are made available with this review for the first time
(at https://datadryad.org/resource/doi:10.5061/dryad.77471/2, p. 3), marking a small but significant victory
for open science.
Before receiving the full reports, we resumed reviewing the remainder of the material that we had received
in 2011. This mainly consisted of module 2s (Roche terminology for pre-study documents). Module 2s
contained the information originally denied to us by Roche: study protocols with their amendments,
randomisation lists, blank CRFs, certificates of analysis describing appearance and content of active and
control capsules and, at times, SAPs. CRFs are containers for the rawest form of recorded data at the
individual participant level.
We had no tools for reviewing and synthesising this information so, again, we had to create our own.
The instrument is made up of three parts each with a separate function. In the first part there is a template
for a brief summary description of the trial. The format fits into the RevMan (RevMan 5.3; The Cochrane
Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) Characteristics of Included Studies
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Table (CIST) and is mainly descriptive. The second part is the appraisal of the trial following the Cochrane
risk-of-bias format. The third part reconstructs the trial timeline and provides a checklist and position in the
document of the various elements, such as protocol, protocol amendments and study period with dates.
The last part aims to check the internal consistency and coherence of each element (such as numbers
screened, numbers randomised, interventions, comparators) across all the different documents, starting
from the earliest available version of the protocol. The form also contains suggestions on where to look for
the information. This is based on our experience gained in this review and in a descriptive review11 of 78
CSRs of 14 different drugs and biologicals.
While designing the tool, we also asked ourselves whether or not access to module 2 information (and
later the full study reports) changed our perception of the trial and specifically our risk-of-bias assessment.
We found that access to what are supposed to be full study reports should provide clarity and remove the
rationale for ‘unclear’ risk-of-bias judgements, and, ideally, remove the concept of risk leaving just ‘bias’, at
least for certain study design elements, such as attrition bias. Either a design element introduces bias or it
does not. In the case of the 15 full oseltamivir CSRs we reviewed when constructing our tool, only one
contained a protocol that predated the beginning of participant enrolment, only two had SAPs that clearly
predated participants’ enrolment and three had clearly dated protocol amendments. No CSR reported a
clear date of unblinding.
During the latter part of 2013, we received from the manufacturers tens of thousands of pages of full
CSRs for both programmes combined.
The history and conclusions form the backdrop to this version of A159.
Oseltamivir studies received from Hoffman La Roche SA in CSR format:
1. WV1627769
2. WV15819/WV15876/WV1597867
3. WV1570760
4. WV15812/WV1587266
5. WV1573062
6. M7600136
7. WV156708
8. WV1567158
9. NV1687157
10. WV15759/WV1587164
11. WV16193
12. WV1582568
13. WV1570861
14. WV1579965
15. WV15673/WV1569759
16. WV1575863
17. NV20235
18. M76006
19. NV20236
20. NP15717
21. PV15616 (=GS-97-801)
22. PV15615 (=GS-97-802)
23. JV16284
24. WV15731
25. NV22155
26. NP15719
27. WP16254
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
146
28. WP16094
29. WP18308
30. WP16225
31. WP16134
32. PP15974
33. NP16472
34. NP15718
35. WP16226
36. NP25139
37. NP25138
38. NP15901
39. WP15525
40. NP25140
41. NP15728
42. NP15810
43. NP15826
44. PP16351
45. WP22849
46. NP22770
47. WP20727
48. PP16361
49. WP15517
50. NP15729
51. BP21288
52. WP21272
53. JP15735
54. WP15647
55. WP15648
56. WP15676
57. WP16263
58. NP15757
59. NV25118
60. NP15743
61. NP15881
62. NP15912
63. WP15979
64. WP16137
65. WP16295
66. NP15827
67. NV25655
68. JV21490
69. JP15734
70. NV22158
71. ML17713
72. ML22789
73. NV25182
74. ML17279 – publication only
75. ML19340 – publication only
76. JV1582374 – English translation of Gaiyo summary
77. JV1582475 – English translation of Gaiyo summary
78. ML17279 (=WV17052)
79. ML19340 (=COSMOS Study).
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Zanamivir studies received from GSK in CSR format:
1. 167-10170
2. JNAI-0171
3. JNAI-0472
4. JNAI-0773
5. NAI3000877
6. NAI3000978
7. NAI3001079
8. NAI3001180
9. NAI3001281
10. NAI3001582
11. NAI3002083
12. NAI3002884
13. NAI3003185
14. NAI3003486
15. NAIA/B200887
16. NAIA/B200988
17. NAIA200589
18. NAIA200690
19. NAIA300291
20. NAIA300392
21. NAIA300493
22. NAIA300594
23. NAIB200595
24. NAIB200696
25. NAIB200797
26. NAIB300198
27. NAIB300299
28. PE-01100
29. 167T3–11
30. NAIA2010.
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Appendix 2 Compliharms: events alternatively
recorded as complications or harms
Roche clinical study report of oseltamivir treatment trial
The following symptoms, signs and common sequelae associated with influenza were excluded from
specific adverse event reporting if they occurred during the period of drug treatment provided
their appearance was in conjunction with one or more other influenza-related symptoms. The
recrudescence of single discrete signs/symptoms associated with influenza syndrome were recorded as
adverse events.61
[Event by body system]
Respiratory cough, pneumonia, bronchitis/tracheitis, sinusitis, dyspnoea/difficulty breathing
Cardiovascular tachycardia
Eyes, ears, nose and throat sore throat, nasal obstruction, earache, otitis, coryza, conjunctivitis
Central nervous system headache, fatigue
Musculoskeletal myalgia
Other fever, rigor, malaise/asthenia, chills
Source: ‘Appendix 1. Events Associated with Influenza Syndrome’. Roche Clinical Study Report No.
W-144117, Protocol WV15707, module I-43.
A 1999 Food and Drug Administration medical review of oseltamivir
As symptoms and common sequelae of influenza were collected as end point data, these symptoms,
signs and common complications were specifically excluded from reporting as adverse events. The
following table [above] lists events associated with influenza syndrome which were excluded from
adverse event reporting. . .In addition, following the alleviation of influenza-like symptoms, the
recurrence of a single respiratory or constitutional symptom was recorded as an adverse event;
however, the reappearance of more than one symptom was recorded as influenza-like syndrome (i.e.
secondary illness). Comment: As the applicant [Hoffman-La Roche] stated in a written response dated
6/11/99, some sites incorrectly reported symptoms occurring prior to the cessation of the primary
illness as secondary illness.109
Emphasis in the original. Oseltamivir Medical Review. US FDA Center for Drug Evaluation and Research,
Application No. 021087, 25 October 1999, p. 15. www.accessdata.fda.gov/drugsatfda_docs/nda/99/
21087_Tamiflu_medr_P1.pdf.
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Appendix 3 Searches of the electronic databases
A lthough this review focuses on the primary data sources of manufacturers, we ran electronic searches inthe following databases to check that there were no published RCTs from non-manufacturer sources:
l CENTRAL (2013, issue 6) limited to year published 2010–13 (20 search results).
l MEDLINE (January 2011 to July week 2, 2013) (56 search results) and MEDLINE (via Ovid) from
1 January 2011 to July week 2, 2013 (56 search results).
l EMBASE (January 2011 to July 2013) (90 search results) and EMBASE.com from 1 January 2011 to
July 2013 (90 search results).
l PubMed (not MEDLINE) no date limit (21 records). We searched PubMed to identify publisher
submitted records that will never be indexed in MEDLINE and the most recently added records not yet
indexed in MEDLINE.
To identify reviews that may possibly have referenced further trials we searched:
l DARE (2013 issue 2 of 4 April; four search results)
l NHS EED (issue 2 of 4 April 2013; two search results) – both resources are part of The Cochrane
Library, www.thecochranelibrary.com (accessed 22 July 2013).
l HEED (searched 22 July 2013; three search results).
Previously, we had searched CENTRAL (eight search results); MEDLINE (via Ovid) from 1 May 2009 to
12 April 2011 (31 search results); EMBASE from 1 January 2010 to 12 April 2011 (54 search results);
DARE (five search results) and NHS EED (five search results). CENTRAL, DARE and NHS EED are part of
The Cochrane Library, www.thecochranelibrary.com (issue 2, 2011, accessed 1 June 2011). All search
results were loaded to an electronic library (EndNote X4; Thomson Reuters, CA, USA).
We used the following search strategy to search MEDLINE and CENTRAL. We combined the MEDLINE
search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE:
sensitivity- and precision-maximising version (2008 revision); Ovid format.223 We adapted the search
strategy for EMBASE. We imposed no publication or language restrictions.
MEDLINE (via Ovid)
1. Influenza, Human/
2. exp Influenzavirus A/
3. exp Influenzavirus B/
4. (influenza* or flu).tw.
5. or/1-4
6. Oseltamivir/
7. Zanamivir/
8. neuraminidase inhibitor*.tw.
9. (oseltamivir or zanamivir or tamiflu or relenza or peramivir or gs4071).tw,nm.
10. or/6-9
11. 5 and 10
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EMBASE.com
17 #13 AND #16
16 #14 OR #15 833616
15 random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ‘cross over’:ab,ti OR
‘cross-over’:ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1
blind*):ab,ti
14 ‘randomised controlled trial’/exp OR ‘single blind procedure’/exp OR ‘double blind procedure’/exp OR
‘crossover procedure’/exp
13 #4 AND #12
12 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
11 oseltamivir:ab,ti OR zanamivir:ab,ti OR tamiflu:ab,ti OR relenza:ab,ti OR peramivir:ab,ti OR laninamivir:
ab,ti OR gs4071:ab,ti
10 ‘sialidase inhibitor’:ab,ti OR ‘sialidase inhibitors’:ab,ti
9 ‘neuraminidase inhibitor’:ab,ti OR ‘neuraminidase inhibitors’:ab,ti
8 ‘sialidase inhibitor’/exp
7 ‘peramivir’/de
6 ‘zanamivir’/de
5 ‘oseltamivir’/de
4 #1 OR #2 OR #3
3 influenza*:ab,ti OR flu:ab,ti
2 ‘influenza virus a’/exp OR ‘influenza virus b’/de
1 ‘influenza’/exp
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Appendix 4 Searches for regulatory information
We searched the following sources:
1. the FDA
2. the EMA
3. Roche
4. the Japanese regulator [Pharmaceuticals and Medical Devices Agency (PMDA)] SBA.
We conducted a search of the FDA regulatory documentation of the NDAs and supplementary NDAs
(sNDAs) of both drugs.224 The FDA NDA documentation includes medical, statistical, microbiological and
other reviews, product labels, reports of site inspections, meetings with manufacturers and records of the
decision-making leading to registration and post-marketing requirements. We also searched ‘Warning
Letters’ dispatched by the FDA.225
To organise receipt of FDA materials, we created a TOC listing all of the regulatory and pharmaceuticals
documents that were accessible to us. The TOC’s function was that of an index, searchable quick reference
guide and research tool to enable us to carry out quantitative (e.g. citation density analysis) and qualitative
analyses (e.g. theme summaries) of the content. We also needed a rapid aide-memoire with brief summaries
of the evidence contained in each regulatory document listed in the TOC. We called this aide-memoire
the table of contents evidence (TOCE). As the TOCE contains copious working personal notes aiming to assist
the understanding of the regulatory narrative, we have not reproduced it here but its content is woven into
the narrative of this review.
Owing to the length and format of regulatory documents, we realised in building the TOC that there was a
need to formalise the search and identification methods of trials referenced in the FDA documentation. We
concentrated on where each trial is mentioned in the documentation by its pharmaceutical code. So, for
example, if trial WV156708 is mentioned 60 times by that code in a particular file then the TOC will report
the page numbers in which it is cited, which could be any number up to 60. The unit of search was the file,
as a FDA PDF file can contain many different types of documents scanned into the same file. TOC and TOCE
are among the tools we specifically constructed for the review (see Appendix 1).
We wanted to validate our new methods, therefore we compared the yield of OCR searching and
hand-searching of the PDF files of the FDA regulatory material using the same trial ID as a working example.
We also searched the material sent to us by Roche for our 2009 update.
We searched the website of the Japanese PMDA (www.info.pmda.go.jp/shinyaku/shinyaku_previous_index.
html) for data relating to NIs approved in 1999 and 2000 and www.info.pmda.go.jp/approvalSrch/
PharmacySrchInit for NIs approved since 2001. We identified 1575 pages of documents relating to the
regulatory review by the PMDA and the Japanese Ministry of Health, Labour and Welfare (JMHLW) and the
Japanese SBA of oseltamivir capsules for treatment (2000), prophylaxis of oseltamivir dry syrup for children
(2002) and oseltamivir capsules for prophylaxis of influenza (2004), and their re-examination results. The
Japanese regulatory body introduced a system to disclose their examination results and SBA in 1999 instead
of the prior system, ‘full disclosure requirement system’, which had been introduced in 1967. Although these
documents included preclinical, methodological, clinical (pharmacological, toxicity and pharmacokinetics with
metabolism) data and clinical (Phase I–III) studies and contain more precise data than the published papers,
no complete CSRs were publicly available. Therefore, one review author (RH) asked the JMHLW on 29 July
2010 to disclose all of the documents reporting the evidence base for the approval of oseltamivir for these
indications. The JMHLW sent RH a letter of refusal dated 2 September 2010, with the explanation ‘because
the disclosure of such documents might hurt the right, position or other fair benefit in the competition of the
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corporation concerned’. We waited for 6 months to take further action hoping that the required CSRs would
be forthcoming from the manufacturers. When this did not happen, RH filed a suit to overturn the JMHLW
decision with the Osaka (Japan) District Court on 28 February 2011. The District Court petition was rejected
on 19 April 2013 and the Osaka High Court rejected it on 29 November 2013. No appeal to the Supreme
Court was made because substantial CSRs had already disclosed from various sources.
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Appendix 5 Modified Consolidated Standards of
Reporting Trials statement-based extraction template
for clinical study reports
Title and drug name
Include source documents used:
Modified CONSORT extraction template www.consort-statement.org/
Introduction CONSORT number
Background and objectives 2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Insert text:
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation
ratio
3b Important changes to methods after trial commencement (such as eligibility
criteria), with reasons
Insert text:
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Insert text:
Interventions 5 The interventions for each group with sufficient details to allow replication,
including how and when they were actually administered
Insert text:
Outcomes 6a Completely defined prespecified primary and secondary outcome measures,
including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Insert text:
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping
guidelines
Randomisation:
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and
block size)
Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as
sequentially numbered containers), describing any steps taken to conceal
the sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants
and who assigned participants to interventions
Insert text:
Blinding 11a If done, who was blinded after assignment to interventions
(e.g. participants, care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary
outcomes
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Title and drug name
Include source documents used:
12b Methods for additional analyses, such as subgroup analyses and adjusted
analyses
Insert text:
Results
Participant flow (a diagram is
strongly recommended)
13a For each group, the numbers of participants who were randomly assigned,
received intended treatment and were analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with
reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Insert text:
Baseline data 15 A table showing baseline demographic and clinical characteristics for each
group
Numbers analysed 16 For each group, number of participants (denominator) included in each
analysis and whether the analysis was by original assigned groups
Insert text:
Outcomes and estimation 17a For each primary and secondary outcome, results for each group and the
estimated effect size and its precision (such as 95% CI)
17b For binary outcomes, presentation of both absolute and relative effect sizes
is recommended
Insert text:
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and
adjusted analyses, distinguishing prespecified from exploratory
Insert text:
Harms 19 All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)
Insert text:
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of
funders
Insert text:
First author
Date of completion
Conflicts of interest
Second author check
Date of check
Conflicts of interest
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Appendix 6 Stage 1 of the 2012 A159 review
Two review authors assessed each study (with studies allocated randomly to three pairs of reviewauthors). The lists of included studies (33 for oseltamivir, 30 for zanamivir, six for peramivir) were
randomly created by the program Edgar II (www.edgarweb.org.uk/2011).226 Every study was openly
allocated to each group according to its number.
We initially included six peramivir trials in the randomisation/allocation sequence but subsequently decided
not to proceed further, as we were informed by the manufacturers that no CSRs would be available until
after registration with the FDA (Bill Sheridan, BioCryst Pharmaceuticals Inc., 20 August 2010, personal
communication). One review author (TJ) was assigned to the attempted reconstruction of CSRs from the
FDA documents.
Two weeks before ‘time lock’ (see Appendix 1) we received the first batch of CSRs from the EMA (formerly
EMEA), containing an additional four CSRs (including one complete four-module CSR) of studies we
wanted to include. This time, random allocation was achieved by writing trial IDs on one set of tickets and
asking an external researcher to allocate them to groups, the names of which had been written on
another set of tickets.
Authors in pairs separately extracted data from the same CSRs of studies included in stage 1 of the review.
When we had more than one copy of the same CSRs from different sources (e.g. CSRs submitted to a
regulatory body and CSRs from a pharmaceutical company), we independently extracted data from each of
the copies and then compared the results. We aimed to record and tabulate disagreements between data
extracted from the same source and between different sources. We extracted data using a modified
CONSORT statement-based extraction template (see Appendix 5).
The modified CONSORT-based extraction template aimed to assemble a concise version of the CSRs,
which would include all important methods as well as define and extract all relevant outcomes.
The CONSORT-based extraction template includes the features that would be expected to be found in
a published trial report but in far greater detail. Our reconstructions do not include introduction or
discussion sections. We extracted the following for each trial:
1. Background and objectives.
2. Methods: including trial design, important changes to methods after trial commencement (such as
eligibility criteria), with reasons.
3. Participants: including eligibility criteria for participants and settings and locations where the data
were collected.
4. Interventions: the interventions for each group with sufficient details to allow replication, including
how and when they were actually administered.
5. Outcomes: prespecified primary and secondary outcome measures, including how and when they
were assessed and changes to trial outcomes after the trial commenced, with reasons.
6. Sample size: how it was determined and explanation of any interim analyses and stopping guidelines.
7. Randomisation: including sequence generation and method used to generate the random
allocation sequence.
8. Blinding: who was blinded after assignment to treatment groups.
9. Statistical methods: methods used to compare groups for primary and secondary outcomes and
methods for additional analyses, such as subgroup analyses and adjusted analyses.
10. Results: participant flow, numbers of participants randomly assigned, losses and exclusions after
randomisation, together with reasons. Baseline demographic and clinical characteristics for
each group.
11. Outcomes: primary and secondary outcome results for each group.
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12. Ancillary analyses: results of any other analyses performed, including subgroup analyses and adjusted
analyses, distinguishing prespecified from exploratory.
13. Harms: all important harms or unintended effects in each group.
One review author completed the CONSORT-based extraction on the template in full (see Appendix 5),
with the name and date of completion and a statement of conflict of interests. A second review author
checked the extraction. We extracted data, text, tables and figures directly from the relevant sections of
the CSRs into the appropriate section of the template. We did not change the text in any way apart from
clarifying abbreviations or spellings, but we highlighted some text. We used three types of text highlighting
in the document.
l Yellow Where text, figures or tables need to be checked with further information (e.g. if an adverse
event is referred to in appendices or a further CSRs module).
l Red Where text or comments were inserted by one or both review authors but required an additional
opinion because of concerns that there is the potential for discrepancies in the CSRs.
l Green Any text or tables added by us to the template (e.g. a reconstructed table of adverse events).
Two review authors (CH and MT) independently piloted the reconstruction method on oseltamivir trial
WV1567158 with data from module 1 of the CSR from Roche and data submitted to UK NICE. We
discussed the pilot reconstruction among the whole review team for clarification. At a face-to-face meeting
we discussed the reliability and completeness of each reconstructed trial in the light of comments and
other information from regulatory sources with a view to inclusion of the trial in stage 2. We resolved all of
the differences in opinion by consensus. We reached decisions on whether or not a trial moved to
stage 2 by consensus. We planned to record dissent when consensus was not possible.
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Appendix 7 Applying inclusion criteria for the
A159 2012 review
For the 2012 A159 review, two review authors (CDM and MT) independently scanned the titles andabstracts identified from the searches of the published literature. None of the identified items was a
published version of a trial unknown to us. Four review authors (TJ, CH, MJ and RH) independently read all
of the data relating to the studies on the list constructed during our search and selected studies that
seemingly fulfilled our inclusion criteria. One review author (PD) compiled the assessments into a single
sheet for another review author (CDM). One review author (CDM) resolved disagreements by discussion.
We assigned three categories to identified trials from our complete list:
1. definitely included
2. definitely excluded
3. trials for which we needed further information.
We excluded studies definitely not meeting inclusion criteria on the basis of available information (e.g. the title
described the trial as a pharmacokinetic study). Where appropriate, we requested further information from
the trial’s sponsor, usually copies of the CSRs (minus participant identification) for each trial that was definitely
included or for which we needed further information. We did not contact first/corresponding authors of
published versions of the trials on the basis of our experience with the 2009 A047 review.
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Appendix 8 Post-protocol hypotheses: methods
and results
This text is carried over from the 2012 version of this review and is provided for 
record completeness
Methods
The hypotheses (expressed as null hypotheses) are listed below, in order of their 
generation (not necessarily of importance). Their rationale is explained further down 
the text.
Hypothesis 1. Incidence of certain harms is not associated with placebo content.
Hypothesis 2. Oseltamivir (or zanamivir) does not affect antibody production in 
treatment trials.
Hypothesis 3. Oseltamivir does not affect antibody production in post-exposure (or 
secondary prophylaxis) trials.
Hypothesis 4. The number of trial centres and centre withdrawals does not affect the 
proportion of placebo patients subsequently diagnosed with influenza infection 
(originally the outcome was effect size).
Hypothesis 5. In oseltamivir treatment trials there is no association between the order 
of randomisations and naso-pharyngeal swabbing (i.e. randomising participants first 
and then swabbing or swabbing first and then randomising) and the proportion of 
placebo patients subsequently diagnosed with influenza infection.
Hypothesis 1. Incidence of certain harms is not associated with placebo content.
Rationale. While reviewing the US Food and Drug Administration (FDA) critique of 
zanamivir, we noted the regulators' concern over the apparent drop in forced 
expiratory volume (FEV) following zanamivir inhalation (FDA 1999a), which 
appeared to be enhanced by the lactose powder excipient content of the active blister 
(FDA 1999b). The powder, which causes bronchospasm in susceptible individuals, 
was contained in both the active and the placebo blisters. This principle of using a 
matching placebo is of course correct but may have had the effect of increasing the 
incidence of bronchospasm (or asthma-related episodes) in both arms. This is clearly 
reported as a warning in the 1999 FDA label "Because the placebo consisted of 
inhaled lactose powder, which is also the vehicle for the active drug, some adverse 
events occurring at similar frequencies in different treatment groups could be related 
to lactose vehicle inhalation" (FDA 2000b p.10).
We reasoned by analogy and reviewed the medication content of the available clinical 
study reports of oseltamivir trials. The detailed information comparing content and 
physical characteristics and batch numbers is in Table 11. Roche's use of the word 
'matching' is not strictly correct as two principles present in the placebo capsules 
(dehydrocholic acid and dibasic calcium phosphate dihydrate) are not listed as being 
present in the active oseltamivir capsules. We could not locate the reason for such a 
choice in the clinical study reports but both substances may have gastrointestinal 
action if consumed in large enough quantities.
On this basis we formulated two hypotheses:
1a. There is no association between incidence of gastrointestinal harms and a placebo 
containing dehydrocholic acid in oseltamivir trials.
1b. There is no association between incidence of asthma-related events and a placebo 
containing lactose powder in zanamivir trials.
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To test hypothesis 1a we assessed the oseltamivir trials for which we had clinical 
study reports Module 1 (M76001; WV15670; WV15671; WV15707;
WV15812/WV15872; WV15730; WV15819/WV15876/WV15978; WV15758;
WV15799) for gastrointestinal tract (GIT) harms including nausea, vomiting and 
diarrhoea as well as participants withdrawing from the studies due to adverse events. 
We meta-analysed the results from these studies using the inverse variance random-
effects method. We assessed heterogeneity using the Chi2 test and used Tau2 to 
estimate between-study variance. To investigate whether placebo containing 
dehydrocholic acid may be associated with gastrointestinal harms we compared 
adverse event rates in placebo groups from the oseltamivir trials (where placebo 
contained dehydrocholic acid) with adverse event rates in the placebo groups from the 
zanamivir trials (where placebo did not contain dehydrocholic acid). This comparison 
was done informally using 1) data obtained from the FDA labels of oseltamivir and 
zanamivir (FDA 2000b; FDA 2011a) as well as 2) the trials for which we have 
clinical study reports. As a sensitivity analysis we assumed a similar gastrointestinal 
adverse event rate in the placebo groups of the oseltamivir trials as was observed in 
the placebo groups of the zanamivir trials and then repeated the meta-analysis (as 
described above). We also speculated that withdrawals in the placebo groups due to 
gastrointestinal adverse events were possibly related to dehydrocholic acid and 
removed these for the sensitivity analysis.
For hypothesis 1b we assessed asthma-related events in nine zanamivir trials for 
which we had clinical study reports (NAIA3002; NAIB3002; NAIA2005; NAIB2005;
NAIB2007; NAIB3001; NAIA3005; NAI30010; NAI30009). We meta-analysed the 
results from these studies using the inverse variance random-effects method. We 
assessed heterogeneity using the Chi2 test and used Tau2 to estimate between-study 
variance. To investigate whether placebo containing lactose powder may be 
associated with asthma-related events we informally compared event rates in placebo 
groups from the zanamivir trials (where placebo contained lactose powder) with event 
rates in the placebo groups from the oseltamivir trials (where placebo did not contain 
lactose powder). As a sensitivity analysis we assumed a similar asthma-related event 
rate in the placebo groups of the zanamivir trials as was observed in the placebo 
groups of the oseltamivir trials and then repeated the meta-analysis (as described 
above).
Hypothesis 2. Oseltamivir (or zanamivir) does not affect antibody production in 
treatment trials.
Rationale. All oseltamivir influenza treatment trials specify the primary efficacy 
analysis population as the influenza-infected population, not the randomised 
intention-to-treat (ITT) base population. The influenza-infected population (known as 
ITTI, or intention-to-treat-infected in clinical study reports) is determined post-
randomisation based on the results of laboratory testing by culture and/or antibody 
rise (comparing paired sera from the same participant). The sample for culture and the 
first sample of sera are taken before commencement of trial product but the second or 
the third sera are taken after patients are treated with trial medication. It is vital that 
placebo and active groups of patients have the same odds of being classified as 
influenza-infected, otherwise any comparison between influenza-infected groups will 
be potentially affected by bias and will essentially be a non-randomised comparison. 
If trial medication affects the production of antibodies, the selection of the influenza-
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infected population (which is partly based on antibody production) is confounded by 
taking the trial medication.
Roche have stated on multiple occasions (Smith 2006; Ward 2005; section 3.2.4.2 
Serology WV15799) that ingestion of oseltamivir does not affect antibody production 
and the FDA supports this, stating that "In studies of naturally acquired and 
experimental influenza, treatment with TAMIFLU did not impair normal humoral 
antibody response to infection" (FDA 2011a).
However, we noticed unequal numbers of individuals in the influenza-infected 
population subgroup in numerous trials. In addition, Takahashi et al reported that 
oseltamivir significantly suppressed respiratory mucosal secretory immunoglobulin 
(Ig) A responses to antigen (Ag)-specific antibody (Ab) production and also the 
induction of Ag-specific IgA Ab-forming cells in an animal experiment (Takahashi 
2010). If taking oseltamivir affects the production of IgG antibody as well, it may 
affect the selection of the influenza-infected population.
We are also unsure of the implication for immunisation with influenza vaccine. 
According to the FDA, no influenza vaccine interaction study has been conducted 
with oseltamivir (FDA 2011a).
To test the hypothesis we compared: (1) the odds of participants in the ITT population 
subsequently classified as influenza-infected; and (2) the odds of participants in the 
ITT population with a four-fold or more rise of antibody between the placebo and 
active arms of the trials. If ingestion of oseltamivir does not affect antibody 
production then we expect the odds of being classified as influenza-infected to be the 
same for the placebo and active arms. Therefore, we tested a null hypothesis that the 
odds of having a four-fold or more rise of antibody was the same for the placebo and 
active arms. We meta-analysed the results from these studies using the inverse 
variance random-effects method. We assessed heterogeneity using the Chi2 test and 
used Tau2 to estimate between-study variance. The trials included in this analysis 
were the 10 oseltamivir treatment trials analysed by Kaiser 2003 plus WV15758 for 
oseltamivir and NAIA3002, NAIB3002, NAIA2005, NAIB2005, NAIB2007,
NAIB3001, NAI30009 for zanamivir. These are all the treatment trials for which we 
have clinical study reports Module 1. In an additional analysis we also assessed the 
oseltamivir trial conducted in China by Shanghai Roche Pharmaceutical Ltd for which 
we have a partial clinical study report (ML16369).
Hypothesis 3. Oseltamivir does not affect antibody production in post-exposure (or 
secondary prophylaxis) trials.
Rationale. According to the clinical study report of WV15799, the trial programme 
assessing the effects of oseltamivir in post-exposure prophylaxis (PEP) consisted of 
two trials: WV15799 and WV16139. The Module 1s of both trials together with 
copious FDA notes on trial WV15799 were available to us at 'time lock'. However the 
PEP trial WV16139 was not standard care or placebo-controlled and so we excluded 
it from the review.
WV15799 was a double-blind, cluster-randomised trial in which contact clusters of 
index cases were randomised to oseltamivir 75 mg a day or placebo for seven days. 
The trial formed an integral part of the "pivotal" trials package for the supplementary 
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application and review for prophylaxis use of oseltamivir 75 mg in people aged more 
than 13 years of age, submitted to the FDA on 22 May 2000, approved on 20 
November 2000 (FDA 2000c). In the clinical study report Module 1 the manufacturer 
claimed that the trial provided evidence of the drug's capacity to prevent influenza in 
contacts by interrupting its transmission from index cases. Since all index cases were 
left untreated except for a paracetamol rescue pack, it is hard to see how such a claim 
can be made. The interruption of transmission claim has two components: reduction 
of viral spread from index cases (measured by nasal shedding of influenza viruses) 
and prevention of onset of influenza in contacts. This latter claim was based on the 
definition of (prevented) influenza cases: a mixture of symptoms signs and 'laboratory 
confirmation' (i.e. viral culture from the upper airways and/or at least a four-fold rise 
in antibody titres measured between baseline and two to three weeks later). The 
results of the trial later formed the basis for claims of the drug's effectiveness in 
interrupting transmission from person to person (WHO 2007) and allow time before 
the arrival of vaccines in the event of a pandemic. The interruption of transmission 
claim provided a powerful rationale for stockpiling oseltamivir (see for example vol 
8, p.61-62 NICE 2000: "Ro 64-0796 successfully interrupts the transmission of 
influenza within households ... and suggests that Ro 64-0796 [oseltamivir] would 
control the spread of influenza in other closed communities associated with high risk 
of transmission, such as nursing homes" … "Ro 64-0796 also effectively interrupted 
virus transmission within households.")
The interruption of transmission indication was accepted by agencies such as the 
World Health Organization (WHO) and the US Centers for Disease Control and 
Prevention (CDC), but the US FDA refused to register and allow publicity based on 
any further indication beyond treatment and prophylactic effects on symptoms (FDA
2000f). Review of the evidence from the study protocol and Module 1 together with 
the FDA criticism explains the rationale for the FDA not supporting the 
manufacturers' claims. The design of the trial did not allow for comparison of the 
effects of treating index cases with oseltamivir versus placebo (as all index cases were 
not medicated) and a repeat viral culture was not performed for all participants. Viral 
culture was performed at baseline for all participants and thereafter only in 
participants with influenza-like illness symptoms (see Schedule of assessment for the 
contact case, WV15799, and the FDA Medical Officer report (FDA 1999c)). Any 
participants presenting at follow-up with symptoms of influenza had throat and nasal 
swabs taken in order to confirm the presence or absence of influenza infection (FDA
2000c), thereby missing out on potential asymptomatic infected people. However, a 
recent review of transmission studies has found no convincing evidence of spread 
from pre-symptomatic or asymptomatic subjects (Patrozou 2009), which might 
explain the FDA's caution in sanctioning any such claim for oseltamivir.
Our review of the clinical study report's Module 1 identified further problems with the 
conduct and reporting of the trial and discrepancies both within the clinical study 
reports and between the study and its protocol. In the protocol (version H) there is no 
mention of viral shedding measurement. This appears to be a post-protocol addition, 
which would explain the unsystematic nature of the viral excretion measurement 
remarked on by the FDA (i.e. taken from symptomatic contacts only). The primary 
population of analysis is the so called ITTIINAB population (contacts of ITT 
influenza-infected index cases who had negative virology at baseline). Although 
defined in the protocol, the selection and presentation of results for the intention-to-
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treat contacts of the influenza-infected index case not infected at baseline (ITTIINAB) 
population has the effect of excluding 57% of the placebo (200/456) and 59% of the 
oseltamivir (205/497) participants. The effect of selection on the clustering was not 
formally tested in a sensitivity analysis. Nor is the potential weakness of such a choice 
discussed in the WV15799 clinical study report. We carried out an analysis using 
Fisher's exact test, which showed that there was no statistical evidence that the 
placebo and oseltamivir groups' cluster sizes were distributed differently based on 
households with an infected index case (P = 0.56) (Table 2). By analysing the 
population by influenza status of the index case, instead of unit of randomisations (all 
index cases), the beneficial effects of the cluster-randomisations are potentially lost, 
introducing unknown biases into the analysis. In addition, the generalisability of the 
conclusions may not be easily applied to clinical practice where testing of suspected 
influenza cases is often not practical. Cross-checking the definition of ITTIINAB with 
that reported in the protocol of the other PEP trial, WV16193 (excluded from this 
review) yields a different definition (PDF page 589) "The primary outcome in this 
study (WV15799) was the incidence of influenza occurring among contacts of 
influenza-infected index cases (the intent-to-treat-index-infected population)".
Throughout the clinical study report of trial WV15799 there are many other 
apparently contradictory statements on important aspects of the trial, for example, on 
how many viral swabs and paired sera tests were carried out. The text at page 50 of 
the Module 1 reports that "For 21 of the 26 contacts with laboratory-confirmed 
clinical influenza in the ITTIINAB population the diagnosis was confirmed by 
culture" but Table 19 shows the 26 contacts as shedding virus at days two to eight.
The same table reports that 178 placebo contacts and 201 oseltamivir contacts were 
negative for virology (which suggests that they were tested) at days two and eight. 
However, viral testing only took place at baseline and thereafter only in symptomatic 
participants. The number of contacts in which influenza was diagnosed only by 
serology is unclear but it appears to be five (26 minus 21). These inconsistencies 
highlight one of the fundamental conceptual problems in understanding the whole 
oseltamivir prophylaxis trial programme: the mode of action of the drug. Our 
interpretation of the text suggests that oseltamivir does not prevent infection and does 
not affect influenza antibody response. As stated above, the claim that oseltamivir 
does not affect antibody responses has been made by the manufacturers. However, an 
antibody response is part of the definition of influenza. We are unsure how it is 
possible that oseltamivir could prevent influenza by stopping symptoms appearing 
and antibodies rising while at the same time leaving antibody production unaffected.
It is for this reason that we decided to test whether administration of oseltamivir for 
PEP affected the production of antibodies to influenza viruses. The distribution of 
change in antibodies from baseline to follow-up was compared between the arms of 
the trials for contacts of the index cases. Analysis was performed using Wilcoxon 
two-sample test separately for each type of antibody in each trial. An additional 
analysis of proportion of contacts having a four-fold or greater rise in influenza-
specific antibody titre in antibodies was compared between groups using the Chi2 test. 
Antibody data were not available for index cases, who were left untreated. In 
WV15799, antibody testing may have been undertaken at day 1, day 8 and at day 21 ± 
4 days for all contacts. Day 8 blood samples for influenza antibody analysis were 
stored to measure influenza antibody levels only in those contacts who did not attend 
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the follow-up visit (day 17 to 25). Analysis was based on data from the ITTIINAB 
population at pages 59-60 and Appendix 60 of the clinical study report's Module 1.
Hypothesis 4. The number of trial centres and centre withdrawals does not affect the 
proportion of placebo patients subsequently diagnosed with influenza infection 
(originally the outcome was effect size) and Hypothesis 5. In oseltamivir treatment 
trials there is no association between the order of randomisations and naso-pharyngeal 
swabbing (i.e. randomising participants first and then swabbing or swabbing first and 
then randomising) and the proportion of placebo patients subsequently diagnosed with 
influenza infection (originally the outcome was effect size).
Rationale. The proportion of ITT population in the treatment trials of NIs that are 
subsequently diagnosed as infected with influenza is higher (~ 50% to 80%) than is 
usually seen in the course of the winter season in routine clinical care, although high 
peaks can occur for a very limited period. We know that in some treatment trials, such 
as WV15670 and WV15671, centres were activated to "recruit subjects during an 
influenza outbreak in the locality, detected using standardised surveillance 
techniques." We postulated that unreported procedures may also have been used in 
the trials to obtain these high proportions of influenza to ILI cases. Two procedures 
that may have been used are: 1) use of rapid influenza tests to screen out patients 
based on negative results; 2) dropping of centres that recruited low proportions of 
infected patients. The use of rapid testing of patients prior to randomisation has been 
reported in at least one of the zanamivir treatment trials (NAIB3001), in oseltamivir 
trial WV15670 as a means of excluding infection with H5N1 in the Hong Kong 
Centre, as a pilot surveillance in suburban London during the 1998 to 1999 winter 
(NICE 2000 vol.1) and in most oseltamivir paediatric trials to exclude respiratory 
syncytial virus (RSV) infection. In addition, the schedule of testing varies by trial for 
the oseltamivir trials with swabbing performed either before randomisation or after 
randomisation. In at least one oseltamivir treatment trial (WV15730) it was reported 
that no viral culture was performed at centres from South America (FDA 1999c). As a
result of these observations we reformulated Hypothesis 4 as follows: the number of 
centres and centre withdrawals does not affect the proportion of placebo patients 
subsequently diagnosed with influenza infection (originally the outcome was primary 
outcome effect size) in oseltamivir treatment trials and Hypothesis 5 as in oseltamivir 
treatment trials there is no association between the order of randomisations and naso-
pharyngeal swabbing (i.e. randomising participants first and then swabbing or 
swabbing first and then randomising) and the proportion of placebo patients 
subsequently diagnosed with influenza infection.
To test hypothesis 4, we used Spearman's rank method to estimate the correlation 
between average number of patients recruited per centre and the proportion of placebo 
patients subsequently diagnosed with influenza infection. The placebo patients were 
used for the proportion of patients subsequently diagnosed with influenza infection 
because, as we show later in the review, there is evidence that oseltamivir interferes 
with antibody production and antibody response was used to diagnose influenza 
infection. We did not analyse the number of centres dropped from studies because 
information on this variable was not available in Module 1s of the clinical study 
reports for the included trials (information on patients recruited to each centre is 
reported in Module 2 which we do not currently have access to).
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Hypothesis 5 was generated to attempt to explain the seemingly high proportion of 
influenza-infected influenza-like illness cases in treatment trials. However, we did not 
formally test this hypothesis as there was only one clinical study report reporting 
randomisation first then swabbing second (WV15819/WV15876/WV15978) (see also 
Appendix 9).
Results
The results of our post-protocol analyses are also reported in Figure and/or Table 
format.
Hypothesis 1a tested in a sensitivity analysis whether the incidence of gastrointestinal 
harms may be associated with exposure of participants to a placebo containing 
dehydrocholic acid. The data obtained from the oseltamivir trials clinical study 
reports is shown in Table 15.
Overall, the crude adverse event incidence in the placebo groups of the oseltamivir 
trials was 5.5% for nausea, 3.6% for vomiting and 7.0% for diarrhoea. This compares 
with crude incidence in the nine zanamivir treatment trials' placebo groups of 4.1%
for nausea and vomiting (reported as a combined outcome in the clinical study 
reports) and 2.8% for diarrhoea. Two studies (WV15670; WV15671) compared three 
treatment groups: oseltamivir 150 mg bid, oseltamivir 75 mg bid and placebo. To 
maintain the blinding in these trials, each participant took two pills twice daily. 
Therefore the participants in the oseltamivir 75 mg bid group took one placebo tablet 
twice daily. We note that in trial WV15671 there was evidence of a dose-response 
effect of placebo on incidence of diarrhoea: oseltamivir 150 mg bid (5.9%), 
oseltamivir 75 mg bid (8.7%) and placebo (11.8%) (P = 0.036). However, there was 
no evidence found of a similar trend in trial WV15670 (P = 0.88). We were unable to 
carry out a similar analysis for paediatric treatment trial WV15758 because a detailed 
content of the placebo preparations is not available (see Table 11).
Random-effects meta-analysis of the data in Table 15 provided the following results.
Nausea: increased odds of adverse events due to oseltamivir (OR 1.62, 95% CI 1.17 
to 2.26, P = 0.004).
Vomiting: increased odds of adverse events due to oseltamivir (OR 2.32, 95% CI 1.62 
to 3.31, P < 0.001).
Diarrhoea: decreased odds of adverse events due to oseltamivir (OR 0.72, 95% CI 
0.53 to 0.97, P = 0.03).
Withdrawal from treatment due to adverse events: no evidence of a difference 
between treatment groups (OR 1.08, 95% CI 0.66 to 1.76, P = 0.75).
We carried out a sensitivity analysis by assuming placebo rates of gastrointestinal 
adverse events in oseltamivir trials based on those observed in placebo groups of 
similar zanamivir trials. Overall rates of nausea, vomiting and diarrhoea in placebo 
groups of zanamivir treatment trials for adults and adolescents were 3%, 2% and 4% 
compared to oseltamivir treatment trials for adults and adolescents where rates were 
6%, 3% and 10% respectively based on FDA-reported data (FDA 2000b; FDA
2011a). Conversely, other common adverse events such as headaches, cough and 
dizziness had similar incidences of 2% to 3% in the placebo groups of zanamivir and 
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oseltamivir treatment trials (FDA 2000b; FDA 2011a). In the treatment trials of 
children the rates of nausea, vomiting and diarrhoea in placebo groups of zanamivir 
treatment trials were 2%, 3% and 2% compared to oseltamivir treatment trials of 
children where rates were 4%, 9% and 11% respectively. Our conservative estimate is 
that the oseltamivir placebo increased rates of nausea two-fold (risk ratio (RR) = 2), 
vomiting (RR 1.5) and diarrhoea (RR 2.5) compared to the placebo arms in zanamivir 
trials. Based on the adult and adolescent trials we could conservatively speculate that 
the substances in the oseltamivir trials placebo increase nausea, vomiting and 
diarrhoea by 100% (6%/3%), 50% (3%/2%) and 150% (10%/4%) respectively. This 
could also be considered a conservative assumption because it is plausible that the 
lactose powder used as the placebo in the zanamivir trials also induced 
gastrointestinal symptoms, especially in patients that were lactose intolerant. 
Adjusting the actual rates of these events in the oseltamivir trials placebo groups to be 
consistent with the zanamivir trials placebo group rates (as reported by the FDA 
(FDA 2000b; FDA 2011a) and re-running the random-effects meta-analysis we 
obtained the following results.
Nausea: increased odds of adverse events due to oseltamivir (OR 3.33, 95% CI 2.44 
to 4.54, P < 0.001; test for heterogeneity P = 0.33).
Vomiting: increased odds of adverse events due to oseltamivir (OR 3.46, 95% CI 2.51 
to 4.78, P < 0.001; test for heterogeneity P = 0.37).
Diarrhoea: increased odds of adverse events due to oseltamivir (OR 1.86, 95% CI 
1.39 to 2.50, P < 0.001; test for heterogeneity P = 0.50).
The estimated effect sizes for nausea and vomiting have increased based on the 
sensitivity analysis. The effect on diarrhoea has reversed, indicating oseltamivir is 
possibly associated with increased odds of this adverse event. The results of our 
analysis support an alternative interpretation to that of the FDA.
Finally, we carried out a sensitivity analysis of withdrawal from treatment due to 
adverse events by assuming no withdrawals due to gastrointestinal events in the 
placebo group. In total there were nine patients in the oseltamivir trials' placebo 
groups that withdrew due to gastrointestinal events. When these withdrawals are not 
included the following result is obtained based on random-effects meta-analysis:
Withdrawal from treatment due to adverse events: no evidence of a difference 
between treatment groups (OR 1.48, 95% CI 0.87 to 2.51, P = 0.15; test for 
heterogeneity P = 0.40).
We conclude that participants in placebo arms of oseltamivir treatment trials 
experience a higher rate of gastrointestinal adverse events compared to their 
zanamivir counterparts. As the zanamivir trials' inclusion criteria were similar to the 
oseltamivir trials (fever and two additional symptoms of influenza-like illness (ILI)) 
this observation cannot plausibly be explained by an incremental role of influenza 
infection in the genesis of such heterogeneity. It is possible that the difference in 
reported gastrointestinal adverse events in the placebo groups of zanamivir and 
oseltamivir trials is due to differences in the collection of these events. However, 
other common adverse events such as headaches, cough and dizziness had very 
similar rates in the placebo groups of zanamivir and oseltamivir trials. Despite the 
results of this sensitivity analysis it is impossible without a clear statement of dosage 
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and rationale of use to assess the role of dehydrocholic acid and possibly calcium 
phosphate in the causation of such a high incidence of gastrointestinal adverse events.
For hypothesis 1b the data obtained from the zanamivir treatment trials clinical study 
reports are shown in Table 16.
Over all the nine zanamivir trials the incidence of asthma (including asthma 
exacerbation) in the placebo groups was 2.1% compared to 0.9% in the placebo 
groups of the oseltamivir trials. Random-effects meta-analysis of the data in Table 16 
provided the following results for the combined outcome of any asthma event:
Asthma: decreased odds of adverse events due to zanamivir (OR 0.54, 95% CI 0.34 to 
0.86, P = 0.01).
We carried out a sensitivity analysis by assuming placebo rates of asthma-related 
adverse events in zanamivir trials based on those observed in similar oseltamivir 
trials. If we assume a rate of asthma events in the placebo groups of the nine 
zanamivir trials similar to that observed in the oseltamivir trials we obtain the 
following result based on random-effects meta-analysis:
Asthma: no evidence of a difference between treatment groups (OR 1.27, 95% CI 
0.71 to 2.26, P = 0.42; test for heterogeneity P = 0.68).
We conclude that zanamivir trial placebo recipients appear to have a higher incidence 
of asthma-related events than their oseltamivir counterparts. Again, as the inclusion 
criteria were similar for both trial programmes this finding is not likely to be due to 
severity of influenza infections but associated with exposure to lactose powder and 
possibly to the active principle. This is a point remarked on by the FDA.
For hypothesis 2 (oseltamivir (or zanamivir) does not affect antibody production in 
treatment trials) the relevant trials showed strong and consistent evidence that patients 
randomised to active treatment had reduced odds of being classified as influenza-
infected (OR 0.83, 95% CI 0.73 to 0.94, P = 0.003) with no evidence of heterogeneity 
(heterogeneity Chi2 test = 2.80 (df = 7) P = 0.90; estimate of between-study variance 
Tau2 = 0.00) (see Table 14). There was also strong evidence that patients randomised 
to active treatment had reduced odds of having four-fold or higher rise in antibody 
titres (OR 0.79, 95% CI 0.70 to 0.90, P < 0.001) with no evidence of heterogeneity 
(heterogeneity Chi2 test = 4.61 (df = 7) P = 0.71; estimate of between-study variance 
Tau2 = 0.00) (see Table 14).
In contrast, the zanamivir trials showed no evidence that patients randomised to active 
treatment had reduced odds of being classified as influenza-infected (OR 1.05, 95% 
CI 0.90 to 1.24, P = 0.52) with no evidence of heterogeneity (heterogeneity Chi2 test
= 3.03 (df = 6) P = 0.81; estimate of between-study variance Tau2 = 0.00).
These results have important implications for the oseltamivir treatment trials 
programme and for all ongoing trials. All influenza-infected populations are selected 
post-randomisation and post-trial termination on the basis of laboratory findings (all 
ITT participants being symptomatic at entry, with aetiology unknown). However, as 
oseltamivir appears to affect antibody production (or perhaps testing, or both), there 
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may be some participants in the oseltamivir group who were infected with influenza 
but not diagnosed by the antibody rise and were therefore not counted in the 
influenza-infected population. These may have subsequently been excluded from the 
efficacy analysis. It is also possible that the strength of the antibody production limit 
to qualify for an influenza infection-induced antibody rise (four-four fold and above 
from baseline) had the effect of selecting the 'stronger' responders into the influenza-
infected subgroup of the oseltamivir arm. This would mean that the best antibody 
producers were selected and this may have led to inflated treatment estimates of 
efficacy in influenza-infected populations.
To investigate this possibility we calculated the correlation between the odds of being 
classified as infected in the oseltamivir group compared to the placebo group and the 
size of the primary treatment effect (time to alleviation of symptoms in the ITTI 
population). In treatment trials all participants are recruited on the basis of symptoms 
of influenza-like illness. According to the mechanism of action proposed by the 
manufacturer, infected participants given oseltamivir up to 48 hours from symptom 
onset should have an antibody response which, given the effects of randomisation, 
should be similar to that of placebo recipients. Non-responders or weak responders 
should be spread evenly across the trial arms. All treatment trials of oseltamivir 
showing evidence of a treatment effect on the primary outcome of the study were 
included in the analysis. This included two trials for which we did not have clinical 
full study reports (ML16369; JV15823). We included these trials to increase variation 
in the two variables used for the analysis. In addition, two trials were excluded: 
WV15707 which had a total ITTI sample size of 12 participants; and 
WV15812/WV15872, which was a treatment trial in chronically ill adults that showed 
no evidence of a treatment effect. Results showed strong evidence of a correlation 
(Spearman rank correlation = -0.83, P = 0.01) (Table 19). The correlation was highly 
negative, indicating that lower odds of being classified as ITTI in the oseltamivir 
group compared to the placebo group is associated with larger treatment effects for 
the primary outcome of the studies. In contrast, there was no evidence of a correlation 
between the odds of being classified as infected in the oseltamivir group compared to 
the placebo group (Table 19) and the size of the treatment effect in the ITT population 
(Spearman rank correlation = -0.23, P = 0.66). A limitation of this analysis is that data 
for the ITT population for two trials were not available (WV15730; JV15823) (Table 
19).
Thus, all influenza-infected comparisons are potentially confounded by the action of 
the drug (oseltamivir but probably not zanamivir) and are essentially non-randomised 
comparisons. Any analyses should be based on ITT populations in oseltamivir 
treatment trials. Analyses and data considered for inclusion in systematic reviews 
should be based on the ITT (or safety) populations only.
Our analysis of Hypothesis 3 shows that the odds of having a four-fold rise in 
antibodies is 0.33 (95% CI 0.16 to 0.67) for the oseltamivir group compared to 
placebo (hence a much bigger effect compared to the treatment trials). Due to 
insufficient information provided in the clinical study report we were unable to take 
account of the clustering in this analysis, hence the confidence intervals are possibly 
under-estimated; however an analysis that takes into account clustering is unlikely to 
change the conclusions. These results show that oseltamivir prophylaxis is associated 
with lower odds of a four-fold rise in antibodies and this appears to be due to a 
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difference in the distribution of antibody rise in HIAAH3 antibodies but not HIAAH1 
or HIB antibodies (see Table 14). In summary no conclusions can be drawn from the 
available evidence on the effects of the drug on viral transmission. The mode of 
action in prophylaxis appears mainly to be ascribed to symptom suppression or 
control. There is uncertainty around other possible effects of the drug especially given 
its interaction with the production of antibodies.
We rejected Hypothesis 4 and are currently unable to test Hypothesis 5
We rejected Hypothesis 4 as there was no evidence of correlation between average 
recruited subjects per centre and the proportion of placebo patients subsequently 
diagnosed with inﬂuenza infection (Spearman correlation = 0.26; P = 0.53). Two 
studies failed to reach their recruitment target (WV15707 and WV15730) and two 
clinical study reports were made up of multiple trials due to the original trial's poor 
recruitment (WV15819/WV15876/WV15978 and WV15812/WV15872). In addition 
the proportion of placebo patients subsequently diagnosed with inﬂuenza infection
ranged from 63% to 75%, implying little between-trial variation.
We are currently unable to test Hypothesis 5 as only one oseltamivir clinical study 
report (of three trials) reported randomisation ﬁrst then swabbing second 
(WV15819/WV15876/WV15978). In this study the proportion of placebo patients 
that were conﬁrmed as inﬂuenza-infected was 68.1%. This compares with the other 
seven clinical study reports where swabbing was carried out ﬁrst and randomisation 
second and the proportion of placebo patients that were conﬁrmed as inﬂuenza-
infected ranged from 63.2% to 74.9% with mean 68.1%. Hence it seems that 
swabbing after randomisation made no difference in the treatment trial programme 
where this practice is reported. However, with only one clinical treatment study report 
randomising prior to swabbing available to us, the power to detect a difference in the 
proportion of placebo patients subsequently diagnosed with inﬂuenza infection is low. 
We hope to be able to retest this hypothesis as more data become available.
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Appendix 9 Example of contents of a Clinical
Study Report (from p. 1 of WV15670 report)
Final study report modules
This report consists of five modules. Those not supplied in this submission were obtainable from the
sponsor on request.
Module 1: core report and study publications
Introduction.
Rationale.
Objectives.
Methodology.
Efficacy results.
Safety results.
Discussion/conclusions.
Appendices.
Module 2: prestudy documents and study methodology
Protocol and amendment history.
Blank CRF.
Subject information sheet.
Glossary of original and preferred terms.
Randomisation list RAP.
Certificates of analysis.
List of investigators.
List of responsible ethics committees.
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Module 3: individual subject listings of demographic and efficacy data
Demographic data listings.
Previous and concomitant diseases.
Previous and concomitant medications.
Efficacy listings.
Module 4: individual subject listings of safety data
Laboratory parameters.
Vital signs data.
Module 5: statistical report
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Appendix 10 List of excluded studies and
reasons for exclusion
Study Reason for exclusion
105934 Post-marketing study
107485 Dose-ranging study
108127 Non-randomised study
112311 Pharmaco-availability study
112312 Pharmaco-availability study
113268 Pharmaco-availability study
113502 Non-comparative study
113625 Pharmacokinetics study
113678 Non-comparative study
114045 Survey
114373 Not placebo/do nothing controlled
167-02 Dose-ranging Phase I in volunteers, no influenza exposure
167-03 Dose-ranging Phase I in volunteers, no influenza exposure
167-04 Dose-ranging Phase I in volunteers, no influenza exposure
167-05 Dose-ranging Phase I in volunteers, no influenza exposure
167T3-11 An open-label trial of 20mg CG167 (zanamivir) in the treatment of influenza viral infection in
children aged ≤ 5 and < 15 years old (open-label study). Non-randomised; the intervention
group was compared with a survey group; 18-page summary available with no title
ADS-TCAD-PO206 Not placebo/do nothing controlled
BP21288 Pharmacokinetics study
C94–009 Pharmacokinetics study
C94–085 Pharmacokinetics study
GCP/95/045 Pharmacokinetics study
JNAI-02 Unknown study. Only ID traced
JNAI-03 Unknown study. Only ID traced
JP15734 Pharmacokinetics non-comparative study
JP15735 Does not test treatment, prophylaxis or PEP and there was no exposure to influenza
JV16284 Open-label, no control
JV21490 No influenza circulation, Phase IV study with unusual oseltamivir dosages
M76006 Not placebo/do nothing controlled
ML17279 CSR bears no title. Study of community pharmacist availability
ML17713 Non-comparative study
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Study Reason for exclusion
ML19340 Text in French. Community pharmacist availability study
ML20542 Not placebo/do nothing controlled
ML21954 Not placebo/do nothing controlled
ML22789 Not placebo/do nothing controlled
ML22872 Not placebo/do nothing controlled
ML22879 Not placebo/do nothing controlled
ML25018 Bioavailability study
ML25087 Not placebo/do nothing controlled
ML25094 Non-comparative study
ML25157 Pharmacokinetics study
ML25176 Pharmacokinetics study
ML25179 Not placebo/do nothing controlled
ML25265 Non-comparative observational study
ML25266 Pharmacokinetics study
MP20691 Pharmacokinetics study
MV20043 Transmission study
MV20050 Dose-ranging study
MV22926 Non-comparative study
MV22949 Pharmacokinetics study
MV22951 Pharmacokinetics study
MV22963 Pharmacokinetics study
MV22970 Pharmacokinetics study
NAI106784 Pharmacokinetics study
NAI108166 Pharmacokinetics study
NAI10901 Comparator is vaccine
NAI10902 Pharmacokinetics study
NAI40012 Instructional leaflet study
NAIA1009 Pharmacokinetics study
NAIA2010 Open-label, rimantadine-controlled, cluster randomised trial
NAIB1001 Pharmacokinetics study
NAIB1002 Pharmacokinetics study
NAIB1007 Pharmacokinetics study
NCT00297050 Dose-ranging study
NCT00416962 Not placebo/do nothing controlled
NCT00867139 Not placebo/do nothing controlled in immunocompromised people
NCT00957996 Peramivir study – does not have placebo/do nothing comparator
NCT01063933 Pharmacokinetics study
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Study Reason for exclusion
Not applicable (registry) Unknown study. Only ID traced. Identified from Reddy D. J Antimicrob Chemother
2010;65(Suppl. 2):ii35–40 (doi: http://dx.doi.org/10.1093/jac/dkq014) table 2.
http://jac.oxfordjournals.org/cgi/content/full/65/suppl_2/ii35/DKQ014TB2)
NP15525 Pharmacokinetics study
NP15717 Pharmacokinetics study
NP15718 Pharmacokinetics study
NP15719 Pharmacokinetics study
NP15728 Pharmacokinetics study
NP15729 Pharmacokinetics study
NP15743 Palatability study, open-label
NP15757 Pharmacokinetics study
NP15810 Pharmacokinetics study
NP15826 Pharmacokinetics study
NP15827 Pharmacodynamics study
NP15881 Palatability study in children
NP15901 Pharmacokinetics study
NP15912 Palatability study in children
NP16472 Not placebo/do nothing controlled
NP22770 Pharmacokinetics study
NP25138 Not placebo/do nothing controlled
NP25139 Not placebo/do nothing controlled
NP25140 Pharmacokinetics study
NV20234 Immunocompromised participants
NV20235 Immunocompromised participants
NV20237 Resistance study
NV22155 Not placebo/do nothing controlled
NV22158 Registry study
NV25118 Pharmacokinetics study
NV25182 Not placebo/do nothing controlled
NV25655 Open-label pharmacokinetics study
PP15974 Pharmacokinetics study
PP16351 Pharmacokinetics study
PP16361 Pharmacokinetics study
PV15615 Viral challenge study
PV15616 Viral challenge study
WP15517 Pharmacokinetics study
WP15525 Pharmacokinetics study
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Study Reason for exclusion
WP15647 Pharmacokinetics study
WP15648 Pharmacokinetics study
WP15676 Pharmacokinetics study
WP15979 Bioavailability study
WP16094 Pharmacokinetics study
WP16134 Bioequivalence study
WP16137 Bioequivalence study
WP16225 Bioequivalence study
WP16226 Pharmacokinetics study
WP16254 Pharmacokinetics study
WP16263 No influenza circulation, Phase IV study
WP16295 Open-label absorption study
WP17721 Pharmacokinetics study
WP18308 Pharmacokinetics study
WP20727 Pharmacokinetics study
WP20749 Not placebo/do nothing controlled
WP21272 Pharmacokinetics study
WP22849 Pharmacokinetics study
WV15731 No placebo arm
WV16139 Unknown study. Only ID traced. ID could be a typo
WV16193 Not placebo/do nothing controlled
ID, identity number.
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Appendix 11 Symptomatic influenza-like illness
in prophylaxis trials
Introduction
Among the CSRs of prophylaxis studies that we included, no oseltamivir study and only one study of
zanamivir (NAI 3003486) reported the relevant primary outcome ‘symptomatic ILI irrespective of positivity of
laboratory testing’. In the zanamivir CSR (NAI 30034) no significant reduction was observed (9% vs. 10%).
Furthermore, no definition was provided for ILI in the oseltamivir CSRs; however, individual patient data on
symptoms of influenza were provided in module 3.
Methods
Examples of the definitions of categories for lab-confirmed influenza used in the oseltamivir trials
(p. 33, CSR for WV15673–697;59 p. 31, CSR for WV1582568) are given below:
TABLE 25 Definitions of categories for subjects with laboratory-confirmed influenza virus infection
Category Oral temperature Constitutional symptoms Respiratory symptoms
Clinical influenza ≥ 99 °F One or more One or more
Non-clinical influenza
Non-clinical URTI
Febrile URTI ≥ 99 °F None One or more
URTI without systematic disturbance < 99 °F None One or more
URTI with systematic disturbance < 99 °F One or more None
Febrile constitutional ≥ 99 °F One or more None
Asymptomatic influenza < 99 °F None None
≥ 99 °F None None
< 99 °F One or more None
URTI, upper respiratory tract infection.
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TABLE 26 Definitions of categories for subjects with laboratory-confirmed influenza virus infection
Category Oral temperature Constitutional symptoms Respiratory symptoms
Clinical influenza ≥ 99 °F One or more One or more
Non-clinical influenza
Non-clinical URTI
Febrile URTI ≥ 99 °F None One or more
URTI without systematic disturbance < 99 °F None One or more
URTI with systematic disturbance < 99 °F One or more One or more
Febrile constitutional ≥ 99 °F One or more None
Asymptomatic influenza < 99 °F None None
≥ 99 °F None None
< 99 °F One or more None
URTI, upper respiratory tract infection.
These are complex and confusing definitions, in which, for example, the definition for ‘URTI with systemic
disturbance’ is the same as one of the definitions for asymptomatic influenza in WV15673–697.59
Furthermore, the definition for ‘URTI with systemic disturbance’ in WV1582568 and WV15673/WV1569759
is different. No definition is provided for ILI without confirmation of influenza. Asymptomatic influenza
includes those with some symptoms.
In the absence of a definition provided in the CSRs for ILI and the complex and confusing definitions of
categories for lab-confirmed influenza, we classified ILI as two or more symptoms out of nasal congestion,
headache, chills/sweats, sore throat, cough, fatigue, myalgia and fever. Fever was defined as reported in
the original protocols for each trial. We counted the number of patients with ILI during the trial follow-up
for each prophylaxis study of oseltamivir in adults.
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
Results
Oseltamivir did not reduce ILI (RR 0.95, 95% CI 0.86 to 1.06) (Figure 20). In additional analysis we found
that fever is reduced (RR 0.62, 95% CI 0.42 to 0.93) (Figure 21), proportion with laboratory confirmation is
reduced (RR 0.59, 95% CI 0.41 to 0.85) (Figure 22) but symptoms other than fever are not reduced
(RR 0.96, 95% CI 0.86 to 1.07) (Figure 23).
Interpretation
These results suggest oseltamivir suppresses fever, reduces antibody response and viral shedding but does
not reduce the risk of symptomatic illness.
Study or subgroup Events Events
41
5
16
62
1040
190
276
39
3
23
65
1506
Placebo
Total Total
Oseltamivir
Weight
RR
IV, random, 95% Cl
RR
IV, random, 95% Cl
WV15673/WV1569759
WV1570861
WV1582568
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.02; χ2 = 2.39, df = 2 (p = 0.30); I2 = 16%
Test for overall effect: z = 2.31 (p = 0.02)
973 100.0%
519
182
272
58.5%
7.6%
33.9%
0.62 (0.42 to 0.93)
0.52 (0.34 to 0.80)
1.60 (0.39 to 6.58)
0.69 (0.37 to 1.27)
Favours oseltamivir Favours placebo
0.01 0.1 1 10 100
FIGURE 21 Fever in adult prophylaxis. Temperature ≥ 100 °F (WV15673/69759) or ≥ 37.5 °C (WV15825/15708) as
originally defined in the trial protocols. IV, inverse variance.
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Total Total
Oseltamivir
Weight
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WV1570861
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Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.34, df = 2 (p = 0.51); I2 = 0%
Test for overall effect: z = 0.85 (p = 0.39)
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182
272
85.9%
1.7%
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0.97 (0.86 to 1.09)
1.28 (0.55 to 2.96)
0.83 (0.61 to 1.13)
Favours oseltamivir Favours placebo
0.01 0.1 1 10 100
FIGURE 20 All symptomatic ILI in adult prophylaxis. ILI is classified as two or more symptoms out of: nasal
congestion, headache, chills/sweats, sore throat, cough, fatigue, myalgia and fever (with or without lab
confirmation). IV, inverse variance.
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Appendix 12 Oseltamivir observational studies
review search strategies
Database: Ovid MEDLINE (1946 to February Week 1 2013)
Search strategy
1. Influenza, Human/
2. influenzavirus a/ or influenza a virus/ or influenza a virus, h1n1 subtype/
3. (influenza* or flu or h1n1).tw.
4. or/1-3
5. Oseltamivir/
6. (oseltamivir or tamiflu or neuraminidase inhibitor*).tw,nm.
7. Antiviral Agents/
8. antiviral*.tw.
9. or/5-8
10. 4 and 9
11. Hospitalization/
12. hospitali*.tw.
13. exp Mortality/
14. mortality.tw.
15. Death/
16. fatal outcome/
17. (death* or died or fatal*).tw.
18. Critical Illness/
19. (critical* adj2 ill*).tw.
20. or/11-19
21. 10 and 20
22. epidemiologic studies/
23. epidemiology.fs.
24. epidemiol*.tw.
25. exp case-control studies/
26. exp Cohort Studies/
27. cohort*.tw.
28. ((“follow up” or “follow-up”) adj2 (study or studies)).tw.
29. observational*.tw.
30. longitudinal*.tw.
31. retrospectiv*.tw.
32. prospectiv*.tw.
33. Cross-Sectional Studies/
34. (cross-section* or cross section*).tw.
35. (control* adj2 (group* or study or studies or patient* or case*)).tw.
36. or/22-35
37. 21 and 36
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EMBASE (Elsevier)
#15 834
#15.34 #15.19 AND
#15.33
#15.33 #15.20 OR #15.21 OR #15.22 OR #15.23 OR #15.24 OR #15.25 OR #15.26
OR #15.27 OR #15.28 OR #15.29 OR #15.30 OR #15.31 OR #15.32
#15.32 ‘control group’:ab,ti
#15.31 ‘cross-sectional’:ab,ti OR ‘cross sectional’:ab,ti
#15.30 ‘cross-sectional study’/de
#15.29 prospectiv*:ab,ti
#15.28 retrospectiv*:ab,ti
#15.27 longitudinal:ab,ti
#15.26 observational*:ab,ti
#15.25 ((‘follow up’ OR ‘follow-up’) NEAR/2 (study OR studies)):ab,ti
#15.24 cohort*:ab,ti
#15.23 ‘cohort analysis’/de
#15.22 ‘case control study’/exp
#15.21 epidemiol*:ab,ti
#15.20 ‘epidemiology’/de
#15.19 #15.9 AND #15.18
#15.18 #15.10 OR #15.11 OR #15.12 OR #15.13 OR #15.14 OR #15.15 OR #15.16
OR #15.17
#15.17 (critical* NEAR/2 ill*):ab,ti
#15.16 ‘critical illness’/de
#15.15 death*:ab,ti OR died:ab,ti OR fatal*:ab,ti
#15.14 ‘death’/de OR ‘fatality’/de
#15.13 mortality:ab,ti
#15.12 ‘mortality’/exp
#15.11 hospitali*:ab,ti
#15.10 ‘hospitalization’/de
#15.9 #15.3 AND #15.8
#15.8 #15.4 OR #15.5 OR #15.6 OR #15.7
#15.7 antiviral*:ab,ti
#15.6 ‘antivirus agent’/de AND [embase]/lim
#15.5 oseltamivir:ab,ti OR tamiflu:ab,ti OR ‘neuraminidase inhibitor’:ab,ti OR
‘neuraminidase inhibitors’:ab,ti
#15.4 ‘oseltamivir’/de
#15.3 #15.1 OR #15.2
#15.2 influenza*:ab,ti OR flu:ab,ti OR h1n1:ab,ti
#15.1 ‘influenza’/de OR ‘influenza a’/de OR ‘2009 h1n1 influenza’/de OR ‘influenza a
(h1n1)’/de OR ‘pandemic influenza’/de OR ‘swine influenza’/de
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Cumulative Index to Nursing and Allied Health
Literature (EBSCOhost)
Friday, February 15, 2013 2:30:38 AM
# Query Limiters/Expanders Last Run Via Results Action
S35 S21 AND S34
S34 S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33
S33 TI ((control* N2 (group* or study or studies or patient* or case*))) OR AB ((control* N2 (group* or study
or studies or patient* or case*)))
S32 TI (cross section* or cross-section*) OR AB (cross section* or cross-section*)
S31 TI prospectiv* OR AB prospectiv*
S30 TI retrospectiv* OR AB retrospectiv*
S29 TI longitudinal* OR AB longitudinal*
S28 TI observational* OR AB observational*
S27 TI (((“follow up” or “follow-up”) N2 (study or studies))) OR AB (((“follow up” or “follow-up”) N2
(study or studies)))
S26 TI cohort* OR AB cohort*
S25 (MH “Prospective Studies+”)
S24 (MH “Case Control Studies+”)
S23 TI epidemiol* OR AB epidemiol*
S22 (MH “Epidemiological Research”)
S21 S10 AND S20
S20 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19
S19 TI critical* N2 ill* OR AB critical* N2 ill*
S18 (MH “Critical Illness”)
S17 TI (death* or died or fatal*) OR AB (death* or died or fatal*)
S16 (MH “Fatal Outcome”)
S15 (MH “Death”)
S14 TI mortality OR AB mortality
S13 (MH “Mortality+”)
S12 TI hospitali* OR AB hospitali*
S11 (MH “Hospitalization”)
S10 S4 AND S9
S9 S5 OR S6 OR S7 OR S8
S8 TI antiviral* OR AB antiviral*
S7 (MH “Antiviral Agents”)
S6 TI ( oseltamivir or tamiflu or neuraminidase inhibitor* ) OR AB ( oseltamivir or tamiflu or neuraminidase
inhibitor* )
S5 (MH “Oseltamivir”)
S4 S1 OR S2 OR S3
S3 TI (influenza* or flu or h1n1) OR AB (influenza* or flu or h1n1)
S2 (MH “Influenzavirus A”) OR (MH “Influenza A Virus”) OR (MH “Influenza A Virus, H1N1 Subtype”)
S1 (MH “Influenza”) OR (MH “Influenza, Human”) OR (MH “Influenza, Pandemic (H1N1) 2009”)
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Latin American and Caribbean Health Sciences
Literature (BIREME)
(mh:“Influenza, Human” OR grippe OR “influenza humana” OR “gripe humana” OR influenza* OR flu OR
h1n1 OR mh:“Influenzavirus A” OR mh:“Influenza A virus” OR mh:“Influenza A Virus, H1N1 Subtype”) AND
(mh:oseltamivir OR oseltamivir OR tamiflu OR “neuraminidase inhibitor” OR “neuraminidase inhibitors” OR
“inhibe la neuraminidasa” OR “inibe a neuraminidase” OR mh:“Antiviral Agents” OR antivirales OR
antivirais OR antiviral*) AND (mh:“Epidemiologic Studies” OR “Estudios Epidemiológicos” OR epidemiol* OR
mh:“Case-Control Studies” OR “Estudios de Casos y Controles” OR “Estudos de Casos e Controles” OR
“Case-Base Studies” OR “Case-Comparison Studies” OR “Case-Referent Studies” OR “Matched Case-
Control Studies” OR “Nested Case-Control Studies” OR “Combined Case-Control Studies” OR “Grupos de
Estudio” OR “Estudios de Comparación de Casos” OR “Estudios de Referencia de Casos” OR “Estudios de
Casos y Controles por Apareamiento” OR “Estudios de Casos y Controles Anidados” OR “Estudios de Casos
y Controles Combinados” OR “Grupos de Estudo” OR “Estudos de Comparação de Casos” OR “Estudos de
Referência de Casos” OR “Estudos de Caso-Controle com Emparelhamento” OR “Estudos de Caso-Controle
Aninhados” OR “Estudos de Caso-Controle Combinados” OR mh:“Cohort Studies” OR “Estudios de
Cohortes” OR “Estudos de Coortes” OR “Cohort Analysis” OR “Closed Cohort Studies” OR “Concurrent
Studies” OR “Historical Cohort Studies” OR “Incidence Studies” OR “Análisis de Cohortes” OR “Estudios
Cerrados de Cohortes” OR “Estudios de Concurrencia” OR “Estudios Históricos de Cohortes” OR “Estudios
de Incidencia” OR “Análise de Coortes” OR “Estudos Fechados de Coortes” OR “Estudos Históricos de
Coortes” OR “Estudos de Incidência” OR cohort* OR longitudinal OR retrospectiv* OR prospectiv* OR
“follow up” OR “follow-up” OR “control group” OR mh:“Cross-Sectional Studies” OR “Estudios
Transversales” OR “Estudos Transversais” OR “cross sectional” OR “cross- sectional”) AND db:(“LILACS”)
Web of Science (Thomson Reuters)
#7 452 #6 AND #5
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
#6 1,897,044 Topic=(epidemiol* or cohort* or ((“follow up” or “follow-up”) NEAR/2 (study or studies)) or
observational* or longitudinal or retrospectiv* or prospectiv* or “cross section*” or
“cross-section*” or (control* NEAR/2 (group* or study or studies or patient* or case*)))
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
#5 1527 #4 AND #3
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
#4 1,158,683 Topic=(hospitali* or mortality or death* or fatal* or died or (critical* NEAR/2 ill*))
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
#3 6592 #2 AND #1
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
#2 56,113 Topic=(oseltamivir or tamiflu or “neuraminidase inhibitor” or “neuraminidase inhibitors”
or antiviral*)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
#1 86,524 Topic=(influenza* or flu or h1n1)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
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Appendix 13 Template of letter sent to
corresponding authors of included studies
Dear Dr. X*,
We read with interest your paper:
(citation)*
We are conducting a systematic review of observational studies of antivirals for inﬂuenza and are 
contacting you in the hope of obtaining a copy of the patient data you analyzed, as we would like to 
conduct a further analysis of these data considering the time-dependent nature of antiviral exposure.  
Would this be possible? We would of course acknowledge your help in any papers or reports arising 
from this research. We recognize the need to protect patient privacy and hope that the data can be de-
identiﬁed before sharing. Our protocol can be obtained from the following website:
Mark Jones, Rokuro Hama. Effect of oseltamivir on mortality in treatment of 2009A/H1N1 inﬂuenza 
patients. PROSPERO 2012:CRD42012002245 Available from 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002245
The variables we are particularly interested in for each patient are:
Patient ID
Hospital ID
Age and Sex of patient
Underlying Co-morbidities
Date of onset of symptoms (fever, or other symptoms in the case of no fever)
Date of ﬁrst presentation at a medical facility
Date of admission to hospital
Antiviral treatment: start date (with time), type (oseltamivir/zanamivir/other/none), dose, duration
Antipyretic treatment: date, type (paracetamol/ibuprofen/aspirin/other NSAID) and dose  
Corticosteroid treatment: date, type and dose 
Date of admission to ICU
Date (with time) of start of artiﬁcial ventilation
Hospital outcome (death/discharge/unknown)
Date of death/discharge
Any other variable that is associated with hospital outcome
Yours sincerely,
CDM
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Appendix 14 Reasons for exclusion of studies
based on full manuscripts
Reason for exclusion Number of studies Citationsa
Most (or all) patients received antiviral medication 77 1–57, 59–61, 63, 67, 68, 71–73,
102–111
Overlap with other included studies 10 58, 62, 64–66, 69, 70, 74–76
Did not provide a breakdown of numbers of patients dying by
oseltamivir exposure
12 77–88
Fewer than five deaths 12 89–100
Not a clinical study 5 101, 112–115
Other reasons 8 116–123
a These citations refer to the reference numbers in this appendix and not the main reference list.
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Appendix 15 Illustration of time-dependent bias
using individual patient data from the Canadian study
We illustrate the effect of time-dependent bias using the data from one of the included studies.Of 578 patients with a survival time, 540 received oseltamivir [of which 105 (19%) died] compared
with 38 who did not receive an antiviral [of which 12 (32%) died]. A simple chi-squared test gives weak
evidence of a difference in survival (p= 0.072) and Cox regression, assuming that treatment exposure
uniformly occurs at hospital admission provides evidence of reduced risk of death for patients receiving
oseltamivir (HR 0.52, 95% CI 0.29 to 0.95; p= 0.033). See Table 27 for a life table and Figure 24 for a
Kaplan–Meier plot of the data assuming treatment exposure occurred at hospital admission.
An alternative analysis that takes into account the fact that treatment with oseltamivir does not occur at
hospital admission but rather occurred at a mean of 0.62 days (range 0–45 days) after hospital admission
shows a markedly different result. Cox regression assuming time-dependent treatment exposure gives
no evidence of reduced risk of death for patients receiving oseltamivir (HR 0.87, 95% CI 0.48 to 1.61;
p= 0.66). See Table 28 for a life table and Figure 25 for a survival plot of the data using the method of
Simon and Makuch.227
The life tables and survival plots are shown for the first 11 days, as this is where most of the mortality
occurred. When standard survival analysis is used there is an implicit assumption that treatment exposure
begins at baseline, which, in this case, is hospital admission. Therefore, at baseline there were 540 patients
at risk in the oseltamivir group and 38 patients at risk in the no-treatment group (see Table 27 and see
Figure 24). This incorrect assumption is what leads to time-dependent bias.
In the alternative analysis the timing of exposure to treatment is taken account of correctly by considering
how many patients were exposed or unexposed to treatment on a daily basis. If the data were available
the computation could be done more accurately, for example on an hourly basis. Table 28 shows that in
fact there were only 423 patients exposed to oseltamivir in the first 24 hours of hospital stay. By simple
subtraction we also know that 155 patients had no exposure to oseltamivir during the first 24 hours of
hospitalisation. This more accurate data then leads to more accurate estimates of the cumulative mortality.
If we were to use hourly data then we would obtain more accurate estimates and reduce time-dependent
bias further.
Severity of illness and competing risks analysis
Of 578 patients, 517 had an APACHE II score recorded, with the proportion missing being greater for the
untreated patients than the treated patients (37% vs. 9%; p< 0.0001). Mortality was not significantly
higher in the patients with missing APACHE II score (25% vs. 20%; p= 0.35). In those with an APACHE II
score recorded there was no evidence of a difference between treated and untreated patients [untreated
mean (SD) 19 (10)12 vs. treated mean (SD) 21 (10);10 p= 0.39]. Owing to the large difference in proportion
missing between untreated and treated patients combined with similar observed scores in the two groups,
unadjusted competing risks analysis was conducted using the method of Fine and Gray.180 Results show
insufficient evidence of a difference in mortality (HR 0.84, 95% CI 0.41 to 1.73; p= 0.64) or discharge
(HR 1.41, 95% CI 0.73 to 2.74; p= 0.31).
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TABLE 27 Time from admission to death by time-fixed treatment status
Days since
admission
Number at
risk (AV)
Number
dead (AV)
Cumulative mortality
(%) (AV)
Number at
risk (no AV)
Number
dead (no AV)
Cumulative mortality
(%) (no AV)
1 540 4 0.7 38 3 7.9
2 536 14 3.3 35 3 15.8
3 519 4 4.1 32 0 15.8
4 507 2 4.5 31 0 15.8
5 498 3 5.0 29 0 15.8
6 485 4 5.8 27 1 18.9
7 467 6 7.0 26 1 22.0
8 449 4 7.9 25 0 22.0
9 441 4 8.7 23 1 25.4
10 422 8 10.4 22 0 25.4
11 394 7 12.0 22 1 28.8
12 375 6 13.4 20 0 28.8
AV, antiviral.
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FIGURE 24 Kaplan–Meier plot of time to death. AV, antiviral; TF, Tamiflu (oseltamivir).
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TABLE 28 Time from admission to death by time-dependent treatment status
Days since
admission
Number at
risk (AV)
Number
dead (AV)
Cumulative mortality
(%) (AV)
Number at
risk (no AV)
Number
dead (no AV)
Cumulative mortality
(%) (no AV)
1 423 4 1.0 155 3 2.0
2 484 14 3.9 87 3 5.5
3 487 4 4.7 64 0 5.5
4 485 2 5.1 53 0 5.5
5 481 3 5.7 46 0 5.5
6 472 4 6.6 40 1 8.0
7 459 6 7.9 34 1 11.0
8 442 4 8.8 32 0 11.0
9 434 4 9.7 30 1 14.4
10 415 8 11.7 28 0 14.4
11 388 7 13.5 28 1 18.0
12 370 6 14.8 25 0 18.0
AV, antiviral.
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FIGURE 25 Survival plot for time-dependent treatment exposure. AV, antiviral; TF, Tamiflu (oseltamivir).
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Appendix 16 Feedback
1 From Michael Power, Sowerby Centre for Health Informatics at Newcastle, 15 
December 2010 
Summary 
From: Michael Power <michael.power@schin.co.uk>
Date: 15 December 2010 18:51
Subject: Neuraminidase inhibitors for influenza - HTA project
To
Hi
I picked up Carl’s Twitter request for comments on your draft protocol "Neuraminidase inhibitors for preventing 
and treating influenza in healthy adults and children - a review of unpublished data". So, here are my two 
comments on the content.
The title confused me: I expected it to be a review of unpublished trials to complement your review of published 
trials. It would be longer but clearer if you could call it "Neuraminidase inhibitors for preventing and treating 
influenza in healthy adults and children - a review of clinical study reports for published and unpublished trials".
The section "How the intervention might work" could be reorganized along the lines of:
0) Metabolism: oseltamivir phosphate (OP), Tamiflu, is the pro-drug of oseltamivir carboxylate (OC), the 
effective form. OP dissociates in the gastrointestinal tract to form oseltamivir (OT) which is absorbed and 
metabolised into OC by hepatic carboxylesterase (h-CE).
1) Reducing the ability of the virus to penetrate the mucus in the very early stage of infection (Bhatia 2007; 
Matrosovich 2004; Moscona 2005; Ohuchi 2006).
2) Inhibiting neuraminidase, which enables influenza viruses to exit host cells (Liu 1995; Moscona 2005).
3) Central depression by OT (Hama 2008) may cause hypothermia (Ono 2008).
4) Inhibition by NIs of human sialidase may cause abnormal behaviour (Li 2007).
You have obviously put a huge amount of work and expertise into developing the protocol, and have an even 
bigger task ahead to complete the review. Congratulations for taking this on.
Best wishes
Michael
Reply 
Thanks for the constructive comments.
We have re-titled the Protocol to address this concern (and that of feedback from GSK, see below);
We have re-examined the "How the intervention might work" section but made only small adjustments in the 
interest of keeping this section short;
We are not sure what problems you might have had printing the pdf file, and hope they are resolved with this 
new version.
Contributors 
Chris Del Mar
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2 From Juan C. Vergara, Intensive Care, Hospital Cruces, 48901 Barakaldo, Spain, 24 
February 2011
Summary 
From: JUAN CARLOS VERGARA SERRANO <JUANCARLOS.VERGARASERRANO@osakidetza.net>
Date: 24 February 2011 12:48
Subject: oseltamivir
To: 
I've read your Intervention Protocol: Neuraminidase inhibitors for preventing and treating influenza in healthy 
adults and children - a review of unpublished data. And may be you can be interested in this letter I wrote to de 
BMJ: http://www.bmj.com/content/340/bmj.c789.extract/reply
1. Early use of oseltamivir does not reduce swine flu mortality, Juan C. Vergara, MD. Intensive Care Unit, 
Hospital Cruces. 48901 Barakaldo. Spain
As you say, in July the National Pandemic Flu Service started providing oseltamivir to anybody who telephoned 
with a plausible set of symptoms. From 23rd July to 1st December, the National Pandemic Flu Service (NPFS) 
in the UK, has provided more than one million courses of antiviral medication. By that time the Spanish Health 
Secretary General, José Martínez Olmos, at the Congress of Deputies, announced that only 6.000 patients (most 
of them hospitalised) had received oseltamivir in Spain. At the end of January there have been 411 deaths 
reported due to pandemic (H1N1) 2009 in the UK, and about 300 in Spain. That means 6.7 and 6.5 deaths per 
million, respectively. These data create serious doubts about the real utility of early use of oseltamivir in 
preventing deaths from Influenza A H1N1.
http://www.nhsdirect.nhs.uk/article.aspx?name=SbSwineflu
http://www.congreso.es/public_oficiales/L9/CONG/DS/CO/CO_411.PDF
Competing interests: None declared
Yours sincerely;
J. C. Vergara
Reply 
Thank you for your interest.
Contributors 
Chris Del Mar
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3 From Dr Helen Steel, GSK, UK, 30 March 2011
Summary 
GSK comments on Cochrane Collaboration protocol: neuraminidase inhibitors for preventing and 
treating influenza in healthy adults and children - a review of unpublished data
General:
The term ‘unpublished data’ is used extensively in the protocol. However, it does not appear to be clearly 
defined either in the protocol or in Jefferson’s comment in the 15 Jan 2011 edition of the BMJ. Additionally, 
the term ‘unpublished data’ is misleading. It appears the Cochrane Group use this term interchangeably with 
Clinical Study Reports, regardless of whether a primary manuscript is available for a given study. We suggest 
this is clarified or preferably replaced, especially since the term appears extensively in the protocol including the 
title. Readers are likely to use the terms ‘unpublished data’ and ‘unpublished trials’ (trials for which no primary 
publication appears in the scientific press) interchangeably. A suggested replacement is ‘Clinical Study 
Reports’ since this term is not easily misinterpreted and is clearly defined in Jefferson’s BMJ comment.
The ‘scope of clinical trial data’ are defined in Jefferson’s BMJ 15 Jan 2011 comment, as mentioned above (i.e. 
definitions for clinical study reports, raw data, unpublished trial, published trial, regulatory data). It would seem 
important that these and any other definitions introduced in the protocol are included in the protocol.
Description of Intervention
This section incorrectly describes Relenza as ‘nebulized zanamivir’. Relenza is formulated in Rotadisks 
containing foil blisters with a powder mixture of zanamivir and lactose. Relenza is administered by oral 
inhalation using a breath-activated device called the Diskhaler. Earlier clinical studies explored several methods 
of administration, including nebulized and intranasal routes but marketing approval in nearly all countries is 
currently available only for oral inhalation via Rotadisk/Diskhaler.
Types of Studies
To meet the objective of providing a comprehensive review of neuraminidase inhibitors in preventing and 
treating influenza, it would seem appropriate that clinical trials from all sources (including sponsors other than 
industry) be included in this meta-analysis. Please clarify if this is your intent.
Outcome Measures
More details should be provided on the outcome measures section in the final protocol.
For example, broad outcome measures are stated in the protocol but specific endpoints are not provided. The 
primary and secondary endpoints of the meta-analysis should be clearly defined in the final protocol.
e.g.1. A stated primary outcome in the treatment studies is ‘symptom relief’. Does this refer to ‘the time to 
alleviation of symptoms’ or ‘reduction in symptom score’ or another endpoint? Time to alleviation of clinically 
significant symptoms was the primary endpoint used in the majority of GSK treatment studies.
e.g.2. Another stated primary outcome is ‘Harms’. Please provide the specific endpoints. Will this refer to 
‘incidence of most common AEs’ or ‘incidence of common SAEs’, ‘incidence of complications’ or another 
endpoint? It is not clear if ‘harms’ are the same as ‘compliharms’. It is not clear what specific events will 
comprise compliharms.
Prophylaxis studies: Several types of prophylaxis studies were conducted by GSK: household prophylaxis 
(post-exposure prophylaxis), community prophylaxis and outbreak control in nursing homes, and as such the 
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designs and/or endpoints are different. It is possible to measure ‘prevention of onset of influenza in contacts’ in 
these studies but not ‘reduction in viral spread from index cases’ in the majority of prophylaxis studies.
Hospitalisations: As studies were generally conducted in the setting of acute uncomplicated influenza, limited 
hospitalisation data were collected, and are available only for some studies.
Extracting compliharms: There is a statement that ‘AEs are reported for all participants while complications are 
only reported for infected subjects’. This statement is not accurate for GSK trials. AEs are reported for all study 
participants. However, AEs of ILI were not collected in the treatment studies unless the symptoms were 
considered to be worse than expected for the normal progression of illness. Without knowing the specific safety 
endpoints, it is unclear whether this will affect the outcome of some of the harms analyses.
Data collection and analysis:
The protocol indicates that clinical study reports will be requested (minus participant identification). In fact 
many documents for each study will need to be redacted not just to remove participant identification but any 
personally identifiable information including author and investigator identification.
Missing Data. The protocol states "At the participant level (i.e. within a trial) we will not make any assumptions 
about missing data." This is not possible, because an analysis of data that is collected in a trial can only be done 
in the context of assumptions about potential mechanisms that led to data being missing (e.g., missing 
completely at random, or missing at random).
Meta-analysis Method. Little detail is given in the protocol. The protocol states that "Whether or not 
heterogeneity is detected, we will perform a random effects meta-analysis. Random-effects methods will be used 
to compare the dichotomised outcomes (RR and absolute risk reduction (ARR) for efficacy and safety)." There 
are several different Random Effects methods available (Bayesian or frequentist, DerSimonian & Laird or 
Maximum-likelihood or REML), and different approaches to handling rare events (various "corrections" to 
include trials with zero counts). Furthermore, would random-effects methods also used to compare the 
continuous outcomes?
Fixed-effects Model. The protocol also states that fixed-effects models will be used in a sensitivity analysis. No 
details are given with regard to which fixed-effects models will be used. There are several fixed-effects models 
available including Inverse Variance, Mantel-Haenszel, and Peto’s method. The appropriate method used 
should also depend on the outcome measures (dichotomous vs. continuous; relative vs. absolute). The approach 
and choice of models for sparse data and rare events should be provided. Furthermore, various methods in the 
framework of fixed-effects model may be explored to evaluate the robustness of the results.
Hazard Ratio. The protocol states "We will convert medians of treatment groups into (log) hazard ratios 
(estimating the variance of these) to enable meta-analysis of time to event outcomes." Although hazard ratio 
(HR) is a standard analysis and widely recommended approach for time-to-event data in clinical trials, the 
HR analysis may not be suitable for the Relenza studies with relatively short follow-up time because the 
assumption of proportional hazards required for the proportional hazards model may not hold. GSK did not 
follow this approach for the original analysis due to the concern stated above. Further the clinical and regulatory 
interest centred on differences in the time to alleviation not in the relative hazard between treatments. The above 
issues would be best addressed by using subject level rather than summary data, which GSK have offered to 
provide to the Cochrane Group.
Analysis Populations. The protocol does not specify which populations will be used for the various analyses, for 
example, intent-to-treat or influenza-positive or other. We believe that influenza positive population is 
appropriate, especially for the efficacy analysis using time to alleviation of influenza symptom as a primary 
endpoint consistent with the prescribing information for Relenza.
Study Duration. No details are given in the protocol with regard to how studies with different follow-up times 
will be handled.
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Trials with no Events. No details are given in the protocol with regard to how to deal with trials in which there 
are no events (such as death). By excluding studies with no events will make the event appear more common 
than it actually is. There are various techniques: Bayesian approach, continuity correction, combining similar 
trials to avoid having any components of the analysis that have no events.
Sensitivity Analyses. Sensitivity analyses using different outcome measures, statistical models and/or continuity 
correction factors to assess the robustness of the results are strongly encouraged.
Reply 
General:
'unpublished data'. We agree that this term is confusing, and are attracted to the proposal of using 'clinical 
study reports' instead.
We have attempted to ensure all terms are clear.
Description of intervention
Description of zanamivir (Relenza): we have corrected 'nebulized zanamivir' to 'powder inhalation'.
Types of studies
Yes, we intend to comprehensively review clinical trials from all sources (including sponsors other than 
industry). This intent is clear from the subsection 'Electronic searching' under the 'Search methods for 
identification of studies' section.
Outcome measures
Our specified outcomes are those of interest to patients, and their clinicians and policy-makers. They are 
therefore likely to be broader than the more specific endpoints selected by trialists. The purpose of Cochrane 
Reviews are usually to set clinically relevant review questions, and search the literature (or other sources) for 
answers to them. Sometimes answers to some questions are not available, and this is also documented. Where 
possible we report outcomes as pre-specified in the trial protocols, or as pre-specified in the review protocol, or 
otherwise reported as a post-hoc analysis.
e.g. 1. 'symptom relief' may refer to 'the time to alleviation of symptoms' or 'reduction in symptom score', or any 
other endpoint (including 'area under the curve of symptom score and time').
e.g. 2. 'Harms' include common adverse events (AEs) as well as serious AEs. We agree about the confusion of 
harms and complications, and have tried to capture the totality of these with the neologism 'compliharms' to 
avoid classification errors between their different labellings.
Prophylaxis studies: We understand that it is possible to measure 'prevention of onset of influenza in contacts' in 
some GSK studies but not 'reduction in viral spread from index cases' in others.
Hospitalisations: We understand that hospitalisation data may only be available for some studies. However 
patient hospitalisation is usually classified as a serious adverse event therefore we expect to identify 
hospitalisations (not reported separately) in that way.
Extracting compliharms: Your statement that "AEs of ILI were not collected in the treatment studies unless the 
symptoms were considered to be worse than expected for the normal progression of illness" underlies the 
complexity of analysing AEs and complications (our 'compliharms'). We have noted in the protocol that the 
limitation of complications only reported for the infected patients is relevant to the Roche trials only.
Data collection and analysis:
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We are interested that not only subject identification would be required to be removed from any documents of 
clinical study reports but also information personally identifying authors and investigators. We wonder why. 
Missing data. We have removed this statement.
Meta-analysis method. DerSimonian & Laird method will be used. Note that in the case of zero cells (e.g. no 
events in one group) the RevMan software (which we will use for the analysis) automatically adds 0.5 to each 
cell of the 2×2 table for any such study. There are no continuous outcomes specified in this review.
Fixed-effects model. Mantel-Haenszel method will be used except in the case of sparse data, in which case 
Peto's method will be used (as recommended in the Cochrane Handbook).
Hazard ratio. We note the concerns with this outcome hence we will also consider analysis of this outcome as a 
continuous outcome noting that the data are likely to be skewed. We will use the inverse-variance random-
effects method for this analysis.
Analysis populations. All analysis will be using the intent-to-treat population as this is the most 
methodologically rigorous and clinically relevant.
Study duration. We have specified in the protocol, where appropriate, that we will report outcomes for the on-
treatment and off treatment time periods. If data are not available in the clinical study reports for any time 
period of the study then we will write to the relevant manufacturer to request the missing data.
Trials with no events. As stated above the RevMan software automatically adds 0.5 to each cell of the 2×2 table 
for any such study.
Sensitivity analyses. We note this point and agree. Where appropriate, a realistic sensitivity analyses will be 
conducted.
Contributors 
Chris Del Mar
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4 Feedback from Wolfgang Becker-Brueser, 30 January 2012 
Summary 
Dear Tom Jefferson,
I read your review about NI for prevention and treating influenza with interest. It's an important work. In the 
chapter "Why it is important to do this review" I found a small mistake concerning the worldwide stockpiling of 
oseltamivir which is mentioned to be "CHF 7.6 billion worth of oseltamivir (JACK 2009)". This would be an 
enormous amount "prior (!) to the emergence of influenza A/H1N1 in 2009". But Andrew JACK wrote in the 
cited Financial Times (May 13, 2009): "Governments around the world had stockpiled 220m treatments to date, 
swelling sales since the start of 2003 to SFr7.6bn, largely on the basis of preparation for a pandemic virus that 
has yet to appear." So 7.6 billion SFr represent sales and not stockpiling.
Wolfgang Becker-Brueser (physician and pharmacist)
Reply 
Thank you. The extent of stockpiling is a closely guarded secret this is why these are estimates. We will 
probably never know.
Contributors 
Tom Jefferson MD
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5 From Frederick G. Hayden, M.D., 02 February 2012
Summary 
I am writing to comment on the recently updated meta-analysis by Jefferson and colleagues published through 
the Cochrane Collaboration and to request clarifications on several points, as well as to suggest some additional 
analyses that would be helpful in terms of taking greater advantage of this useful database. While I fully 
support access of Jefferson and other interested investigators to all of the published and unpublished data from 
the RCTs of oseltamivir and zanamivir for further analyses, this analysis only focuses on RCTs in ambulatory 
patients with uncomplicated influenza (the vast majority of whom were previously healthy) and on the period 
before the 2009 H1N1 pandemic. Consequently, I would urge these investigators to extend their efforts to other 
populations and datasets examining the risks and benefits of using neuraminidase inhibitors (NAIs) for 
treatment and prophylaxis. Furthermore, the authors should acknowledge the limitations of their analyses more
explicitly and avoid inappropriate extrapolation to populations and influenza events that the RCTs did not 
adequately address. Differences in disease pathogenesis related to virus and host factors, as well as time to 
treatment, have important effects on the utility of antiviral agent interventions. My specific comments and 
recommendations for additional analyses follow:
1. Use of Intention to Treat (ITT) and ITTI-Infected Groups. The exclusive focus in the current treatment 
analysis on the ITT population is a readily rectified shortcoming. Outcomes in all three groups of relevance 
(ITT, ITT-infected, and ITT-noninfected) should be presented, so that readers can examine both clinical 
effectiveness and efficacy for the key endpoints, as well as events in those without documented 
influenza. Because NAI treatment would not be expected to provide any benefit in non-influenza illness, not 
presenting the ITT-infected outcomes in the analysis underestimates possible beneficial drug 
effects. Assessment of the non-infected group provides a valuable control and also enables a determination of 
whether there was a potential drug-disease adverse interaction of NAI treatment in non-influenza patients. Of 
note, our earlier pooled analysis of physician-diagnosed lower respiratory tract complications leading to 
antibiotic use found a significant benefit of oseltamivir in the influenza-infected patients but not in those 
enrolled in whom influenza infection was not detected by culture or serology [Kaiser 2003].
2. Sample size considerations. Severe outcomes of influenza infection are sufficiently uncommon in previously 
healthy people that even large RCTs or combining multiple RCTs would be very unlikely to detect them with 
confidence. The same point applies to very uncommon endpoints like microbiologically documented bacterial 
complications and rare adverse effects of treatment. Consequently, conclusions that there is no evidence (from 
trials) that NAIs reduce the risk of pneumonia, hospitalisations, deaths are overstated, as the evidence 
considered in this analysis is insufficient to properly address these questions.
The US CDC has estimated age-related influenza-related hospitalisation and mortality rates for both seasonal 
epidemics and the 2009 pandemic [Shrestha 2011]. Jefferson and colleagues should use such event estimates 
and others to make calculations of the necessary sample sizes to detect reductions in these severe outcomes with 
NAI therapy in a controlled RCT across a range of clinically relevant effect sizes (e.g., 20%, 35%, 50% 
reductions). In a related fashion, they should also provide more quantitative estimates for their ability to detect 
such outcomes with their existing database and comment more precisely on their power to capture particular 
endpoints.
3. Complications in ambulatory patients. Other clinically relevant endpoints in these previously healthy and at-
risk persons warrant investigation. With regard to influenza-related complications, the most frequent in 
previously healthy children and adults are respiratory tract infections (otitis media, bronchitis) leading to 
antimicrobic use. These are usually not severe and typically not microbiologically documented with respect to 
etiologies but physician-diagnosed complications leading to antibiotic use is an outcome that has important 
clinical and public health implications (i.e., cost, antibiotic resistance, side effects) and also is sufficiently 
frequent to demonstrate effects of antivirals. We showed such a benefit in adults in our earlier pooled analyses 
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of the then available RCT data on inhaled zanamivir [Kaiser 2000] and oral oseltamivir [Kaiser 2003]. The 
oseltamivir effect was confirmed in a recent meta-analysis [Hernan 2011], and another recent Cochrane report 
confirms an effect on otitis media in children [Wang 2011].
Given the large amount of data available to the investigators, it would be a valuable contribution to also explore 
the clinical outcomes in greater detail and to clarify the use of terms like severe outcomes. Although uncommon 
in the populations enrolled in these RCTs, endpoints such as radiographically documented pneumonia, 
microbiologically documented infections, and hospitalisation or death are clear and should be listed separately 
in those with or without proven influenza infection. Because of the importance of hospitalisations as an 
endpoint, it would be helpful to examine not only all-cause hospitalisations but also relevant subgroups based on 
likely causation (e.g., events in which influenza was documented or likely implicated including exacerbations of 
co-morbidities vs others like accidents, elective surgeries, conditions unlikely to be influenza-related). In 
addition to these events, exacerbations of underlying conditions (e.g., asthma, COPD, diabetes, CHF) are of 
medical importance in influenza outpatients with co-morbidities and should be examined.
4. Data from observational studies. Typically the patients who are most at risk of severe outcomes (older 
people, infants and young children, those with underlying chronic conditions) are not included in RCTs. In this 
regard, the current analysis is limited to placebo- or active-controlled RCTs largely done in previously healthy 
persons and does not consider the multiple observational studies from different countries that have consistently 
showed protective effects against severe outcomes like pneumonia and hospitalisation, particularly in those with 
co-morbidities, as well as reduced mortality if patients have been hospitalised. A considerable amount of new 
treatment data was generated in many countries during the 2009 H1N1 pandemic that found timely NAI 
treatment to be associated with a lower risk for intensive care admission and death (reference list available upon 
request).
While such data and analyses are weaker than RCT data and subject to bias, these observational studies address 
key endpoints in at-risk and seriously ill populations, including patients admitted to a hospital at the time of 
initiating therapy, that the available RCTs cannot and do not address. Furthermore, the standard of care has 
evolved such that placebo-controlled RCT in such patient groups would not be acceptable to investigators or 
ethics committees. The decision by Jefferson and colleagues not to consider and critically analyse the large 
amount of observational data with modern techniques means that they are not incorporating key information and 
many important patient groups in which the available data suggests medically important benefits from early NAI 
therapy. Such findings from observational data can inform antiviral treatment in more severely ill patients when 
no other data are available. As discussed above, not to include observational data means that conclusions of no 
effect on uncommon events or no severe adverse events being detected are almost inevitable. This should be 
made explicit in the design and the conclusion of the current report.
4. Influenza diagnosis and serologic results. The Jefferson report raises questions about the possible inhibitory 
effects of oseltamivir therapy on influenza-specific serologic rises and introduction of bias into the outcomes 
analysis. Further analyses might help to assess these possibilities. They should compare the primary endpoint of 
illness alleviation between the oseltamivir and placebo subgroups that were culture-positive (irrespective of 
serologic findings) at enrolment, and separately those that were culture-negative but had serologic evidence of 
infection.
Of note, one prior study of oseltamivir treatment in pandemic 2009 H1N1 patients, although not in seasonal 
influenza patients, suggested that early treatment could reduce antibody responses [Cowling 2010]. Jefferson 
and colleagues should examine the age-related frequencies of HAI seroconversions and the GMT titre rises in 
those with influenza-culture positive illness and separately in those with such HAI rises in absence of culture 
positivity. Of course, if still available, it would be interesting to test the culture-negative enrolment samples by 
RT-PCR.
The RCT data were generated over multiple seasons in which different influenza A and B viruses were 
circulating. Influenza B neuraminidases are generally less susceptible to oseltamivir carboxylate and several 
observational studies indicate that oseltamivir is less effective in influenza B- than influenza A-infected children 
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[Sugaya 2007; Sato 2008]. It would be useful to examine the primary outcome in relation to virus type (A vs. B) 
and if possible A subtype (H3 vs. H1) in those with documented infections to expand on this point.
5. Other treatment endpoints of interest. Since those enrolled in the RCTs were outpatients, it would be useful 
to explore other endpoints that reflect patient recovery and impacts on the healthcare system (e.g., nonscheduled 
return visits for complications or adverse events). Perhaps more important than the time to alleviation endpoint 
used in the registrational trials might be the times to resumption of usual activities and return to pre-morbid 
status.
The authors raise the possibility that oseltamivir might have non-specific antipyretic effects, and one animal 
model study has also suggested possible adverse immunomodulatory effects of oseltamivir in RSV infection 
[Moore 2007]. Consequently, it would be interesting to examine the course of fever resolution (a much earlier 
event than cough resolution) and of symptoms in oseltamivir- and placebo-treated patients with and without 
documented influenza infections. In addition, it would be valuable to examine the correspondence (or lack 
thereof) between influenza virologic measures (e.g., enrolment virus titre, time to culture negativity, change in 
viral titres over time) and symptom resolution measures in both oseltamivir and placebo groups.
Various cost-effectiveness analyses on NAI therapy in low-risk populations have been published with widely 
divergent outcomes, largely depending on the input assumptions. Using this large database, a more refined 
analysis that incorporates both the direct and indirect (productivity losses) costs of influenza would be 
informative.
6. Adverse events with treatment. With regard to drug tolerability, it is important to examine not only the 
frequencies of reported adverse events but also assess indicators of their severity and interference with 
compliance (e.g., symptom days, patient reported severity, premature cessation of study drug).
Comparisons of AEs in the placebo groups across zanamivir and oseltamivir studies need to be interpreted with 
caution, since these studies were performed in different influenza seasons viruses and locations, with different 
protocols and case record forms, and by different investigators. Only one head-head RCT of treatment 
comparing these drugs has been published to date to my knowledge but the design did not include placebo only 
groups [Duval 2010]. In particular, comparisons in children (page 24) need to be age-adjusted as there were 
major differences in those enrolled into the zanamivir (5 years and older) and oseltamivir trials (1 year and 
older), and the frequencies of gastrointestinal manifestations are much higher in younger children with influenza 
and other acute illnesses.
7. Prophylaxis endpoints of interest. The analysis of prophylaxis outcomes and the associated discussion 
requires clarification. The statement on page 5 says: "The FDA has also not allowed an indication for 
interference of viral transmission within households (the key concept behind post-exposure prophylaxis)." The 
key concept behind post-exposure prophylaxis is prevention of illness in exposed persons, and the primary 
endpoint in most prophylaxis studies has been symptomatic, laboratory-confirmed influenza illness. FDA and 
other regulatory agencies have approved both NAIs for post-exposure prophylaxis in households and also for 
longer duration pre-exposure chemoprophylaxis [reviewed in Khazemi 2009].
The Jefferson analysis seems to focus exclusively on the effect of chemoprophylaxis in "preventing the spread" 
of influenza, with endpoints presumably determined by evidence of culture or serologically confirmed infection 
irrespective of illness. While this is one endpoint of interest in such studies, the primary outcome of medical 
interest is prevention of influenza illness in those exposed. There is abundant RCT data, as well as observational 
data from the 2009 pandemic, that both inhaled zanamivir and oral oseltamivir have both statistically significant 
and medically important effects on preventing influenza-specific illness. Of note, the development of serologic 
evidence of infection without illness is advantageous in those receiving chemoprophylaxis, as it likely is an 
immunizing event that protects against future infection and illness by that strain. In addition several oseltamivir 
RCTs have shown significant but lesser effects on influenza infection in prophylaxis recipients [Welliver 2001; 
Hayden 1999]. The authors should present all of the relevant endpoints in their analysis of the prophylaxis trials.
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8. Adverse effects with prophylaxis. The prophylaxis studies are particularly useful in assessing drug 
tolerability as symptoms of acute illness present in treatment studies are not confounders and there is a more 
prolonged duration of drug exposure. However, it is essential to examine not only the frequencies of reported 
adverse events but also indicators of their severity and possible interference with compliance (e.g., symptom 
days, patient reported severity, premature cessation of study drug).
For example, the Jefferson posting states that "Similarly, a published prophylaxis trial (Hayden 1999a, known 
by its trial ID WV15673/WV15697) describes headache as having "occurred in similar proportions of subjects 
in the three groups (39 to 47 per cent)." but indicates that Japanese regulatory documents reached a different 
conclusion. My own review of the adverse event tabulations from our 6-weeks prophylaxis study (tables 
provided by the sponsor) indicates that the proportions of subjects reporting headache (not otherwise specified) 
that might have been related to study drug (unrelated reports excluded) during the treatment phase were similar 
across the placebo (N=116, 22.4%), oseltamivir 75 mg once (N=124, 23.8%), and oseltamivir 75 mg twice 
(N=132, 25.4%) daily dose groups [Hayden 1999]. Most of these reports indicated mild or moderate intensity 
and were self-limited. As indicated in the published paper [Hayden 1999], study withdrawals for AEs or illness 
occurred infrequently across these same groups (N=10, 1.9%; N= 8, 1.5%; N= 7, 1.3%). Of note, the specified 
causes for AE-related withdrawals included three reports of headache associated with other symptoms in the 
placebo group. In contrast, there were no reports of headache as reason for the withdrawals receiving 
oseltamivir; gastrointestinal complaints accounted for withdrawals in 4 of 8 oseltamivir 75 mg and 3 of 7 
oseltamivir 75 mg twice daily recipients. The total numbers of patients with premature study withdrawal for any 
reason was 21 (4.0%), 17 (3.3%), and 16 (3.1%) across the three groups, respectively. Overall, severe AEs were 
reported in 82 (15.8%) of placebo, 75 (14.4%) of oseltamivir 75 mg, and 77 (14.8%) of oseltamivir 75 mg twice 
daily recipients. We were unable to include these details in the paper because of space limitations but my 
interpretation remains that no excess of clinically relevant oseltamivir-related headache occurred during this 
study. This type of detailed AE analysis incorporating severity measures provides necessary context in 
interpreting the possible importance of AEs.
9. Peer review. The questions raised and opinions expressed in this and earlier Cochrane reports on NAIs by 
Jefferson and colleagues have resulted in debate and sometimes confusion among practitioners and policy 
makers regarding the appropriate use of NAIs in seasonal and pandemic influenza responses. Given the 
importance of these issues, it would be helpful for any future updates to have proper independent review before 
posting or publication by the Collaboration, as the Cochrane methodology of publication and then independent 
peer review is not well understood by many people.
Thank you for the opportunity to provide comments. I look forward to seeing the responses from Dr. Jefferson 
and his colleagues on these points.
Sincerely,
Frederick G. Hayden, M.D.
Stuart S. Richardson Professor of Clinical Virology
Professor of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia, USA
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Reply 
Response to Dr. Hayden’s comments of 2 February 2012.
We thank Dr. Hayden for his detailed feedback. However nothing he writes allays our basic concerns that:
(1) despite the 16,000 pages we analysed, we currently only have access to a very limited dataset hence cannot 
carry out many of the analyses Dr. Hayden suggests;
(2) analysing the "influenza infected" population in Roche oseltamivir trials, as Dr. Hayden proposes, will lead 
to misleading results because the treatment groups are not comparable for this population;
(3) the observational studies Dr. Hayden urges us to consider are generally of poor quality and only represent 
the small proportion of patients who are hospitalised with influenza;
(4) the Kaiser et al (2003) analysis is seriously flawed;
(5) data have been selectively reported.
Below, we provide point-by-point responses to Dr. Hayden's concerns. (Please note that point 4 appears twice, 
to follow the numbering in Dr. Hayden’s letter.)
1. Use of intention to treat (ITT) and ITTI-infected [sic] groups
We agree, in principle, to conduct analysis using the ITT-infected (ITTI) sub-population provided that it is 
appropriately selected by the results of testing completed before the start of the trial (for example by using only 
the results of viral culture or rapid testing before randomisation).
However we argue that this is not possible in Roche oseltamivir trials. In these trials, the selection of "infected" 
or "non-infected" was dependent on the results of serology that is affected by "use" and "non-use" of 
oseltamivir. And the selection of those with "serology-positive results" appears to have given advantage to the 
oseltamivir group. Hence the method of selecting the ITT-Infected population in the trials has fundamental 
flaws and therefore the results are less reliable than those obtained using the ITT population.
2. Sample size considerations
The Kaiser et al analysis has a number of fundamental problems. First, analyses were performed on the ITT-
infected sub-population which we have shown to be non-comparable between treatment groups. Second, the 
authors analysed an outcome that was different to that pre-specified in the trials. In the trials, complications 
included otitis media and sinusitis but in the Kaiser et al paper these were not included. This is an example of 
selective reporting or "cherry picking". Third, complications were not objectively or consistently measured in 
the trials. Fourth, outcomes such as pneumonia and bronchitis could be either reported as a complication or as 
an adverse event according to a classification criteria we do not understand and is not discussed in the Kaiser et 
al paper. And finally the data from the 10 trials was not meta-analysed, rather, it was combined as if generated 
from one single trial.
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We could potentially address most of these limitations (except for the third) but we have not been given access 
to the data despite repeated requests to the manufacturer. However we were able to compare hospitalisations as 
those data were available to us for the ITT population.
We found no evidence of effect on hospitalisations based on seven studies with a median placebo group event 
rate of 0.84% (range 0% to 11%): odds ratio (OR) 0.95; 95% CI 0.57 to 1.61, P = 0.86). This result is quite 
different to that reported by Kaiser et al based on the (non-comparable) ITT Infected population.
In terms of power analysis, to detect a significant difference at this level of difference of 0.84% (placebo) vs 
0.80% (oseltamivir), with alpha of 0.05 and power of 0.8, a RCT with approximately 800,000 participants is 
required.
3. Complications in ambulatory patients
As we have illustrated above the Kaiser et al (2003) analysis has fundamental flaws that we cannot address 
because the manufacturer refuses to provide us with the data necessary to conduct a proper analysis.
Analysis of the "population with proven influenza infection" (ITT-infected population) is not appropriate (see 
above). Data for the analysis of "population without proven influenza infection" are not available to us.
As we have shown above, the power to detect a difference in all-cause hospitalisation is very small hence to do a 
subgroup analysis on this outcome seems unwarranted.
The pharmacological/toxicological adverse effects of oseltamivir can be classified into two major types [3]. One 
is sudden type occurring during the hypercytokinemic state in the early phase of infection including sudden 
death [3,4], accidental death after abnormal behaviours and vomiting induced by the central depressing action of 
unchanged oseltamivir [4]. The second are delayed type of reactions including recurrence or exacerbation of 
influenza and/or other infection, diabetes, bleeding, renal impairment and delayed type neuropsychiatric 
reactions related to inhibition of the host’s neuraminidase [3]. Sudden type adverse effects should be collected 
and analysed only during the early phase of influenza (for example, vomiting was only significantly increased 
within one day of treatment in the paediatric RCTs). However, delayed type adverse effects should be collected 
and analysed for a longer period to detect those reactions after a full course of treatment (for example the 
increase of pneumonia in the off-treatment period in the paediatric RCTs).
A recently published proportional mortality study has indicated that oseltamivir increases sudden type of death 
(odds ratio: 5.9) compared with zanamivir users by analysing all death cases among approximately 20 million 
2009A/H1N1 influenza patients in Japan. This effect was also true for the comparison of oseltamivir users with 
non-users of antivirals [4].
4. Data from observational studies
Observational studies during the 2009 H1N1 influenza outbreak have assessed the effects of oseltamivir on a 
selected population of hospitalised patients. These represent a very small proportion of the total population who 
get influenza. While subgroup analyses are important, it is important to not lose sight of the fact that the use and 
governmental stockpiling of oseltamivir is for its routine use in asymptomatic and symptomatic members of the 
community. Our review thus considers the evidence base that applies to the vast majority of people.
In addition, the studies Dr. Hayden appears to be referring to are retrospective observational studies in which 
apparent treatment effects may be the result of an effective treatment but could also be due to confounding 
effects. Unfortunately there is no way to determine which of these possibilities is true. That is why drug 
regulators require evidence from RCTs to determine whether or not a drug is approved for use. According to the 
analysis by Jones and Hama [5], apparent protective effects against severe outcomes like pneumonia, 
hospitalisation and mortality are possibly derived from survivor treatment selection bias (or immortal time-bias). 
This is not an issue for randomised controlled trials because follow up begins at the time of randomisation 
which is the same for patients allocated to active drug and patients allocated to placebo. However in the case of 
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observational studies treatment can begin at varying times (up to several days) after the onset of symptoms. 
Therefore a naive comparison that compares a binary outcome, such as death (or other adverse event), or time to 
an event (survival time) is at high risk of survivor treatment selection bias (also referred to as immortal time bias 
or simply time dependent bias). This bias can occur, for example, because patients who die early are not given 
the opportunity to receive treatment. In addition patients who are extremely sick may not be given the 
opportunity to receive antivirals because other treatments and procedures take priority. This bias can be 
addressed with an appropriate analysis however this has not been done in any of the observational studies of 
antiviral use for influenza that we have seen.
4. Influenza diagnosis and serologic results
We do not have access to the data required to conduct all these analyses. 
5. Other treatment endpoints of interest
We do not have access to the data required to conduct these analyses (time to resumption of usual activities and 
return to pre-morbid status) using the ITT population. 
By mentioning the evidence and possible mechanism of action for oseltamivir, we are arguing that fever 
alleviation and symptom reduction may not be caused by the reduction of viral load but may be the result of 
inhibition of host’s immune functions including induction of cytokines and antibody production by inhibition of 
the host’s neuraminidase in addition to central depression by oseltamivir.
Analysis of the population with documented influenza infection (ITT-Infected population) is not valid (see 
above). Hence we are unable to conduct a valid analysis in the influenza positive population and data for the 
influenza negative population has not been provided.
Antibody titre is one of the ways of selecting only subjects infected with influenza. However we have shown 
that the production of antibodies was consistently lower in the oseltamivir group compared to the placebo group 
in the treatment trials. Therefore the use of antibody production to confirm influenza in prophylaxis trials is not 
valid. Moreover comparison of the proportion with confirmed infection between the oseltamivir group(s) and 
the placebo group will provide misleading results.
Nor are "virus titre", "time to culture negativity" or "change in viral titres over time" a true measure of viral 
load, because oseltamivir as a neuraminidase inhibitor may conceal positivity by inhibiting the influenza virus 
from leaving the surface of host respiratory cells (which are covered by a mucous layer on the surface of the 
cells).
6. Adverse events with treatment
In principle we agree. However, there are many data that show the classification of severity is questionable: for 
example, we believe that psychosis or hallucinations should be classified as "severe" but this has not always 
been followed. Therefore, we are planning to propose using new classification methods for the analysis of 
adverse events in the next update of our review.
We agree that comparisons of adverse events in the placebo groups across zanamivir and oseltamivir studies 
need to be interpreted with caution.
We agree that the spectrum and severity of adverse events/reactions are different among age groups. Therefore, 
we propose analysing adverse events/reactions stratified by age, if possible, according to the data in the Clinical 
Study Reports or individual patients' data in the next step of our systematic review.
7. Prophylaxis endpoints of interest
As described on page 7 of our systematic review, the primary outcome measures for prophylaxis studies are:
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influenza (both symptomatic and asymptomatic and laboratory-confirmed) and influenza-like illness (ILI);
hospitalisation and complications;
interruption of transmission (in its two components, reduction of viral spread from index cases and prevention 
of onset of influenza in contacts);
harms.
We did not meta-analyse data from the prophylaxis trials in this systematic review because the substantial 
documents for prophylaxis trials were obtained after the time lock of 12 April 2011.
Due to the problems we have illustrated above on using virus titre to confirm influenza infection we plan to 
amend the primary endpoint for prophylaxis trials to influenza-like illness (ILI).
There is some fear that those with serologic negative infection without symptoms may be more easily infected 
with influenza virus in the future, because evidence from animal experiments shows that IgA antibody in the 
respiratory mucosa is reduced (to about 20% of the control group), while reduction of those of systemic IgG 
antibody (HI antibody) was slight and not statistically significant [6].
8. Adverse effects with prophylaxis
We agree that the prophylaxis studies are particularly useful in assessing drug tolerability.
As we discussed above ("7. Adverse events with treatment"), there are many data that show the classification of 
severity is questionable. For example, we believe that psychosis or hallucinations should be classified as 
"severe" but this has not always been followed. Therefore, we are planning to propose using new classification
methods for the analysis of adverse events in the next step of the review.
We mentioned the statement "occurred in similar proportions of subjects in the three groups (39 to 47 per cent)" 
as an example of reporting bias present in the paper (Dr. Hayden’s reference no. 3; known by its trial ID 
WV15673/WV15697).
The numbers for headache are 47% (242/520) in high-dose oseltamivir group, 43% (335/520) in low-dose 
oseltamivir group and 39% (202/519) in placebo group. These proportions are not similar and show a
significant linear trend of increase with oseltamivir dose (P = 0.013).
In addition, we would be grateful if Dr. Hayden were to supply the definition of "drug related headache among 
headaches reported as adverse events"? In particular, how was it decided whether a headache was drug-related 
or not? We cannot suggest signs or symptoms to distinguish oseltamivir-induced headache from placebo-
induced headache.
We propose analysing adverse events in clinical study reports, including those for prophylaxis trials.
9. Peer review
We agree that there is confusion among policy-makers and practitioners but believe this to be justified: the data 
published and accessible to them appear to have some flaws that need to be resolved. We are encouraged by Dr 
Hayden’s support for our obtaining all the data necessary to clear the confusion.
Cochrane systematic reviews are stringently peer-reviewed. Not only are they peer-reviewed by independent 
experts prior to publication but the protocols are also peer-reviewed before being undertaken, to reduce a priori 
biases. In addition, protocols are available for comment from outside the internal review process – Dr Hayden 
himself, or employees of Roche the manufacturer of oseltamivir, could have provided input about suggested 
alterations to the protocol which we would have been glad to receive. To this extent the peer-review process is 
more stringent than that employed by most other scientific journals.
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6 Additional feedback from Frederick G. Hayden, 10 August 2012
Summary 
I am writing to respond to the comments and questions raised by Jefferson and his colleagues to my letter of 2 
February 2012 about their report published through the Cochrane Collaboration. While the authors have 
provided helpful clarifications to many points, I remain concerned about their selective approach to data 
analysis and presentation. Resolution of these issues is important in anticipation of future analyses by Jefferson 
and colleagues or by others. Many of their responses indicate that analysis of the cohorts with proven influenza 
infection (ITT-infected) are not appropriate but further analyses of patient level data should be able to address 
their concerns (see below). Also they identify biases that could make oseltamivir look better but not those that 
could make it look worse than its effectiveness and tolerability likely are in reality. An impartial analysis would 
identify biases in both directions and attempt to deal with them in a balanced appraisal.
My specific comments and recommendations for additional analyses follow:
1. Use of intention to treat (ITT) and ITTI-infected groups. One obvious means of addressing the concern 
about selection bias in defining the ITT-infected (ITTI) population for analysis is to focus on those who were 
influenza virus-positive (irrespective of serologic results) at enrolment. These individuals (ITTI-virus) 
represented approximately 70-85% of those enrolled into the ITTI cohorts across the various RCTs.
In addition, those who were included in the ITTI group solely on the basis of seroconversion could be analysed 
separately to assess overall comparability in terms of symptom resolution and complications to those who were 
both virus-positive (ITTI-virus) and showed serologic rises. This might also help determine whether inclusion of 
data from virus-negative seroconverters would affect overall findings.
In contrast to the Cochrane statement that "And selection of those with "serology-positive results" appears to 
have given the advantage to the oseltamivir group", it might alternatively be disadvantageous (bias toward the 
null) or neutral in effect. If oseltamivir is most beneficial in preventing lower respiratory tract (LRT) 
complications leading to antibiotic use in those in whom it also prevents seroconversion, as one might expect if 
its overall treatment effect varies between patients based on timing of administration, individual 
pharmacokinetics or other factors, then its protective effect on complications will be underestimated because the 
benefits in those for whom it prevents seroconversion will not be counted. If, on the other hand, treatment works 
effectively only in those infected who seroconvert and has little or no effect in those in whom it prevents 
seroconversion, this would increase the apparent benefit. However, the only way in which this sequence seems 
possible would be if late treatment does not interfere with seroconversion but early treatment does AND late 
treatment is more effective than early. This is biologically implausible and inconsistent with the observed effects 
on time to treatment for other outcomes, in which early treatment is associated with greater 
effects. Alternatively, if oseltamivir treatment has a similar effect on LRT complications in infected who 
seroconvert and those who do not, this would reduce the numbers in the treated group with and without 
outcomes in a non-differential way.
In addition to a possible non-specific immunomodulatory effect of oseltamivir on serologic responses or 
possible confounding effect of prior inactivated influenza vaccine which might blunt antibody responses in 
those with proven influenza (1), one explanation for the apparently lower seroconversion rate in oseltamivir 
recipients would be that some oseltamivir recipients had low viral replication levels at enrolment that were 
quickly reduced by treatment and did not stimulate antibody rises, so that in these persons treatment prevented 
seroconversion. If one assumes that clinical outcomes are linked to viral replication levels as other reports 
suggest, such individuals would probably have shorter illness duration and also be less likely to develop LRT 
complications. Consequently, not counting them in the oseltamivir group would bias towards the null and 
under-estimate the effect of treatment on both illness resolution and complications. In this regard, comparing 
outcomes in the ITTI-virus seroconverters vs non-seroconverters would be of interest if sufficient numbers are 
available. Also, as stated previously, analysis of the serologic responses based on time from symptom onset to 
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enrolment, including both frequency of seroconversion and observed titres rises in the ITTI-virus group 
compared to placebo, might help address this possibility.
If I have interpreted their report correctly, the post-hoc analyses by Jefferson and colleagues found an absolute 
difference of 3.4% in overall infection rates between placebo (68.9%) and oseltamivir (65.5%) groups across the 
studies they analysed (Figure 5, Table 14). This difference presumably approximates the fraction of virus-
negative, non-seroconverting but possibly influenza-infected subjects in oseltamivir group. To what extent this 
difference might bias outcomes is uncertain but its relatively modest size suggests that misclassification would 
not be a major confounder in either the ITTI or ITT-non-infected groups. Optimally in future studies more 
sensitive nucleic acid amplification testing will be used to detect infection by influenza and other respiratory 
viruses and facilitate more clear delineation of the groups of interest.
In summary, further analyses of the RTCs on oseltamivir and zanamivir, the outcomes in all groups of relevance 
(ITT, ITTI, ITTI-virus, and ITT-non-infected) are important and should be presented as fully as possible. As 
stated previously, separate assessment of the ITT-non-infected group provides a valuable control and also 
enables a determination of whether there was a potential drug-disease interaction of NAI treatment in non-
influenza patients. As specific antiviral treatment would not be expected to provide benefit on illness resolution 
or complications in non-influenza illness, examining the ITT-non-infected groups allows this point to be tested 
directly. An analysis of 11 oseltamivir RCTs (2) confirmed lack of treatment effect on LRT complications in 
non-influenza-infected subjects compared to placebo. The failure to present outcomes in the ITT-infected or 
ITT-virus cohort underestimates possible beneficial drug effects, whereas full data presentation would enable 
readers to examine the event rates and magnitude of treatment effect sizes for key outcomes across all relevant 
groups for themselves.
2. Sample size considerations. The endpoint used in our pooled analysis of oseltamivir RCTs (3) was 
prospectively defined before the analysis was undertaken and was based on findings in our earlier study of 
zanamivir treatment effects (4) that indicated inhaled zanamivir reduced LRT illnesses leading to antibiotic 
prescriptions (RR, 0.60; 95% CI 0.42-0.85) but not upper respiratory tract ones (RR 0.90; 95% CI 0.63-
1.27). The oseltamivir analysis used all studies available to us at the time, including unpublished clinical study 
reports, in order to avoid selection bias. The other endpoints of upper respiratory tract complications leading to 
antibiotic use (6.8% oseltamivir vs 5.9% placebo) and overall antibiotic use (14.0% oseltamivir vs 19.1% 
placebo; P <.001) were described in our 2003 paper (page 1760). Of note, the reductions in overall antibiotic 
use in influenza outpatients were similar for zanamivir (28%) and oseltamivir (27%) treatment. The limitations 
of the clinical diagnoses and retrospective approach used in these studies were described more fully in the 
earlier zanamivir paper (4). However, the simple pooled analysis we undertook in the oseltamivir paper did not 
correct for the higher proportion of influenza-infected, at-risk individuals in the placebo group, and this was a 
shortcoming. In any case, we pointed out this difference in the paper (page 1669) and presented the data by 
each group of interest (previously healthy or at risk) in Tables 3 and 4.
More importantly, our finding that early oseltamivir treatment reduced the likelihood of physician-diagnosed 
LRT complications leading to antibiotic use has been confirmed and extended (37% reduction in oseltamivir 
group; risk ratio 0.63 [95% CI 0.48, 0.82]) in a subsequent meta-analysis (that controlled for pre-enrolment risk 
status and included events from the time of enrolment) of the same 10 RCTs included in our paper and one 
additional one (2). Furthermore, this analysis found that the unpublished trials for which Jefferson and 
colleagues apparently do not have data were found to be no more favourable to oseltamivir than the published 
ones. When only the two published trials in previously healthy persons were considered, the reduction in the 24-
day risk of LRT complications treated with antibiotics was 65% (risk ratio, 0.35; 95% CI 0.15, 0.82) in the 
oseltamivir arms.
3. Complications in ambulatory patients. Their comments on possible oseltamivir adverse events, including 
sudden death and neuropsychiatric adverse events (NPAEs), raises important points about the effects of 
influenza infection itself and possible drug-disease interactions. A well-documented relationship exists between 
NPAEs and influenza infection itself. Differing age-related patterns of influenza-associated 
encephalopathy/encephalitis and NPAEs have been reported in Japanese children and adolescents, and also age-
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related differences exist in NAI prescribing patterns in Japan. Consequently, careful analysis is required to 
assess possible associations. It is important to point out that causal relationships between oseltamivir use and 
such events remain to be proven. Some analyses have indicated comparable or lower NPAEs rates in 
oseltamivir-treated compared to non-treated influenza patients (reviewed in (5)) and no higher rates of NPAEs 
have been found in hospitalised infants in the USA (6). Oseltamivir administration to those with influenza-
associated NPAEs does not appear to worsen manifestations (7;8). Of note, the crude reporting rates for 
possible oseltamivir-associated NPAEs in Japan and USA were significantly lower during the 2009 pandemic 
than during preceding influenza seasons (9). 
As pointed out by Jefferson and colleagues, the possibility of late-onset adverse events requires that sufficient 
follow-up be incorporated into study design to examine both possible adverse and beneficial effects. However, 
the low frequencies of such events would likely require much larger numbers of subjects than enrolled in most 
RCTs. One approach is retrospective examination of large databases that link healthcare visits, clinical 
diagnoses, and drug administration registries. For example, one cohort study involving over 150,000 subjects 
(49,238 oseltamivir recipients, 102,692 control patients) reported that oseltamivir treatment of presumed 
influenza was associated with lower risk of TIA or stroke in the subsequent six months (10). This kind of 
observational study approach has been undertaken for investigation of outcomes and possible adverse events 
following influenza immunisation and should also be extended to antivirals.
4. Data from observational studies. Jefferson and colleagues indicate that possible survivor treatment 
selection bias in observational studies can occur because patients who die early are not given the opportunity to 
receive treatment. However, there is also the opposite concern that sicker patients, especially in a rapidly 
evolving illness like influenza, are more likely to initiate therapy at any given time after symptom onset than 
less ill ones. This would be a conservative bias and reduce the likelihood of observing a treatment 
effect. Clinical experience during the 2009 H1N1 pandemic indicated that late NAI treatment in critically ill or 
non-surviving influenza patients was frequently due to delayed consideration of the diagnosis or failure to 
appreciate the potential value of starting treatment beyond two days after symptom onset in those with 
progressive illness or high-risk conditions. This occurred often despite some of these patients having had prior 
outpatient contact for their acute illness. Although the published reports indicate that most critically ill patients 
ultimately received antiviral therapy, delayed treatment commonly led to initiation of NAI administration as part 
of a salvage effort in a deteriorating patient. In part because of critical care support, even those patients who 
died in hospital usually survived into the second week of illness or later. Those analysing the large amount of 
observational data that has been generated in recent years, particularly in the context of the 2009 H1N1 
pandemic, need to keep these clinical observations in mind. Of note, a recent analysis of critically ill pandemic 
H1N1 patients in California compared mortality in untreated patients who survived at least to the day after 
symptom onset when NAIs were first given to the NAI-treated ones and found that cases who received NAI up 
to 4 days after symptom onset were more likely to survive (P < 0.05 for each day 0-4) (11).
An independent report on the observational studies of influenza antivirals published up to November 2010 (12) 
conducted a meta-analyses of the few studies providing effects adjusted for confounders and, while 
acknowledging the low quality of the evidence based on the GRADE assessment approach, concluded that in 
high-risk populations, oral oseltamivir may reduce mortality (odds ratio, 0.23 [95% CI 0.13 to 0.43]) and 
hospitalisation (odds ratio, 0.75 [95% CI 0.66 to 0.89]). In addition, as reported in multiple studies of 
hospitalised pandemic 2009 A(H1N1) patients, including high-risk ones like pregnant women and those 
admitted with pneumonia, treatment with oseltamivir up to 4 days and in some studies later after illness onset 
has been associated consistently with better outcomes (11;13-21). Such observations have served to reinforce 
US CDC recommendations for using influenza antivirals as early as possible in those with severe or progressive 
illness, those hospitalised with suspected or proven influenza, and outpatients at higher risk for influenza 
complications (22). Furthermore, given that the circulating influenza viruses have continued to change, with the 
pre-2009 A(H1N1) seasonal viruses being entirely replaced by A(H1N1)pdm09 and now antigenically drifted 
A(H3N2) and B viruses, ignoring observational data means that only information concerning NAI treatment for 
influenza viruses that are now no longer circulating is being considered.
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5. Other treatment endpoints of interest. The possibility that oseltamivir might have non-specific antipyretic 
or immunomodulatory actions unrelated to its antiviral effects has been raised in part on the basis of murine 
studies (23;24). These possibilities or other symptom- modifying effects could be addressed by comparison of 
the course of fever and individual symptom resolution between oseltamivir and placebo recipients for those 
enrolled in the RTCs who did not have laboratory evidence for influenza (ITT-non-infected). Of note, 
antipyretics were provided to participants in these trials, so that use of paracetamol (acetaminophen) needs to be 
included as a confounder in such analyses.
In the published pivotal RCTs of oseltamivir treatment in adults, the fever and symptom reductions observed in 
oseltamivir recipients were in addition to the effects of paracetamol (acetaminophen). One previous RCT in 
adults with uncomplicated influenza compared amantadine to aspirin and found faster fever resolution in aspirin 
recipients but slower resolution of other symptoms and higher rates of adverse effects leading to drug cessation 
(25). While fever resolution is an objective endpoint of interest, it is generally short-lived and of limited clinical 
importance relative to other endpoints like time to symptom alleviation, time to return to usual 
activities/premorbid status, and complications reductions. 
The comment by Jefferson and colleagues on measuring viral loads is confusing. Virologic endpoints like 
quantitative virus titres (infectious and in recent studies viral RNA), time to culture negativity, and changes in 
titres over time are essential to determining whether a putative influenza antiviral treatment is exerting an 
antiviral effect and the magnitude of that effect. Failure to detect an antiviral effect raises questions about issues 
like compliance, drug absorption and disposition, lack of potency, and resistance emergence. Examining such 
virologic measures also serves to confirm the likely mechanism of antiviral action of NAIs, inhibiting release 
from infected cells and spread in respiratory tract secretions to initiate subsequent rounds of replication. Several 
observational studies during the 2009 pandemic found that early antiviral treatment (<2-3 days from symptom 
onset) was associated with reduced duration of viral RNA detection (26-28). Consequently, in the context of the 
oseltamivir RCTs, it would be valuable to examine the correspondence between upper respiratory tract influenza 
virologic measures and symptom resolution and LRT complications in both oseltamivir and placebo groups.
7. Prophylaxis endpoints of interest. As indicated in my initial letter, the key efficacy endpoint for an 
influenza antiviral used for prophylaxis should be symptomatic, laboratory-confirmed influenza illness. Given 
the potential for other respiratory viruses to cause febrile respiratory illness, a focus on ILI as the primary 
endpoint will inevitably underestimate the protective effects of an influenza-specific chemoprophylactic agent. 
Of note, various definitions of symptomatic illness and ILI have been used in the influenza prophylaxis RCTs to 
date, so that further analyses using standardised definitions would be a helpful contribution. Other secondary 
endpoints of interest include laboratory documented infection (irrespective of symptoms), ILI, virus-positive 
ILI, and laboratory-confirmed illnesses not meeting the ILI definition. Laboratory confirmation based on both 
viral culture and in future studies viral RNA detection would take advantage of the greater sensitivity of RNA
detection.
8. Adverse effects with prophylaxis. As detailed in the oseltamivir seasonal prophylaxis study protocols and 
report, the relationship between drug receipt and adverse events, including headache, in these trials (29) was 
determined by the study staff and investigators during the trial under blinded conditions before data lock. The 
assessment of causality in adverse events (unrelated, remote, possible, probable) as related to drug 
administration was made using pre-specified criteria in the protocol (see Appendix 1) on an individual basis by 
both interviewing the affected participant and considering various factors including past patterns of headaches, 
associated symptoms, duration and severity, timing in relation to study drug, and whether the symptom persisted 
during drug administration. Because of its background frequency in the population, headache is a very common 
event in longer term studies. When it is mild or transient despite continued drug administration, or when it 
occurs in context of other events (URI, trauma, stress), headache is unlikely to be drug-related. Using these 
criteria and the analysis report provided by the sponsor Roche, we observed headache (not otherwise specified, 
NOS) that was probably, possibly, or remotely related to study drug administration in 22.4% of placebo, 23.8% 
of once daily oseltamivir, and 25.4% of twice daily oseltamivir recipients during the 6 weeks of prophylaxis 
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(29). The proportions were 10.2%, 8.7%, and 10.8%, respectively, for headache (NOS) that was possibly or 
probably related to study drug administration.
Headache is a good example of where it is essential to examine not only the frequencies of reported adverse 
events but also their severity and functional impact, including premature cessation of study drug. In our 6-week 
prophylaxis trial (29), severe headache (NOS) irrespective of relationship to study drug administration was 
reported in 5.0% of placebo, 3.3% of once daily oseltamivir, and 6.9% of twice daily oseltamivir, respectively. 
Overall premature study withdrawals were found in 21 (4.4%) of placebo, 17 (3.3%) of once daily oseltamivir, 
and 16 (3.1%) of twice daily oseltamivir recipients. In three placebo but no oseltamivir recipients, headache was 
listed as a contributory factor. However, headache was reported to be a factor leading to cessation of oseltamivir 
prophylaxis in one subject in another prophylaxis study (30) and was also reported at a higher frequency during 
6-weeks prophylaxis in a nursing home-based RCT (5.5% placebo vs 8.3% oseltamivir)(31), so that further 
analyses are warranted.
9. Peer review. I thank Jefferson and his colleagues for their clarifications on the Cochrane peer review 
process, and as indicated above, I have provided my own suggestions on the design of future analyses by them 
and others. In addition, I have provided a list to the Cochrane Editorial Unit of several dozen potential expert 
reviewers for future protocols and reports on influenza antivirals.
Thank you for the opportunity to provide these responses and comments.
Sincerely,
Frederick G. Hayden, M.D.
Richardson Professor of Clinical Virology
Professor of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia, USA
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Appendix 1 Definition of Adverse Event Relationship to Treatment
Probable
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This category applies to those adverse events which are considered, with a high degree of certainty, to be 
related to the test drug. An adverse event may be considered probable if:
1. It follows a reasonable temporal sequence from administration of the study drug.
2. It cannot be reasonably explained by the known characteristics of the subject’s clinical state, environmental 
or toxic factors, or other modes of therapy administered to the subject.
3. It disappears or decreases on cessation or reduction of dose. (There are important exceptions when an 
adverse event does not disappear upon discontinuation of the drug, yet drug- relatedness clearly exists; e.g., (1) 
bone marrow depression, (2) tardive dyskinesias).
4. It follows a known pattern of response to the study drug.
5. It reappears upon re-challenge.
Possible
This category applies to those adverse events in which the connection with the test drug administration appears 
unlikely but cannot be ruled out with certainty. An adverse event may be considered possible if or when:
1. It follows a reasonable temporal sequence from the administration of study drug.
2. It may have been produced by the subject’s clinical state, environmental or toxic factors, or other modes of 
therapy administered to the subject.
3. It follows a known pattern of response to the study drug.
Remote
In general, this category is applicable to an adverse event which meets the following criteria:
1. It does not follow a reasonable temporal sequence from administration of the study drug.
2. It may readily have been produced by the subject’s clinical state, environmental or toxic factors, or other 
modes of therapy administered to the subject.
3. It does not follow a known pattern of response to the study drug.
4. It does not reappear or worsen when the drug is re-administered.
Unrelated
This category is applicable to those adverse events which are judged to be clearly and incontrovertibly due only 
to extraneous causes (disease, environment, etc.) and do not meet the criteria for drug relationship listed under 
remote, possible, or probable.
Probable Possible Remote Unrelated
Clearly due to extraneous causes - - - +
Reasonable temporal association with drug administration + + - -
May be produced by subjects clinical state - + + +
Known response pattern to suspected drug + + - -
Disappears or decreases on cessation or reduction in dose + - - -
Reappears on re-challenge + - - -
Reply 
Reply to Hayden Letter 10 August 2012
Thank you for taking the trouble to provide further feedback to our responses to your first set of feedback 
comments.
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You remain concerned about 1) "…selective approach to data analysis and presentation…", especially with 
respect to our concern that ITT-infected (ITTI) criteria are inappropriate; and 2) our identification of biases that 
may exaggerate the effectiveness of oseltamivir. You detail these concerns in more detail:
1. ITT and ITTI
You propose an analysis of ITTI in which patients are categorised not by an immune response (which we regard 
as potentially flawed because our interpretation of the data suggests the drug may interfere with the immune 
response) but instead by determining whether patients were seroconverting excreting influenza virus at 
enrolment.
This sounds sensible, and were the data of symptoms and baseline infectivity (by serology or even virus 
shedding) available to us in suitable format, we would include this analysis. By this, we would expect the 
randomisation of patients into the two groups to be independent of the initiation of the drug (that is the 
"influenza-positive" or "-negative") before the drug was administered, in case (as may be with the immune 
response) the drug interferes with virus excretion (as the manufacturer claims in some of its literature).
You also propose an analysis of those grouped by ITTI from serological conversion with those grouped by virus 
excretion. This also would be useful, to determine whether or not a bias exists in the current data (in either 
direction, as you point out – the possible mechanisms you outline are plausible).
However, your hypothesis "If oseltamivir is most beneficial in preventing lower respiratory tract (LRT) 
complications" IS one of the main issues to be confirmed.
As already described in our review, you reported a reduction of cytokine production in response to influenza 
infection by oseltamivir in humans:
Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase 
inhibitor oseltamivir to prevent influenza. New England Journal of Medicine 1999;341(18):1336-43
These findings suggest that reduction of antibody production cannot simply be assumed to be the result of 
reduced viral load.
2. Sample sizes
You describe in more detail the Kaiser 2003 pooled analysis of complications:
Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related 
lower respiratory tract complications and hospitalisations. Arch Intern Med 2003;163:1667-72
This was central to the start of our unease, after it was pointed out to us (in this Feedback section!) by Hayashi 
that over half of the data in it were of unpublished trials. You state that the end-points were established a priori 
and not post hoc. You admit to shortcomings of the paper but point out that they were declared in the paper 
itself. You suggest that because the two published trials meta-analysed had no more favourable drug results than 
the unpublished, bias is less likely.
We think this is to misunderstand our central concern: we are unable to critically appraise the trials in the usual 
way because they are not available to us, nor, apparently, any other group unselected by the manufacturer. 
Incidentally we note that you yourself, even as an author, admit you were unable to locate the data for this paper 
on request, referring us instead to the sponsoring manufacturer, Roche:
Cohen D. Complications: tracking down the data on oseltamivir. BMJ 2009;339:b5387.
This inability by you (authors) or sponsoring manufacturer to provide data for independent scrutiny is 
disgraceful, a view shared by others, http://bmj.com/tamiflu.
3. Adverse effects of NIs
We find it interesting that you call these adverse events 'complications'. You point to our concerns about 
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neuropsychiatric adverse events (NPAEs), and (correctly) state that any association recorded in the literature 
"…remains to be proven…" with some references (all were retrospective studies and mostly sponsored by the 
manufacturer) that suggest that there is no increase over control groups. We have other references suggesting the 
opposite:
Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal 
relationship. Int J Risk Safety Med: 20 (2008): 5-36: http://npojip.org/english/no11.html
Nakamura K, Schwartz BS, Lindegårdh N, Keh C, Guglielmo BJ. Possible neuropsychiatric reaction to high-
dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis. 2010 Apr 1;50:e47-9.
Kruker AT, Krause M. ["Oseltamivir-induced delirium"]. Ther Umsch. 2010 Dec;67(12):613-5. German.
Chung S, Joung YS. Oseltamivir (Tamiflu) induced depressive episode in a female adolescent. Psychiatry 
Investig. 2010 Dec;7(4):302-4. Epub 2010 Nov 11.
The following are prospective cohort studies that aimed to analyse the association of NPAEs and administration 
of NIs, in particular oseltamivir.
Fujiwara F, Ikushima S, Hibi N et al. An analysis of risk factors of abnormal behavior in two seasons (07, 08) of 
influenza infection. Presentation at the 40th annual meeting of the Japanese Society for Paediatric Infectious 
Diseases held on 15 and 16 (2008)
Fujita T, Fujii Y, Watanabe Y, Mori M, Yokota S. A pharmacoepidemiological study on the relationship 
between neuropsychiatric symptoms and therapeutic drugs after influenza infection. Jap J Pharmacoepidemiol 
2010; 15: 73-92.
This preliminary report on the analysis of randomised controlled trials of oseltamivir for prophylaxis contains 
our response to Roche’s report discussing NPAEs and oseltamivir:
Jones M, Hama R, Jefferson T, Doshi P. Neuropsychiatric adverse events and oseltamivir for prophylaxis 
(letter). Drug Safety, 2012, 35 (12): 1187-90.
A proportional mortality study indicates that oseltamivir increases sudden death (odds ratio: 5.9) compared with 
zanamivir users in an analysis of all deaths among ~ 20 million 2009A/H1N1 influenza patients in Japan. This 
effect is also observed for the comparison of oseltamivir users with non-users.
Hama R, Jones M, Okushima H, Kitao M, Noda N, Hayashi K, Sakaguchi K. Oseltamivir and early 
deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza. Int J Risk Saf Med. 
2011;23(4):201-15. http://iospress.metapress.com/content/5257410g24403m68/fulltext.pdf
We have presented many of these studies in our previous reply to you, without response.
Of course the uncertainty about causation is true for many drug adverse events: our duty is to ensure that any 
such uncertainty is clearly articulated.
Nevertheless we entirely agree that "…observational studies … undertaken for investigation of outcomes and
possible adverse events following influenza immunisation … should also be extended to antivirals." However, 
because this Cochrane review is limited to randomised data, such observational studies would be conducted 
outside this particular review.
4. Observational data
You point to our concerns about observational data in general for answering intervention questions. We 
acknowledge the plethora of observational data available, and even the meta-analysis of some of them. This 
does not detract from our continued concern that the best data for answering these questions are randomised, 
and to leave most of these data unavailable for independent scrutiny is unforgivable.
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Moreover, the observational studies are regarded as poor in quality. A recent systematic review and meta-
analysis of observational data for antivirals for the treatment of influenza concluded, "…therapy with oral 
oseltamivir and inhaled zanamivir may provide a net benefit over no treatment of influenza. However the 
confidence in the estimates of the effects for decision making is low to very low."
Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al. Ann Intern Med. 2012 Apr 3;156(7):512-
24. doi: 10.1059/0003-4819-156-7-201204030-00411. Epub 2012 Feb 27. Antivirals for treatment of influenza: 
a systematic review and meta-analysis of observational studies
Incidentally, we are interested in rigorously meta-analysing these data ourselves, and have put in a protocol to 
do just that. (Jones M, Hama R. Effect of oseltamivir on mortality in treatment of 2009A/H1N1 influenza 
patients. PROSPERO 2012:CRD42012002245. Available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002245
The proportional mortality study (above), analysing all influenza deaths in Japan and estimating populations 
who took antivirals and did not take them as the denominators, provides far more reliable estimates of risk from 
drug exposures than retrospective analysis of surveillance cases without exposed populations (denominators). 
Contrary to your suggestion "…there is also the opposite concern that sicker patients, especially in a rapidly 
evolving illness like influenza, are more likely to initiate therapy at any given time after symptom onset than 
less ill ones…", no such tendency was detected in this study. Proportions of patients treated with antivirals 
within 12 hours from the onset of fever were significantly lower in the "not mild" cases (26.5%) than "mild" 
cases (35.4%) at the time when antiviral was prescribed [Table 2b]. However, no patients who deteriorated 
before the first presentation at medical facilities were treated with antivirals before deterioration [Table 2a], 
while 78% of "mild" cases and 55% of "not mild" cases were prescribed antivirals within 48 hours from onset of 
fever [Tables 2a and 2b]. These may be related to the lower positive results (45%) of rapid testing for influenza 
virus in the "not mild" cases than that in the "mild" cases (60%) at the first consultation:
Hama R, Jones M, Okushima H, Kitao M, Noda N, Hayashi K, Sakaguchi K. Oseltamivir and early 
deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza. Int J Risk Saf Med. 
2011;23(4):201-15. http://iospress.metapress.com/content/5257410g24403m68/fulltext.pdf
5. Other treatment endpoints of interest
Does oseltamivir have non-specific antipyretic or immune-modulatory actions unrelated to its antiviral effect?
We have already noted the hypothermic and immune-suppression effect of oseltamivir in humans, some from 
your own writing.
Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal 
relationship. Int J Risk Safety Med 2008:20:5-36
Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor 
oseltamivir in experimental human influenza: randomised controlled trials for prevention and treatment. JAMA 
1999;282:1240-6.
Your suggestion that antipyretic actions of oseltamivir be tested by comparing those randomised to oseltamivir 
against those not in the non-ITTI group is worth consideration (although the results might be difficult to 
interpret). Again, as mentioned above, it would be good to have access to sufficient data to allow this analysis 
and others we have outlined in the protocol.
We note your criticism about over-focusing on fever as a proxy for symptom resolution. We are of course 
interested in any good measure of the latter that is not only objective but also common to all trials. Nevertheless, 
despite your criticism, fever is a reasonable marker of 'illness' from infections such as influenza, and probably 
correlates reasonably well with symptom resolution (especially in the prophylaxis trials) and in the treatment 
trials (if fever is measured until complete resolution) – it is, after all, a cardinal symptom – and has the great 
advantage of being clearly measured.
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You suggest that we test whether viral excretion correlates with symptoms of influenza. We agree that this 
would be an interesting analysis, were the data available to us (see above).
7. (Note there was no Point 6) Should we be focusing so much on influenza-like illness (ILI)?
Of course, if oseltamivir neither reduces antibody production to influenza virus nor conceals testing positivity, 
selecting only laboratory-confirmed influenza might be a reasonable end point for prophylaxis trials. However 
the facts suggest these cannot be assumed. 
In any case, the Cochrane Collaboration is dedicated to finding the best available evidence to enable patients 
and their clinicians to make best-informed decisions. To that end, ILI is what the vast majority of clinicians and 
their patients will be facing. Therefore this is an end-point of direct relevance to them, and we make no apology 
for including it.
8. Adverse events in prophylactic trials
Thanks for this detailed information. Further analyses are indeed what we would like to undertake according to 
our protocol.
9. Peer review
Thanks for offering a list of your own colleagues to act as peer reviewers. We adhere to the principle of ensuring 
there is methodological expertise as well as content expertise. Your list will be useful to consider when finding 
peer reviewers.
As you may be aware, because this particular Review Group (Acute Respiratory Infections) has its Co-
ordinating Editor as an Author on this review, the handling of the manuscript is managed by the Central 
Editorial Unit to minimise any potential conflict of interest.
Contributors 
Chris Del Mar, Tom Jefferson, Rokuro Hama, Mark Jones, Peter Doshi, Carl Heneghan, Matthew Thomson.
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
230
7 Feedback from Adam Jacobs, 13 February 2013
Summary 
Comment: The selection criteria in the review seem highly unusual. The authors describe a 2-stage process for 
including trials.
In the first stage, they require that the trial reports they analyse have "external consistency". As far as I can tell, 
this means that they must be able to verify the contents of the report from an external source.
This seems an extraordinarily high bar to set. I am not aware that it is part of standard Cochrane methodology. If 
it were applied across Cochrane reviews more generally, I imagine that very few Cochrane reviews would 
include any evidence at all, especially given that most Cochrane reviews are done perfectly happily with 
published papers, whereas this one had the advantage of clinical study reports, which are generally far more 
reliable and comprehensive than published papers.
It is almost as if the authors have gone out of their way to exclude the evidence, which does not help to answer 
important questions about the efficacy of neuraminidase inhibitors.
It is also noteworthy that no specific reasons were given for exclusion of studies from stage I of the process: we 
are only told that "insufficient information was available". In the interests of transparency, it would be better to 
know specifically what information was lacking.
May I suggest that the authors either explain the reason why they felt the need to use far stricter inclusion 
criteria than is normal in Cochrane reviews, or revisit their inclusion criteria so that the studies can be analysed.
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in 
the subject matter of my feedback.
Adam Jacobs, Director, Dianthus Medical Limited
Reply 
Adam Jacobs writes:
"The selection criteria in the review seem highly unusual. The authors describe a 2-stage process for including 
trials. In the first stage, they require that the trial reports they analyse have "external consistency". As far as I 
can tell, this means that they must be able to verify the contents of the report from an external source."
At page 11 of the review we provide the definition: "External consistency. Consistency of data as reported in 
regulatory documents, other versions of the same clinical study reports/unpublished reports and other references, 
to be established by cross-checking"
"This seems an extraordinarily high bar to set. I am not aware that it is part of standard Cochrane 
methodology. If it were applied across Cochrane reviews more generally, I imagine that very few Cochrane 
reviews would include any evidence at all, especially given that most Cochrane reviews are done perfectly 
happily with published papers, whereas this one had the advantage of clinical study reports, which are 
generally far more reliable and comprehensive than published papers".
And
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"May I suggest that the authors either explain the reason why they felt the need to use far stricter inclusion 
criteria than is normal in Cochrane reviews, or revisit their inclusion criteria so that the studies can be 
analysed."
Our review is the first systematic review that we are aware of to be completely based on regulatory 
information. As our basic element of data synthesis was different, we had to develop new methods which we did 
transparently and are described in the review. It was a fact that we had received partial clinical study reports for 
the same trials from both Roche and EMA. We felt the need to ensure these reports were consistent. Whether 
our methods were an "extraordinarily high bar" or a reasonable bar or too low a bar is a judgement readers can 
make for themselves.
The background history which informed our methodology is explained in the review itself. At pages 4 and 5 of 
the review we write:
"In 2009, a reader posted a comment in response to the (then current) 2006 version of this review (Jefferson 
2006). He pointed out that the review had endorsed the claim regarding a reduction in complications based on 
the uncritical inclusion of the Kaiser meta-analysis (Doshi 2009). The reader pointed out that only two of the 10 
’Kaiser trials’ had been published (Nicholson 2000; Treanor 2000) and the information provided by the Kaiser 
text about the remaining eight was insufficient for their appraisal. Our subsequent efforts to retrieve and review 
the eight unpublished trials (representing 2691 patients) were unsuccessful, raising the possibility that the 
findings of our previous review were not an accurate estimate of the benefits and safety of the drug. In addition, 
we found clear evidence of possible publication bias (see below) amid concern that some evaluations have not 
been available to scrutiny by the scientific community (Cohen 2009; Doshi 2009; Freemantle 2009; Godlee
2009)."
"This review is focused on healthy adults and children. It represents the amalgamation of two long-standing 
Cochrane reviews on the effects of NIs for influenza in healthy adults (Jefferson 2010a, also published as 
Jefferson 2009a) and children (Matheson 2007). The reviews were combined to pool our collective expertise 
and time in extracting and assessing data from clinical study reports, which in the case of some oseltamivir 
trials, report both adult and paediatric outcomes. Cochrane reviews of NIs in both children and adults generated 
intense interest from clinicians and media during the influenza outbreak declared a pandemic by the WHO in 
2009. The Cochrane review of NIs in healthy adults highlighted the high risk of publication bias (Jefferson
2010a). In 2009, a reader posted a comment in response to the (then current) 2006 version of this review 
(Jefferson 2006). He pointed out that the review had endorsed the claim regarding a reduction in complications 
based on the uncritical inclusion of the Kaiser meta-analysis (Doshi 2009). The reader pointed out that only two 
of the 10 'Kaiser trials' had been published (Nicholson 2000; Treanor 2000) and the information provided by the 
Kaiser text about the remaining eight was insufficient for their appraisal. Our subsequent efforts to retrieve and 
review the eight unpublished trials (representing 2691 patients) were unsuccessful, raising the possibility that 
the findings of our previous review were not an accurate estimate of the benefits and safety of the drug. In 
addition, we found clear evidence of possible publication bias (see below) amid concern that some evaluations 
have not been available to scrutiny by the scientific community (Cohen 2009; Doshi 2009; Freemantle 2009; 
Godlee 2009).
Our attempts to reconcile published and unpublished evidence by contacting the manufacturer and study authors 
failed (the latter were unable to provide us with the necessary data; some were not in possession of the data and 
others may have been restricted by confidentiality agreements). Together with the British Medical Journal 
(BMJ)we ascertained that ghostwriters had been involved, which means the named authors may not have been 
in full control of the trial publications (Cohen 2009). We also identified several key differences in licensed 
indications for oseltamivir between regulatory systems (mainly between the US, Europe and Japan) and under-
reporting of harms. The differences are detailed elsewhere (Doshi 2009) but of particular concern was the 
insistence of the FDA that oseltamivir has not been shown to reduce complications (FDA 2011a). The FDA has 
also not allowed an indication for interference of viral transmission within households (the key concept behind 
post-exposure prophylaxis). This undermined our confidence in published data and in the findings of our 
previous Cochrane reviews. In the background of all this were suggestions that NIs may not be as safe as 
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
232
previously assumed, with associations between oseltamivir use and neuropsychiatric adverse reactions of 
particular concern (Hama 2008)."
Adam Jacobs writes:
"It is almost as if the authors have gone out of their way to exclude the evidence, which does not help to answer 
important questions about the efficacy of neuraminidase inhibitors."
A page 5 of the review we write:
"During the preparation of the 2010 review and of the current review, we realised that there were multiple 
sources and different levels of granularity of clinical trial data (see 'The Scope of Clinical Trial Data' table in 
Jefferson 2011). We decided that clinical study reports and regulatory comments were likely to provide the least 
biased, most complete and most insightful set of data for our review".
And
"We identified that 60% (3145/5267) of patient data from randomised, placebo-controlled phase III treatment 
trials of oseltamivir have never been published. This includes M76001, the biggest treatment trial ever 
undertaken on oseltamivir (with just over 1400 people of all ages). Exclusion of unpublished data changed our 
previous findings regarding oseltamivir's ability to reduce complications of influenza (Doshi 2009; Jefferson 
2009a)."
Our attempts at identifying and retrieving all available evidence from regulators and manufacturers since 2009 
are documented at http://bmj.com/tamiflu.
Adam Jacobs writes:
"It is also noteworthy that no specific reasons were given for exclusion of studies from stage I of the process: we 
are only told that "insufficient information was available". In the interests of transparency, it would be better to 
know specifically what information was lacking."
In Table 9 (page 186) we list all studies included in Stage 1 and report details of what data for each were 
available to us. For, example for trial MV22940 we know that it is likely to be a randomised trial assessing 
effects of oseltamivir on post exposure prophylaxis but no other data are available to us. In these circumstances 
we cannot proceed to assessment until the information is available, as explained in the text of the review. 
However these studies are not excluded but are marked as pending assessment.
We invite Adam Jacobs to read the review and the references which document the history of the review, 
background and rationale for withdrawing the original review and developing the current version. We also invite 
Mr Jacobs to clarify what business relation his firm has if any with Roche, GSK and BioCryst Ltd.
It is possible that future Cochrane reviews will include an increasing proportion of regulatory information to 
minimize the effects of reporting bias. This type of speculation is however beyond the scope of the review.
Contributors 
Cochrane Neuraminidase Inhibitors Review Team, 5 March 2013
Prof Chris Del Mar, Coordinating Editor, Acute Respiratory Infections Cochrane Review Group, Australia
Dr Peter Doshi, Postdoctoral Fellow, Johns Hopkins University, USA
Dr Rokuro Hama, Physician, Pharmaco-epidemiologist, Japan Institute of Pharmaco-vigilance, University of 
Osaka, Japan
Dr Carl Heneghan, Clinical Reader, Department of Primary Care Health Sciences, University of Oxford, UK
Dr Tom Jefferson, Epidemiologist, Acute Respiratory Infections Cochrane Review Group, Italy
Dr Mark Jones, Statistician, University of Queensland, Australia
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Dr Matthew Thompson, Clinical Reader, Department of Primary Care Health Sciences, University of Oxford, 
UK
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8 Feedback from Harri Hemilä, 06 May 2013   
Summary   
Comment: Oseltamivir (Tamiflu) shortens the duration of influenza-like illness by 13% (95% CI 8% to 18%)  
In studies measuring dichotomous outcomes, relative risk (RR) is a standard measure for comparing study 
groups. The purpose of using RR is to adjust for baseline variability in the occurrence of disease. It is easier to 
compare two trials on the basis of their RR estimates than on the basis of their absolute effects. 
The relative effect should also be calculated for continuous outcomes. Although the duration of disease may 
vary randomly in placebo groups, there are also biological reasons why diseases in different placebo groups 
differ in their severity and duration. For example, in Analysis 1.1 of this review, the duration of influenza-like 
illness in the placebo group of trial WV15671 is 35% shorter than in the placebo group of trial 
WV15819/WV15876/WV15978 (Z = 6.5; P = <0.00001; 125h/192h). Such very large baseline differences are 
not explained by chance. Differences in the study populations, influenza seasons, study protocols, etc. are 
plausible explanations for the baseline variation. The above-mentioned baseline difference is much greater than 
any of those between the oseltamivir (Tamiflu) and placebo groups in the five trials of Analysis 1.1. As for 
dichotomous outcomes, the baseline variability of continuous outcomes can be adjusted for by calculating the 
effect in percentages, i.e., the relative effect. Furthermore, the percentage effect is informative for an average 
reader because the reader may form an opinion on whether, for example, a 10% or 20% average decrease in the 
duration is worth the cost and effort of the treatment. Separate from the absolute effect in days, the percentage 
effect shows whether the effect is small or large. 
Therefore the effect of oseltamivir should be calculated also as a percentage effect. I calculated the relative 
effects for the five trials listed in Analysis 1.1, pooled them using the fixed effect inverse variance method of 
RevMan, and found that the average effect of oseltamivir is a 13% (95% CI 8 to 18%) decrease in the duration 
of influenza-like illness. 
Furthermore, the relative effect estimate makes it possible to compare the effects of treatments for related 
conditions. Influenza-like illness has substantial overlap with the common cold. In our Cochrane review on 
vitamin C and the common cold we calculated that ≥1 g/day of vitamin C shortens colds in adults by 8% (95% 
CI 4 to 12%) and in children by 18% (95% CI 9 to 27%) [1]. Another meta-analysis found that a high dose of 
zinc (>75 mg/day) as zinc acetate lozenges decreased the duration of colds by 42% (95% CI 35 to 48%) and as 
zinc lozenges made with other salts by 20% (95% CI 12 to 28%)[2]. The mechanism of the effect of vitamin C 
and zinc lozenges is not understood; however, there is no reason to assume that their effects are specific, for 
example, to the rhinovirus. If vitamin C and zinc lozenges have effects on diverse respiratory viruses, they 
might also have an effect on influenza viruses. In mice, influenza infection decreased vitamin C concentration in 
bronchoalveolar lavage fluid [3]. In mice, vitamin C deficiency increased lung pathology caused by influenza 
infection [4]. An early study with influenza patients reported that the occurrence of pneumonia was 80% lower 
(2 vs. 10 cases) in the vitamin C group, suggesting that vitamin C might also have an effect on influenza in 
humans [5,6]. If the effects of vitamin C and zinc lozenges on influenza-like illness are of the same magnitude 
as their effects on the common cold, then the effects of these treatments compare reasonably with oseltamivir. 
The comparison of the percentage effects of oseltamivir, vitamin C and zinc lozenges may be useful when 
considering how future research resources concerning the treatment of respiratory virus infections might be 
allocated. In this respect, the type of effect measure has a much wider importance than just its use in evaluating 
the effectiveness of oseltamivir as an issue of its own. 
Thus the relative effect estimate adjusts for baseline variations between trials, it is informative for most readers 
because people are familiar with percentages, and it makes it easier to compare different treatments for related 
conditions. For these reasons I would like to encourage the authors to calculate and report the relative effect 
estimates for oseltamivir in the next revision of the review. 
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Reply 
Thank you for your suggestion and comprehensive argument why you think it is important. Indeed in our 2006 
and 2009 updates of A047 (the previous review on antivirals for influenza in otherwise healthy adults), we 
pooled hazard ratios and reported relative effects for time to alleviation of symptoms. However GSK, the 
manufacturer of zanamivir, made the comment that hazard ratios may not be appropriate due to non-
proportional hazards. Therefore for A159 we reported absolute treatment effects for time to alleviation of 
symptoms but not relative effects. We agree with your argument and will report absolute and relative effects for 
time to alleviation of symptoms and other outcomes in the next update of 'Neuraminidase inhibitors for 
preventing and treating influenza in healthy adults and children' due at the end of 2013.
Contributors 
Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ
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9 Review amendments, 16 May 2013 
Summary 
As reported in the current version of our review, we will complete the review of regulatory information which 
arrived after our original time lock. We will assess additional evidence from oseltamivir Module 2s, evidence on 
adverse events following exposure to neuraminidase inhibitors (NIs) and clinically relevant outcomes.
A rationale and description of our methods follows.
Evidence from Module 2s (Ms2) of oseltamivir trials
1. Summary and background 
This part of the document will describe our efforts to determine whether the additional information included 
within Module 2s (Ms2) of clinical study reports (CSRs) would change the risk of bias assessment, identify 
additional useful or relevant information, and conclusions of the overall body of evidence contained within our 
existing review. A second aim is to construct and test a tool that could be used to extract, organise and appraise 
study information contained in such modules.
The items which are most commonly found in the M2 of the oseltamivir trials are: Certificates of Analysis (a 
report on the colour, composition and content of active and control substance capsules, blank Case Report 
Forms (case notes for each participant), follow-up cards/diary cards (on which each participant recorded 
information such as symptoms), informed consent text and participant contract (to be administered to and signed 
by each participant), lists of investigators in the trial, investigation review board, ethics committees and study 
sites' addresses, the Reporting Analysis Plan (Roche's term for the Statistical Analysis Plan or SAP detailing the 
types of data analyses to be carried out), randomisation list (used to allocate participants and the study Protocol 
with its amendments when appropriate or available.
1.2 Methods
We received 12 CSR Ms2 from 31 studies requested from EMA by July 2011. Before we reviewed Ms2 we 
knew they contained protocols, with their amendments, certificate of analyses, blank case report forms, 
randomisation and participating centres’ lists. However, we had no precise idea whether this was a 
comprehensive list or whether further items would be identified once we started reviewing. We also noted that 
the same info was reported elsewhere in the CSRs (for example in the core report) but in a different level of 
detail. A good example of this is the statistical analysis section of the core report which is a few pages long 
chapter, compared to the Statistical Analysis Plan (SAP), which is a self contained document included in M2. In 
addition we were not aware of the existence of any readily available tool to allow us to extract, organise and 
appraise the information contained in the Ms2.
As consequence we decided to develop our own tool. Our plan is to do this by identifying the types of items 
contained in the Ms2 available to us and their location in the Ms2. The outline content of all items identified will 
be checked in the Ms2 because of the potential for differing titles for the same item. For example we have 
already noticed that Research Analysis Plan (RAP) is sometimes called Data Analysis Plan (DAP) or Statistical 
Analysis Plan (SAP). Another example are the Protocol Amendment Histories and Protocol Modification 
History Document. These represented different ways of identifying the same item and need to be given a single 
identifier. Items such as Data Reporting and Analysis Manual (DRAM) are only cited in one M2. We will also 
conduct a pilot to identify with certainty which items are present more frequently. We will make a list of what 
we thought were most present and important items contained in the Ms2 and create a grid based on the sequence 
of development of the trial design and analysis plan. For example, we want to track whether the reporting of the 
trial study design in the relevant section of the protocol and its amendments (in M2) is consistent with that 
described in the core report (in M1). We will also make an initial extraction frame to reconstruct the timeline of 
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the study documents, summarising the number of protocol changes and their dates in sequence. This has the 
purpose of giving an overview of the main timeline points of the key items of study design and analysis.
We will then pilot our extraction sheet and make changes following discussion with all authors. We will extract 
the data in the same groups we worked in the original review.
We will define the impact of adding M2 information by measuring the change in risk of bias (ROB) assessment 
in our review as well as reporting our summary description and appraisal of each trial before and after addition 
of the data and comparing it with the manufacturer's assessment.
The detailed questions addressed by our analysis are:
Does addition of M2 to M1 change the risk of bias evaluation compared to M1 alone?
Does reading M2 and M1 in CSRs change the risk of bias evaluation compared to using published papers?
Is the current risk of bias tool adequate for assessing trials based on reading M2 then M1 in the CSRs?
Does reading M2 and M1 in the CSRs identify additional useful relevant information for systematically 
reviewing a trial programme?
We will primarily use descriptive methods to answer the questions. To answer question 1 we will compare the 
risk of bias in our 2012 review with risk identified after addition of M2 information to our current review using 
a 3 by 3 contingency table. We will repeat this procedure to answer question 2, by comparing risk of bias in our 
2009 BMJ review to our current assessment. This analysis will be based on the subset of trials that were 
published and included in our 2009 review.
To answer question 3 we will list all the components of other risk of bias in the current review and compared 
these with previous reviews (2012 and 2009).
To answer the final question we will provide a summary of the items that were identified in our assessment of 
the trials using the new M2 tool. This will allow us to summarise discrepancies between what was planned in 
the protocol, what was carried out (RAP, protocol amendments), what was reported in M1, and what was 
reported in the published papers. The focus would be on the trial programme of research i.e. issues that appeared 
consistently over the trials.
Adverse events
2. Summary and background 
This document outlines how we will conduct the analysis of adverse events as part of the wider Cochrane 
review of neuraminidase inhibitors (NIs) for prophylaxis and treatment of influenza in healthy adults and 
children (A159).
We use the term 'adverse events' throughout this document rather than harms or adverse reactions as these latter 
terms imply causality which may or may not be appropriate.
In keeping with the methods of our previous review we will not use data from journal publications for this 
proposed analysis. We now have access to multiple clinical study reports (CSRs) for both oseltamivir and 
zanamivir. To our knowledge this is the first time some of these data have been available outside manufacturers 
and regulators, and allows for the exploration of events in more detail than is possible using the limited 
information on safety reported in journal publications. This potentially allows us to address some of the 
concerns that have arisen in the post marketing period about the possible relationship between neuraminidase 
inhibitors, oseltamivir in particular, and neuropsychiatric and other harms. The documents available to us 
contain listings and summaries of adverse events recorded in the trials including narrative summaries of serious 
adverse events and adverse events leading to study withdrawal.
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The adverse events are classified by relationship to the study drug and also, by intensity (mild, moderate, severe, 
life-threatening and death). The duration of events is reported and they are also lumped into body systems such 
as gastrointestinal, neurological, etc.
2.1 Methods
All CSRs of oseltamivir and zanamivir will be included in our analysis. CSRs for prophylaxis, for treatment of 
adults and for treatment of children will be analysed separately. Adverse events will be initially descriptively 
compared over the entire treatment and follow-up period but then potentially stratified by on-treatment and off-
treatment periods if it appears there may be a difference between treatment groups.
2.2 Adverse events for comparison
2.2.1 Common events
For common events of any intensity with an overall incidence of 2% or more we will compare the incidence 
between treatment groups. The cut-off of 2% is based on a power analysis where assuming 4000 patients in total 
(this is approximately how many patients we have access to in oseltamivir treatment trials of adults as well as in 
oseltamivir prophylaxis trials of adults), we will have 80% power to detect an odds ratio of 1.75 with 5% level 
of significance.
2.2.2 Uncommon events
Due to a lack of data to compare uncommon events we will compare events lumped into body systems between 
treatment groups. If we find evidence of a difference in incidences between groups lumped into a body system 
we will conduct further analysis if appropriate. This further analysis is to determine whether the difference in 
incidence is due to any common events included in that body system. For example, in the case of neurological 
body system, if we found evidence of a difference between treatment groups we would remove all common 
neurological events such as headaches and repeat the analysis.
2.3 Severe, serious events and events leading to study withdrawal
As well as the analysis described in section 2.2 above we will also conduct a subgroup analysis of just the events 
with severe intensity, serious events and events leading to study withdrawal. We will use the same definitions of 
"severe" and "serious" as specified in the CSRs. However we will check the classifications using all the 
information available in the CSRs including line listings of events, narratives provided for serious events and 
also for events leading to study withdrawal. Any disagreements with the original classifications will be recorded 
and any reclassifications will be assessed in a sensitivity analysis. Given it is unlikely there will be sufficient 
events to conduct separate statistical analysis at the level of body system we will compare the overall 
distribution of events by body system between treatment groups.
2.4 Incidence of adverse events in the CSRs
As a further check on the validity of the data on adverse events contained in the CSRs we will conduct 
descriptive comparisons of the incidence of adverse events in the prophylaxis and treatment trials.
This is because of the unclear methods of collecting and classifying adverse events in the trials. A potential 
adverse event could have been classified as a symptom of influenza, an efficacy outcome (such as complication 
of influenza) or an adverse event. Hence an informal comparison of the incidence of adverse events in the trials 
where participants had influenza (or influenza-like-illness) and the trials where participants did not have 
influenza may help show where adverse events could have been under-reported. We will take into account 
factors such as age of participants and duration of treatment exposure for these informal analyses. In addition if 
it is clear that an adverse event was not reported as an adverse event but was included elsewhere in the CSR 
(e.g. in the efficacy section), we will include that data in our adverse event analyses.
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We will also construct a table showing the definitions specified in each CSR for classifying potential adverse 
events as adverse events, complications or symptoms of influenza.
2.5 Antibody titre
We have already reported that antibody production was lower in the oseltamivir group than in the placebo group 
in the systematic review of treatment trials of oseltamivir (2012). We will update this analysis by including 
additional oseltamivir trials as well as assess antibody production in the zanamivir trials.
We will assess antibody production in the prophylaxis trials of oseltamivir and zanamivir by the following 
methods.
We will first identify the participants who had influenza-like illness (ILI) or pyrexia. If the proportion is similar 
between active group and placebo group, the proportion of participants who had four times or higher increase of 
antibody will be compared between groups. 
2.6 Dose-response analysis
A number of trials included two or more active treatment arms with different doses of study medication given to 
participants in each of the arms. For these trials we will investigate the dose-response relationship for common 
adverse events (as defined above).
2.7. Details of analysis
Initial analysis will be descriptive only where we will report the numbers and percentages of events by treatment 
group. If there is a potential difference in the pooled percentages between treatment groups (e.g. if there is more 
than a two standard error difference between percentages) then we will conduct formal meta-analysis. If 
indicated we may also conduct additional analyses taking into account event intensity and/or duration.
2.8 Limitation and exploratory analysis
The methods presented above are those that we have pre-specified prior to formal analysis of the data. A 
limitation of these methods is that we may fail to detect differences in rare adverse events because these events 
will be compared along with other types of events within body systems. Therefore in the process of conducting 
our formal analysis we may generate further hypotheses or conduct additional exploratory analyses. If this is the 
case then we will clearly label these analyses as exploratory and interpret the findings accordingly.
Types of outcome measures
3. Background
For most people, influenza is a self-limiting illness. However the disease can at times lead to serious 
complications such as pneumonia and hospitalisations, and if treatment with neuraminidase inhibitors can 
reduce the risk of severe outcomes, this would be an important public health benefit. Another potentially 
important public health benefit would be the ability of antivirals to interrupt person to person transmission of 
influenza. Current evidence for these outcomes is scarce or inconclusive. A positive balance of effects on 
complications and viral spread versus harm profile is the main reason for using NIs in a public health context, 
especially the orally administered oseltamivir.
All analysis will be based on the intention-to-treat (ITT) or safety populations as our prior review discovered 
compelling evidence that the ITTI (the subpopulation deemed to be influenza-infected) populations were not 
balanced between treatment groups in the Roche oseltamivir trials. In addition, estimates from the ITT 
population will be more generalisable to clinical practice where routine testing for influenza is not common in 
many countries (and even where used, remains of variable accuracy). Analysis will be conducted separately for 
prophylaxis trials, treatment trials of adults and treatment trials of children.
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The list of outcomes given below includes all potential outcomes that we believe are clinically important. 
However a number of them may not be formally comparable in this review because there are insufficient 
numbers of events (e.g. mortality) or they were not adequately measured or reported (e.g. drug resistance).
3.1 Outcome measures for treatment studies
Complications~
Harms*
Symptom relief
Hospitalisation
Viral excretion
Drug resistance
Mortality
3.2 Outcome measures for prophylaxis studies
Influenza-like-illness^
Complications~
Harms*
Hospitalisation
Viral excretion
Drug resistance
Mortality
~Complications (secondary illnesses) include pneumonia, bronchitis, otitis media, sinusitis or other respiratory 
tract infection after influenza-like illness. Initially we will construct a table to illustrate the design methodology 
used for each study. The table will include the following variables:
Study/trial ID
Where complications are first defined in the CSR (e.g. "as secondary endpoint in 3rd version of protocol six 
months into trial and two months prior to trial unblinding")
Definition of "complication" including types of events, population and time period at risk
How complications were measured (see diagnosis methods criteria shown below)
Availability of complications data for the ITT population
We will then stratify our analysis by method of diagnosis with three possible criteria:
a. Lab-confirmed diagnosis (e.g. based on radiological or microbiologically confirmed evidence of infection).
b. Clinical diagnosis without laboratory confirmation (diagnosed by a doctor after a clinical examination).
c. Other type of diagnosis such as self-reported by patient
*A separate section provides the details of our proposed analysis of harms.
^The main outcome of interest is any symptomatic influenza-like-illness (ILI). However, we will also conduct 
separate analyses of influenza (symptomatic and asymptomatic) and non-influenza ILI.
Reply 
TJ
Contributors 
Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ
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10 From Peter Gross, Hackensack University Medical Center, USA, 17 April 2014 
Summary 
Comment: Can Cochrance compare their results on inﬂuenza neuraminidase inhibitors with the reduction in 
symptoms when penicillin is given for strep throat? I think they may be comparable. That would be an important 
perspective.
I agree with the conﬂict of interest statement below:
I certify that I have no afﬁliations with or involvement in any organization or entity with a ﬁnancial interest in  
the subject matter of my feedback.
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